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 This Doctor of Philosophy thesis investigates two key concepts (namely 
vaccination and elicitation of host immune responses) in the prevention of respiratory 
virus infections, focusing specifically on SARS coronavirus (SARS-CoV) and 
influenza virus (InfV).  
Firstly, a new approach to increasing DNA vaccine efficacy was investigated, 
exploiting the fact that integrins are critical for initiating T-cell activation. The 
integrin-binding motif, Arg-Gly-Asp (RGD), was incorporated into a mammalian 
expression vector expressing codon-optimized extra-cellular domain of SARS-CoV 
spike protein, and tested by immunizing C57BL/6 mice. Immune responses were 
characterized using 
51
Cr release assay and IFN-gamma secretion ELISPOT assay 
against RMA/S target lines presenting predicted MHC class I H2-K
b
 epitopes, 
including those spanning residues 884-891 and 116-1123 within the S2 subunit of 
SARS-CoV spike. Immunization with both DNA vaccine constructs namely Spike-
RGD/His motif and Spike-His motif generated robust cell-mediated immune 
responses. The latter also elicited a significant humoral response. Moreover, we have 
identified additional novel T-cell epitopes within the SARS-CoV spike protein that 
may contribute towards cell-mediated immunity. 
Next, the role of interferon regulatory factor-4 (IRF-4) transcription factor in 
the mouse model of InfV infection was investigated. IRF-4 is essential for the 
function and homeostasis of B and T lymphocytes, but it is unknown whether it acts 
as a direct transducer of virus-mediated signaling.  IRF-4 +/+, +/- and -/- mice in the 
C57BL/6 background of both sexes, were infected intra-tracheally with a lethal dose 
of InfV A/Puerto Rico/8/1934 H1N1. Weight loss (monitored daily until terminal 
phase whereby a 25% reduction was reached), and lung histopathology scores were 
 xi 
 
similar in all three genotypes of infected mice. IRF-4 -/- mice had the highest lung 
viral titres compared to other infected groups and most importantly, were not able to 
mount a detectable antibody response in virus neutralization test, thus indicating a 
defect in B cell lineage and function. Other studies conducted showed that cell-
mediated immune response was absent as well. Pro-inflammatory cytokines were 
dysregulated in the absence of IRF-4. There was suppression in IL-1β and IL-6 levels 
and an augmentation of GM-CSF and TNF-α. Th-1 cytokines of IL-2 and IFN-γ 
showed a marked reduction whereas Th2 cytokines of IL-4 and IL-10 showed an 
increase. Chemokine CXCL1 indicated a dysfunctional level of neutrophil attractant. 
IFN-α and IFN-β mRNA levels were not affected by the IRF-4 gene knockout despite 
the influenza virus infection. However, IFN-γ mRNA was non-existent possibly due 
to dysfunctional T lymphocytes which are responsible for IFN-γ secretion, chiefly 
CD4+ T helper and CD8+ T lymphocytes. Microarray analysis revealed that besides 
being involved in signaling pathways of both innate and adaptive immune responses, 
the IRF-4 gene also played multiple roles in other previously unknown pathways.  
The absence of IRF-4 which has critical function in the development of 
lymphoid and myeloid cells appears to be detrimental to InfV-infected mice, resulting 
in the failure to arm the mice with the necessary protective immunity to mount an 
efficient adaptive immune response.  
 xii 
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CHAPTER 1  
1.1 Prologue 
 
This thesis describes the study on the immunity and immunization against 
respiratory viral pathogens in the mouse animal model system. 
Immunization represents an important strategy to contain potential pandemic 
outbreaks of respiratory viral pathogens as a serious public health issue. Compared to 
other methods of immunization such as conventional protein or peptide vaccines, 
DNA vaccines readily induce humoral as well as cellar immune responses. While 
showing great promise, the use of DNA vaccine does have its drawbacks. Among 
them is the low immunogenicity demonstrated in large animal models and humans as 
well as its low transfection efficiency. The 2003 outbreak of the Severe Acute 
Respiratory Syndrome (SARS) caused by the then newly-identified SARS 
coronavirus (SARS-CoV) provided an opportunity for us to investigate whether 
various immunological fusion motifs were able to increase the immunogenicity of 
DNA vaccines. Chapter 2 ‘A Novel DNA Vaccine against SARS Coronavirus’, 
describes the work done where a novel fusion motif was incorporated into a DNA 
vaccine to investigate its potential in increasing the efficacy and efficiency of this 
immunization method.  
 Various DNA vaccines expressing the codon-optimized extracellular 
component of the SARS-CoV Spike glycoprotein fused to ligands were expeditiously 
constructed, generated, modified and purified. The novel ligand of interest was the 
integrin-binding motif [Arg-Gly-Asp (RGD)] domain. As integrins are required for 
the initiation of T-cell activation events, we investigated whether the incorporation of 
the RGD integrin-binding motif into a mammalian expression construct would result 
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in enhanced efficiency of DNA vaccination for inducing immune responses against 
SARS in a mouse animal model.  
Concentrating primarily on the H2-Kb haplotype of the murine MHC, we first 
did in silico epitope prediction for the SARS-CoV Spike glycoprotein. While it was 
understood that there exist other haplotypes present within the murine MHC system, 
the H2-Kb was selected as a restricted-epitope of this haplotype to act as a positive 
control was known, ie. the chicken ovalbumin H2-Kb-restricted epitope 257-264aa 
(SIINFEKL). This epitope was included in all assays to act as a positive control. A list 
of potential restricted-epitopes was generated from two epitope prediction neural 
networks. From its location within the SARS-CoV spike glycoprotein structure, its 
hydrophilicity/hydrophobicity character was examined using the Kyte-Doolittle and 
Hopp-Woods plots.  MHC-peptide binding assays were then performed to deduce its 
binding capacity to real life MHC molecules. 
Over the course of the study, we discovered that a SARS-CoV spike 
glycoprotein transfected cell line was difficult to come by, despite numerous attempts. 
This cell line expressing the spike glycoprotein would be critical in assessing the 
cytotoxicity of splenocytes harvested from mice immunized earlier with the Spike 
DNA vaccine. It appeared the transfection was more transient than a stable one 
resulting in the non-expression of the intended protein. The solution to this problem 
came in the form of the RMA/S cell line. Devoid of the TAP2 molecule, we were able 
to pulse a homogenous species of synthetic restricted-epitope onto the unstable MHC 
molecules present on the cell surface of the RMA/S cells. Doing so, the RMA/S cells 
acted as the antigen-presenting cell, in in vitro restimulation assays. It also acted as 
the target cell in cytotoxicity assays as well as in the IFN-γ secretion assays. 
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  The cell mediated immune response was demonstrated by its cytotoxicity and 
interferon-gamma secreting functions whereas antibody response against the spike 
glycoprotein was used to demonstrate its humoral immune response.  Additionally, 
we screened the SARS-CoV Spike glycoprotein for potential epitopes against a mouse 
major histocompatibility complex (MHC) haplotype through the use of in silico 
prediction algorithms and functional binding assay. However a lab-acquired incident 
within the National University of Singapore campus had changed the circumstances 
of the investigation. This incident raised concerns on biological safety usage of an 
attenuated SARS-CoV and its use as a challenge virus in the DNA vaccine 
investigation. Had we be allowed to continue as planned, like any other study 
involving vaccine studies, we would have conducted live or attenuated SARS-CoV 
challenge protocol against mice pre-vaccinated with the DNA vaccines constructed 
from this study. 
In keeping to the overall theme, the Influenza A virus (InfAV) was next 
selected as the model pathogen to be used for further studies as both the InfAV and 
SARS-CoV can be classified as respiratory viruses. Additionally, the use of Influenza 
viruses (InfV) in the laboratory requires a bio-containment level that is much lower 
than that of SARS-CoV. Furthermore, as an added protection, annual vaccines are 
widely available and effective against InfV, which can be given in advance, to 
laboratory research staff involved in such research work. Without a working 
prophylactic vaccine available for the SARS-CoV, a bio-containment level 3 facility 
will be needed for research work to be done. This is difficult to come by as such local 
facilities are limited.  
  Innate immunity represents the first line of defense in higher organisms 
towards invading pathogens. Its role includes the recognition of structures present in 
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microbes that are distinct from the host, as well as effecting the release of 
antimicrobial substances and cytokines. This ultimately recruits inflammatory cells to 
infection sites. On the other hand, responses from adaptive immunity are slower in 
development and involve the specific recognition of foreign, microbial antigens by 
receptors of B and T lymphocytes. Antibodies produced by B lymphocytes have the 
ability to neutralize infections through the opsonization for phagocytosis and through 
activation of the complement system. Through the coordination of cellular responses 
by genetic regulatory networks, transcription factors are able to control the expression 
of a diverse set of target genes to orchestrate and control homeostatic mechanism of 
host defense. One such transcription factor within the immune system is the Interferon 
(IFN) Regulatory Factor (IRF) family. Consisting of 9 members, IRFs play a pivotal 
role in the regulation of both innate and adaptive immune responses. IRF-3, -5 and -7 
is well known to induce the expression of Type I IFN (IFN-α and –β) genes in 
infected cells. These cytokines enhance antiviral effector function by affecting the 
activities of innate (macrophages, natural killer [NK]) and adaptive (dendritic cells 
[DC] and lymphocytes) immune cells by increasing antigen presentation, cell 
trafficking and differentiation. The IRF-4 is known for its oncogenic properties and is 
involved in the development of various immune cells. Nonetheless, its role in viral 
infection immune responses is unknown. Therefore, using the mouse animal model, 
the role of IRF-4 in InfAV infection was investigated in the hope of elucidating 
immune mechanisms that may be useful in protective immunity and vaccination. 
Chapter 3 ‘Understanding the role of Interferon Regulatory Factor-4 (IRF-4) 
transcriptional factor in severe influenza pneumonitis’, describes the work done where 
the Influenza A/Puerto Pico/8/1934 H1N1 (PR8) and the Influenza A/Aichi/2/1968 
H3N2 (Aic68) viruses were used to infected C57Bl/6 mice. Mice of both sexes either 
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had a complete and functioning IRF-4 gene (IRF-4 +/+ [Wildtype]), a single allele 
IRF-4 absent (IRF-4 +/- [Heterozygous]) or both allele absent (IRF-4 -/- [Knockout]). 
This novel study investigated the involvement of the IRF-4 gene in Influenza virus 
infections as well as examined the gene dosage hypothesis, the contribution of host’s 
sex and viral strains in the outcome of a respiratory viral infection. The project 
intended to examine the effect the IRF-4 gene on the adaptive immune response from 
a PR8 infection, as the IRF-4 transcription factor is critical in B- and T-lymphocytes 
development. IRF-4 mice infected with a lethal dose of the PR8 were culled only 
upon near death. Weight loss in infected mice acted as a gross measurement for the 
virulence and pathology of the InfV infection. Weight loss in infected mice also acted 
as surrogate to survival studies as this was not allowed under the protocols laid down 
by the Institutional Animal Care and Use Committee (IACUC).  Lung histopathology 
provided a more direct evidence of the damage caused to the infection site during the 
InfV infection. A scoring system consisting of a set of pre-determined criteria was 
used to generate a quantitative score from the qualitative observation. Even though 
performed in a double-blinded manner, the lung histopathology scoring was 
ultimately very subjective. Lung viral load titres were examined by conducting plaque 
assay and confirmed with qRT-PCR of the PR8 NS1 mRNA. 
As the project had the objective of examining the adaptive response of the 
PR8 and the involvement of the IRF-4 gene, mice were culled near death ie. Days 7-
11 Post Infection. This allowed for its humoral immune response to be examined.  
The cytokine analysis of lung homogenate was then analyzed using BioPlex 
multiplexing technology. A cytokine profile in terms of pro-inflammatory cytokines, 
Th1 and Th2 cytokines and chemokines were generated. In order to gain a better 
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understanding of mRNA expression of cytokines as well as other IRF family members 
in the lung homogenate, qRT-PCR studies were conducted.  
Microarray analysis of the lung homogenate was also performed to elucidate 
the involvement of the transcription factor. While pathways of innate and adaptive 
immune responses were identified, other unknown pathways such as senescence and 
autophagy were deemed to involve IRF-4. More work needs to be done to decipher 
this unknown, but yet interesting, transcription factor. 
Preliminary work on the infection of a mouse-adapted Aic68 was also done. It 
appears that there was strain specificity difference in the histology seen. More in 
depth work needs to be done to demonstrate the full results. 
Also presented was the observation of tumorigenesis observed throughout the 
mouse model of the InfAV. While definitely not a complete work, we present the 
somewhat interesting observation where recovered Aic68-infected mice demonstrated 




 The study hypotheses are centered upon the key concept that a functional host 
adaptive immune response is paramount for the development of prophylactic 
strategies in the control of respiratory viral infections. 
 
Hypothesis I 
 The incorporation of the integrin binding motif (RGD) into the C-terminal of 




 Interferon Regulatory Factor-4 (IRF-4) is essential for the modulating or 




1.3. GENERAL INTRODUCTION 
1.3.1. The respiratory system 
 The respiratory system, which consists of the airways, lung and respiratory 
muscles functions to obtain oxygen from the external environment and to remove 
carbon dioxide from the body. The respiratory tract must therefore be able to defend 
against airborne particles and microorganisms present in the air. The airway is made 
up of the upper and lower respiratory tract, where the former includes the nasal 
sinuses and nasopharynx and the latter begins at the larynx and continues to the 
trachea, terminating at the alveoli. The lung, having the largest epithelial surface area 
in the body to facilitate efficient gas exchange, is especially prone to the entry of 
airborne pathogens.  
  
1.3.2 Pulmonary Host Defense 
An array of pulmonary host defenses is distributed throughout the respiratory 
tract to maintain the sterility of the lungs. This includes the nonspecific mechanical, 
chemical blockades and specific immune processes. The mechanical defense 
component is made up of aerodynamic filtration, mucociliary clearance/transport and 
cough, where they function as physical barriers that trap and expel particulate, as well 
as infectious matter introduced into the respiratory tract. Pathogens and particles 
evading the first line proximal defenses, in the form of anatomical structures of the 
nose and multiple bifurcations of the tracheal bronchial tree will encounter the 
phagocytic defenses of the alveoli. Phagocytosis, handled predominantly by the 
resident alveolar macrophages can be broken into four steps: chemotaxis, adherence, 
ingestion and digestion. Macrophages are capable of interacting with inflammatory 
(in the form of secretory products) and immune (in the form of lymphocytes and the 
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complement system) stimuli. Neutrophils also show phagocytic ability but instead of 
residing in the lungs, they are present in the circulation and adhere to the pulmonary 
vascular endothelium. The migration of neutrophils into the interstitium and alveolar 
air spaces is controlled by chemotactic factors and plays an important microbicidal 
function, in addition to the release of collagenases and proteases. The final and most 
intricate tier of the pulmonary host defense lies in the development of a specific 
immune response contributed by lymphocytes. These are mainly found in discrete 
locations such as the bronchial submucosa and regional lymph nodes 
 
1.3.3 Respiratory Viral Pathogens 
 
Respiratory viruses contribute to significant morbidity and mortality in 
humans and cause large economic losses worldwide. The infections that these 
pathogens cause are mostly self-limiting in healthy adults but are important factors in 
the illness and death of the very young, immunologically-compromised and elderly 1. 
It is estimated that respiratory viral pathogens account for about 5% of all deaths and 
for about 60% of deaths related to related to respiratory disease (Welliver and Ogra 
1988). Species within the Adenoviridae, Coronaviridae, Herpesviridae, 
Orthomyxoviridae, Paramyxoviridae and Picoviridae are classified as causes of 
respiratory tract infection. More than 200 antigenically distinct viruses have been 
documented as causes of sporadic or epidemic respiratory infection in infants, 
children and adults (Mackie 2003). Of these viruses that replicate in the respiratory 
tract, coronaviruses, influenza virus, parainfluenza virus, respiratory syncytial virus 
and rhinoviruses produce infections that are primarily restricted to the respiratory 
mucosa and are not generally accompanied by systemic disease. Serious respiratory 
diseases are observed with infection by adenoviruses, cytomegalovirus, nonpolio 
enteroviruses (echoviruses and coxsackieviruses), Epstein-Barr, measles and varicella 
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zoster viruses. Clinical syndromes for different respiratory viruses vary with severity 
(Welliver and Ogra 1988).  In mild infections these range from the common cold 
(coryza), febrile ‘flu-like’ illness (cough, myalgia, malaise) and pharyngotonsilitis 
which mostly resolve without any complications. In more serious disease 
manifestations, laryngotracheobronchitis, bronchiolitis, wheezing, pneumonia, apnea 





 A Novel DNA Vaccine Against SARS Coronavirus 
2.1 INTRODUCTION 
2.1.1 Coronaviruses 
Coronaviruses causes a myriad of animal diseases ranging from those present 
in economically-significant farm animals (such as Transmissible Gastroenteritis in 
porcine, Winter Dysentery in bovine), domesticated pets (such as Feline Infectious 
Peritonitis, enteric and respiratory infections in canine), avian (infectious brochititis) 
to humans.  Human coronaviruses (HCoV) is currently made up of HCoV-OC43, 
HCoV-229E, HCoV-NL63, SARS-HCoV and HCoV-HKU1.  Human coronaviruses 
are thought to be responsible for 10 - 30% of all common colds, infecting the 
respiratory tract and manifesting as bronchitis, bronchiolitis and pneumonia.  
 
2.1.1.1 Structure 
Coronaviruses are spherical, enveloped viruses, ranging from 80 – 160nm in 
diameter and contain a single-stranded positive-sense RNA genome. Proteins that 
contribute to the structure of the virion include that spike (S), envelope (E), 
membrane (M) and nucleocapsid (N) proteins. The RNA genome is associated with 
the N phosphoprotein and forms a long, flexible, helical nucleocapsid (Holmes and 
Lai 1996). A lipoprotein envelope originating from the budding of intracellular 
membranes encompasses the nucleocapsid (Griffiths and Rottier 1992). The envelope 
structure contains the S and M glycoproteins. The M glycoprotein penetrates the lipid 
bilayer where a large carboxyl-terminal domain lies underneath (Holmes and Lai 
1996). The M glycoprotein are targeted to the Golgi apparatus and is absent from the 
plasma membrane. It is thought that the M protein probably binds the helical 
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nucleocapsid to the viral envelope during virus budding. The distinctive crown-like 
appearance of coranaviruses is formed by the club-shaped peplomers which project 
from the envelope and populate the virion surface (Holmes and Lai 1996). The S 
protein drives the entry of the virion into target cells via receptor-mediated 
endocytosis (Gillim-Ross and Subbarao 2006). It also functions as the major viral 
attachment protein that is critical to virus binding and fusion of the viral envelope 
(Holmes 2001).  
 
Source: (Holmes 2001) 
Figure 2.1: Structural diagram of a Coronavirus virus. Coronaviruses are enveloped 
with a helical symmetrical, positive-sense single-stranded RNA. The genome contain 
between 6 and 11 functional Open Reading Frames (ORFs) that encodes structural 
proteins, namely, the large surface Spike glycoprotein, integral Membrane lycoprotein 
and the Nucleocapsid phosphoprotein. Some coronaviruses have the Hemagglutinin-





2.1.2 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) 
 
The severe acute respiratory syndrome (SARS) was unprecedented in the 
rapidity and extent of its spread, in the magnitude of its impact on health systems and 
economies. A total of 774 deaths were reported out of 8,096 SARS-CoV infection 
cases in 29 countries. 
The cellular entry of the SARS-CoV involves the S protein and ACE2 receptor. 
The spike (S) protein of SARS-CoV is a type 1 transmembrane glycoprotein(Leth-
Larsen, Zhong et al. 2007). The S1 subunit is responsible for virus binding to the 
Angiotensin-Converting Enzyme 2 (ACE2) receptor (Li, Moore et al. 2003, 
Prabakaran, Xiao et al. 2004) where the ACE2 receptor-binding domain lie within 
amino acids (aa) 318-510 of the S1 subunit (Dimitrov 2003, Xiao, Chakraborti et al. 
2003, Wong, Li et al. 2004). The S2 subunit contains a putative fusion peptide and 
two heptad repeats HR1 and HR2. The structure is also responsible for the fusion of 
the viral and target cell membranes. Four regions with highly immune reactivity are 
located at 67-119 aa, 265-345 aa, 588-645 aa and 1120-1234 aa (Wang, Chen et al. 
2004, Wang, Sin et al. 2004). SARS-CoV may also gain entry into cell through pH-
dependent endocytosis, mediated by the S protein (Yang, Huang et al. 2004). 
Additionally, it has been reported that the S protein-driven cell-to-cell fusion can also 
occur in the absence of low pH (Dimitrov 2003). It is possible that the S protein may 
be able to mediate membrane fusion in both pH-dependent and –independent manner. 
The ACE2 metallopeptidase was originally thought to have direct effects on cardiac 
function (Boehm and Nabel 2002), but was discovered to be a functional receptor for 
SARS-CoV (Li, Moore et al. 2003, Wang, Chen et al. 2004) by binding to the S 
protein. Besides being expressed predominantly in vascular endothelial cells of the 
heart and the kidneys, it is present in human lung alveolar Type I and Type II 
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epithelial cells, enterocytes of the small intestine, the brush border of the proximal 
tubular cells of the kidney and endothelial cells of arteries, veins and arterial smooth 
muscle cells in several other organs (Hamming, Timens et al. 2004). ACE2 is not 
expressed on B or T cells, macrophages in spleen of lymphoid organs. The 
localization of ACE2 may explain the tissue tropism of SARS-CoV in the lung, small 
intestine and kidney (Ding, He et al. 2004). 
 
2.1.2.1 Innate immune responses to SARS-CoV infection 
In clinical cases of SARS infections, the host immune response undergoes 
several unique events: lymphopenia (occurring progressively in the early course of the 
infection, reaching the minimum during the second week of the infection), production 
of specific antibodies (IgG persisted indefinitely while IgM expressed transiently) 
together with a distinct cytokine profile (increased in levels of IFN-γ and IL-10 
whereas decreased in IL-4 levels) (Zhu 2004). Innate immunity functions as the first 
host defense against viral infections. The key componetns include natural killer (NK) 
cells, the IFN response, chemokines and cytokines. 
NK cells in peripheral blood form clinical SARS cases correlated with the 
severity of disease and the presence of antibodies against the virus (SARS 2004). 
Antiviral IFN response is mediated by IFN production and signaling or by direct 
inactivation of effector molecules. In SARS-CoV infection, there is an unusual lack of 
an antiviral IFN response (Chen and Subbarao 2007). SARS-CoV is thought to have 
developed mechanisms necessary to block activation of IFN regulatory pathways at 
the initial stages following the nuclear transport of the IFN regulatory factor-3 (IRF-3) 
(Spiegel, Pichlmair et al. 2005). The IRF family of transcriptional factors has diverse 
roles, among them the regulation of host defense in the innate and adaptive immune 
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responses. IRF-3 is primarily responsible for the activation of Type I IFNs (IFN-α and 
IFN-β). Clinical data suggests that these IFNs were undetectable in patients and 
neither was it induced in infected cells in vitro. The SARS-CoV infection upregulates 
the expression of chemokines IP-10, MCP-1, MIP-1α and RANTES in macrophages 
and dentritic cells (Cheung, Poon et al. 2005, Law, Cheung et al. 2005, Yilla, 
Harcourt et al. 2005). Levels of IP-10, IL-8 and MCP-1 were found to be elevated in 
lungs and peripheral blood of patients where IL-6, IL-8 and MCP-1 were found in 
lungs of fatal cases (Jiang, Xu et al. 2005). There was not change in TNF-α level in 
clinical samples (Wong, Lam et al. 2004). 
 
2.1.2.2 Adaptive cellular responses to SARS-CoV infection 
 A rapid development of lymphopenia is characteristics of the adverse outcome 
of the disease, with CD4
+
 T cells being more severely reduced than CD8
+
 T cells 
during acute infection (He, Zhao et al. 2005). Progressive lymphopenia occurred in 
the early course of the disease and reached its lowest point in the second week in most 
cases. It has been hypothesized that the cause may be related to virus-induced 
infection and destruction of lymphocytes, chemokine-mediated lymphocyte 
trafficking/redistribution and sequestration of lymphocytes in the lung, bone marrow 
suppression or apoptosis (O'Donnell, Tasker et al. 2003, Panesar 2003, Wong, To et al. 
2003). 
 IFN-γ is known to increase over the progression of a SARS-CoV infection 
(Zhu 2004). This Th1 cytokine is associated with potent cell-mediated immunity and 
resistance to intracellular pathogens. However, IL-4 levels were found to be decreased 
after the onset of the infection. This indicated that a Th1 dominant response is 
responsible for the elimination of the virus from the body as IL-4 is a dominant Th2 
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cytokine which also promotes humoral immunity. On the other hand, IL-10 was found 
to be elevated. As IL-10 is produced by Th2 cells and has dual effect on T 
lymphocytes in suppressing Th1 cells from producing IL-2, IFN-γ and TNF while 
promoting proliferation and cytotoxicity of CD8
+
 T cells and NK cells. IL-10 
expression increase may be associated with the susceptibility of the infection (Zhu 
2004) 
 
2.1.2.3 Humoral immune response to SARS-CoV infection 
 Clinical cases reveal that humoral responses towards the virus became 
apparent during the convalescent phase. Serum IgG, IgM and IgA occurred around 
with same time with most cases seroconverting by day 14 after illness onset (Hsueh, 
Huang et al. 2004). IgG levels persisted for a long time but IgM was detected to be 
present for a shorter time. This suggested that IgG antibody against the virus 
represents the primary humoral immune response for protection. Among the structural 
proteins, only the S protein elicits neutralizing antibody (Buchholz, Bukreyev et al. 
2004), with the major S protein immunodominant epitope existing between amino 
acids 441 and 700 (Lu, Manopo et al. 2004). 
 
2.1.3 Vaccines 
 The development of vaccines has been an important achievement of 
immunology and medicine and contributes significantly to human and livestock health. 
The goal of vaccination is to alter the adaptive immune system to obtain clinical 
benefits. Attenuated vaccines made up of physiochemically-altered or genetically 
manipulated live pathogens, are most productive as they stimulate the most effective 
and lasting immunity to any natural infection. These vaccines are able to elicit an 
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adaptive immune response leading to the generation of humoral antibody and cell-
mediated responses. However, there is a slight possibility that such vaccines are able 
to revert back to a natural pathogenic form. 
 Unable to revert back to its pathogenic form, killed whole viral vaccines 
presents a safer option then live attenuated ones. Even though these vaccines maintain 
the full antigenic spectrum, they are less effective as they are promptly cleared from 
the body and some antigenic proteins are destroyed during the inactivation process. 
The activation of inflammatory responses recruits dendritic cells in providing a more 
efficient antigen presentation.  
 Subunit vaccines may compose of one or various immunodominant viral 
component structures. This allows for the targeting of immune responses against the 
specific immunodominant antigens where an effective immune clearance can be 
mounted against the challenging pathogen. However being sequestered components 
from pathogens, these vaccines are unable to mount a broad and robust response as 
compared to while organism vaccines. Cell-mediated immunity is particularly weak 
from usage of such vaccines. However, adjuvants such as alums (aluminium 
hydroxide crystals) are used concurrently to initiate a local inflammatory response 
which enhances antigen uptake and prolonged antigen release. Attenuated viruses 
such as vaccinia are also used as recombinant vaccine vectors that express foreign 
antigens.  
 Epitope-based vaccines consist of synthetic peptides that has been 
characterized antigenically and immunogenically to be capable of inducing effective 
specific immune responses, while avoiding undesirable effects. However peptide 
molecules suffer from low immunogenicity, compared to multi-epitope antigenic 
proteins or whole pathogens used in conventional vaccines. Its immunogenicity can 
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be augmented by the usage of macromolecular carriers where epitopes can be attached 
and complexed. 
  
2.1.3.1. DNA vaccines against respiratory viruses and use of integrin to 
enhance its efficacy 
 DNA vaccines represent a novel and powerful alternative to conventional 
vaccine approaches (Kim and Jacob 2009). Its production speed, simplicity, ability to 
elicit humoral as well as cellular immune responses against native antigenic proteins 
without the need for live vectors, makes this an attractive vaccination technique. A 
vast delivery methods exist which includes needle injection, fluid jet injection, 
injection followed by electroporation, bombardment with gold-particles coated-DNA, 
and topical administration to various mucosal sits such as the guy, respiratory tract, 
skin and eye. The most commonly used plasmid DNA vaccine consists of an origin of 
replication, a bacterial antibiotic resistance gene acting as a selectable marker, a 
promoter such as cytomegalovirus promoter or simian virus 40 promoter that is active 
in eukaryotic cells and RNA transcripts stabilized by polyadenylation signal 
sequences (van Drunen Littel-van den Hurk, Gerdts et al. 2000).  
 DNA-based vaccines have been shown to induce significant immune 
responses against several viral agents, including human immunodeficiency virus 
(Wang, Ugen et al. 1993), bovine herpesvirus (Cox, Zamb et al. 1993), hepatitis B 
virus (Davis, Michel et al. 1993), influenza virus (Fynan, Webster et al. 1993), rabies 
virus (Xiang, Spitalnik et al. 1994) and hepatitis virus (Lagging, Meyer et al. 1995). 
 Gene gun-delivered DNA initiates responses by transfected or antigen-bearing 
epidermal Langerhans cells that move in the lymph from the bombarded skin to the 
draining lymph nodes (Arnon 2011). The intramuscular injection is a more common 
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administered route for DNA vaccines. Following immunization, cells transfected with 
the plasmid DNA encode the protein of interest. This protein is then processed and 





 cells. Direct priming by somatic cells such 
as myocytes and keratinocytes provide a possible mechanism for this process. 
Alternatively after intramuscular injection, functional DNA appears to move as free 
DNA which then enters the bloodstream to reach the spleen (Robinson and Torres 
1997). The direct transfection of professional APCs such as DCs and cross-priming 
where secreted protein while taken up by professional APCS are presented to T cells 
through the MHC Class I-dependent pathways. Muscles cells have been shown to be 
critical in the protein expression and cellular immunity initiation of direct priming 
(Wolff, Malone et al. 1990). Factors as such cell-associated or secreted DNA-
expressed antigens, DNA inoculation and delivery route (Arnon 2011) determine the 
nature of immune response. CD4
+
 T-helper cells involvement would encompasses 
either a type I or type 2 response where the former would promote a cellular mediated 
response involving cytotoxic CD8
+
 T cells whereas the latter would promote a 
humoral immune response involving B-cells and antibody production. Despite the 
absence of costimulatory molecules, muscle cells are able to initiate cellular immunity 
by secreting proteins that are taken by DCs to cross-prime CD8
+
 T cells at the DNA 
immunization site (Kim and Jacob 2009).  
 DNA vaccines offer the unique advantage over conventional protein-based 
vaccines/killed vaccines, in that the DNA is non-infectious and non-replicating. 
Unlike live attenuated vaccines, DNA vaccines only encode the protein of interest, not 
viral antigens. This would reduce unwanted side effects but still enabling the use of 
multiple vaccinations to be administered to individuals without provoking an 
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immune-dampening vector-specific response. Unlike conventional vaccines 
employing either killed virus or purified antigens, DNA vaccination efficiently elicits 
cellular immune responses including cytotoxic T-lymphocyte (CTL) responses in 
addition to humoral immunity (Poh, Narasaraju et al. 2009). 
 Most protein-based and killed vaccines do promote a good humoral immune 
response but fail to induce a significant CMI response, as these are cleared up by 
professional APC, processed through the MHC Class II pathway and presented to 
CD4
+
 T cells, which in turns helps in the production of high-affinity antibodies by B 
cells. Live attenuated vaccines are able to induce both CMI and humoral responses. 
There are concerns that some live vaccines may be associated with virus shedding and 
genetic mutation, causing the reversion to a wild-type phenotype (Cinatl, Michaelis et 
al. 2007). 
 However, DNA vaccines are not without shortcomings. The mechanisms by 
which DNA vaccines generate immune responses are complex. For intramuscular 
delivery of DNA, the majority of plasmids are thought to transfect muscle cells, 
which are poorly or only partially effective at presenting antigen and priming naïve 
immune cells (Nagaraju 2001). Instead, these cells are thought to produce antigen, 
which then transfer the antigen in some form to professional antigen-presenting cells 
(APCs) via a mechanism of cross-presentation such that MHC class I-restricted 
cytolytic T-cell responses can be elicited. In addition, plasmid DNA appears not to be 
simply an inert vector for delivering the gene (Liu, Wahren et al. 2006, Ulmer, 
Wahren et al. 2006). There is a possibility of integration of the DNA vaccine into the 
host genome, resulting in malignancy (Kim and Jacob 2009). Plasmid DNA encoding 
a small amount of protein may also induce autoimmunity as well as cause tolerance  
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rather than immunity due to the persistent production of this small amount of foreign 
antigen.  
 Among the approaches used to improve DNA vaccine efficacy includes the 
use of better promoter/enhancer (Harms and Splitter 1995, Garg, Oran et al. 2004), 
increasing the proteins availability in the cytosol, coadministration of 
immunomodulatory cytokines (Chow, Huang et al. 1997, Sailaja, Husain et al. 2003), 
optimizing vaccine administration and delivery (Babiuk, Baca-Estrada et al. 2002, 
Sharpe, Lynch et al. 2007), protein boosting following DNA vaccination (Epstein, 
Kong et al. 2005) (Richmond, Lu et al. 1998), use of adjuvants (Ozaki, Yauchi et al. 
2005), direct targeting of DNA vaccines to APCs (Deliyannis, Boyle et al. 2000, Lew, 
Brady et al. 2000) and vectors encoding antigens fused to molecules that facilitate 
antigen spread and cross-priming (Ross, Xu et al. 2000, Hung, Cheng et al. 2001).  
Targeting moieties have been explored as a means to enhance DNA vaccination, 
including various ligands such as transferin, antibody fragments, sugars, insulin and 
folate (Harbottle, Cooper et al. 1998). 
 Integrins are a class of related heterodimeric transmembrane surface receptors 
involved in cell-cell adhesion, and in the promotion of interactions between cells and 
components of the extracellular matrix glycoproteins (e.g. fibronectin and vitronectin), 
while their intracellular domains interact with the cytoskeleton. Integrin receptors 
mediate adhesive events that are critical for specific and effective immune responses 
to foreign pathogens. Integrin-dependent interactions of lymphocytes and APCs to 
endothelium regulate the efficiency and specificity of trafficking into secondary 
lymphoid organs and peripheral tissues. Within these sites, integrins function to 
facilitate cell movement through interactions with the extracellular matrix, and to 
promote and stabilize antigen-specific interactions between T-lymphocytes and APCs 
 22 
 
that are critical for initiating T-cell activation events (Pribila, Quale et al. 2004). The 
integrin-binding activity of adhesion proteins can be reproduced by short synthetic 
peptides containing the Arg-Gly-Asp (RGD) motif. Such peptides promote cell 
adhesion when insolubilized onto a surface, but inhibit adhesion when presented to 
cells in solution (Ruoslahti 1996).  
 
2.1.4. Animal Models in SARS CoV Infections 
 A wide spectrum of animal species has been used to experimentally infect 
with SARS CoV. These includes animal models of cats, ferrets, hamsters, mice, non-
human primates and (Kuiken, Fouchier et al. 2003, Martina, Haagmans et al. 2003, 
McAuliffe, Vogel et al. 2004, Subbarao, McAuliffe et al. 2004, Roberts, Paddock et al. 
2005, Roberts, Vogel et al. 2005, Haagmans and Osterhaus 2006). In animal models, 
the kinetics of the SARS-CoV replication and resolution of the infection are much 
more rapid as compared to human cases (Roberts, Lamirande et al. 2008). No one 
model fully reflects the clinical illness spectrum (in terms of morbidity and mortality), 
associated pathology and viral replication. Although viral replication can be replicated 
efficiently in respiratory tissues, most animal model species are incapable of showing 
clinical signs of disease (Haagmans 2011). Animal models of SARS differ from 
human clinical cases in that the incubation period between infection and peak of 
disease or viral load is shorter than that of humans. The disease in models is also self-
limited and rarely progresses to fatal outcome (Chen and Subbarao 2007). Although 
these animal models do not accurately represent the full spectrum of human infection, 
they are still capable of providing insights into the pathogenesis of SARS. Nonhuman 
primates have been shown to be susceptible to SARS-CoV (Gillim-Ross and 
Subbarao 2006). However, although the virus replicates in the respiratory tract of 
 23 
 
African green monkeys, rhesus and cynomolgous macaques, clinical disease is not 
always observed (McAuliffe, Vogel et al. 2004, Rowe, Gao et al. 2004, Qin, Wang et 
al. 2005). 
 Several inbred mouse strains have been used successfully to demonstrate 
SARS-CoV replication (BALB/c, C57BL/6, 129S), pneumonitis (129S) and clinical 
signs of SARS (aged BALB/C) (Glass, Subbarao et al. 2004, Hogan, Gao et al. 2004, 
Subbarao, McAuliffe et al. 2004, Roberts, Paddock et al. 2005). Even though 
BALB/C mice are susceptible to SARS-CoV infection, no clinical disease 
manifestations were identified when infected with a SARS-CoV clinical isolate 
(Subbarao, McAuliffe et al. 2004). Although in infected young adult mice of six- to 
eight-weeks old show only minimal clinical disease, viral loads were found to be high 
in lungs and nasal turbinates (Subbarao, McAuliffe et al. 2004) and viral nucleic acid 
detected in lungs and intestines of these mice (Wentworth, Gillim-Ross et al. 2004). 
Lung virus titres peak by Days 2 to 3 Post-Infection, viruses are cleared by Days 5 to 
7 Post-Infection and protective neutralizing antibodies can be detected by day 28. 
Infected older BALB/C mice of 12 to 14 months presented weight loss, hunching and 
ruffled fur as clinical signs of infection and theses gets resolved by day 7 post-
infection with no mortality observed (Roberts, Vogel et al. 2005). Lung viral titres 
were detected in lungs at Days 2 to 5 Post-Infection and virus cleared from nasal 
turbinates and liver day 2 to 5 post-infection. Aged BALB/C mice develop more 
severe disease in a pattern of age-related severity that mimics SARS outbreaks. 
 129S6 mice seem to be more susceptible to SARS-CoV associated disease 
than are BALB/C or BL/6 mice (Hogan, Gao et al. 2004). Infection model of SARS 
CoV infection in C57BL/6 mice has been described (Glass, Subbarao et al. 2004). A 
clinical isolate of the SARS-CoV was introduced intra-nasally where it replicated 
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transiently to high level in C57BL/6 mice, where it peaked on day 3 and cleared by 
Day 9 Post-Infection. The virus was found to be induced the production of 
proinflammatory chemokines in the lungs. Th1 and Th2 cytokines were undetectable 
with little leukocytes accumulation. Besides the lung, the infection spread to the brain. 
It was concluded that C57BL/6 mice supported transient nonfatal systemic infection 
with the virus in the lungs, and dissemination to the brain. In this strain, 
proinflammatory chemokines may coordinate a rapid and highly effective innate 
antiviral response in the lung of which NK cell and the adaptive immune response is 
unrequired for viral clearance (Glass, Subbarao et al. 2004). BALB/C mice are 
considered to have a Th2 bias in their immune responses whereas BL/6 mice are 
considered to be Th1-biased. Differences in background could lead to different viral 
clearance rates and clinical manifestations. Nonetheless, C57BL/6 mice have been 
used routinely in SAR-CoV infection studies (Glass, Subbarao et al. 2004, Kim, Lee 
et al. 2004, Zakhartchouk, Viswanathan et al. 2005, Zakhartchouk, Viswanathan et al. 
2007, Sheahan, Morrison et al. 2008, Kang, Chen et al. 2009, Poh, Narasaraju et al. 
2009). 
 
2.1.5. Spike glycoprotein in SARS-CoV DNA vaccines 
  The spike (S) glycoprotein plays a major role in the biology, viral entry, 
membrane fusion and pathogenesis of SARS-CoV infection (Godet, Grosclaude et al. 
1994, Gallagher and Buchmeier 2001). It is responsible for the binding to its main 
cellular receptor angiotensin-converting enzyme 2 (ACE2) present on host cells (Li, 
Moore et al. 2003). The glycoprotein is considered a major surface antigenic 
determinant which is capable of inducing neutralizing antibodies, thereby conferring 
protective immunity (Buchholz, Bukreyev et al. 2004, Ho, Wu et al. 2004, Yang, 
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Kong et al. 2004). The ACE2 receptor binding domain, located within amino acids 
318-510 of the S glycoprotein is known to induce highly potent neutralizing 
antibodies as well (He, Lu et al. 2005, Zeng, Hon et al. 2006). The S glycoprotein is 
therefore regarded to be an important protective antigen candidate for targets in 
vaccine designs.  
 Early work on full length S gene DNA vaccines used to immunize BALB/C 
mice was successful in inducing the production of specific IgG antibody against 
SARS-CoV (Zhao, Ke et al. 2004). Humoral responses were further characterized by 
administering mice with various secreting S gene fragments. It was found that 
subunits of S1 and S2, as well as residues 18-495 of the N-terminus of S1 subunits, 
were capable of eliciting SARS-CoV specific antibodies (Zeng, Chow et al. 2004). It 
was also discovered that the region located next to the N-terminus of the S1 contained 
immunogenic determinant for SARS-CoV antibody secretion. A Th1-mediated 
antibody isotype switching was observed in mice immunized with plasmids encoding 
the S1 fragments as well. The study revealed the possible of role of both S1 and S2 
subunits in host cell docking and entry as it demonstrated the cooperative nature of 
mouse antibodies in neutralizing SARS-CoV, which were elicited separately by S1 
and S2 subunits plasmids.  
Native and alternatives forms of S have been analyzed and compared in 
inducing a T cell and neutralizing antibody response as well as protective immunity 
(Yang, Kong et al. 2004). Expression vectors encoding both forms induced a robust 
immune response mediated by CD4 and CD8 cells accompanied by significant 
antibody titres. The inclusion of its transmembrane domain still elicited neutralizing 
antibodies. Protection was found to be mediated by a humoral but not a T-cell 
dependent immune mechanism. 
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Mechanically, alterations to the plasmid backbone of DNA vaccine and the 
addition of leader sequences derived from human CD5 gene were made to increase 
efficiency. Full length cDNA of the S gene under the control of the human CMV 
promoter and intro A were compared to codon-optimized S gene linked to either 
signal sequence from human CD5 only, or CD5 signal sequence fused at the C 
terminus with a bovine herpesvirus type 1 (BHV-1) VP22 protein (Zakhartchouk, 
Viswanathan et al. 2007). The authors found that the usage of codon optimized gene 
inserts and the use of the VP-22 protein greatly increase the immunogenicity of the 
tested DNA vaccines.  
Optimized codon usage for protein synthesis may be different depending on 
species. Ranging from prokaryotic and eukaryotic protein expression systems, codon 
optimization is known as an important aspect in improving protein expression 
(Burgess-Brown, Sharma et al. 2008). However most mammals including humans and 
mice have very similar codon usage (Nakamura, Gojobori et al. 2000). This situation 
comes about from the differences in the frequency of occurrence of synonymous 
codons in coding DNA. The over-abundance in the number of codons allows many 
amino acids to be encoded by more than one codon. Different organisms often show 
particular preferences for one of the several codons that encode the same amino acid, 
having a greater frequency of one will be found than expected by chance (Comeron 
and Aguade 1998, Fox and Erill 2010).  
An improved plasmid vector containing donor and acceptor splice sites, as 
well as heterologous viral RNA export elements of Woodchuck hepatitis virus was 
used to demonstrate the efficient expression of S gene in DNA vaccines. The presence 
of splice sites markedly improved immunogenicity of DNA vaccines (Callendret, 
Lorin et al. 2007). The immunoregulatory activity of IL-2 as well as immunization 
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route has been exploited in DNA vaccines as well. Specific humoral and cellular 
immune responses were significantly higher in BALB/C mice when co-immunised 
with IL-2 expressing plasmids (Hu, Lu et al. 2007). Oral vaccination evoked a 
vigorous T-cell response and a weak response predominantly with IgG2a subclass 
antibody whereas intramuscular immunization evoked a vigorous antibody response 
but a weak T-cell response. Immunization by electroporation evoked a vigorous IgG1 
antibody response and a moderate T-cell response.  
 A comparison of the immune responses of DNA vaccines encoded by 
different gene fragments of SARS-CoV was also performed (Wang, Yuan et al. 2005). 
Fragments of the membrane (M), nucleocapsid (N), and spike were cloned separately 
into the pcDNA3.1 vector and immunized intramuscularly into BALB/C mice. 
Humoral and cellular immune responses were detectable for all groups. However, the 
M construct stimulated the highest cellular immune response whereas the spike 
constructs were able to stimulate the highest humoral immune response. While all 
genes were capable of eliciting an immune response, the study demonstrated that 
magnitudes of immune responses varied with respect to the immunized gene.   
A plasmid DNA encoding residues 681-1120 of the S2 subunit domain was 
used to immunize BALB/C mice (Guo, Sun et al. 2005). The plasmid caused a Th1-
polarized immune response as compared to a Th2-response as seen in recombinant S2 
fragment and inactivated SARS-CoV vaccine. The authors concluded that the S2 
domain was efficient in eliciting a specific immune response and a high titre of total 
IgG, but have weak elicitation of neutralizing antibodies as these were only detectable 





2.1.6. Novel SARS-like Coronavirus 
 On 23 September 2012, the Health Protection Agency United Kingdom 
reported a human infection case exhibiting severe respiratory illness which was 
diagnostically-confirmed to be caused by a new type of CoV (Corman, Eckerle et al. 
2012). This new CoV was named HCoV-EMC (Zaki, van Boheemen et al. 2012) and 
has since identified to be of bat-origin. Similar to SARS, the infection manifests 
clinically with fever, cough, shortness of breath and breathing difficulties before 
progressing to acute renal failure. However the HCoV-EMC does not genetically 
resemble the SARS-CoV (van Boheemen, de Graaf et al. 2012), having a gene 
organization that is very similar to other bat-derived CoV (such as the HKU4 and 
HKU5 strains).  
 It is feared that with the discovery of HCoV-EMC marks the beginning of 
another SARS-like pandemic (Chan, Li et al. 2012). However, as of May 2013, 
infected individuals have been confined to the Arabian Peninsula, France and the 
United Kingdom. Other than the latter, most of the infected cases showed no evidence 
of person-to-person transmission. Despite the low transmissibility of this novel virus, 




The specific objectives of the study encompassed in this chapter include to: 





2. Investigate the prospect of increasing the efficiency and efficacy of a DNA 
vaccine construct which expresses the SARS coronavirus extracellular spike 
domain that is fused to the RGD integrin binding site. 
 
3. Characterize the adaptive cell-mediated immune and humoral responses in 
C57BL/6 mice immunized intramuscularly with the DNA vaccine through in 
vitro functional assays. 
 
2.3. Hypothesis 
 The incorporation of the integrin binding motif (RGD) into the C-terminal of 
the SARS-COV spike protein could enchance host humoral and cell-mediated 
immune responses. 
 
2.4. MATERIALS AND METHODS 
2.4.1. Screening for H2-Kb-restricted peptides within the SARS spike 
glycoprotein 
The amino acid sequence of the Tor2 strain of SARS-CoV (GenBank 
accession no. NP828851) was used in the peptide prediction. To identify the potential 
H2-Kb-restricted CD8+ T-cell epitopes, computer-based programs were accessed 
through RankPep (Reche et al., 2002), and SYFPEITHI Epitope Prediction websites 
(Rammensee et al., 1999). 10 potentially H2-Kb-restricted epitopes from the SARS-
CoV spike glycoprotein were selected. The Ova257-264 epitope of chicken ovalbumin is 






Lyophilized peptides were purchased from Peptron Inc. (Daejeon, South 
Korea), and their purity was confirmed by mass spectrometry. All peptides were 
dissolved in dimethyl sulfoxide (DMSO) to a concentration of 20 μg/μl, and stored at 
-80°C. 
 
2.4.3. Cell lines 
TAP2-deficient RMA-S cells are derived from T-cell lymphomas related to 
the Rauscher murine leukemia virus-induced RBL-5 cell line (kindly provided by 
Mariapia Degli-Esposti, University of Western Australia, Perth). Cell lines were 
cultured in a humidified atmosphere containing 5% CO2 using Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with 10% heat-inactivated fetal bovine 
serum (HyClone, Logan, Utah), penicillin (100U/ml), streptomycin (100µg/ml) and 
55μM  2-mercaptoethanol (Gibco BRL / Invitrogen, Carlsbad, CA). 
 
2.4.4. MHC-peptide binding assay 
To determine whether synthetic peptides could bind to H2-Kb molecules, 
peptide-induced H2-Kb upregulation on RMA/S cells was examined. To measure the 
relative amounts of H2-Kb-peptide complexes formed, 2 × 10
5
 cells in 100μl of 
0.25% BSA and RPMI were seeded into Nunclon Surface 96-well round-bottom 
plates (Nunc, Denmark), and maintained overnight at room temperature. Each peptide 
in 100μl of medium was then added to final concentration of 100μM and incubated 
for 1h. The cells were then transferred to 37C for 2h to allow any remaining peptide-
free MHC molecules to denature. The cells were then washed with FACS buffer, and 
cell surface expression of H2-Kb molecules was detected by flow cytometry using 
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fluorescein isothiocyanate-labeled goat anti-mouse H2-Kb antibody (clone CTKb, 
Pharmingen / BD Biosciences, Franklin Lakes, NJ). Samples were run on a FACScan 
flow cytometer, and the data were analyzed using CellQuest software (Becton 
Dickinson Immunocytometry System,USA).  The binding activity of each peptide was 
calculated as a ratio of the mean fluorescence of RMA/S cells loaded with peptide to 
the mean fluorescence of RMA/S without peptide. 
 
2.4.5. Plasmid construction 
 The construct consisting of the extracellular domain of the SARS-CoV 
spike domain (Tor2 strain) in pcDNA3.1 backbone (Invitrogen, Carlsbad, CA), 
designated pScod-Harv was kindly provided by Dr Michael Farzan, Harvard 
University (Fig. 2.2). It has been shown that codon optimization of the SARS-CoV S-
protein gene substantially enhanced S-protein expression (Moore, Dorfman et al. 
2004). The construction of this codon-optimized SARS-CoV spike ectodomain is 
more effective for spike protein expression during transfection in mammalian cells by 
replacing the natural codons with optimum codons. Nucleotide sequence of codon-
optimized spike glycoprotein and original Tor2 strain showed 70% similarity 






Figure 2.2. Codon-optimized SARS spike protein gene 
  





Structure of pScod-Harv plasmid in pcDNA3.1
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 A HindIII enzymatic cleavage site was first created in the extracellular-
transmembrane border of spike protein gene with human CD5 signal peptide cloned in 
pScod-Harv using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA) and primer pair: 
5′-GTACGAGCAGTACATCAAGCTTCCTTGGTATGTGTGGCTG-3′  
and 5′-AGCCCAATCCAAGGAAGCTTGATGTACTGCTCGTAC-3′.  
 The human IgG Fc fragment cDNA was generated by PCR amplification 
of spleen cDNA which was reverse-transcribed from spleen total RNA with a pair of 
primers containing HindIII sites:  
5′-CCCAAGCTTAAAACTCACACATGCCCACC-3′ 
and 5′-CCCAAGCTTTCATTTACCCGGAGACAGG-3′.  
The 6×His tag DNA fragment with HindIII sites at both ends was generated by a pair 
of oligonucleotides: 5′-CGCTCCACCAGCCAGAAGCTTATCGTGGCCTACACC-
3′ and 5′- GGTGTAGGCCACGATAAGCTTCTGGCTGGTGGAGCG-3′. 
 The RGD-His tag DNA fragment with HindIII sites at both ends was 




 The Fc, 6×His tag and RGD-His tag DNA fragments were inserted into the 
HindIII sites of the HindIII–restricted pScod-Harv plasmid to generate spike 
extracellular domain-Fc fusion protein (Spike-Fc), spike extracellular domain-His tag 
fusion protein (Spike-His), and spike extracellular domain-RGD-His tag (Spike-
RGD/His), respectively (Fig. 2.3).  
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 (1) HindIII site created in the extracellular-transmembrane border of spike 
protein gene with human CD5 signal peptide cloned in pcDNA3.1 vector (pScod-
Harv)  with mutagenesis using two mutation primers,  forward 5’ GTA-CGA-GCA-



























(i) The human IgG Fc fragment cDNA is generated by PCR amplification 
from spleen cDNA which was reverse-transcripted from spleen total RNA 
with a pair of primers containing hind III sites : 
Forward: 5’ CCCAAGCTTAAAACTCACACATGCCCACC 3’ 
 and 
         Reverse: 5’ CCCAAGCTTTCATTTACCCGGAGACAGG 3’ 
 
(ii) 6×His tag DNA fragment with Hind III sites in both ends is generated by 
annealing a pair of oligo:-  
Forward: 
 5’ CGCTCCACCAGCCAGAAGCTTATCGTGGCCTACACC 3’  
and  
Reverse: 
 5’ GGTGTAGGCCACGATAAGCTTCTGGCTGGTGGAGCG 3’ 
 
(iii) RGD-His tag DNA fragment with Hind III sites in both ends is generated 
by annealing a pair of oligo:  
Forward-RGD-His:  
5’ AGCTTGGCCGCGGCGACTCCCCCCATCATCACCATCACCATT 
GAA 3’  
and 
Reverse-RGD-His: 
 5’ AGCTTTCAATGGTGATGGTGATGATGGGGGGAGTCGCCGCGG 
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1189aa          EC                              TM         
Hind III cutting site created in the extracellular-transmembrane border of the 
full-length S-protein gene with QuikChang XL Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, USA) using two mutation primers,  forward 5’ GTA-
CGA-GCA-GTA-CAT-CAA-GCT-TCC-TTG-GTA-TGT-GTG-GCT-G 3’ and  
reverse 5’ CAG-CCA-CAC-ATA-CCA-AGG-AAG-CTT-GAT-GTA-CTG-CTC-
GTA-C 3’.  
 
pSpike-cod-Hind III-m plasmid  
Codon-optimized spike protein gene 
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(iv) Insert Fc, 6×His tag and RGD-His tag DNA fragment into Hind III sites of 
Hind III –mutated pScod-Harv plasmid to generate spike extracellular 
domain-Fc fusion protein (pScod-Harv-EC-Fc) spike extracellular 
domain-His tag fusion protein (pScod-Harv-EC-His) and spike 
extracellular domain- RGD-His tag respectively.  
 
                                       
 















Figure 2.3. CD5 signal peptide-Fc fusion protein constructs.  
 
(1) Amplifying CD5 signal peptide fragment tailed at 3’ terminus with the 
first 12bp of Fc fragment (fragment1) from pScod-Harv plasmid using 
frimer1: 5’ TGCTCTAGA(XbaI)AA CCATGCCCATGG 3’ and 
primer2: 5’ TGTGTGAGTTTT(Fc)GGCTAGCA CGGAAGCGAC 3’.  
 
(2) Amplifying Fc fragment tagged at 5’ terminus  with the last 12bp of 
CD5 SP fragment(fragment2) from pScod-Harv-EC-Fc plasmid using 
primers3:  
 5’ TCCGTGCTAGCC(CD5SP)AAAACTCACACATGCCCAC 3’  
 
and 
  primer4:  
  5’ CCCAAGCTT(HindIII)TCATTTACCCGGAGACAGG 3’ . 
 
(3) Amplifying CD5SP-Fc fragment from mixture of fragment1 and 
fragment2 as the template by PCR using primer1 and primer4. 
 
(4)  Inserting CD5SP-Fc fragment into XbaI and Hind III sites of 
pcDNA3.1 vector to generate CD5-Fc fusion protein gene expression 
vector (pcDNA 3.1CD5Fc). 
XbaI 
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Figure 2.4. Construction of DNA vaccines pcDNA3.1CD5-Fc 
 
  
 To construct the CD5 signal peptide-Fc fusion protein, the CD5 signal 
peptide (CD5SP) fragment tail was first amplified at the 3′ terminus with the first 12 
bp of Fc fragment (Fragment 1) from the pScod-Harv plasmid using primers 1 and 2 
(5′-TGCTCTAGA(XbaI)AACCATGCCCATGG-3′ and 
5′-TGTGTGAGTTTT(Fc)GGCTAGCACGGAAGCGAC-3′).  
 The Fc fragment tagged at 5′ terminus was then amplified with the last 12 
bp of CD5SP fragment (Fragment 2) from the pScod-Harv-EC-Fc plasmid using 




 The CD5SP-Fc fragment from the mixture of fragments 1 and 2 was used 
as the template, and amplified by PCR using primers 1 and 4. The CD5SP-Fc 
fragment was then inserted into the XbaI and HindIII sites of the pcDNA3.1 vector to 
generate CD5-Fc fusion protein gene expression vector (CD5-Fc) (Fig. 2.5).  
XbaI 
CD5 SP 







Figure 2.5. Schematic diagram of DNA vaccines used. 
 
2.4.6. Mice 
Four to six-week-old female C57BL/6 mice were obtained from the Centre for 
Animal Resources (CARE), Singapore, and were kept under normal animal holding 
conditions. Animal experiments were performed according to approved guidelines of 
the Institutional Animal Care and Use Committee, National University of Singapore. 
 
2.4.7. Immunizations 
For DNA immunization, plasmids were replicated in Escherichia coli TOP10, 
and cultured in LB culture medium for 24h at 37°C. Plasmids were prepared, 
extracted and purified using an endotoxin-free plasmid extraction kit (Qiagen GmbH, 
Germany). The ratios of optical density at 260nm and 280nm wavelength ranged from 
1.8 to 2.0. The endotoxin content from purified plasmid DNA was below 20U/ml. 
Female 4-6 week-old C57BL/6 mice (n = 7 per DNA vaccine group) were 
anesthetized, and given intramuscular injections into separate sites on each side of the 
quadriceps muscle, with a total dose of 100μg plasmid DNA dissolved in 100μl sterile 
Spike EC domain hFc fragment 
Spike EC domain CD5 SP 
CD5 SP 
CD5  











phosphate-buffered saline. This was followed by three booster vaccinations of the 
same dose at three week intervals. 
 
2.4.8. Splenocyte re-stimulation in vitro 
To assess the cellular immune responses following priming injections, 
C57BL/6 mice were immunized intramuscularly with SARS-CoV spike DNA 
vaccines, i.e. S-RGD/His, S-His, S-Fc). Mice splenocytes were harvested three weeks 
after the last of four DNA vaccine immunizations. In vitro re-stimulation of primed 
splenocytes was achieved by using RMA/S cells as stimulators. Five different sets of 
RMA/S cells were maintained at 26ºC overnight in IMDM and 0.25% BSA without 
FCS, and were pulsed with 20μM of each respective peptide (S436, S497, S525, S884, 
S1116) for 1h at room temperature. Peptide-pulsed RMA/S cells were then irradiated at 
7800Rads. The ratio of splenocytes (responder) to individual peptide-pulsed RMA/S 
cells (stimulator) was 100:1. The splenocytes were stimulated with RMA/S cells 
pulsed with equal concentrations of the five high-binding epitopes. Given that there 
were five peptides used for the restimulation, the combined ratio was therefore 20:1. 
Cells were cultured in 10ml of IMDM with 10% FCS in each T-25 flask for 4 days, 
with a maximum cell number of 7 × 10
6 
per flask. Viable lymphocytes were harvested 
by density separation using Lympholyte-M (Cedarlane, Ontario, Canada), and 
cytotoxic T-lymphocyte assay and IFN-γ ELISPOT assay were performed.  
 
2.4.9. Cytotoxic T-lymphocyte assay 
In vitro restimulated splenocytes were tested for cytotoxicity in a standard 4-h 
51
Cr release assay. Target RMA/S cells were maintained overnight at room 
temperature, and pulsed with 20μM peptide at room temperature for 1h.  
 39 
 
The target cell lines used in the cytotoxic T-lymphocyte assay were: EL4, a 
murine thymoma cell line of H-2
b
 haplotype; RMA/S cells, a mutant T cell line 
defective in H-2
b





; E.G7-Ova, a murine thymoma EL4 cells stably transfected 
with the complementary DNA of chicken ovalbumin expressing the Ova epitope as a 
unique antigen.  
The target cells were then labeled with 
51Cr (100 μCi or 3.7 MBq per 106 cells) 
for 1h at 37°C. The 
51
Cr-labeled target cells (RMA/S) were then washed three times 
in a full volume of RT 1xPBS in a 15ml Falcon™ centrifuge tube and centrifugation 
at 500 x g at RT for 5min. Supernatant of the washes were then discarded. Cell 
numbers were determined by using a hemocytometer where viable cells were 
determined by the trypan blue exclusion method. Finally, 4 × 10
3
 cells were seeded 
into each well. These were then mixed with graded doses of effectors cells (in vitro 
restimulated splenocytes) in Nunclon Surface™ 96-well round-bottom plates (Nunc, 
Denmark).  
The effector cell used as positive controls in this assay was from splenocytes 
harvested from OT1 mouse, which contains transgenic inserts for mouse T cell 
receptors TCRα-V2 and TCRβ-V5 genes where the receptors recognize ovalbumin 
residues 257-264 in the context of H2K
b
. 
The effector-to-target cell ratios (E:T) were adjusted from 100:1 to 11:1 (4 x 
10
5
 effector cells:4 x 10
3
 target cells to 4.4 x10
4
 effector cells:4 x 10
3
 target cells), 
targets cells were kept constant for all measurements at 4 x 10
3
 cells/well. After 
incubation at 37°C for 4h, 40μl of supernatant was transferred to a Luma plate, and 
radioactivity was counted using a TopCount (Beckman Coulter, Fullerton, CA) 
gamma counter. Each assay was performed in triplicates, and the percentage of 
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specific lysis was calculated by the formula: (experimental release - spontaneous 
release) divided by (maximum release - spontaneous release). Experimental release 
represented mean counts per min released by target cells in the presence of effector 
cells. Maximum release represented the radioactivity released after lysis of target cells 
with 1% Triton X-100. Spontaneous release represented the radioactivity counted in 
the medium derived from target cells alone.  
 
2.4.10. IFN-γ ELISPOT assay 
This assay was performed using the ELISPOT mouse set (Pharmingen / BD 
Biosciences, Franklin Lakes, NJ) following the manufacturer’s protocol. The 96-well 
polyvinylidene difluoride (PVDF)-backed plate was pre-coated with 5μg/ml of rat 
anti-mouse IFN-γ monoclonal antibody in PBS overnight at 4°C. Plates were then 
washed thrice with PBS containing 0.25% Tween-20, and blocked with IMDM with 
10% fetal calf serum, antibiotics, and 55μM β-mercaptoethanol at 37°C for 2h. 
Splenocytes were pooled from two groups of four and three mice. In vitro 
restimulated splenocytes as effector cells (5 × 10
4
 per well, replicated six times) and 
irradiated peptide-pulsed RMA/S cells (5 × 10
4
 per well, replicated six times) were 
seeded in 200μl of IMDM with 10% FCS for 16h at 37°C. Wells were extensively 
washed with PBS containing 0.05% Tween-20, and subsequently incubated with 
2.0μg/ml of biotinylated anti-mouse IFN-γ detection antibody for 1h at room 
temperature. After washing, wells were incubated with 5μg/ml of streptavidin-
horseradish peroxidase antibody for 1h at room temperature. Wells were washed 
again, final substrate was added, and color development was monitored and stopped 
by washing with water. After drying overnight at room temperature, spots were 




2.4.11. Enzyme-linked immunosorbent assay (ELISA) 
Sera from immunized mice of different groups were collected before and after 
the complete course of DNA vaccination. The antibody titers for SARS-CoV were 
measured by ELISA. Plates were coated with 6×His-tagged spike protein S1-1190 (at 
10μg/ml and 100μl per well) of SARS-CoV Beijing BJ302 strain (Immune 
Technology, Yonkers, NY), and incubated overnight at 4ºC. Excess antigen was then 
decanted from wells, the plates were blocked with 100μl per well of blocking solution 
(5% BSA, 1×PBS, 0.05% Tween-20), and incubated for 30min at room temperature. 
The plates were then washed thrice with 1× PBS with 0.05% Tween-20. Primary 
antibody (100μl of sera diluted 1:500 in 1× PBS) was added to each well. The plates 
were incubated in the dark at room temperature for 1.5h, and then washed thrice. 
Secondary anti-mouse antibody tagged with HRP (100 μl per well) was added, 
incubated for 1.5h at room temperature, and the plates washed thrice. O-phenylene 
diamine dihydrochloride substrate was added (100μl per well), and incubated for 15 
min in the dark. The reaction was stopped by adding 50μl of 3M HCl, and the 
absorbance was read at 490nm. 
 
2.4.12. Nucleotide and amino acid sequence alignment 
 In order to perform nucleotide and amino acid sequence alignment, sequences 
of the codon-optimized Spike glycoprotein construct was compared against SARS-
CoV spike glycoprotein of Toronto TOR2 (Accession number AAP41037.1) and 
Beijing BJ302 (Accession number AAP30030.1) SARS-CoV strains were obtained 
from GenBank within the National Center for Biotechnology Information (NCBI) 
website (http://www.ncbi.nlm.nih.gov).  
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 Using the blastn (nucleotide-nucleotide BLAST) and blastp (protein-protein 
BLAST) algorithms (Altschul, Madden et al. 1997, Zhang, Schwartz et al. 2000), the 
codon-optimized spike sequence was compared against the TOR2 and Beijing BJ302 
spike sequences. 
 
2.4.13. Statistical analysis  
All data were expressed as means ± SD for the immunized mice per group. 
The SPSS 13.0 software for Windows was used for statistical analysis.  A value of P 




2.5.1. Kyte–Doolittle Hydropathy and Hopp–Woods Hydrophilic plots to 
determine antigenic regions 
 
The Kyte–Doolittle hydropathy plots evaluates the hydrophilicity and 
hydrophobicity of a protein along its amino acid sequence (Kyte and Doolittle 1982). 
The hydrophilic and hydrophobic characteristics of the 20 amino acid side chains are 
used in composing a hydropathy scale where a moving-segment approach is used in 
the plots within a predetermined segment length as it advances through the amino acid 
sequence. The scores are then plotted from the amino to the carboxyl terminus. A 
midpoint represents the hydropathy grand average. Surface regions are identified as 
peaks below this midpoint. Therefore, the Kyte-Doolittle method is a widely applied 
scale for delineating hydrophobic character of a protein. Regions with values above 0 
are hydrophobic in character.  
The E2 glycoprotein precursor sequence (NP828851) of the Tor2 isolate of the 
SARS coronavirus was used to determine the hydropathicity by using the ProtScale 
 43 
 
software from Swiss Institute for Bioinformatics (http://au.expasy.org/tools/protscale-
doc.html) (Fig. 2.6). The Kyte–Doolittle plot for the SARS Spike protein at a window 
size of 21 reveals that the minimum value exist at amino acid 444, with a value of -
1.914 (Fig. 2.6). This indicates that the region surrounding amino acid 444 is most 
exposed and hydrophilic, thereby perhaps most antigenic. The most hydrophobic 
region lies at amino acid 1208 with a value of 2.7. This region lies towards the 
carboxyl end. The numerical Kyte-Doolittle plot (Table 2.1) also shows the values of 
known H2-K
b
-restricted epitopes of SARS Spike protein. They are Amino acids at 
position 436, 497, 525, 884 and 1116. The hydropathy values of these regions are -























Figure 2.6. Kyte–Doolittle Hydropathy plots of SARS Spike Protein (Window Size 
21). ProtScale (http://au.expasy.org/tools/protscale-doc.html) was used to determine 
the hydropathicity of the SARS coronavirus spike glycoprotein by inputting the E2 
glycoprotein precursor sequence (NP_828851) of the TOR2 isolate. Window size 
refers to the amino acids length used for profile computation where a size of 21 will 
make hydrophobic, membrane-spanning domains stand out clearly. Values above 0 
denote a hydrophobic region. The most hydrophilic region lies at the region of amino 
acid 444 (-1.914), while the most hydrophobic region lie at amino acid 1208 (2.700). 
 
 
Table 7: Kyte–Doolittle Hydropathicity Plot SARS Spike Protein. 
Table 2.1. Numerical score of Kyte-Doolittle plot of SARS Spike Protein. 
 45 
 
The Hopp–Woods plot represents another method of predicting the 
hydrophilicity character of a protein. Similar to the Kyte–Doolittle plot, the Hopp–
Woods plot is accomplished by assigning each amino acid a numerical value 
(hydrophilicity value) and then repetitively averaging these values along the peptide 
chain (Hopp and Woods 1981). The highest point of local average hydrophilicity is 
invariably located in, or immediately adjacent to, an antigenic determinant. This scale 
was designed for predicting potentially antigenic regions of polypeptides. Values 
greater than 0 are hydrophilic, and are likely to be exposed on the surface of a folded 
protein. 
Using ProtScale, the Hoop–Woods plot (with a window size of 21) for the 
SARS Spike protein reveals the maximum value exist amino acid position 562, with a 
value of 0.857, indicating that the region is most exposed and hydrophilic, thereby 
perhaps most antigenic. The minimum value exists at amino acid position 1206 with a 
value of -1.581, indicating that the region is most hydrophobic (Fig. 2.7). This region 
corresponds with the Kyte–Doolittle scale. The numerical Hoop-Woods hydrophilic 
plot (Table 2.2) shows values of known H2-K
b
-restricted epitopes of SARS Spike 
protein. They are amino acids at position 436, 497, 525, 884 and 1116. The 





















Figure 2.7. Hopp–Woods Hydrophilicity Plot of SARS Spike Protein (Window Size 
21). ProtScale (http://au.expasy.org/tools/protscale-doc.html) was used to determine 
the hydrophillicity of the SARS coronavirus spike glycoprotein by inputting the E2 
glycoprotein precursor sequence (NP_828851) of the TOR2 isolate. Window size 
refers to the amino acids length used for profile computation where a size of 21 will 
make hydrophobic, membrane-spanning domains stand out clearly. Values above 0 
denote a hydrophilic region. The most hydrophilic region lies at the region of amino 
acid 561 (0.857), while the most hydrophobic region lie at amino acid 1206 (-1.581). 
 
Table 2.2. Numerical score of Hopp-Woods plot for SARS Spike Protein. 
 




2.5.2. Screening and identification of H2-Kb-restricted peptides within the 
SARS-CoV spike glycoprotein by MHC-peptide binding assay 
Based on computer software predictions by Rankpep and SYFPEITHI, 10 
candidate octameric peptides (Table 9) with the highest estimated half-time 
dissociation from H2-K
b
 were selected and synthesized. To evaluate the binding 
affinities of these peptides to H2-K
b
 molecules, RMA/S cell-MHC-peptide binding 
tests were performed. This assay measures the increase in H2-K
b
 molecules induced 
on RMA/S cells following exposure to exogenous H2-K
b
-restricted peptides, with 
high affinity peptides inducing H2-K
b
 upregulation more strongly than low affinity 
peptides. Representative of histograms of the MHC-peptide binding assay of 
candidates epitopes are shown in Figure 2.8. 
Of the 10 candidate peptides, S497, S525, S884 and S1116 were found to be high 
affinity epitopes, with mean fluorescence increase (MFI) of 6.58, 6.6, 4.81 and 1.89, 
respectively. Although S436 was previously identified as the dominant H2-K
b
 epitope, 
we obtained an MFI of only 1.23. The positive control Ova257 peptide bound H2-K
b
 
strongly with an MFI of 3.68, whereas no binding was associated with the negative 
controls, i.e. non-peptide bound (MFI = 1), H2-K
d
-restricted hemagglutinin (HA204) 




 mouse MHC class II-restricted chicken 













Figure 2.8. Representative of histograms of MHC-Peptide Binding Assay. MHC-
peptide binding assay was carried out by seeding 2 × 10
5
 cells in 100μl of 0.25% BSA 
and RPMI into 96-well round-bottom plates, and maintained overnight at room 
temperature. Each synthetic peptide in 100μl of medium was then added to final 
concentration of 100μM and incubated for 1h. The cells were then transferred to 37C 
for 2h to allow any remaining peptide-free MHC molecules to denature. The cells 
were then washed with FACS buffer, and cell surface expression of H2-Kb molecules 
was detected by flow cytometry using fluorescein isothiocyanate-labeled goat anti-
mouse H2-Kb antibody (clone CTKb). Samples were run on a FACScan flow 














1 N/A N/A 
HA 204-212 1.14 N/A 1 to 2 
Ova 323-339 1.03 N/A 1 to 6 
Ova 257-264 3.68 N/A 25 
S 436-443
* 
1.23 100 29 
S 884-891
* 
4.81 94 24 
S 525-532
* 
6.6 89 21 
S 1116-1123
* 
1.89 85 21 
S 987-994 1.26 85 17 
S 175-182 1.63 81 21 
S 833-840 1.73 80 22 
S 760-767 1.71 79 17 
S 497-504
* 
6.58 79 21 
S 348-355 1.09 78 22 
 
Table 2.3. MHC binding assay and prediction of epitopes within the SARS-CoV spike 
glycoprotein. Mean fluoresence increase (MFI) values from the MHC-peptide binding 
assay, and epitope-binding constants from Rankpep and SYFPEITHI programs. The 
amino acid sequence of TOR2 strain of SARS CoV (accession no. NP828851) was 
used for peptide-binding prediction. Epitopes with asterisk (*) were selected for 
further characterization. The mean fluorescence increase (MFI) was derived from the 
ratio of the fluorescence of peptide-loaded RMA/S to the fluorescence of unloaded 
RMA/S. Data are expressed as the means from two experiments conducted in 





2.5.3. Use of RMA/S cells as antigen-presenting cells in 
51
Cr release assay 
To determine whether the use of RMA/S cells were feasible for use as antigen-
presenting cells in 
51
Cr release assay, proper control experiments were carried first. 
Crude OT-1 splenocytes were first harvested and cultured in 10 µg/ml ConA for three 
days before subjecting stimulated splenocytes to a cytotoxicity assay involving 
various target cells (EL4 pulsed with Ova257-264 peptide, RMA/S cells pulsed with 
Ova257-264 peptide and E.G7-Ova transfected cells). OT-1 splenocytes were then 
harvested and processed as single cell suspensions. They were then subjected to 
51
Cr 
release assay which measured the cytotoxicity of OT-1 lymphocytes against 
appropriate targets. RMA/S cells non-pulsed or pulsed with Ova257-264 peptide and 
SARS CoV Spike436-442 (as described elsewhere in Materials & Methods) together 
with EL4 cells or E.G7-Ova (kind gift from Michael Bevan, University of 
Washington, USA) was used as target. The Ova257-264-pulsed RMA/S cells were able 
to efficiently lyse as compared to the E.G7-Ova transfected cells (Fig. 2.9). The 
RMA/S line was also specific enough that non-pulsed RMA/S or S436-pulsed RMA/S 
did not show 
51
Cr release.  
Next C57BL/6 mice were immunized with γ-irradiated RMA/S pulsed with 
OVA257-264 -peptide. Splenocytes from these mice were harvested two weeks later and 
CD8
+
 T cells were positively purified using magnetic beads (EasySep,USA). Cells 
were determined to be 95% pure by flow cytometry (data not shown). The purified 
CD8
+
 T cells were then in vitro stimulated with RMA/S pulsed with Ova257-264 peptide 
for 4 days before 
51
Cr assay was performed. RMA/S pulsed with Ova257-264 peptide 
had the highest cytotoxicity followed by the E.G7-Ova cells. Non-pulsed RMA/S 
cells and EL4 were not lysed (Fig. 2.10). Cytotoxicity was found to not vary a lot 
when non-purified splenocytes were used as the effector cells. 
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 As proof of principle of the method, the SARS CoV Spike436-442, a known H2-
K
b
 epitope was used to first pulse RMA/S, irradiated before being immunized into 
C57BL/6 mice. Two weeks later, splenocytes were harvested processed and in vitro-
stimulated with RMA/S pulsed with the Spike436-443 peptide. After four days in vitro 
stimulation, cytotoxcity of splenocytes were determined by 
51
Cr release assay. 
Splenocytes were able to lyse RMA/S cells pulsed with the Spike436-442 peptide, 
whereas EL4 and non-pulsed RMA/S cells were not lysed (Fig. 2.11). 
 
2.5.4. Cytotoxic T-lymphocytes are activated following SARS-CoV DNA 
immunization 
A standard 4-h 
51
Cr release assay was performed to characterize the 
cytotoxicity of the in vitro restimulated splenocytes. RMA/S cells (4 x 10
3
) pulsed 
with each of the five specific high-binding epitopes (S436, S497, S525, S884 and S1116) 
were used as targets. Assays with an effector-to-target ratio of 100:1 to 11:1 were 
performed in triplicate.  
 The negative controls, i.e. RMA/S cells pulsed with an irrelevant epitope 
(Ova257-264) as well as non-epitope-presenting RMA/S cells, showed no cytotoxicity. 
Restimulated splenocytes of mice immunized with PBS (Fig. 2.12) as well as vector 
alone (Fig. 2.13) did not show any cytotoxicity. The highest cytotoxicity levels were 
observed for restimulated splenocytes of mice immunized with S-RGD/His and S-His 
against S1116-pulsed RMA/S cells. The cytotoxicity of S-His cultures (Fig. 2.14) was 




Figure 2.9. 4 hour-
51
Cr Cytotoxicity assay of OTI splenocytes effector cells in vitro 
stimulated with ConA against various target cells (EL4 pulsed with 20µM Ova257-264 
peptide, RMA/S cells pulsed with 20µM Ova257-264 peptide and E.G7-Ova transfected 
cells) labeled with 100μCi 51Cr  (in the form of Na2[
51
Cr]O4). Effector cells, from 
splenocytes harvested from OT1 mouse (stimulated with ConA for three days before 
being subjected to the cytotoxicity assay) were added at a specific number to a 
constant number (4 x 10
3
 cells/well) of the three target cell lines (EL4 pulsed with 
Ova257-264 peptide, RMA/S cells pulsed with Ova257-264 peptide and E.G7-Ova 
transfected cells). Con-A-in vitro-stimulated OTI splenocytes were able to effectively 
lyse and kill all three target cell lines.  
 
% specific lysis = [(experimental release-spontaneous release) / (maximum release-spontaneous release)]. 










Figure 2.10. 4 hour-
51
Cr Cytotoxicity assay of purified-CD8
+
 cytotoxic T cells from 
C57BL/6 spleen, previously primed with irradiated RMA/S-Ova257-264-peptide-pulsed 
cells, then in vitro-stimulated with Ova257-264-peptide-pulsed RMA/S cells, against 
various target cells (Unpulsed-EL4 cells, E.G7-Ova transfected cells, 
Unpulsed/Unloaded-RMA/S cells and H2-K
b
-restricted-OVA257-264-pulsed RMA/S 
cells) labeled with 100μCi 51Cr  (in the form of Na2[
51
Cr]O4). Splenocytes were from 
C57BL/6 mice immunized intra-peritoneally twice with 5 x 10
5
 irradiated peptide-
pulsed RMA/S cells at two-week intervals. These cells were in vitro-stimulated with 
7800 Rads-irradiated Ova257-264-peptide-pulsed-RMA/S cells for three to five days 
before being purified using a EasySep™ Mouse CD8a Positive Selection Kit 
(StemCell Technologies, Canada). Purified CD8
+
 T cells were then subjected to 
cytotoxicity assay. Prepared targets cells labeled with 
51
Cr were dispensed to 96-well 
round bottom plate at 4 x 10
3
 cells/well. A graded increase in effector cells numbers 
were then mixed to specific wells containing a constant number of the target cells. 
Minimum or no cytotoxicity was observed against unpulsed EL4 and 
unpulsed/unloaded RMA/S target cells.  
% specific lysis = [(experimental release-spontaneous release) / (maximum release-spontaneous release)]. 






Figure 2.11. 4 hour-
51
Cr Cytotoxicity assay of crude/unpurified C57BL/6 splenocytes, 
previously primed with irradiated RMA/S-Ova257-264-peptide-pulsed cells, then in 
vitro-stimulated with Ova257-264-peptide-pulsed RMA/S cells, against various target 
cells (Unpulsed-EL4 cells, E.G7-Ova transfected cells, Unpulsed/Unloaded-RMA/S 
cells and H2-K
b
-restricted-OVA257-264-pulsed RMA/S cells). Splenocytes were 
harvested from C57BL/6 mice immunized intra-peritoneally twice with 5 x 10
5
 
irradiated peptide-pulsed RMA/S cells at two-week intervals. These cells were in 
vitro-stimulated with 7800 Rads-irradiated Ova257-264-peptide-pulsed-RMA/S cells for 
three to five days before being subjected to cytotoxicity assay. Prepared targets cells 
labeled with 
51
Cr were dispensed to 96-well round bottom plate at 4 x 10
3
 cells/well. 
A graded increase in effector cells numbers were then mixed to specific wells 
containing a constant number of the target cells. Splenocytes showed cytotoxicity 
against Ova257-264-peptide pulsed RMA/S. Only a mild cytotoxicity was observed 
against E.G7-Ova transfected cells. Minimum or no cytotoxicity was observed against 
unpulsed EL4 and unpulsed/unloaded RMA/S target cells.  
% specific lysis = [(experimental release-spontaneous release) / (maximum release-spontaneous release)]. 












Figure 2.12. Cytotoxicity of PBS control immunised mice. 
51
Cr cytotoxicty assay of 
in vitro stimulated splenocytes of mice immunized with PBS, No cytotoxicity was 
observed for in vitro stimulated splenocytes of mice mock-immunized with PBS or 
vector only. RMA/S cells were cultured overnight, and pulsed with 20μM of each 
respective peptide for 1h. Each target line was pulsed with 50μCi of 51Cr at 37ºC for 
1h. Assays were performed in triplicate, and cytotoxicity was calculated as (sample 
release – spontaneous release) divided by (maximum release – spontaneous release). 
Data are expressed as the means of triplicate wells. 
 
 
Figure 2.13. Cytotoxicity of splenocytes from mice immunized with DNA vector 
alone. 
51
Cr cytotoxicty assay of in vitro stimulated splenocytes of mice immunized 
with pcDNA3.1 Vector only. No cytotoxicity was observed for in vitro stimulated 
splenocytes of mice mock-immunized with vector only. RMA/S cells were cultured 
overnight, and pulsed with 20μM of each respective peptide for 1h. Each target line 
was pulsed with 50μCi of 51Cr at 37ºC for 1h. Assays were performed in triplicate, 
and cytotoxicity was calculated as (sample release – spontaneous release) divided by 





Figure 2.14. Cytotoxcity of splenocytes from mice immunized with S-His DNA 
vaccine. 
51
Cr cytotoxicty assay of in vitro stimulated splenocytes of mice immunized 
with S-His. RMA/S cells were cultured overnight, and pulsed with 20μM of each 
respective peptide for 1h. Each target line was pulsed with 50μCi of 51Cr at 37ºC for 
1h. Assays were performed in triplicate, and cytotoxicity was calculated as (sample 
release – spontaneous release) divided by (maximum release – spontaneous release). 
Data are expressed as the means of triplicate wells. 
 
 
Figure 2.15. Cytotoxcity of splenocytes from mice immunized with S-RGD/His DNA 
vaccine. 
51
Cr cytotoxicty assay of in vitro stimulated splenocytes of mice immunized 
with S-RGD/His. RMA/S cells were cultured overnight, and pulsed with 20μM of 
each respective peptide for 1h. Each target line was pulsed with 50μCi of 51Cr at 37ºC 
for 1h. Assays were performed in triplicate, and cytotoxicity was calculated as 
(sample release – spontaneous release) divided by (maximum release – spontaneous 




2.5.5. IFN-γ ELISPOT assay reveals T-cell epitopes of the SARS-CoV spike 
glycoprotein 
The IFN-γ-secreting capability of restimulated cells towards a stimulator was 
examined using by a mouse IFN-γ ELISPOT assay. Splenocytes were cultured in the 
presence of peptide-pulsed and irradiated RMA/S targets, incubated, and spots 
counted with an ELISPOT reader.  
An initial study involving splenocytes from mice immunized with S-Fc, S-
RGD/His, S-His, vector only and CD5-Fc, as well as RMA/S stimulators presenting 
all ten candidate epitopes (S175, S348, S436, S497, S525, S760, S833, S884, S987 and S1116) 
was carried out. S-RGD/His samples against the S1116, S833, S884 and S525 epitopes 
exhibited the greatest number of spots (Fig. 2.16).  
Based on MHC-peptide binding data and preliminary ELISPOT data, 
additional experiments were conducted on selected S-His and S-RGD/His samples for 
confirmation, and the responses towards the five strongly binding epitopes (S436, S497, 
S525, S884 and S1116) were evaluated. Both S-His and S-RGD/His responded vigorously 
towards RMA/S cells presenting S436, S525 and S1116 epitopes (Fig. 2.17) when the 





Figure 2.16. ELISPOT of IFN-γ response against putative T-cell epitopes of SARS-
CoV Spike protein after immunization with various DNA vaccine constructs. 
Splenocytes (1 × 10
4
) were added to peptide-pulsed and irradiated RMA/S target cells 
(4 × 10
3
) at an effector-to-stimulator ratio of 2.5:1. ELISPOT assays were performed 
in triplicates, and spots were counted with an ELISPOT reader. ELISPOT data 
expressed as ratio of responders in the the presence of peptide-pulsed over non-pulsed 
RMA/S Stimulators. Data are expressed as the means of triplicate wells. 
* denotes statistical significance at 0.05 level by Dunnett t 2-sided test for ELISPOT 
























Figure 2.17. Mouse IFN-γ ELISPOT for splenocytes of C57BL/6 mice immunized 
with selected S-RGD/His and S-His DNA vaccines to confirm T-cell epitopes of spike 
protein. Splenocytes (5 × 10
4
) were added to peptide-pulsed and irradiated RMA/S 
target cells (5 × 10
4
) at an effector-to-stimulator ratio of 1:1. ELISPOT assays were 
performed in triplicates, and spots were counted with an ELISPOT reader. Data are 
expressed as the means from six replicates of wells. Standard deviation (± SD) values 
are shown.  
* denotes statistically significance at 0.05 level by Dunnett t 2-sided test for ELISPOT 
cultures + S436-, S525- and S1116-RMA/S stimulators within both S-His and S-
RGD/His groups. 
** denotes statistically significance at 0.05 level by Bonferonni method for ELISPOT 






2.5.6. Mice immunized with SARS-CoV S-His DNA vaccine induce significantly 
higher humoral immune responses compared to S-RGD/His immunized mice  
The production of antigen-specific antibody induced by the SARS-CoV spike 
DNA vaccinations was assessed by using full-length spike protein (amino acid 1-1190) 
(at 10 μg/ml and 100 μl per well) of SARS-CoV Beijing BJ302 strain (Immune 
Technology, USA) as the antigen. ELISA was performed on the sera of individual 
C57BL/6 mice (n = 7 per group) immunized with S-His or S-RGD/His DNA vaccines. 
Sera from C57BL/6 mice immunized with the S-His construct demonstrated 
approximately 3.5-fold higher levels of antibody to the spike glycoprotein than sera 
from mice immunized with the S-RGD/His DNA vaccine (Fig. 2.18). As expected, 
sera from mice immunized with vector only revealed antibody levels close to the 
background.  
Hence, the antibody response against the 6xHis-tagged Spike protein was 
likely to be specific against the spike protein component as both the S-His and S-
RGD/His constructs contained the 6xHis tag.  
A BLASTn nucleotide and BLASTp amino acid sequence comparison was 
also performed on the codon-optimized spike glycoprotein used to immunized mice 
and compared against the original TOR2 spike glycoprotein amino acid sequence as 
well as the Beijing BJ302 spike protein used in ELISA. While there was only a 70% 
similarity between the nucleotides sequence of the codon-optimized and original 
TOR2 sequence, there was high similarity of 99% in the amino acid sequences 
(Appendix 8.3). The codon-optimized amino acid sequence also showed high 






Figure 2.18. Antibody response ELISA. SARS-CoV spike glycoprotein-specific 
ELISA of C57BL/6 mice groups before and after DNA vaccine immunizations. The 
wells were coated with spike-His protein of BJ302 strain, and blocked with 5% BSA, 
PBS and 0.05% Tween-20. Each serum sample was diluted 1:500 in PBS, and goat 
anti-mouse IgG HRP (1:5000) served as the secondary antibody. O-phenylene 
diamine dihydrochloride was used as substrate, the reaction was stopped by adding 
3M H2SO4, and absorbance was read at 490nm. The means of absorbance at 490nm 
from 7 animals per group before and after vaccination are shown together with 
standard error bars.  
* denotes statistically significance at 0.05 between final sera of S-His and S-RGD/His 




The use of RMA/S cell lines came unexpectedly when the planned stable 
transfection of a codon-optimized SARS CoV extracellular spike protein gene failed. 
The RMA/S cells are TAP2-deficient (Transporter-Associated Protein) and were 
derived from T-cell lymphomas related to the Rauscher murine leukemia virus-
induced RBL-5 cell line (Ljunggren, Ohlen et al. 1991). This H2-K
b
 line has been 
used widely in MHC-peptide binding assays because of the lack of TAP-2 molecules, 
which are responsible in the stabilization of the endogenously processed and restricted 
peptide, in association with the MHC molecule, migrates to the cell surface for 
recognition with its corresponding T cell receptor (Schumacher, Heemels et al. 1990, 
Aosai, Ohlen et al. 1991, Ortiz-Navarrete and Hammerling 1991, Esquivel, Yewdell 
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et al. 1992, Hosken and Bevan 1992). This absence of the TAP-2 molecule ensures 
that a high probability of endogenously processed peptides never bind to form 
complexes with this MHC partner, thereby mostly MHC molecules are presented on 
the cell surface and recycled back (Day, Esquivel et al. 1995). A small proportion of 
MHC-peptide complexes do still get presented on the cell surface. Therefore, MHC-
peptide complexes within the RMA/S cytosol are unstable upon reaching the cell 
surface at which case it falls apart and gets recycled back. The in vitro incubation of 
restricted peptides with RMA/S lines stabilizes the ‘empty’ MHC molecules with the 
peptides, thereby, the complexes remains on the cell surface. The mutant phenotype is 
known to be normalized upon incubation of RMA/S cells at 25°C (Ljunggren, Stam et 
al. 1990, Rock, Gramm et al. 1991). Increased expression of class I heterodimers was 
thought to be dependent on culturing RMA/S cells in bovine serum or with purified 
bovine beta 2-microglobulin (Rock, Gramm et al. 1991). Furthermore, epitopes that 
are associated with class I MHC molecules that have bound xenogeneic beta 2-
microglobulin are preferentially formed on RMA-S cells cultured at 25 degrees C. 
These heterologous class I molecules are thermolabile. Increased expression of class I 
molecules has also been observed on RMA-S cells incubated at 37 degrees C in the 
presence of class I-restricted peptides.  
 The induction of primary CTL responses in vitro with peptide pulsed RMA/S 
cells was found to be feasible (De Bruijn, Schumacher et al. 1991, Esquivel, Yewdell 
et al. 1992, Sijts, De Bruijn et al. 1992, Zhou, Glas et al. 1993, Bellone, Iezzi et al. 
1994). Pre-culture of RMA/S cells at room temperature allows for the accumulation 
of empty MHC Class I at the cell surface. Primary peptide-specific CTL responses 
induced by peptide-pulsed RMA/S cells were CD4
+






 We thereby argued that while the peptide-pulsed RMA/S cells were successful 
in priming of cytotoxic T lymphocytes in vitro, the method ought to work in vivo. We 
proceeded to pulse the well-characterized chicken ovalbumin Ova257-264 peptide 
before irradiation and immunized into C57BL/6 mice. We decided that the use of 
irradiation as used in the original protocols were still valid for our purposes. In fact 
while in the original in vitro setting, the use of irradiation or mitomycin C treatment 
was to stop intracellular processes which included MHC processing and recycling. 
For our in vivo setting, the irradiation was given at a dose sufficiently enough to cause 
apoptosis. It is known that apoptotic cells deliver processed antigens to dendritic cells 
for cross-presentation (Bellone, Iezzi et al. 1997, Blachere, Darnell et al. 2005). In 
fact apoptotic cell death can induce inflammation and activate innate and adaptive 
immunity. We proceeded to use the RMA/S cells to pulse for the Spike 436-442 
peptide. This epitope was found to be the most H2-K
b
 immunodominant by (Zhi, 
Kobinger et al. 2005). By 
51
Cr release assay, the cytotoxicity of splenocytes from 
mice immunized with such protocol was able to be demonstrated. It shows that by 
using irradiated whole cell peptide-pulsed immunization, the elicitation of CD8
+
 T 
cell responses is possible.  
 While the most straightforward method of using construct-transfected cells to 
use as stimulators and cell targets during in vitro stimulation and cell cytotoxicity 
assay, respectively, it was demonstrated by using the described, an alternative method 
can be used. The method of pulsing the RMA/S cells is attractive as peptide-pulsing 
the cells before such assays ensures that only one single homogenous restricted 
peptide population exist to bind and stabilize MHCs and therefore available to CD8
+
 
T cell receptors. It enables an easier method for the investigator to study CD8
+
 T cell 
response toward any one single epitope at a time. It has been demonstrated previously 
 65 
 
as well as in this study that the use of peptide-pulsed RMA/S cells is indeed a feasible 
method to use in in vitro stimulation and other functional assays such as 
51
Cr release 
assay and ELISPOT. 
 
2.6.1. Enhancement of SARS Spike DNA vaccine efficacy fused to the integrin 
binding motif 
DNA vaccination shows great promise for eliciting protection against 
infectious diseases and other immune disorders although the efficacy of DNA 
vaccines can vary widely due to different transfection efficiency in target tissues 
(Tuting, Austyn et al. 2000). DNA vaccines are mostly delivered through 
intramuscular route which are poorly populated by immune cells such as dendritic 
cells, macrophages or lymphocytes. Myocytes are the dominant cell types that express 
DNA vaccines. These are not antigen-presenting cells (APC) and the expressed 
antigens must be presented to APCs, such as dendritic cells, which migrate to draining 
lymph nodes to induce immune responses (Condon, Watkins et al. 1996, Tuting, 
Austyn et al. 2000). Mechanisms that facilitate APC uptake of antigens are expected 
to enhance the efficacy of vaccines. In the present study, the integrin binding motif 
Arg-Gly-Asp (RGD) was fused to the C-terminal end of the SARS-CoV spike protein 
antigen. This is to evaluate whether the short RGD tag enhances immune responses 
against the spike protein antigen. Dendritic cells phagocytose apoptotic cells through 
the v5 integrin which promotes cross-presentation of antigens. v5 is a RGD-
binding integrin. In a previous study, RGD fusion to synthesized peptide antigens has 
been shown to enhance the immunogenicity of the peptide antigens which may 
involve αvβ5–mediated antigen uptake (Yano, Onozuka et al. 2003, Yano, Onozuka et 
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al. 2005) Antigen-specific antibodies were induced by intranasal immunization with 
RGD-tagged antigens without adjuvants.  
 The sequence and composition of a DNA vaccine may contribute some role in 
its immunogenicity (Arnon 2011). However its efficacy is directly related to the 
expression levels of the encoded protein in eukaryotic cells. Alteration of codon usage 
of viral antigens, to remove regulatory sequences and deletion of functional sequence 
elements are known to be useful for augmenting the immunogenicity of DNA 
vaccines Codon-optimized cDNA constructs increase protein antigen expression 
(Babcock, Esshaki et al. 2004). The gene encoding the S protein of SARS-CoV 
contains many codons used infrequently in mammalian genes for efficiently expressed 
proteins (Haas, Park et al. 1996, Marra, Jones et al. 2003, Rota, Oberste et al. 2003). 
A study was done to compare different codon-optimized forms of the S-protein gene 
and its expression with its native viral sequence (Moore, Dorfman et al. 2004). Indeed 
the codon-optimized gene expressed more than twice as much protein as the native 
viral sequence.  
As such we used the same codon-optimized SARS-CoV spike protein cDNA 
to modify and express the RGD-tagged antigen (Yang, Kong et al. 2004, Zhong, 
Zhong et al. 2006). Codon-optimized S gene SARS-CoV has been incorporated in the 
construction of DNA vaccine plasmids expressing either the full-length or segments 
of S protein (Wang, Chou et al. 2005). High titer S-specific IgG antibody responses 
were elicited in rabbits immunized with DNA against various segments of the S 
protein.  
The spike protein antigen is expressed without the transmembrane and C-
terminal domains with RGD being fused to the C-terminal end followed by a His tag 
for antigen purification and analysis.  A spike protein DNA vaccine without tags was 
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shown to generate neutralizing antibody and protective immunity in mice (Yang, 
Kong et al. 2004). They also managed to demonstrate that humoral response in mice 
vaccinated with an expression vector encoding the spike glycoprotein which includes 
its transmembrane domain elicited neutralizing antibodies. However, it was concluded 
that protection was mediated by a humoral but not a cell-mediated immune 
mechanism. A secreted recombinant expression plasmid of the pVAX family that 
encoded a partial S glycoprotein fused to a signal peptide was constructed and 





accompanied by an increase in IFN-γ level in serum where levels of IL-4 were 
undetectable, indicated that humoral and cellular immune responses were elicited (He, 
Tang et al. 2005).   
In our experiments, the spike protein vaccine was also potent in antibody 
induction. When the antigen is tagged with RGD, it showed decreased rather than 
increased antibody induction suggesting that either the RGD tag rendered spike 
protein less immunogenic or it polarizes immune responses away from humoral 
immunity. This became clearer when cellular responses were assessed. With some 
epitopes, S-RGD induced higher CTL activation than S-His. When IFN-γ induction 
was examined, it was found more effectively induced by S-RGD as compared with S-
His. Therefore, the RGD tag appears to polarize the host from humoral to cellular 
responses which is in line with that initially hypothesized.   
An unexpected observation after S-RGD DNA vaccine immunization is that 
the mice exhibit increasing fur loss with each booster dose leading to complete 
alopecia following the last boost. Alopecia was reported before in human scalp 
xenografts upon laminin-10 inhibition using antibodies specific for either (Li, Rao et 
al. 2003, Li, Tzu et al. 2003). In the latter settings, laminins are major components of 
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basement membranes to which epithelial cells attach and interruption of these 
attachments are expected to cause skin abnormalities (Hynes 1992, Engvall and 
Wewer 1996, McGowan and Marinkovich 2000). It is unclear how immunity against 
the RGD-tagged spike protein antigen or the antigen itself may cause skin 
abnormalities. 
In addition, Zhi et al. (2005) demonstrated that codon optimization of the 
SARS-CoV S gene can greatly enhance S-specific CD8 T-cell responses in mice 
immunized with the recombinant S protein expressed by a simian adenoviral vaccine 
vector. In the present study, pcDNA-SS was more effective in eliciting humoral and 
cellular immune responses in vaccinated mice than pLL70. Although pcDNA-SS 
expressed codon-optimized S gene from the Urbani SARS-CoV strain and pLL70 
noncodon optimized S gene from the Tor-2 strain, there is only one amino acid 
residue difference between the S protein sequences of these strains (serine to alanine 
in the position 577). It is unlikely that substitution of one amino acid will dramatically 
affect immunogenicity of the SARS-CoV S protein. Therefore, we suggest that 
genetic codon optimization and=or foreign signal sequence may play a major role in 
the enhancing of the immunogenicity of a DNA vaccine based on the SARS-CoV S 
protein. 
A number of studies have found the receptor-binding domain to be the major 
immunodominant portion and to harbor potent neutralizing epitopes on the S protein 
(Zhang, Wang et al. 2004, Zhou, Wang et al. 2004, Chen, Zhang et al. 2005, He, Lu et 
al. 2005, Keng, Zhang et al. 2005, Wang, Chou et al. 2005). The spike protein is 
necessary for the infectivity and pathogenicity of coronaviruses. Neutralization 
domains have been identified on the S protein, one at the N-terminus (Ser12-Thr535) 
and the other at the C-terminus (Arg797-Ile1192) (Wang, Chou et al. 2005). B-cell 
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epitopes were also identified from the S glycoprotein. A multi-epitope DNA vaccine 
containing S437-459 and M1-20 were intramuscularly immunized into mice where a 
long-term memory humoral response was generated. The authors concluded that a 
DNA-prime-protein boost strategy greatly enhanced the antibody generation (Wang, 
Xu et al. 2008). 
Identification of functional dominant epitopes for T cells is crucial for the 
understanding of cellular immune responses elicited by SARS-CoV DNA vaccine. 
Zhi et al. (2005), identified the H-2
b
-restricted S436- and S525-epitopes, and 
concluded that the latter epitope to be more dominant in C57BL/6 mice. The strength 
of these epitopes appeared to correlate with the binding affinity to H2-K
b
 predicted by 
the SYFPEITHI algorithm. In contrast to these data by Zhi et al. (2005), it was found 
that the S436 epitope is a relatively weak MHC binder with an MFI of only 1.23. 
Although S436 was ranked the highest MHC binder by the Rankpep and SYFPEITHI 
predictions, the S497, S525 and S884  epitopes exhibited higher MFI values (6.58, 6.6 
and 4.81, respectively) than S436. Two spike-specific CD8 T-cell epitopes in mouse 
hepatitis virus (MHV)-infected C57BL/6 mice were previously identified. These were 
the S510-518 (dominant) and S598-605 (subdominant) (Castro and Perlman 1995, 
Bergmann, Yao et al. 1996).  The dominant S510-518 epitope is located in a 
hypervariable region of the spike protein that appears to be readily deleted without 
loss of viability of MHV (Parker, Gallagher et al. 1989). In comparison, the S436-443 
dominant epitope resides in the minimal region of S1 required for interaction with its 
cellular receptor, ACE2 (Babcock, Esshaki et al. 2004, Tan, Lim et al. 2005). In a 
study with SARS patient sera, Lu et al. 2004 discovered a fragment of spike protein 
(amino acid 441 to 700) to be the major immunodominant epitope.  
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This study demonstrated that prime-immunization of mice with SARS-CoV 
spike DNA vaccine constructs S-RGD/His and S-His induced antigen-specific cellular 
immune responses. In fact the cellular and humoral immune responses elicited by 
different combinations of gene-based and inactivated viral particles with various 
adjuvants were assessed (Kong, Xu et al. 2005). T cell responses were found to be 
altered by different prime-boost immunization, where optimal CD8
+
 T cell response 
induced by DNA priming and replication-defective adenoviral vector boosting. 
Humoral immune response is known to be enhanced most effectively through the use 
of inactivated virus with adjuvants, associated with CD4
+
 T cells stimulation. After a 




 T cell 
responses are induced (Huang, Ma et al. 2006). Boosting mice intramuscularly with a 




 T cell responses in both 
lymphoid and non-lymphoid organs persistent over months. In fact a single-plasmid 
DNA vaccine encoding the S glycoprotein was given in three priming-boost doses to 
humans to evaluate safety and immune responses (Martin, Louder et al. 2008). 
Antibody against the SARS-CoV was detected in 80% of subjects where all mounted 
neutralizing antibody response. CD4
+
 T-cell specific response was detected in all 
subjects but only 20% mounted a CD8
+
 T-cell specific response. 
While the S-RGD/His vaccine was not more efficacious than the S-His 
vaccine, Figure 3 appears to suggest that S-RGD is more potent in IFN-γ induction 
and Figure 2C/D suggests S-RGD also induced more CTL. Babcock et al. (2004) 
speculated that amino acids 1 to 510 of the spike glycoprotein represented a unique 
domain containing the receptor-binding site. Additionally, He et al. (2005) 
characterized the minimal receptor-binding domain to be between residues 318-510. 
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Therefore this gives more evidence that a vaccine targeting this region to be 
promising.  
Based on the present study, the S436- and S497- epitopes which lie within 
these regions are highly immunogenic. CTLs induced by both S-His and S-RGD/His 
DNA vaccines kill RMA/S cells which were pulsed with the S436, S497, S525, S884 
and S1116 epitopes. These epitopes also stimulate IFN-γ secretion. Besides the S436 
and S525 epitopes (Zhi, Kobinger et al. 2005), the S884 epitope was discovered to be 
another strong MHC binder which elicits cytotoxic T-cell responses. The S1116 
peptide was predicted to be a weak MHC binder in this study, but it induced the 
highest cytotoxic response of all peptide tested. It is also induced the strongest IFN-γ 
production. The S884 and S1116 epitopes are close to the carboxyl end of spike 
protein where the S2 subunit resides. A S1167 epitope (RLNEVAKNL) within the S2 
subunit was found to be able to induce peptide-specific CTLs in both HLA-A2.1/Kb 
transgenic mice and human PBMCs (Wang, Sin et al. 2004). Two more S2 subunit 
epitopes S978 and S1203 were recognized by peripheral blood cells of recovered 
SARS patients with HLA-A*0201 (Wang, Chen et al. 2004, Chen, Hou et al. 2005).  
Additionally, Tsao et al. (2006) reported that the S787 and S1042 epitopes were 
HLA-A*0201 restricted, with the latter being able to induce recall responses in 
PBMC harvested from SARS-recovered-patients when in vitro incubated against their 
cognate antigen (Tsao, Lin et al. 2006). HLA-A*0201 transgenic mice were primed 
intramuscularly with a DNA vaccine encoding the S glycoprotein and boosted 
subcutaneously with its haplotype-restricted peptides (Zhao, Yang et al. 2010). CD8
+
 
T cell responses in the transgenic mice were found to be elicited by epitopes from the 





Our findings suggest that the S2 subunit S884 and S1116 epitopes are potent 
inducers of cytotoxic responses and IFN-γ production. While the S1 domain has been 
shown to be crucial for the development of immunogenic vaccines against SARS-
CoV, the S2 domain is also an important target for vaccine development in cytotoxic 
T cell induction. The S2 subunit domain functions to complement the S1 domain 
which has been demonstrated to be crucial for the development of immunogenic 




Understanding the role of Interferon Regulatory Factor-4 (IRF-4) 
transcriptional factor in severe influenza pneumonitis 
3.1. INTRODUCTION 
3.1.1. Influenza Virus 
 The Orthomyxoviridae viruses can be characterized by having a negative-
sense, single-stranded and segmented genome (Palese and Shaw 2006). Influenza 
viruses A, B, C are among the genera of Orthomyxoviridae. These viruses are 
distantly related to human parainfluenza viruses which belong to the Paramyxovirus 
family. The influenza A, B and C viruses are distinguishable based on the antigenic 
differences of the nucleoprotein (NP) and matrix (M) proteins. The viruses are similar 
in overall structure (Büchen-Osmond 2006, Büchen-Osmond 2006, Kawaoka, Cox et 
al. 2006). The virion is 80 – 120 nm in diameter and is usually spherical (Lamb and 
Choppin 1983, Büchen-Osmond 2006). Influenza A viruses can be subtyped based on 
the antigenic nature of the hemagglutinin (HA) and neuraminidase (NA) 
glycoproteins: 16 HA subtypes (H1 – H16) and 9 NA subtypes (N1 – N9).  
 The genomes of Influenza A and B consist of 8 separate segments covered by 
the nucleocapsid protein. Together these build the ribonucleoprotein (RNP), which is 
made up by RNA segments, nucleoprotein (NP) and three viral polymerases: 
polymerase acid (PA), polymerase basic 1 (PB1) and polymerase basic 2 (PB2).  The 
virus possesses a lipid bilayer membrane that is derived from the host cell which 
harbors the homotrimeric HA, homotetrameric NA and M2 proteins that projects from 
the virus surface. These proteins form a dense layer of spikes embedded in a lipid 
bilayer. The lipid bilayer membrane also covers the matrix formed by the M1 protein 
which in turns encases the RNP complex (Gurtler 2006). Three other viral proteins are 
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somewhat excluded from virions of infected cells (Yewdell and Hackett 1989). The 
non-structural 1 (NS1) and non-structural 2 (NS2) proteins are produced from the 
same gene segment. The matrix protein 2 (M2) is an integral membrane protein 
produced by mRNA splicing which encoded M1 (Fig. 3.1) 
 
   
Source: (Kaiser 2006) 
Figure 3.1. Structural diagram of the influenza virus. 
The external virion surface is made up of the homotrimeric hemagglutinin (HA) and 
homotetrameric neuraminidase (NA) which forms a dense layer of spikes embedded 
in a lipid bilayer (which is derived from the host cell). The matrix 1 (M1) protein 
underlies the envelope and interacts with the surface proteins, as well as, encases the 
ribonucleoproteins (RNPs). The RNPs is composed of the viral genome, 
nucleoprotein (NP), viral polymerases complex heterotrimer: PA, PB1 and PB2. The 
viral genome is made up of 8 single-stranded negative sense RNA gene segments. The 
matrix 2 (M2) [an integral membrane protein produce by the splicing of mRNA that 




3.1.1.1. Hemagglutinin (HA) 
 Hemagglutinin is the major surface glycoprotein present on influenza virion. 
The HA forms homotrimers and several trimers form a fusion pore. Each HA 
structure is made up of a globular head on a stalk. The head (made up exclusively of 
HA1) contains the receptor-binding cavity and in addition to most of the antigenic 
sites of this protein. The stalk is made up partly of HA1 and HA2, where the carboxy-
terminal region contains hydrophobic transmembrane sequence and terminal 
cytoplasmic anchor sequence. At low pH, the fusion peptide is turned to an interior 
position. The antigenic sites are presented at the head of the molecule, while the stalk 
is embedded in the lipid layer. The structures function during its replicative cycle in: 
(i) binding to sialic acid-containing receptor on cell surface, whereby the attachment 
of the infectious virion to the susceptible host cell’s plasma membrane is established; 
(ii) initiation of the infection cycle by mediating the fusion of endocytosed virus 
particle with endosomal membrane, where the HA is activated by proteolytic cleavage 
resulting in the viral RNA being released into the cytoplasm (Lamb 1989). The 
protein is also the major antigen of the virus against which neutralizing antibodies are 
produced. Changes in its antigenic structures cause recurring influenza epidemics. 
 
 The HA is subjected to a very high rate of mutation due to the error-prone 
viral RNA polymerase activity (Webster, Bean et al. 1992). It is estimated that there is 
one base substitution in the HA gene per virus generation. The selection for amino 
acid substitution is driven by immune pressure, as the HA is a major target of the host 
immune response. In nature, there are presently 16 recognized subtypes of HA 
(Wright, Neumann et al. 2006). These differ by at least 30% in amino acid sequence 
of HA1 and are serologically not cross-reactive.  
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3.1.1.2. Neuraminidase (NA) 
 Neuraminidase is a glycoprotein, which is present as projections on the virion 
surface where it forms a homotetrameric structure. The molecule presents its 
globularhead at the outer surface of the cell, spans the lipid layer, and has a small 
cytoplasmic tail. It functions to cleave sialic acid from the HA molecule as well as 
other NA molecules, glycoproteins and glycolipids present on the cell surface. It is 
necessary for the virion penetration through the mucin layer of the respiratory 
epithelium and serves as an important antigenic site (Gurtler 2006). The structures 
function to free virions from host cell receptors, to permit progeny virions to escape 
from the host cell and to facilitate virus spread (Webster, Bean et al. 1992). 
 
 As with HA, NA is highly mutable with variant selection in response to host 
immune response. Nine subtypes of NA have been identified in nature (Webster, Bean 
et al. 1992) 
 
3.1.1.3. Influenza virus replication 
 The HA  of Influenza viruses binds to neuraminic acids (sialic acids) present 
on cell surfaces to initiate infection and replication (Palese and Shaw 2006).  The 
sialic acid linkage to the penultimate galactose determines host specificity. Human 
viruses preferentially bind to these penultimate galactose sugar by an α2,6 linkage 
(SAα2,6 Gal), whereas avian viruses bind to sialic acid with an α2,3 linkage (Connor, 
Kawaoka et al. 1994). Human tracheal epithelial cells contain mostly SAα2,6 Gal 
(Couceiro, Paulson et al. 1993). In ducks gut epithelium are mostly SAα2,3 Gal (Ito, 
Couceiro et al. 1998). The virion is taken up by the host cell through a clathrin-coated 
receptor-mediated endocytosis process. Upon internalization, the clathrin molecules 
 77 
 
are released and the vesicles containing whole viruses fuse with the endosomes. The 
vesicles’ contents are digested by a stepwise of lowering pH within the endosome 
(Gurtler 2006) . The change in pH is halted by the M2 protein which induces a partial 
liberation of the fusion HA peptide.  
 The fusion activity is induced by a structural confirmative change in the HA 
where the precursor HA0 is cleaved into the HA1 and HA2 subunits. Within the 
acidic environment of the endosome, the HA molecule undergoes conformational 
change which exposes the fusion peptide at the N-terminus of the HA2. This enables 
the interaction with the endosomal membrane (Stegmann 2000). The ion influx from 
the endosome to the virus particle leads to disconnection of the different viral 
proteins; the M1-protein aggregation is disrupted and RNPs no longer adhere to the 
M1-protein complex (Gurtler 2006). The concerted structural change of several HA 
molecules opens a pore that releases the contents of the virion containing the RNPs 
into the cytoplasm. 
Upon transport of the RNPs to the nuclease, the polymerase complex binds 
and cleaves the viral RNA (vRNA) by endonuclease activity while simultaneously 
elongates it. NP restricts the vRNA production while supports mRNA production. 
Both the vRNA and mRNA are transported out to the cytoplasm where de novo viral 
proteins are synthesized at the ribosome. The M1 and NS2 are synthesized from viral 
RNA the without further cleavage from vRNA that is spliced by cellular enzymes. 
Some of the de novo proteins are transported back to the nucleus where they bind to 
vRNA to form the RNPs, while others, the viral glycoproteins HA and NA, are 
processed in the endoplasmic reticulum and Golgi apparatus where glycosylation 
occurs. These modified proteins are transport to the cell membrane where they reside 
within the lipid bilayer till a high enough concentration is achieved where the RNPs 
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and M1 aggregate together and condense to form new virions. These particles bud out 
from the membrane and are released by the NA (Gurtler 2006) (Fig. 3.2). 
 
 © 2009 QIAGEN, all rights reserved 
Figure 3.2. Influenza virus (InfV) replication. InfV enters through the airways and 
specifically attaches to the surface of epithelial cells. The viral membrane envelop, 
contains the NA structure which is important for the efficient release of newly 
produced viruses. The M2 ion channel promotes viral structural changes during 
cellular entry. The HA structure is a key player during viral internalization which 
facilitates viral binding to sialic acid-decorated receptors and subsequently viral 
fusion.  Proteolytic cleavage by host enzymes is critical for the activation of HA 
trimers. Soluble or cell-bound host proteases cleave precursor HA to 2 parts: HA1 and 
HA2. InfV particles are internalized into early endosomes by clathrin-mediated 
endocytosis. In late endosomes, pH drops, triggering conformational change of 
cleaved HA molecules. The HA1 opens to allow HA2 to form a triple-helix bundle 
which extends to the endosomal membrane. Once the fusion peptide is anchored in 
the endosome membrane, the whole HA molecule folds back allowing the fusion viral 
and endosomal membrane. After fusion, the viral genome is released into the cytosol. 
The 8 viral RNA segments make their way to the cell nucleus and production of new 
viruses begins. Hours after the initial infection, new viruses will bud off the cell 




3.1.1.4. Pathology and Pathogenesis 
 Human influenza viruses replicate exclusively in superficial cells of the 
respiratory tract. While the virus is release from the apical surface of cells, this may 
limit more systemic spread but facilitate the accumulation of the virus in the 
respiratory tract lumen for transmission to the next host (Wright, Neumann et al. 
2006). Alveolar macrophages and dendritic cells may be infected and play a role in 
influenza viral immune response by processing antigens and presenting them for 
immune recognition in the medestinal lymph nodes. Virus replication peaks about 48 
hours after inoculation and declines at a slow rate thereafter with little virus shedding 
after day 6 to 8. Even after no infectious virus can be recovered, viral antigens can 
still be detected for several days in cells and secretions of infected individuals.  
 The virus induces changes throughout the respiratory tract but has the most 
significant pathology in the lower respiratory tract (Wright, Neumann et al. 2006). 
Acute diffuse inflammation of the larynx, trachea and bronchi accompanied with 
mucosal inflammation and edema can be observed in uncomplicated infections. 
Submucosal edema and hyperemia occur with an infiltration by neutrophil and 
mononuclear cells. In severe cases where primary viral pneumonia occurs, there is am 
interstitial pneumonitis with marked hyperemia and alveolar wall broadening with a 
predominantly mononuclear leukocyte infiltration with capillary dilation and 
thrombosis. Virus specific antigen is present in type 1 and 2 alveolar epithelial cells 
and intra-alveolar macrophages (Guarner, Shieh et al. 2000). Necrotizing change may 
also occur with rupture alveoli and bronchioles walls. As the virus shuts down cell 
protein machinery and induces apoptosis, cell destruction occurs (Hinshaw, Olsen et 
al. 1994). Mitoses appear in the basal cell layer from the third to fifth day after illness 
 80 
 
onset and epithelium regeneration begins. Reparative and destructive processes are 
known to occur simultaneously.   
 
3.1.1.5. Innate immune responses in influenza virus infections 
 Influenza virus infection causes an acute infection in the host where it  
initiates a cascade of immune responses that activates most parts of the immune 
system. Early innate responses are characterized by the IFN Type I release, neutrophil 
and NK cells influx (Mandelboim, Lieberman et al. 2001, Achdout, Arnon et al. 
2003). Toll-like receptors, TLR-3 and TLR-7 recognizes the virus and trigger the 
intracellular cascades that lead to these initial host responses. TLR-3 is expressed on 
respiratory epithelial cells and recognizes dsRNA and act through the stimulation of 
IRF-3 pathway to IFN production (Guillot, Le Goffic et al. 2005). TLR-7 is expressed 
on dendritic cells and recognizes ssRNA and has the ability to induce IFN pathway 
and produce inflammatory cytokines in those cells (Lund, Alexopoulou et al. 2004, 
Barchet, Krug et al. 2005). 
 Innate immune responses are an essential prerequisite for the later and 
subsequent adaptive immune response. This more specialized response functions to: 
(i) limit the initial viral replication and antigen load, and (ii) produce co-stimulatory 
molecules that, when induced on cells of the innate immune system during their 
interaction with viruses, go on to activate antigen-specific lymphocytes of the 







3.1.1.6. Adaptive immune responses in influenza virus infections 
 The adaptive immune response requires some days to be initiate but is 
efficient in containing virus spread, clearing the virus and establishing a memory 
response resulting in a long-lived resistance to re-infection with homologous virus. In 
influenza virus infections, both systemic and local antibody immunity as well as 
cytotoxic T cell responses are induced (Fig. 3.3). 
 Antibodies against HA, NA, NP and M proteins are produced as the result of 
the infection (Behrens and Stoll 2006), of which antibodies to HA and NA are 
associated with resistance to infection whereas antibodies to M1 and NP are not. HA 
antibodies can prevent infection by neutralizing the infectivity of the virus whereas 
NA antibodies mediate the antiviral effect primarily after infection has been initiated 
by restricting viral release from the host cell and curbing the spread of the virus 
within the respiratory tract of the host (Wright, Neumann et al. 2006). IgM, IgA and 
IgG levels peak between four to seven weeks after virus inoculation. IgA is 
transported across mucosal epithelium of the upper airway where it neutralizes and 
clears the viral infection whereas IgG is primarily responsible for the protection of the 
lower respiratory tract (Palladino, Mozdzanowska et al. 1995, Renegar, Small et al. 
2004).  
 Human Class I-restricted CD8
+
 T cells recognize either the HA glycoprotein 
or M, NP, PB2 non-glycoproteins antigens (Treanor 2004). These shows subtype-
specific and cross-reactive specificities, respectively (Fleischer, Becht et al. 1985). 
Individuals differ considerably in the peptides that their CD8
+
 T cells can recognize 
due to the HLA haplotype. CD4
+
 T cells function to provide help both to B cells for 
antibody production and to Class I-restricted CD8
+
 T cells for their proliferation 
(Lamb, Woody et al. 1982). Helper T cells specific for M or NP proteins are known to 
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provide help to B cells secreting HA antibody and is able to enhance the antibody 
response to protective antigens.  CD4
+
 T cells also have cytolytic activity with antigen 
specificities similar to CD8
+





memory T cells subsets respond to and mediate the control of an influenza virus re-
infection which is contrast to the primary infection where viral clearance have been 
found to depend on CD8
+
 T cells (Woodland 2003). 
  
 
Source: (Behrens and Stoll 2006) 
Figure 3.3. Late phase immune response in an influenza virus infection: Adaptive 
immune response (consisting of the humoral and cell-mediated arms). Humoral arm 
of immune response involves antibody-secreting plasma cells differentiated from B-
lymphocytes, after an initial contact with the Influenza virus. Cellular mediated 
immune response arm involves the presentation of viral antigen (Ag) proteins on 
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MHC Class I and II by antigen-presenting cells (such as Dendritic cells) to T cells (T 
helper and cytotoxic T cells). This leads to the activation, proliferation and 
differentiation of these Ag-specific T cells which develop effector functions. These 
cells function in the release of cytokines or mediate cytotoxicity which results in the 
elimination of infected target cells. 
 
3.1.2. Cytokines in Virus Infections 
 
Viruses trigger cellular responses, including the secretion of cytokines leading 
to immune responses which involves cytokines. These infections are cleared by a 
combination of humoral and cell-mediated immunity. The overproduction of certain 
cytokines during acute infections may have profound systemic and pathological 
consequences (Meager 1998).  
Early phases of virus replication stimulate Type I IFNs (IFN-α/-β) and the 
development of non-specific responses such as the NK cell cytotoxic activity. Late 
phases of replication generate antigen-specific immune responses which are 
dependent on specific CD4
+ 
Th1 and/or Th2 cell populations. Activated Th1 cells 
trigger phagocyte-mediated host defense mechanisms (Mosmann and Coffman 1989). 
Th1 lymphocytes produce IL-2 and IFN-γ and are effectors of intracellular cell–
mediated immunity. Type I IFNs are also able to stimulate IgG2a antibody production 
where these are effective in activating complement and the opsonization of antigens 
for phagocytosis. Activated Th2 cells are involved in phagocyte-independent host 
defence mechanisms. These cells produce IL-4, -5, -10 and -13, induce IgE and IgG1 
antibodies, induce growth and activation of mast cells (by IL-3, -4 and -10), induce 
proliferation and activation of eosinophils (by IL-5) and suppress 







3.1.3. Cytokines and Chemokines in the pathogenesis of Influenza Virus 
infections 
 
Following H1N1 or H3N2 virus infection, the virus is detected in nasal 
secretions within 1 day after inoculation. Peak levels are reached by day 2 and are no 
longer detectable after 5-7 days of shedding. Together with symptom formation and 
lung pathology, an early rise of proinflammatory cytokines and chemokines such as 
IFN-α, IL-6, IL-8, TNF-α, CCL3 (MIP-1α), CCL4 (MIP-1β) and CCL2 (MCP-1) has 
been described in bronchoalveolar lavage (BAL) fluids or lung homogenates to peak 
within two or three days after inoculation  (Vacheron, Rudent et al. 1990, Hennet, 
Ziltener et al. 1992, Peper and Van Campen 1995, Kurokawa, Imakita et al. 1996, 
Gentile, Doyle et al. 1998). In plasma and serum, lower levels of cytokines are 
detected.  
Type I interferons (IFN-α/β) are produced by infected epithelial cells and 
monocytes/macrophages (Ronni, Sareneva et al. 1995, Sareneva, Matikainen et al. 
1998). Epithelial cells produce CCL5 (RANTES), CCL2 (MCP-1) and IL-8 but are 
poor producers of IFN-α/β and proinflammatory cytokines (IL-1, IL-6, TNF-α) 
(Adachi, Matsukura et al. 1997). Monocytes/ macrophages produce a larger quantity 
of proinflammatory cytokines and chemokines, including CCL3 (MIP-1α), CCL4 
(MIP-1β), CCL5 (RANTES), CCL2 (MCP-1), CCL7 (MCP-3), CCL20 (MIP-3α) and 
CXCL10 (IP-10) (Sprenger, Meyer et al. 1996, Bussfeld, Kaufmann et al. 1998) TNF-
α and IL-1 stimulate neutrophil and macrophage as well as upregulate leokocyte 
adhesion molecules on vascular endothelium by the sequestration of neutrophils and 







Figure 3.4. Cytokine production in InfAV-infected epithelial cells and macropahges. 
In InfV infections, susceptible infected epithelial cells produce anti-viral IFN-α/β and 
RANTES (regulated and normal T cell expressed and secreted) [CCL5] whereas 
macrophages produce a wider range of chemokines and proinflammatory cytokines. 
IFN- α/β and IL-18 enhance NK and T cell production of IFN-γ production and the 




3.1.4. Generation of transgenic and knock-out mice as animal models for 
studying respiratory virus infection 
 
3.1.4.1. Transgenic mice  
 A transgenic animal is one that carries a foreign gene that has been 
deliberately inserted into its genome (Brett and Johansson 2009) (Fig. 3.5). The 
foreign gene is constructed using recombinant DNA methodology. Transgenic mice 
were first generated by injecting DNA into the pronucleus of one-cell mouse embyros 
(Gordon, Scangos et al. 1980). The transgenic construct consists of a selected 
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enhancer and/or promoter, which may direct gene expression to a specific tissue or 
development state, linked to the sequence to be expressed (Bockamp, Maringer et al. 
2002). The role of selected gene products, dominant negative mutants or specifically 
designed proteins can then be tested.  
 
3.1.4.2. Knockout mice 
 A knockout mouse is a genetically engineered mouse in which one or more 
genes have been turned off through a targeted mutation (Fig. 3.6). The generation of 
knockout mice was made possible with the discovery of murine embryonic stem (ES) 
cells and the knowledge that mammalian cells do undergo homologous recombination 
of DNA sequences on the chromosome (Bockamp, Maringer et al. 2002). An 
advantage of gene-targeting approaches over transgenic techniques is that 
homologous recombination of ES cells defines the integration site and allows for the 
actual genetic change to be introduced. A gene-targeting construct consists of a core 
region containing the desired genetic change together with a positive selection 
cassette (usually in the form of a neomycin antibiotic resistance) which is flanked by, 
two regions of sequence identical to the targeted regions so that homologous 
recombination can take place. However, homologous recombination in ES cells is rare.  
Knockout mice are often surprisingly unaffected by their deficiency. Many genes turn 
out not to be indispensable. The mouse genome appears to have sufficient redundancy 
to compensate for a single missing pair of alleles. Most genes are pleiotropic. They 






Source: (Bockamp, Maringer et al. 2002) 
Figure 3.5. Representation of transgenic mice production. A transgenic construct 
containing a specific promoter (Pspec), the gene of interest, and a polyadenylation 
signal (pA) are shown. This construct is injected into fertilized oocytes to be 
subsequently transferred into pseudo-pregnant recipient mothers. Pups are then 





Source: (Bockamp, Maringer et al. 2002) 
 
Figure 3.6. Generation of null mutant mice using homologous recombination in 
embryonic stem (ES) cells.  
A: Strategy for generating a knockout genotype using homologous recombination. 
The wild-type locus with 5 exons (E1–E5) will recombine with the targeting construct, 
introducing a selection marker and deleting E3.  
P, promoter driving expression of the selectable marker; pA, polyadenylation signal.  
 
B: Homologously recombined ES cells are injected into a blastocyst and transferred 
into a pseudo-pregnant recipient mother. As the injected ES cells contribute to all 
tissues, chimeric mice can be generated. The previously introduced recombination is 





3.1.4.3. Animal models in Influenza Virus Infection 
 
 There are several mammalian models of influenza: ferrets, monkeys, pigs, 
horses and mice with each model having its particular advantages and disadvantages 
(Sweet, Macartney et al. 1981, Smith and Sweet 1988, Sweet, Jakeman et al. 1988, 
Cottey, Rowe et al. 2001).   
Ferrets can be naturally infected with human influenza isolates, develop a 
fever and exhibit infection primarily of nasal turbinates with lesser amounts of 
infection of the trachea, bronchi and lungs.  
 Much understanding of the pathogenesis and host defense against influenza 
was defined in mice and only later confirmed in humans (Small 1990, Bender and 
Small 1992). Mice make a suitable animal model for the study of influenza virus 
infection, even though the ferret closely resembles the anatomy of the human airway. 
Following an intranasal inoculation of influenza virus, mice develop an illness that 
closely resembles the infection in humans. It is a progressive upper and lower 
respiratory tract disease with virtually identical histopathology. Advantages of using 
the mouse model are that they are small, easily handled, relatively short-lived and 
have a well characterized immunological response to influenza. The severity of 
influenza infection in the mouse can be influenced by the virulence of the virus, the 
immune status of the host and the method of infection. Most strains of influenza virus 
can be used to infect mice although prior adaptation of the virus by multiple passages 
through mouse lung allows for selection of viral mutants that are able to replicate 
efficiently in the murine respiratory tract (Mount and Belz 2010).  
In mice, influenza infection induces a strong Th1 response where the protective 
immunity is mediated by Th1-like responses. CD8
+
 T cell responses in humans peak 
at about 14 days post infection and levels of influenza-specific CTLs correlate with a 
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reduction in the duration and level of virus replication. Memory CD8
+
 T cells may 
play a role in improving the disease severity and facilitating recovery upon 
reinfection. Several distinct phases are recognized in which the first phase is mediated 
by memory T cells that reside in the lung airways (Woodland and Randall 2004). 
These memory cells are able to respond to an infection when the viral load is at its 
initial stages. The second stage is mediated by memory T cells that are recruited to the 
airways within few days of the infection which is then followed by the third stage 
where antigen-driven expansion of memory T cells occurs in the secondary lymphoid 
organs. Memory cells proliferate for several days in the lymphoid organs only to be 
recruited to the airways after 5 days post-infection (Woodland and Randall 2004). 
 An example of the use of the mouse model in influenza is the observation that 
CD8
+
 T cells are the primary cell population needed for clearance and recovery from 
influenza infection. Nude mice have a deteriorated or absent thymus, resulting in an 
inhibited immune system due to a greatly reduced number of T cells fail to recover 
from an influenza infection unless adoptively transferred with viable CD8
+
 T cells 
from normal donor animals (Wells, Ennis et al. 1981). Adoptive transferred cloned 
murine CTL lines against influenza virus were able to provide protection to mice 
lethally infected by influenza virus (Lukacher, Braciale et al. 1984). CD8
+
 T cells-
mediated response where found to be more efficient that CD4
+
 T cells in recovery 
from an influenza infection where β2m
-/-
-mice cleared a viral challenge at a slower 
pace compared to normal mice (Eichelberger, Allan et al. 1991, Bender, Croghan et al. 
1992). Graham et al. (1994) generated Th1 and Th2 clones from influenza virus-
specific CD4+ T cell clones from influenza-primed BALB/c mice. Th1 clones were 
found to be cytolytic and protective against lethal challenge with virus in vivo. Th2 
clones were non-cytolytic, non-protective and exacerbates pulmonary pathology. 
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They concluded that virus-specific Th2 CD4+ T may not play a primary role in virus 
clearance and recovery. It may even lead to immune mediated potentiation of injury 
(Graham, Braciale et al. 1994). 
 
3.1.5. Antiviral innate signaling pathways activated by interferons 
 A key aspect of the antiviral innate immune response is the synthesis and 
secretion of the Type I IFNs. The IFNs are a family of multifunctional secreted 
proteins that share a significant amino acid homology with each other and exhibit 
similar biological effects on target cells such as being involved in antiviral defense, 
cell growth regulations and immune activation (Pestka, Langer et al. 1987, Platanias 
1995, Pfeffer, Dinarello et al. 1998, Stark, Kerr et al. 1998). The IFNs are classified 
into two distinct types. Type I IFNs, are produced in response to virus infection, and 
are the product of  the IFN-α multigene family which is predominantly synthesized by 
leukocytes and IFN-β gene which is synthesized by most cell types in particular 
fibroblasts (Goodbourn, Didcock et al. 2000). Type II IFNs consist of the product of 
the IFN-γ gene and is synthesized in response to the recognition of infected cells by 
activated T cells and NK cells (Vilcek and Sen 1996). While the two types of IFNs 
may share amino acid homology (Platanias and Fish 1999), they do not share any 
obvious structural homology (Goodbourn, Didcock et al. 2000).  
 Type I IFNs bind to the Type I IFN receptor, which is a multichain structure 
on normal and malignant hematopoietic cells (Uze, Lutfalla et al. 1995), and is made 
up of two distinct components, IFNAR1 and IFNAR2. The two receptors are capable 
of transducing signals and mediate the biological effects of interferons (Colamonici, 
Domanski et al. 1994). Induction of IFN-α and –β genes are mediated by the pattern 
recognition receptors (PRRs) which includes TLRs (Takaoka and Yanai 2006). The 
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IFNs are crucial in bridging the two aspects of host defense which is the innate and 
adaptive immune systems.  
 
3.1.6. Jak-Stat pathway in Type I IFN signaling 
 The biological activities of IFNs are initiated by binding of the IFNs to their 
cognate receptors on cells surface. A major pathway for the generation of IFN signals 
involves the activation of tyrosine kinases of the Janus family (Jak kinases) and 
tyrosine phosphorylation/activation of Stat-proteins (signal transducers and activators 
of transcription). Two members of the Janus family of tyrosine kinases, Tyk2 and 
Jak1 are constitutively associated with IFNAR1 and IFNAR2 (Uddin, Chamdin et al. 
1995). 
 The outcome of the signaling is the activation of transcription of target genes 
that are usually quiescent. The IFN signaling involves five major steps (Fig. 3.6), in 
which the IFN-driven dimerization of the receptor outside the cells leads to the 
initiation of a tyrosine phosphorylation cascade within the cell that results in the 
dimerization of the phosphorylated STATs and in return activating them for transport 
into the nucleus where these then bind to specific DNA sequences and stimulate 
transcription. The upstream regulatory sequences of more IFN-inducible genes 
contain a variation of the Interferon Stimulating Response Element (ISRE) consensus 
sequence. Prior to stimulation, cytoplasmic domains of the IFNAR1 are associated 
with Tyk2, and IFNAR2, associated with Jak1. In addition to this, IFNAR2 is also 
associated with STAT2. The two subunits associate together upon the IFN binding, 
allowing the transphosphorylation and activation of Tyk2 and Jak1 (Novick, Cohen et 
al. 1994). IFNAR1 is then phosphorylated by Tyk2 and thereby creating a new 
docking site for STAT2 through the SH2 domain on IFNAR1. Tyk2 also goes on to 
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phosphorylate STAT2 which in turns recruits STAT1. STAT1 is subsequently 
phosphorylated. The phosphorylated STAT1/STAT2 heterodimers then dissociated 
from the receptor and translocate to the nucleus to form the ISGF3 heterotrimeric 
complex which binds the ISRE of the IFN-responsive genes (Goodbourn, Didcock et 
al. 2000). 
 
Source: (Takaoka and Yanai 2006) 
Figure 3.7. Activation of Jak-Stat pathway and signaling cascades by Interferons 
(IFNs). 
IFNs are important regulator of the Jak-Stat pathway. Type I IFNs (IFN-α/-β) binds to 
the IFN-α/β receptor, which is made up of two subunits: IFNAR1 and IFNAR2. Both 
of these form a heterodimer upon IFN stimulation such as those encountered during a 
viral infection. The heterodimerization in return activates the two Janus-family 
tyrosine kinases: Jak1 and Tyk2, which in return, phosphorylate STAT1 and STAT2. 
The phosphorylated STAT proteins then dissociate from the heterodimer receptor and 
binds IRF-9, forming a trimeric IFN gene factor (ISGF3) complex [Interferon-
Stimulated Transcription Factor-3]. This complex translocates to the nucleus and 
binds to the element ISRE (IFN-stimulated Response Element) where the 
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transcription of several IFN-inducible genes is initiated. The binding of IFN-γ to its 
receptor, IFNGR-1 and -2, leads to the tyrosine phosphorylation of JAK1 and JAK2, 
which results in the phosphorylation of only STAT1. The phosphorylated STAT1 
protein then homodimerizes to form the GAF-AAF complex. The complex then 
translocates to the nucleus and binds to the GAS element present in most IFN-γ-
inducible genes. Type III IFNs Induces a Type I IFN-like response but utilizes a 
receptor complex different from that of type I IFN, thought to be consisting of 




3.1.7. Interferon Regulatory Factors 
 Interferon Regulatory Factors (IRFs) were first characterized as transcriptional 
regulators of Type I IFNs and IFN-inducible genes. However, its function has been 
found to play a crucial role in the regulation of innate and adaptive immune responses. 
The IRF family of transcriptional factors consists of 9 members in humans and mice 
(Table 3.1): IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-8 (also known as 
ICSBP) and IRF-9 (also known as ISGF3γ) (Mamane, Heylbroeck et al. 1999, 
Taniguchi, Ogasawara et al. 2001). Additionally, IRF-10 while present in chickens are 
absent in humans and mice. Members of the IRFs family share significant homology 
within the conserved N-terminal DNA-binding domain (DBD) which bears a 
resemblance to the binding domain present on Myb transcription factors (Veals, 
Schindler et al. 1992). The DBD present in IRFs are made up of five conserved 
tryptophan repeats which forms a helix-helix domain and recognizes a DNA sequence 
corresponding to the IFN-stimulated response element (ISRE) (Darnell, Kerr et al. 
1994). With the exception of IRF-1 and -2, the C-terminal region contains an IRF-
associated domain (IAD). The region varies among IRF members and promotes 
versatile biological functions where it is responsible for the homo- and heteromeric 
interactions with other family members or other transcription factors.  
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 IRF family members may be classified into four categories based on their 
distinctive functions (Takaoka, Tamura et al. 2008). They are (i) interferonic IRFs, (ii) 
stress-responsive IRFs, (iii) hematopoitetic IRFs, and (iv) morphogenic IRF.  
 
3.1.7.1. Interferonic IRFs 
IRF-3 and IRF-7 are specifically involved in type I IFN gene expression. They 
are related in terms of their primary structures (Nguyen, Hiscott et al. 1997). IRF-3 is 
expressed constitutively in all tissues where it resides in the cytoplasm. It is not 
induced by viral infection or IFN treatment (Au, Moore et al. 1995). On the other 
hand, while being ubiquitously expressed, IRF-7 is totally dependent on IFN-α and –β 
signaling. The phosphorylation of IRF-3 occurs when the susceptible cell is infected 
with viruses. Upon recognition of dsRNA, pattern recognition receptors (PRR) are 
activated which includes Toll-like receptor 3 (TLR3), TLR4, RIG-I, MDA-5 
(Takaoka, Tamura et al. 2008). IRF-3 and IRF-7 form a homodimeric or 
heterodimeric complex with each other and act differentially on Type I IFN gene 
family members. IRF-3 potently activates IFN-β gene whereas IRF-7 preferentially 
activates the IFN-α gene (Sato, Suemori et al. 2000). Resembling their control of the 
IFN-β gene, virus-activated IRF-3 and IRF-7 regulates IFN-λ1 (IL-29) gene. Whereas 
resembling IFN-α genes expression, IRF-7 solely controls the gene expression of 
IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B) (Osterlund, Pietila et al. 2007) 
IRF-2 is known to be a negative regulator to attenuating IFN-α and –β-induced 
gene transcription by antagonizing IRF-1 and IRF-9 (Tamura, Yanai et al. 2008). 
Localized in the nucleus, it is constitutively expressed and IFN-inducible in various 
cell types (Savitsky, Tamura et al. 2010). IRF-9 is also expressed in a variety of 
tissues and has been shown to be essential for the antiviral responses by IFN-α/-β and 
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IFN-γ.(Darnell, Kerr et al. 1994, Taniguchi, Ogasawara et al. 2001). IRF-9 plays an 
important role in the anti-viral effect of Type I IFN. IRF-9 is a major DNA binding 
component of the STAT1 and STAT2 complex whereby becomes the tertiary 
complex ISGF3, in turn binds the ISRE element of ISG and initiates transcription. 
Impairment of this transcription factor effects both Type I and Type II IFN signaling 
(Darnell, Kerr et al. 1994, Kimura, Kadokawa et al. 1996). 
 
3.1.7.2. Stress-responsive IRFs 
 IRF-1 has been shown to participate in Type I IFN gene induction of TLR 
signaling (Negishi, Ohba et al. 2005). It has crucial functions in the development and 
activation of various immune cells and plays an important role in cell cycle regulation 
and apoptosis in response to a variety of genotoxic stresses. 
 The expression of IRF-5 is upregulated in response to Type I IFN signaling 
and viral infection (Mancl, Hu et al. 2005). It plays a critical role in the innate 
immune responses and is involved in TLR-mediated induction of proinflammatory 
cytokines such as IL-6, IL-12 and TNF-α. The transcription factor has been identified 
as a risk factor for systemic lupus erythematosus (Graham, Kozyrev et al. 2006, 
Demirci, Manzi et al. 2007). It also promotes cell cycle arrest and apoptosis in 
response to DNA damage (Yanai, Chen et al. 2007).  
 
3.1.7.3. Hematopoietic IRFs 
 The IRF-4 together with IRF-8 are restricted to hematopoietic cells, including 
lymphocytes, macrophages and dendritic cells (Eisenbeis, Singh et al. 1995). The 
binding affinity in this sub-family is weak and is able to bind to DNA by dimerization 
with other transcription factors.  
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 IRF-8 plays an important role in the differentiation of CD8
+
 DC and 
plasmacytoid DC. It induces IL-12 and is involve in the Th1 response and is therefore 
critical for the regulation of both immunity and oncogenesis.  
 
3.1.7.4. Morphogenic IRF 
 IRF-6 is structurally related to IRF-5 but the former acts as a key regulator of 
keratinocyte proliferation. While the known functions of other IRFs seem to be 
associated with immune responses, apoptosis or growth regulatio, IRF-6 is critical in 
skin, limb and craniofacial morphogenesis (Ingraham, Kinoshita et al. 2006). 
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Source: (Tamura, Yanai et al. 2008) 





3.1.8. IRFs and TLR Signaling 
 The mammalian Toll-like receptor (TLR) family consists of germline-encoded 
transmembrane receptors. Each TLR recognizes various pathogen-associated 
molecular patterns (PAMPs) derived from bacteria, fungi, protozoa or viruses 
(Janeway and Medzhitov 2002). TLRs contain an intracellular Toll/IL-1 receptor (TIR) 
domain which functions to transmit downstream signals by recruiting TIR-containing 
adaptor proteins. One such adaptor is MyD88. Signaling through TLRs can be broadly 
categorized into two pathways: The MyD88-dependent pathway and the MyD88-
independent pathway. All TLRs activate the MyD88-dependent pathway except for 
TLR3. The pathways are linked to the activation of two important downstream 
pathways which is the NF-Kb pathway and the mitogen-activated protein kinase 
(MAPK) pathway (Honda and Taniguchi 2006). Several members of the IRF family 
have been found to be activated by this MyD88-dependent and MyD88-independent 
pathways and contribute to the specific gen-expression programs induced by TLRs.  
 The IRF-4 has been found to form a complex with MyD88 (Negishi, Ohba et 
al. 2005). Despite being localized within the nucleus, a significant amount of IRF-4 
resides in the cytoplasm where it interacts with MyD88. IRF-4 has been found to 
negatively regulate TLR signaling. Honma et al. (2005) and Negishi et al. (2005) have 
found levels of TLR-induced-proinflammatory cytokines are increased in IRF-4
-/-
 
cells. Upon induction with the proinflammatory cytokine inducer CpG-B, IRF-4
-/-
 
mice have been found to be sensitive to endotoxin shock (Krieg, Yi et al. 1995, 
Hemmi, Kaisho et al. 2003). It is of interest to note that IRF-4 and IRF-5 share the 
same binding region on MyD88. TLR-induced IRF-4 can compete and inhibit the 
sustained binding of IRF-5 to MyD88. It has been suggested that IRF-4 function in a 
negative-feedback regulation of TLR signaling. IRF-4 is thought to be able to 
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selectively control MyD88-dependent gene regulation in a cell-specific manner as its 
expression is restricted to B and T lymphocytes, macrophages and DCs (Mittrucker, 
Matsuyama et al. 1997, Suzuki, Honma et al. 2004). 
3.1.9. Interferon Regulatory Factor -4 (IRF-4) 
 IRF-4 has been characterized in several different contexts with different 
terminologies (Taniguchi, Ogasawara et al. 2001): (1) Pips, a binding factor to murine 
immunoglobulin light change enhancer Eλ2-4 in association with PU.1 (Eisenbeis, 
Singh et al. 1995), (2) LSIRF, an IRF family member expressed only in lymphoid 
cells (Matsuyama, Grossman et al. 1995), and (3) ICSAT, a factor that binds to the 
promoter region of human IL-5 gene (Yamagata, Nishida et al. 1996).  
 IRF-4 is restricted in its expression appearing only in B lymphocytes and 
activated T lymphocytes (Matsuyama, Grossman et al. 1995). The transcription factor 
is not induced by interferons but is strongly induced by antigen stimulation such as T- 
and B- cell receptor crosslinking. IRF-4 has been found to bind the MHC-Class I 
interferon stimulated response element (ISRE). The human homolog of IRF-4 was 
cloned and was found to be a 450 amino acid protein with a mass of 51.6 kDa 
(Grossman, Mittrucker et al. 1996) that possesses a high amino acid homology in the 
DNA-binding domain with other IRF family members.  
 Mittrücker, Matsuyama et al. (1997) generated IRF-4
-/-
 by replacing exons 2 
and 3 of the IRF-4 gene that was originally isolated from a 129J genomic library and 
with the neomycin resistance cassette. Positive-transfected E14 embryonic stem cells 
were injected into CD1 blastocysts before chimeric offsprings were mated with 
C57BL/6 mice. Lymph nodes and spleens of young IRF-4
-/-
 mice showed normal 
lymphocyte distribution and cellularity. However at the age of three to four months 
old onwards, splenomegaly had occurred with the spleens being enlarged three to 
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three to five times that of normal mice. Progressive generalized lymphadenopathy was 





 T and B lymphocytes. The thymi of IRF-4
-/-
 mice were found to be 
normal and had normal thymic cell distribution.  
 T cell surface marker analysis revealed that CD2, CD11a, CD18, CD25, CD28, 
CD45, CD54, Fas and Thy-1 were normal. However an increase in CD69
+
 activated T 
cells was observed. B cell surface marker analysis revealed that CD43, IGM, IgD, Igĸ, 
B220 and I-A expression were unremarkable indicating a normal early B cell 
development as with the peritoneal CD5
+
 B1 B cell development. IRF-4
/
 




, and B cell 




. Late stage peripheral B cell 




 B cell subpopulation was 
absent. IRF-4
/  
mice were also lacking plasma
 
cells within the spleen and lamina 
propria. These 6- to 8-week-old IRF-4
/
 mice showed a reduction in serum 
concentrations of all Ig subclasses. It is therefore not surprising that IRF-4
/
 mice 




 Strangely, proliferation of IRF-4
/
 B cells was reduced after LPS stimulation 
and was absent after IgM
 
stimulation. This defective proliferation of IRF-4
/
 B cells 
could not be rescued even with the addition of IL-4. Ig secretion against LPS 




 T cells was reduced 
after exposure to either CD3 mAb, concanavalin
 
A, or the bacterial superantigen 
staphylococcal enterotoxin A
 
(SEA) and was not normalized by the addition of IL-2. 
The peritoneal and splenocytes of IRF-4 had no impairment in MHC processing and 
presentation. IL-2, IL-4 and IFN-  cytokine production after CD3ε mAb stimulation 
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were found to be reduced in IRF4
/
 T cells. IRF4
/
 mice T cells were not able to 
mount a cytotoxic response against lymphocytic choriomeningitis virus (LCMV) after 












 mice were able to mount a allogeneic and provoke a strong T cell 
response.  
 The development of severe lymphadenopathy may be caused by impaired B 
and T cell immune responses in IRF-4
-/-
 mice. Drawing an inference from IL-2
-/-
 mice 
(Willerford, Chen et al. 1995), Mittrücker, Matsuyama et al. (1997) speculated that 
incomplete lymphocyte activation in these mice may affect the  lymphocyte 
homeostasis mechanisms 
 IRF-4 regulates the innate immune response by negatively modulating TLR 
signaling pathways. IRF4
-/-
 were shown to be more sensitive to LPS shock than IRF-4  
+/+ mice (Honma, Udono et al. 2005). In response to LPS and other TLR ligands, 
macrophages from these mice produced higher cytokine levels including TNF-α and 
IL-6 as well as enhanced NF-Kb and mitogen-activated protein kinase (MAPK) JNK 
(c-Jun N-terminal kinase) activation.  
 Conditional deletion of IRF-4 in germinal center B cells-transgenic mice were 
found to lack post-germinal center plasma cells and therefore remains undifferentiated 
as memory B cells (Klein, Casola et al. 2006). This in turn inhibits in generation of 
plasma cells. IRF-4
-/-
 B cells were also found to lack immunoglobulin class-switch 
recombination. Negishi, Ohba et al. 2005 found that IRF-4 binds with MyD88 to form 
a complex to regulate TLR-dependent induction of proinflammatory cytokines and 
type I IFNs. IRF-4 was observed to be a competitor to IRF-5 for MyD88 binding. The 





 peritoneal macrophages showed an enhanced TLR induction of 
proinflammatory cytokines. IRF-4
-/-
 is speculated to participate in the negative-
feedback regulation of TLR signaling where knocked-out mice fared worse in 
MyD88-dependent mediated-unmethylated DNA-induced shock.  
 The immunoglobulin λ light (IgL λ) chain enhancers direct the transcriptional 
regulation of IgL λ chain genes and act as binding sites for tissue-specific and 
ubiquitous transcription factors (Staudt and Lenardo 1991). These enhancers contain a 
cell type-specific composite element that is activated by a B-cell-specific 
heterodimeric protein complex (Pongubala, Nagulapalli et al. 1992), which consists of 
hematopoietic-specific protein PU.1 and IRF-4 (Pongubala, Van Beveren et al. 1993). 
PU.1 is a hematopoietic Ets family transcription factor that is required for the 
development of macrophages, granulocytes and lymphocytes (Scott, Simon et al. 
1994, McKercher, Torbett et al. 1996). Escalante, Brass et al. 2002 and Escalante, 
Shen et al. 2002 cocrystallised the PU.1 Ets and IRF-4 DNA binding domains with a 
composite 21-bp DNA element from the IgL λ gene enhancer containing overlapping 
ETS and IRF sites in order to investigate the stereochemical basis of cooperativity and 
anticooperativity between Ets and IRF. The ternary PU.1/IRF/DNA complex provides 
an insight to the protein-protein and protein-DNA interactions for the selective 
assembly of PU.1-IRF-4 complexes which are involved in the development and 
functioning of the immune system. Cooperatively, PU.1 and IRF-4 bind to the 
composite elements found in promoters and enhancers of B-lymphoid and myeloid 
genes (Eisenbeis, Singh et al. 1995, Brass, Kehrli et al. 1996, Marecki, Riendeau et al. 
2001) While PU.1 binds independently to the recognition site located in the composite 
DNA elements with high affinity, IRF-4 binds weakly to the template DNA when 
PU.1 is absent (Escalante, Brass et al. 2002). 
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 Lohoff, Mittrücker et al. (2002) used mice model of leishmaniasis to elucidate 
the IRF-4 role in Th1 and Th2 differentiation. It was discovered that IL-12-induced 
Th1 cell differentiation was affected in the absence of IL-4, whereas IL-4 had no 
impact on Th2 cell differentiation. IL-4 supported the induction of Th1, characterized 
by IFN-γ and TNF production. In IRF-4-/- Th cells, early IL-4 signaling appeared 
normal but GATA-3 (Trans-acting T-cell-specific transcription factor) responsible for 
IL-4, IL-5, and IL-13 secretion, from these Th2 cells, was not up-regulated after IL-4 
treatment. It appears that IRF-4 acts upon Th cells directly and not through the 
regulation of TL-12 production by APC. 
 Tominaga, Ohkusu-Tsukada et al. (2003) investigated the role of IRF-4 in 
CD4
+ 
T cell function by challenging IRF-4
-/-
 mice with Leishmania major. Mice were 
found to be protected during the early phase of infection and IFN-γ was secreted by 
CD4
+
 T cells in response to L. major antigen. Lymphocytes numbers present within 
the draining lymph nodes dropped during the later stages of the infection which 
resulted in the deterioration of the lesion. This showed that IRF-4 was needed for a 
sustained immune response against the intracellular pathogen. CD4
+
 T cells isolated 
from IRF-4
-/-
 crossed with the OT-II Ova323-339 TCR specific transgenic mice 
revealed that cells were capable of producing IFN-γ and expressed Th1-specific 
transcription factor T-bet under Th1-skewing culture conditions. However, Th2 
development was impaired in CD4
+




 T cells 
proliferation to IL-4 was reduced in IRF-4
-/-
 mice which demonstrated a defect in IL-4 
responsiveness. IRF-4 is critical in CD4
+
T cell subset development and IRF-4 is not 









 T helper (Th) cells are susceptible to apoptosis and 
concluded that IRF-4 may be central in protecting CD4
+
 T cells against proapoptotic 
stimuli. They found that the IRF-4
-/-
 mice developed prototypic lymphadenopathy in 
the lesion-draining lymph nodes just as in wild-type mice four week post-infection. 
The lymphadenopathy however showed a loss of cellularity and enhanced apoptosis 7 




 Th cells activation 
led to an increased in apoptosis compared to wild-type cells. The enhanced rate of 
IRF-4
-/-












survival. This was also not caused by a lack of any cytokine. Despite having a normal 
Fas receptor CD95 expression, which is present on apoptotic cell surface, elevated 
level of CD4
+
 apoptosis was observed after anti-CD95 mAb treatment. Removal of 





 cell apoptosis. Despite normal expression of the IL-4 receptor, the protective 




 T cells.  
 Grumont and Gerondakis (2000) demonstrated that the ConA, anti-CD3 + 
anti-CD28, phorbol ester, LPS, anti-radioprotective or anti-IGM antibodies mitogen 
induced expression of IRF-4 is Rel transcription factor dependent. In lymphocytes, 
Rel/NF-ĸB proteins (Gerondakis, Grumont et al. 1998) are essential for lympchocyte 
activation and immune function. The proteins regulate gene expression by binding to 
specific sequences located within regulatory regions of cellular genes involved in 
acute phase immune and inflammatory responses   (Baeuerle and Henkel 1994, 





This chapter describes experiments conducted with the specific aims to:- 
1. Establish a mouse adaptation model of severe influenza pneumonitis using 
infections of  two antigenically distinct strains of: (i) Influenza A/Puerto 
Rico/8/1934 (PR8) H1N1 and (ii) a Balb/c-mouse strain serially-passage 
Influenza A/Aichi/2/1968 (Aic68) H3N2 viruses in the transcription factor 
IRF-4 wildtype (+/+) and IRF-4 knockout (-/-) mice in C57BL/6 
background. 
 
2. Clarify the role of IRF-4 in Humoral and Cell-Mediated Immune responses 
against two antigenically distinct strains of InfAV, namely A/Puerto 
Rice/8/1934 (PR8) H1N1 and mouse-adapted A/Aichi/2/1968 (Aic68) 
H3N2 infection in infected IRF-4 -/- mice. 
 
3. Determine if IRF-4 affects function of innate immunity, influenza viral 
clearance and lethality of infected mice. 
 
4. Study the pathway through which IRF-4 affects the immunopathology of 
infected mice.  
 
3.3. HYPOTHESIS 
Interferon Regulatory Factor-4 (IRF-4) is essential for modulating or eliciting host 
adaptive immune responses against Influenza A pneumonitis. 
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3.4. MATERIALS AND METHODS 
3.4.1. Experimental Methodology 
 
Figure 3.8. Overview of Experimental Methodology used for this research project, 
summarizing IRF-4 mice of both sexes, age used, experimental numbers and 
experimental repeats conducted. Two Influenza A virus strains (PR8 H1N1 and 
mouse-adapted Aichi H3N2 (Aic68)) were used as the infectious agent. Upon 
infection, mice were monitored daily for its bodyweight change over a two-week 
period. Mice were culled once their bodyweight loss were above 25-30% of their 
original bodyweight and blood and lungs were harvested. Lungs were subjected to 
histopathology scoring in a double-blinded manner. Sera were isolated from blood 
and neutralization test was conducted to determined its antibody response against the 
PR8 InfAV. Lung Viral titres were determined through plaque assay and cross-
referenced with qRT-PCR of NS1. Cytokine expression analysis of mice lung were 
determined  using a 23-Plex Panel of BioPlex Multiplexing Immunoassay. Cytokine 




























Table 3.2. Variables investigated in the PR8 H1N1 InfAV study: three IRF-4 
genotypes (IRF-4 +/+, IRF-4 +/- and IRF-4 -/-), two treatment groups ([uninfected] 
PBS-mock-infected control and PR8 H1N1 InfAV-Infected) and both sex groups 
(male and female). Five mice per variable group were used for the Uninfected Mock-
Control group whereas 10 mice per variable group were used for the InfAV-infected 
group. The study was conducted over two experimental rounds to ensure 




Male and female heterozygous (+/-) and double-knockout (-/-) IRF-4 mice 
with C57BL/6 background were gifts from Toshifumi Matsuyama and Kiri Honma 
(Nagasaki University, Japan). These were used to start the colony housed under 
specific pathogen-free conditions. Littermates of wildtype (+/+) mice were used as 
controls.  
 
3.4.4. DNA extraction from Mouse Tail 
Mice were genotyped at weaning at three weeks of age by tail snipping and 
mincing snips in tail lysis buffer. Approximately 0.5 to 1cm of tail was snipped off 
using alcohol-sterilized scissors and placed into a 1.5ml microcentrifuge tube. 
Bleeding was stopped by applying pressure as well as SuperClot™ (Synergy Labs, 
Florida, USA) styptic gel. A volume of 0.5mL of tail lysis buffer (100mM Tris-HCl 
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pH 8.5, 200mM NaCl, 5mM EDTA, 0.2% SDS) was then added before mincing. 
0.03mg of Proteinase K (Sigma-Aldrich, Missouri, USA) was then added before 
incubation for at least four hours to overnight in a 58°C water bath. The mixture was 
then added with 0.5mL of phenol:chloroform (1:1) (Phenol equilibrated with 10 mM 
Tris HCl, pH 8.0, 1 mM EDTA, Sigma-Aldrich, Missouri, USA) (Chloroform; J.T. 
Baker, New Jersey, USA). The solution was mixed by vortexing for 1 minute before 
centrifuged at 10,000 rpm 10 min at 4°C. The top aqueous layer was then removed to 
a fresh 1.5ml microcentrifuge tube. A volume of 1ml of ice-cold absolute alcohol was 
added, re-capped and mixed by inversion until the DNA precipitated. The DNA was 
then removed to another fresh 1.5mL microcentrifuge tube. A volume of 1ml of 70% 
ethanol was then added to wash the DNA. After removal of ethanol by pipetting, the 
precipitated DNA was air dried before adding 0.1ml of sterile water. The DNA was 
placed on a rocker overnight at room temperature to allow it to dissolve before storage 
at 4°C until use. 
 
3.4.5. Genotyping 
The primers for IRF-4 and Neo are as follows: 
(i) IRF-4 (exon2)   150 bp 
Forward         5'-GCAATGGGAAACTCCGACAGT-3' 
Reverse       5'-CAGCGTCCTCCTCACGATTGT-3' 
(ii) NEO 500bp        
Forward         5'-CCGGTGCCCTGAATGAACTGC-3' 
Reverse        5'-CAATATCACGGGTAGCCAACG-3' 
  Cycling condition is as follows: denaturing at 94’C for 30 sec, annealing at 
60’C for 1min, and extension at 72’C for 1min for 26 cycles, for IRF-4 and NEO 500.  
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The IRF-4 primer pair amplifies a 150bp template residing within exon 2 of IRF-4 
gene whereas the NEO primer pair amplifies a 500bp template within the NEO 
cassette. The PCR products were subjected to gel electrophoresis using 3% NuSieve 
gel made in TBE buffer and ran at 80V for 45 minutes and visualized under UV light. 
                   IRF-4 
              -ve     +/-    -/-    +/+ 
                                                          Ctrl    
 
Figure 3.9. Sample of PCR product for IRF-4 genotyping ran on 3% agarose gel made 
in TBE buffer exhibiting PCR product of Neo (500bp) and IRF-4 (150bp). Genotype 





Influenza A/Puerto Rico/8/1934 H1N1 (PR8) was previously obtained from 
American Type Culture Collection, Virginia, USA, and propagated in 10- to 11-day 
old embryonated chicken eggs by intra allantoic inoculation. Viruses present in 
allantoic fluid were harvested after incubation at 35ºC for two days, aliquoted in 1 ml 
volumes in 1.5ml cryotubes and stored at -80°C until use. Viruses were fully thawed 
on ice, diluted in sterile 1X PBS and filter sterilized using 0.45µm syringe filter units 
(Sartorius Stedim Biotech, Germany) immediately before use and kept on ice until 
administration. 
Influenza A/Aichi/2/68 H3N2 (Aic68) adapted to Balb/c mice through serial 





homogenates were obtained from mice infected with mouse-adapted Influenza 
A/Aichi/2/68 H3N2 which were euthanized 2 days-post infection. Lungs were 
combined and homogenized in phosphate-buffered saline (PBS) containing 1000U/l 
penicillin and 10mg/l streptomycin (Sigma, USA), centrifuged at 10,000 rpm 4°C 10 
min. Serial passaging was repeated until the twelfth (12
th
)-passage was obtained and 
used for mice infection. 
 
3.4.7. Viral plaque assay 
MDCK (Madin-Darby Canine Kidney, ATCC American Type Culture 
Collection, Virginia, USA) cells were maintained in Eagle’s Minimum Essential 
Medium (EMEM), supplemented with 10% fetal bovine serum (Biowest, Florida, 
USA). Confluent MDCK cells grown in T-75 flasks (Corning, New York, USA) were 
detached with Trypsin (PAA Laboratories, Austria)  in 1x PBS twice for three to six 
minutes each at 37°C. Trypsinization was stopped each time with the addition of 
EMEM + 10% FBS.  Approximately 2 x10
5
 MDCK cells/well were seeded in 24-well 
cell culture plate (Greiner Bio-One, Germany) and grown overnight.  Viruses were 





Media were removed from monolayer MDCK cells grown overnight in 24-well cell 
culture plates and washed with 1x PBS. Diluted viruses in 100µl volume of EMEM + 
1µg/ml TPCK-treated trypsin (Sigma-Aldrich, Missouri, USA) were then added to 
cells and incubated at 37°C for 1h to allow viruses to attach to the cells, with 
occasional rocking every 15min. A volume of 100µl of EMEM was added to control 
MDCK cells. After incubation, remaining viruses in media were removed and 1ml of 
1.2% microcrystalline cellulose Avicel RC-581 (FMC BioPolymer, Philadelphia, 
USA; Stock solutions of 2.4% Avicel were dissolved in water on a magnetic stirrer 
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for 1h before sterilizing by autoclaving for 20 min at 121°C and stored at 4°C until 
use) in EMEM was added. Plates were then incubated at 35°C for three days. After 
three days of incubation, Avicel was removed and cells were fixed with 
approximately 1ml 20% formalin for 1hr at room temperature. After removal of the 
formalin, cells were stained with approximately 1ml 1% Crystal Violet (Sigma-
Aldrich, Missouri, USA) earlier dissolved in water, for 1hr at room temperature. 
Wells were then washed with water and air-dried before visible plaques were counted 
and tallied.  
 
3.4.8. TCID50 assay 
2 x 10
4
 of Madin-Darby canine kidney (MDCK) cells suspended in Eagle’s 
Minimum Essential Medium (EMEM) with 10 % Fetal Bovine Serum (FBS) were 
seeded into each well of a sterile 96-well, flat-bottomed polystyrene plate (Cellstar) 
and incubated for 24 hours at 37
o
C under 5% CO2 atmosphere until confluent. 
After the 24 hours incubation, the confluent cell monolayer was washed thrice 
with serum free EMEM and 100μl of serum free EMEM containing 2μg/ml of TPCK-
Trypsin was added to each well. One log10 serial dilution of the samples containing 
influenza virus was carried out in serum free EMEM and 25μl of each dilution was 
inoculated into the cells in duplicates. The 96-well plate was sealed and incubated at 
35°C and 5% CO2 for 72 hours. The cells were observed for cytopathic effect (CPE) 
and the median Tissue Culture Infectious Dose (TCID50) is defined as the highest 






3.4.9. Intratracheal infection 
All animal experiments were carried out under the guidelines of the 
Institutional Animal Care and Use Committee, National University of Singapore. 
Genotyped (+/+, +/- and -/-) eight to sixteen-week old male and female mice were 
kept under specific pathogen-free conditions in individual ventilated cages. Mice were 
anaesthesized intraperitoneally with mice anaesthesia (Comparative Medicine Centre, 
National University of Singapore, Ketamine 7.5mg/mL, Medetomidine 0.1mg/mL) at 
50μL / 10g body weight. Mice were propped cranial side up using a clean dental floss 
supporting the incisor teeth. With the ventral side of the mouse facing the worker, the 
tongue was scooped out, pressed down and secured laterally with a sterile pipette tip 
to restrict deglutition. 50µl of prepared virus solution were then administrated by a 
pipetter into the oropharynx. Nostrils were then immediately closed until all liquid 
was observed to be emptied from the oral cavity. Effects of the mice anaesthesia were 
reversed by administrating intraperitoneally 1:100 dilution of Antisedan
®
 (stock 
5mg/mL Atipamezole Hydrochloride, Pfizer, Australia) at 50μL / 10g body weight. 
Mice body weights were monitored daily.  
 
3.4.10. Intranasal Infection  
Mice were anaesthesized intreperitoneally with 0.3 – 0.4ml of 1.2% Avertin (2, 
2, 2 – Tribromoethanol, Sigma, USA). Mice were held by the scruff of the neck, 
cranial side up. With the aid of a pipetter, 35µl of lung homogenate was delivered 






3.4.11. Mice euthanization, harvesting of organs and serum from blood 
Mice were euthanized by carbon dioxide inhalation in a top-opening chamber 
whereby after animals were placed inside, a flow of 5L/min of CO2 was introduced to 
establish a high concentration at the bottom of the chamber. After the animals 
appeared to be unconscious and all movements appeared to have ceased, the flow was 
increased to 10L/min for an additional 5min. Blood was immediately collected for 
serum preparation by intracardiac puncture using a 1ml syringe and 25 gauge needle 
(Becton, Dickinson, USA).  
Blood (approximately 0.6-0.9 ml) was collected in a 1.5ml micro-centrifuge 
tube and allowed to stand at room temperature to clot before centrifugation at 
12,000rpm for 10min at 4°C (Eppendorf, Germany). The supernatant was then 
transferred to a fresh sterile micro-centrifuge tube and stored in -80°C until use. 
Lungs were harvested by three cross sections of roughly equal sizes of both 
sides of lungs. A pair of lung slice, together with brain and heart was fixed in 4% 
formaldehyde for histologic analyses, whereas remaining lung slices were transferred 
to separate tubes of sterile micro-centrifuge tubes and stored at -80°C until use. 
 
3.4.12. Lung homogenization 
Frozen lung pieces were transferred to gentleMACS™ M tubes (Miltenyi 
Biotec, California USA) containing 0.5ml sterile ice-cold 1xPBS. Lungs were 
homogenized at 4°C in gentleMACS Dissociator (Miltenyi Biotec, California USA) 
on the RNA_02 program. The tubes were pulse-centrifuged to collect contents before 
being transferred to a sterile 1.5ml microcentrifuge tubes and centrifuged at 10,000 
rpm 10min 4°C (Eppendorf, Germany). The supernatant (lung homogenate) was 
collected and transferred to a fresh sterile 1.5ml microcentrifuge tube and used 
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immediately for RNA extraction and purification and the balanced was stored at -
80°C.  
 
3.4.13. RNA extraction and purification 
A volume of 0.3ml (corresponding to no more than 30mg lung in weight) of 
lung homogenate was used in the extraction and purification of total RNA using 
RNeasy kit (Qiagen, Germany). Firstly, 0.6ml of RLT Buffer containing guanidine 
thiocyanate (added with 0.143mmol β-mercaptoethanol/ml of RLT buffer) was added 
to 0.2ml lung homogenate. One volume (0.7ml) of 70% Ethanol was added, mixed 
immediately before transferring to an RNeasy spin column, to allow the binding of 
total RNA to the silica-gel membrane and centrifuged at 8000xg for 20sec at room 
temperature. This was repeated until all of the mixture was centrifuged. The flow-
through was discarded after each centrifugation. The spin columns were then washed 
once with 0.35ml RW1 buffer. 27.3 Kunitz units of DNase I (Qiagen, Germany) in 
80ul of RDD Buffer was added directly to each spin column membrane and incubated 
at room temperature for 15min before being washed once in 0.35ml RW1 Buffer. The 
spin columns were washed twice in 0.5ml RPE Buffer (earlier diluted in four volumes 
of absolute ethanol) by centrifugation at 8000xg for 20 sec at room temperature. RNA 
was eluted twice by applying 30µl RNase-free water each time directly to spin 
column membranes and subjected to centrifugation at 8000xg for 1min at room 
temperature. Purified total RNA was then stored at -80°C until use. 
 
3.4.14. RNA quantification and RNA integrity 
A volume of 2µl purified RNA was used to determine the purity and 
concentration using a ND-1000 Nanodrop spectrophotometer (Thermo Fisher 
 116 
 
Scientific, USA). The ratio of the absorbance at 260 and 280nm (A260/280) was used to 
assess the purity of RNA. Samples were regarded as pure if A260/280 was ~2. The ratio 
of the absorbance at 260 and 230nm (A260/230) was used as a secondary measure of 
RNA purity from organic compounds. Samples were regarded as pure if A260/230 was 
above 2.  
A 1.2% agarose (SeaKem LE Agarose, Cambrex BioSciences, USA) was 
casted in 0.5X Tris-Borate-EDTA buffer (previously diluted in diethyl pyrocarbonate 
(DEPC)-treated water + Ethidium Bromide (10 mg/ml) (Bio-Rad, USA)). A volume 
of equivalent to 500ng extracted total RNA was loaded per well and subjected to gel 
electrophoresis at 50V for 25min. 18s and 28s RNA bands were observed using a UV 
transilluminator (Vilber Lourmat, France).  
 
3.4.15. Reverse Transcription Reaction 
A volume equivalent to 1µg extracted total RNA was added to 0.5µg random 
hexamer primers (Promega, USA), heated in a microcentrifuge tube at 70°C for 5min 
using a PTC-200 thermalcycler (Peltier Thermal Cycler, MJ Research, USA) and 
immediately cooled on ice. To this, a master mix containing 1X Moloney Murine 
Leukemia Virus Reverse Transcriptase (M-MLV RT) reaction buffer (Promega, USA), 
0.5 mM dNTP (dATP, dCTP, dGTP, dTTP) mix (Promega, USA), 25units 
Recombinant RNasin
®
 (Promega, USA) Ribonuclease Inhibitor, 200units M-MLV 
RT (Promega, USA) and topped up to a final volume of 25µl nuclease-free water 
(Promega, USA) was added. The reaction was performed at 1h at 37°C and 





3.4.16. Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR was performed on a LightCycler
® 
480 Instrument (Roche, 
Switzerland) using a 384-multiwell plate. cDNA were diluted 1:5 with nuclease-free 
water (Promega, USA) after which 2.5µl diluted cDNA was used as template for 
qRT-PCR reactions containing 0.5µM forward and reverse primers each and 5µl 2x 
LightCycler
® 
480 SYBR Green I Master and topped up to 10µl with PCR-grade water 
(Roche, Switzerland). Table 3.3: Quantitative Real Time-PCR parameters list the 
running parameters of the qRT-PCR. Primers sequences for Mouse Beta Actin 
(PrimerBank ID 6671509a1), IRF-3 (PrimerBank ID 8393627a1), IRF-4 (PrimerBank 
ID 7305519a1), IRF-7 (PrimerBank ID 8567364a1), IRF-8 (PrimerBank ID 
6680339a1), MyD88 (PrimerBank ID 6754772a1), NFKB2 p49/p100 (PrimerBank ID 
9506921a1) and TNF-α (PrimerBank ID 7305585a1) were obtained from PrimerBank 
(Wang and Seed 2003, Spandidos, Wang et al. 2008, Spandidos, Wang et al. 2010). 
Other primer sequences obtained were mouse IFN-β (Hida, Ogasawara et al. 2000, 
Ogasawara, Hida et al. 2002), mouse IFN-γ (Overbergh, Giulietti et al. 2003), mouse 
IRF-1 (Pattyn, Speleman et al. 2003) and  mouse IRF-5 (Takaoka, Yanai et al. 2005). 
Setup 
Detection Format Block Type Reaction Volume 
SYBR Green 384 10 µl 
Programs 
Program Name Cycles Analysis Mode 
Pre-Incubation 1 None 
Amplification 50 Quantification 
Melting Curve 1 Melting Curves 
Cooling 1 None 
Temperature Targets 
Target (°C) Acquisition 
Mode 





95 None 05:00 4.8 - 
Amplification 
95 None 00:10 4.8 - 




72 Single 00:15 4.8 - 
Melting Curve 
95 None 00:05 4.8  
65 None 01:00 2.5  
97 Continuous - - 5 
Cooling 
40 None 00:10 2.0  


























































































































































































































































































































































































































































































































































































































































































































































































Table 3.4. Forward and Reverse Primers used in Quantitative Real-Time Polymerase 
Chain (qRT-PCR) Reactions to determine Lung Homogenate mRNA levels, Expected 
qRT-PCR Product Length (base pairs) and the amplification temperature used for the 



























Table 3.5. Forward and Reverse Primers used in Quantitative Real-Time Polymerase 
Chain (qRT-PCR) Reactions to determine Lung Homogenate mRNA levels, Expected 
qRT-PCR Product Length (base pairs) and the amplification temperature used for the 













































































































































































































































































































































































































































































































































3.4.17. Analyzing Quantitative real-time PCR data by the comparative CT 
method 
 In essence, for each IRF-4 genotype (IRF-4 +/+, +/- and -/-) and each sex, five 
PBS-mock-infected mice [uninfected] and 10 PR8-infected mice were used. The 
infection study was performed twice to ensure reproducibility. Other studies (such as 
weight lost, lung histopathology, cytokine analysis of the lung homogenate by 
Bioplex) and subsequently microarray analysis, performed in this investigation did 
not show any variability in sex of the mice used, in terms of the PR8 infection. The 
sex variability of experimental mice was then omitted from further analysis. Therefore, 
this analysis consisted of a total of 20 PBS-mock-infected mice [uninfected] and 40 
PR8 H1N1 InfAV-infected mice for each of the three IRF-4 genotypes. However, 
mice found dead over the course of the infection, were excluded from this analysis as 
the degradation of the lung tissue may play an important factor in affecting the 
integrity of the experimental data.  
 The Comparative CT Method, also known as the ΔΔCT Method uses arithmetic 
formulas to achieve the results for relative quantitation (Schmittgen and Livak 2008).  
Data (column number shown in parentheses) and sample calculations shown in 
Appendix 8.10. This involved: 
(i) Calculating the mean values of the replicate CT values for the Target Gene of 
Interest (Column D) and the Housekeeping Gene (normalizer) (Column E) in both 
the PBS-mock-infected Control (Ctrl) and PR8 H1N1 InfAV-infected Test groups.  
Values of CT, is calculated based on the time, which is measured in PCR cycle 
numbers, at which the reporter fluorescent emission increases beyond a threshold 
level, based on the background fluorescence of the system. The CT value is 
correlated to the input target mRNA levels where a greater quantity of input 
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mRNA target results in a lower CT value. This would result in a lower PCR cycle 
required for the reporter fluorescent emission intensity to reach the threshold. 
(ii) Calculating the individual ΔCT value for both PBS-mock-infected Control and 
PR8 H1N1 InfAV-infected Test groups (Column F), whereby;  
ΔCT = CT Target - CT Endogenous Housekeeping Reference  
(iii) Calculating the Group mean ΔCT value (Column G) by determining the average 
from individual ΔCT Control Mock-Infected Samples  
(iv) Calculating the ΔΔCTvalue (Column H), whereby; individual ΔCT Test Infected Samples 
are subtracted from the group mean ΔCT Control Mock-Infected Samples 
ΔΔCT = Individual ΔCT Test Infected Samples – Group Mean ΔCT Control Mock-Infected Samples  
(v) Calculating Comparative Expression Level (Fold Change) (Column I), whereby; 
 Fold Change = 2
-ΔΔC
T;  
The amount of target (Test Infected Samples), normalized to an endogenous 
housekeeping reference (Beta Actin) and relative to a calibrator (Control Mock-
Infected Samples).  
(vi) The Mean Fold Change (Column J) was derived by obtaining the Mean 
Comparative Expression Level.   
(vii) Calculating standard deviation (Column K) of 2-ΔΔCT. 
(viii) If  however ‘ΔCT Test Infected Samples’ is greater than ‘ΔCT Control Mock-Infected Samples’,   
then the value of  2
-ΔΔC
T will be less than 1. This would imply that there was a 
reduction in the expression due to the infection. In this case, the negative inverse 
of 2
-ΔΔC
T will provide the fold change reduction in expression.  
Reduction in fold change due to infection = -1 / 2
-ΔΔC
T  
(ix) Statistical analysis was obtained by performing a one way ANOVA of each Mean 




Formalin-fixed organs (brain, heart and lungs) were processed, embedded in 
paraffin wax and sections of 4µm thickness were cut. Brain, heart and lung sections 
were deparaffinized and hydrated after which sections were stained in Harris’ 
haematoxylin for 6-15min before rinsing in tap water. Differentiation in 0.5% acid 
alcohol was then done in 1-2 quick dips followed by another wash. Sections were then 
dipped two to three times in ammonia water until sections are bright blue and then 
washed in running water for 10-20min. These were then rinsed in 70% alcohol for 15-
30 seconds and counterstained with 1% alcoholic eosin for 1-2min and then 
dehydrated in 95% alcohol, followed by absolute alcohol and xylene before mounting.  
 
3.4.19. Lung Injury Score 
Each slide was evaluated by two separate investigators in a blinded manner. 
To generate the lung injury score, a total of 300 alveoli were counted on each slide at 
x400 magnification. Within each field, points were assigned according to pre-
determined criteria (Table 3.6). All of the points for each category were added and 
weighted according to their relative importance. The injury score was calculated 
according to the following formula: injury score = [(alveolar hemorrhage points/no. of 
fields) + 2 x (alveolar infiltrate points/no. of fields) + 3 x (fibrin points/no. of fields) + 
(alveolar septal congestion/no. of fields)]/total number of alveoli counted (Matute-
Bello, Winn et al. 2001). 
 














delicate in less than 1/3 
of the field 
in 1/3 to 2/3 of 
the field 
in greater than 





At least 5 
erythrocytes per 
alveolus in 1 to 
5 alveoli 
At least 5 
erythrocytes per 
alveolus in 5 to 
10 alveoli 
At least 5 
erythrocytes per 
alveolus in more 







in less than 1/3 
of the field 
Fibrin strands 
in 1/3 to 2/3 of 
the field 
Fibrin strands in 
greater than 2/3 




Less than 5 
intra-alveolar 
cells per field 
5 to 10 intra-
alveolar cells 
per field 
10 to 20 intra-
alveolar cells 
per field 
More than 20 
intra-alveolar 
cells per field 
 
Table 3.6. Quantitative Histopathology Score of Lung Injury 
 
3.4.20. Neutralization Assay 
MDCK (Madin-Darby Canine Kidney, ATCC, USA) cells were maintained in 
Eagle’s Minimum Essential Medium with Earle’s Balanced Salt Solution (EMEM) 
(ATCC, USA) without the addition of Penicillin / Streptomycin antibiotics but 
supplemented with 10% fetal bovine serum (Biowest, USA). Confluent MDCK cells 
grown in T-25 flasks (Corning, New Yoek, USA) were detached with Trypsin (PAA 
Laboratories, Austria)  in 1x PBS twice for three to six minutes each at 37°C. 
Trypsinisation were stopped each time with the addition of EMEE + 10% FBS.  
Approximately, 2 x 10
5
 MDCK cells/ml were seeded in 96-well flat bottom plate 
(Nunclon surface, Nunc, Denmark) and grown overnight.  Media was then removed 
by aspiration and washed twice by using 100µl media. Media was not removed till 
viral neutralization was completed. 
Sera was prepared by filter-sterilizing using Ultrafree
®
-MC 0.45µm 
centrifugal filter device (Millipore, USA) at 12,000xg 4min room temperature and 
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complement inactivated by heating in a waterbath at 56°C 10min. Sera was diluted 
1/8
th
 using 30µl sera which was added to 210µl Eagle’s Minimum Essential Medium 
with Earle’s Balanced Salt Solution (EMEE) (ATCC, USA) without the addition of 
Penicillin / Streptomycin antibiotics nor FBS, to the first column of a 96-well flat 
bottom plate (Nunclon Surface, Nunc, Denmark). 2x serial-dilution was then 
performed by removing 120µl of the 1/8
th
 diluted sera of the first column to the 
subsequent well filled with 120µl media. A total of 7 steps of 2x serial dilution was 
performed ranging from 1 in 8 to 1 in 1024 dilutions of original concentration (1 in 8, 
1 in 16, 1 in 32, 1 in 64, 1 in 128, 1 in 256, 1 in 512 and 1 in 1024 dilutions). A 
volume of 65µl from each well of the original plate was transferred to a fresh plate. 
65µl of Influenza A/Puerto Rico/8/1934 H1N1 virus at a concentration of 100 TCID50 
was added to all wells to give a final concentration of 1 x 10
-3
 TCID50. The contents 
of the plate were mixed by tapping on the sides before incubation in a 5% CO2 
incubator at 35°C for 2 hrs. 
Upon completion of incubation, washes of the MDCK cells was removed and 
100µl media containing TPCK Trypsin (final concentration 3µg/ml per well) (Sigma-
Aldrich, Germany) was added to each well. A volume of 50µl of the 2hr-incubated 
sera + virus was added to the plate containing the MDCK cells in duplicates. The 
plate was incubated for 72hrs in a 5% CO2 incubator at 35°C after which the presence 
of cytopathic effect (CPE) was observed using low-power light microscopy. Wells 





3.4.21. Bioplex Cytokine Assay 
 Bio-Plex Pro™ (Bio-Rad, USA) was used for cytokine level determination 
from lung homogenates. A volume of 198µl of lung homogenate was brought out 
from -80°C and gently thawed on ice. To this was added 22µl of 1X PBS + 10% 
Bovine Serum Albumin (BSA) (Sigma, USA) + 10X Complete Mini (Protease 
Inhibitor Cocktail, Roche, Germany), giving a final concentration of 1% BSA and 1X 
protease inhibitor cocktail. Lyophilized standards were reconstituted in 500µl solution 
of 1X PBS + 1% BSA + 1x protease inhibitor cocktail, mixed and incubated on ice for 
30min. The cytokine concentrations specified for an 8-point standard dilution set have 
been selected for optimized curve fitting using the five-parameter logistic (5PL) 
regression in Bio-Plex Manager™ software. Therefore, 10 4-fold dilutions (1 in 4 to 1 
in 262 144) were performed. A volume of 256µl of the reconstituted standard was 
transferred to a fresh tube containing 144µl buffer. After mixing by pipetting, 100µl 
was transferred to another fresh tube containing 300µl buffer. This was performed a 
total of 10 times, thereafter the first two lowest dilutions were disregarded in the 
actual assay. Concentrated (10x) coupled beads slurry (5µl) were diluted to 1x with 
assay buffer before being dispensed to each well of a pre-wetted 96-well filter plate, 
to give a final volume of 50µl.  A volume of 50µl room temperature-equilibrated 
diluted standards and samples were then dispensed into each well in duplicates. The 
plate was then incubated on a shaker at room temperature for 30min. 1x Detection 
antibody was prepared by diluting 2.5µl per well 10x concentrated detection antibody 
with diluent. The plate was washed three times on a Bio-Plex Pro wash station before 
25µl of 1x detection antibody was dispensed per well. Plates were then incubated on a 
shaker at room temperature for 30min. 1x streptavidin-PE was prepared from 100x 
concentrate by diluting 0.5µl per well concentrate diluted to 1x with assay buffer. 
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Plates were washed three times with the wash station before 50µl were dispensed to 
each well. Plates were incubated at room temperature for 10 min after the incubation, 
plates were washed three times again and 125µl assay buffer were added to each well 
before being incubated with shaking at 1000rpm at room temperature for 30sec. Plates 
were read using a Bio-Plex reader and analysed using the Bio-Plex Manager software 
version 5.0.  
 To calculate the fold change of the PBS-mock control infected groups and the 
PR8-infected test groups and subject the data to statistical analysis, the following 
steps were taken: 
(i) The means were obtained from the absolute concentration for each cytokine 
investigated from the PBS-mock control infected groups for its respective 
genotype. 
(ii) The fold change was derived from the ratio obtained from each individual 
absolute concentration for each cytokine investigated from the PR8-
infected test group over the means obtained from step (i) of the PBS-mock 
control infected group, for its respective genotype. 
(iii) The standard deviation was then calculated based on the data obtained from 
step (ii), for its respective genotype.  
(iv) Statistical analysis was calculated based on a one-way ANOVA of the fold-
change of the three genotypes: +/+, +/- and -/-.  
3.4.22. MouseRef-8 v2.0 expression BeadChip microarray 
3.4.22.1. Illumina® TotalPrep™ RNA Amplification 
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 A description of the complete microarray procedure is found in the Appendix 
8.7. Briefly, the Illumina® TotalPrep™ RNA Amplification kit (Ambion®, Texas, 
USA) was used to prepare RNA samples for microarray analysis. A 500ng 
combined  amount  of  lung total RNA was used for a single array by pooling 
equal amounts lung total RNA of 3 mice for each group. The groups and variables 
investigated were:-  
(i) IRF-4 +/+, Male [Uninfected] PBS-Mock-Infected 
(ii) IRF-4 +/+, Male PR8 H1N1-InfAV-Infected 
(iii) IRF-4 +/+, Female [Uninfected] PBS-Mock-Infected 
(iv) IRF-4 +/+, Female PR8 H1N1-InfAV-Infected 
(v) IRF-4 +/-, Male [Uninfected] PBS-Mock-Infected 
(vi) IRF-4 +/-, Male PR8 H1N1-InfAV-Infected 
(vii) IRF-4 +/-, Female [Uninfected] PBS-Mock-Infected 
(viii) IRF-4 +/-, Female PR8 H1N1-InfAV-Infected 
(ix) IRF-4 -/-, Male [Uninfected] PBS-Mock-Infected 
(x) IRF-4 -/-, Male PR8 H1N1-InfAV-Infected 
(xi) IRF-4 -/-, Female [Uninfected] PBS-Mock-Infected 
(xii) IRF-4 -/-, Female PR8 H1N1-InfAV-Infected 
The kit comprises of firstly, a reverse transcription (RT) step to synthesize 
first-strand cDNA, next second strand cDNA synthesis converted the single strand 
cDNA into a dsDNA template for transcription. The cDNA was the purified using a 
cDNA filter cartridge system which included a cDNA binding step, a wash step 
and a final elution of cDNA. Subsquently, the synthesis of cRNA was performed 
by in vitro transcription.The cRNA generated was purified in cRNA filter cartridges 
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using a cRNA binding buffer, wash buffer and 100% ethanol. The cRNA was eluted 
with nuclease-free water. 
 
3.4.22.2. Whole-genome gene expression direct hybridization assay 
 
The microarray, Single-channel SENTRIX® BeadChip Array MouseRef-8 
v2.0 Microarray for Gene Expression (Illumina®, Inc., California, USA) [version 
MouseRef-8_V2_0_R0_11278551_A] used, was a slide having 8 arrays with 60,000 
features per array. The exact number of features in the each array, inclusive of 
control probes, was 25,697 features.  
The purified cRNA samples generated in the steps above were loaded onto 
the arrays for an18-hour incubation in a rocker at 58°C. After hybridization, the 
microarray slides were washed and stained with Cy3 fluorescent dye. The BeadChip 
were subjected to additional washing and drying steps before scanning. They were 
scanned using the BeadArray Reader (Illumina®, Inc., California, USA) with the 












3.4.22.3.  Microarray data analysis 
 
Figure 3.10.  Workflow of data processing in Genespring GX.  
 
3.4.22.4. GeneSpring GX 12.1 
 
The probe ID, average signal value and detection p-values obtained from 
GenomeStudio (Illumina®, Inc., California, USA) as the sample probe profile and 
were imported into GeneSpring GX 12.1’s (Agilent Technologies, California, USA) 
‘Illumina Single Color Guided Workflow to find differentially expressed genes’ for 
the normalisation of raw data. Initially, three parameters were created for the 
experimental groupings, namely, S e x ,  G enotype and Infection status. 
The 12 experimental groups were as follows:- 
Genotype  Sex  Infection status 
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+/+   Male   Control Mock-Infected 
+/+    Male   PR8-Infected 
+/+   Female  Control Mock-Infected 
+/+   Female  PR8-Infected 
+/-   Male   Control Mock-Infected 
+/-    Male   PR8-Infected 
+/-   Female  Control Mock-Infected 
+/-   Female  PR8-Infected 
-/-   Male   Control Mock-Infected 
-/-    Male   PR8-Infected 
-/-   Female  Control Mock-Infected 
-/-   Female  PR8-Infected 
 
 GeneSpring utilizes Agilent’s naming convention of ‘Detected’, 
‘Compromised’ and ‘Not Detected’. Each probeset was then filtered by assigning one 
flag. For each probe replicate with multiple flags, the order of importance of 
‘Compromised’ > ‘Not Detected’ > ‘Detected’ was applied. To obtain the overall flag 
across all replicates, Genespring excludes ‘compromised’ flag. 
 
3.4.22.5. GeneSpring Fold Change Analysis 
  
Fold change analysis is used to identify genes with expression ratios or 
differences between a treatment and a control that are beyond a threshold. Fold 
change is the ratio between Condition 1 and Condition 2. It is calculated as Fold 
change = Condition 1 / Condition 2. Fold change gives the absolute ratio of 
normalized intensities (no log scale) between the average intensities of the samples 
grouped. A fold-change cut-off of 1.5 was used in the analysis following the 1-way 







3.4.23. Statistical analysis  
 
All data were expressed as means ± SD. The SPSS software for Windows was 
used for statistical analysis.  A value of P < 0.05, denoted with *, was considered to 
be statistically significant. A value of P between 0.05 to 0.01, denoted with **, was 
considered to be very significant. A value of P <0.01, denoted with ***, was 








3.5.1. Titration of Influenza A/Puerto Rico/8/1934 H1N1 virus in C57BL/6 IRF-
4 +/+ and IRF-4 +/- mice by intra-tracheal route 
Virus obtained from ATCC, USA, was propagated by inoculating into 
embryonated eggs before being harvested. It was imperative to titrate and determine 
the appropriate infectious dose needed to be used for the mice infectious model. Three 
male C57BL/6 mice were infected with 100pfu and 500pfu using the intra-tracheal 
route and weight change was monitored. Weight loss was deemed a primary readout 
as mice infected with the influenza virus was shown to lose weight before 
succumbing to the infection (Bantia, Parker et al. 2001).  
In this particular pilot investigation, it was found that mice infected with 
100pfu of PR8 virus were capable of recovery. It was seen that one mouse out of the 
three mice infected with 100pfu made a full recovery after a maximum weight loss of 
approximately 28%. The other two mice infected with 100pfu subsequently 
succumbed to the infection and died Days 10 and 11 Post-Infection, Mice infected 
with a higher dose of 500pfu were found to succumb and died of the viral infection at 
Days 3, 7 and 8 Post-Infection. It was probable that the mouse which died at Days 3 
Post-Infection was due to complications of the intra-tracheal infection (Fig. 3.11).  
Next, a small scale infection study was performed to determine the 
experimental numbers needed for the mouse model of infection. This can be deduced 
from determining the statistical power of the project by observing the infected mice 
weight loss for the three IRF-4 genotypes of IRF-4 +/+, +/- and -/-. It was also an 
opportunity to show whether there was some observable weight loss difference 
between young adult and aged mice infected intra-tracheally with the virus. Three to 
four mice of young (three to five months old) and old (six to 8 months old) IRF-4 +/+, 
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+/- and -/- were used for the determination. In this instance, older IRF-4 +/+ and IRF-
4 +/- had a slower weight loss compared to the younger mice (Fig. 3.12). However it 
can be argued that while 500pfu of virus were inoculated and delivered to the lungs of 
each animal, the weight and body size differences between young adult and aged mice 
may have caused the observable difference. It is also of interest to point out mice of 
IRF-4 genotype, both young adult and aged mice were able to recover fully from the 
infected. Another interesting observation lies in the infected IRF-4 -/- mice not 
succumbing to the infection even until Day 15 where at least a weight loss of 40% 
was reach. Mice were finally culled as specified by IACUC.  
In order to calculate statistical power, the formula of the following was 
used:  N = [(1+ratio)/(2+ratio)] * [1 + (2 * power* sd * sd)/(mean * mean)],  
where ratio : cases to controls and power : 80% (= 7.85); 90% (=10.5). 
From the pilot study, the largest standard deviation for the percent change in 
weight at different time points was 6% (Data not shown). For a power of 90% and a 
2-tailed test of 5%, with a 2:1 ratio, 10 mice was found to be required per active 





Figure 3.11. Titration of 100pfu and 500pfu PR8 H1N1 InfAV in individual IRF-4 
+/+ mice to determine a lethal dose to be used in infection model. Data displays the 
weight loss of individual IRF-4 +/+ mice infected by intra-tracheal route either with 
100pfu or 500pfu PR8 H1N1 InfAV. Three mice (EP#6, 7 and 8) were infected with 
500pfu and another three (EP#9, 10 and 11) were infected with 100pfu. Bodyweight 
were determined until the mice succumbed to the infection. Mice infected with 
500pfu generally succumbed to the infection between Days 3 – 9 Post-Infection, 
whereas those infected with 100pfu, succumbed around Days 10 – 11 Post-Infection. 
A single mouse (EP#11) made a full recovery as demonstrated in its percentage 
bodyweight change. The decision was then to used 500pfu as the infectious dose in 




















Figure 3.12. Intra-tracheal infection of 500pfu PR8 H1N1 InfAV in young adult and 
aged IRF-4 +/+, +/- and -/- mice to determine the statistical power of the experiment. 
From this it was discovered that largest standard deviation to be 6%. Therefore for a 
power of 90% and a 2-tailed test of 5%, a ratio of 2:1 is needed. Therefore to detect a 
significant difference of 10% in bodyweight change, at least 10 infected test 5 mice 
per genotype and sex to 5 mock-infected control mice per genotype and sex would be 






















3.5.2. Intra-tracheal infection of male and female IRF-4 +/+, +/- and -/- mice 
with 500pfu Influenza A/Puerto Rico/8/1934 H1N1 – Bodyweight and Survival 
Studies 
  10 male and female mice of each three genotypes IRF-4 +/+, +/- and -/- were 
infected intra-tracheally with 500pfu PR8 H1N1 Influenza A virus. Five mice of each 
variable were also included as controls where these were mock-infected with sterile 
1X PBS. Mice aged between 8 weeks to 12 weeks old were used. A total of two 
rounds of mice infection were performed in this study, thereby having a total of 180 
mice experimented on. 
Mice were monitored daily for bodyweight change over a period of two weeks 
or until its weight loss was that approaching 30% of its original weight where it was 
then culled, as specific by IACUC protocol, and other downstream investigations 
were carried out. All mock-infected control mice were culled at Days 13 or 14 Post-
Infection and organs / blood harvested for downstream investigations. In male and 
female IRF-4 +/+ mice, their weight loss generally approach 30% of its original 
weight at around Days 7 – 9 Post-Infection and were subsequently culled for its 
organs and blood. However, in both male and female IRF-4 mice, a total of 7 mice 
died at around Days 8 Post-Infection due to succumbing to the infection. In male and 
female IRF-4 +/- mice, it was observed these mice reached the 30% weight loss mark 
at around Days 9 – 10 Post-Infection. However, this group had a higher mortality 
even before the 30% weight loss mark was reached, usually dying at 20% weight loss 
at  around days 8 post-infection. A total of 10 IRF-4 +/- mice succumbed to the 
infection. In male and female IRF-4 -/- mice, weight loss approaching 30% was 
reached at approximately Days 10-11 Post-Infection, where these were then culled. 
Only four mice of the IRF-4 -/- cohort succumbed to the infection. It was determined 
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statistically that the weight loss between the three IRF-4 +/+, +/- and -/- genotypes, 
and sex, caused by the PR8 infection were not significant (Figs. 3.13 (A) and (B)).   
Kaplan-Meier curve for survival was constructed to determine the mortality of 
PR8 H1N1 InfAV-infected mice. As survival studies were prohibited by IACUC 
guidelines, a weight loss of between 25-30% of its original bodyweight was used as a 
surrogate for death. As determined in the pilot study, an intra-tracheal infection of 
500pfu of PR8 H1N1 InfAV would result in a mostly efficient lethal dose resulting in 
close to 100% death in mice infected. According to statistical analysis, there was no 
statistical significance between the sexes of all three genotypes investigated (p = 0.2). 
However when sex of mice was omitted from the statistical analysis, there was a 
significant difference in the survivability of the mice with majority of IRF-4 +/+ mice 
succumbing to the infection on Days 7-9 Post-Infection, while the majority of IRF-4 -

















Figures 3.13 (A) & (B). Weight change of IRF-4 mice infected with 500pfu dose of 
Influenza A/Puerto Rico/8/1934 H1N1. IRF-4 -/- mice and their litter mates of both 
sexes were infected intratracheally with PR8 and its weight monitored daily until Day 
14 Post-Infection or weight loss between 25-30% of its original weight, after which 
mice were culled by CO2 asphyxiation.  No significant difference between the 
genotypes and sexes in terms of:- 
(A) Weight change of IRF-4 infected mice, segregated by sex, and, 
(B) Weight change of all IRF-4 infected mice. Data exhibits the average from 2 
rounds of investigation. 
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‘n’ represents total numbers of mice used in each group, conducted over 2 rounds of 
investigation. 
Uninfect: 50ul PBS-mock infected (n=5 mice/investigation round);   








Figures 3.14 (A) & (B). Kaplan-Meier survival curve of IRF-4 mice infected intra-
tracheally with 500pfu Influenza A/Puerto Rico/8/1934 H1N1. Infected mice (n=10 
mice/investigation round) were weighed daily and culled by CO2 asphyxiation once its 
weight loss was between  25 – 30% of its original weight. This was used as a 
surrogate to death. (A) Survival curve of IRF-4 infected mice, segregated by sex. 
Demonstrates no statistical signifance between sexes (p = 0.2). (B) Survival curve of 
all  IRF-4 infected mice ( P < 0.05 ). Survivability between the IRF-4 genotypes was 
significant (p = 0.03) with majority of IRF-4 +/+ succumbing to the infection on Days 
7-9 Post Infection, while majority of IRF-4 -/- succumbing on Days 9-11 Post 
Infection.  Data exhibits the average from 2 rounds of investigation. 
WT: Wildtype IRF-4 +/+; 
HZ: Heterozygous IRF-4 +/-; 




Male Female Male Female
5 Uninfected Control mice          
&                                                     
10 InfV-Infected mice
5 Uninfected Control mice          
&                                                     
10 InfV-Infected mice
5 Uninfected Control mice          
&                                                 
10 InfV-Infected mice
5 Uninfected Control mice          
&                                                     
10 InfV-Infected mice
Total
Live           
at       
Harvesting




+/+ WT 13 13 14 15 53
+/- HZ 10 14 11 15 50
-/- KO 15 14 12 15 56
159 21180





Treatment groups                




Table 3.7. Data of mice numbers harvested at the end of the monitoring period after 
500pfu intra-tracheal infection of PR8 H1N1 InfAV when weight lost corresponds to 
25-30% of original body weight or Days 14 Post-Infection for PBS-mock-infected 
Control mice. 10 mice per variable group were used for the PR8 H1N1 InfAV 
infection whereas 5 mice per variable group were used for the PBS-mock-infected 
Control. InfAV-infected mice achieved weight lost of  25-30% original body weight 
at approximately Days 7-9 Post Infection in IRF-4 +/+ mice, and at Days 9-11 Post 
Infection in IRF-4 -/- mice. After the daily monitoring, mice with  bodyweight 
surpassing 25-30% of its original body weight were immediately culled by CO2 
asphyxiation and samples were collected for subsequent analysis. Animals which 
were discovered to have succumbed to infection in between weight monitorings were 
discarded and excluded from further analysis. No PBS-mock-infected control mice 
died over the course of the monitoring period. These mice were culled on Days 14 
Post Infection.    
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3.5.3. Lung histopathology 
Mice culled and harvested were included in the lung histopathology scores 
whereas those succumbing to the infection and died were excluded. Harvested pieces 
of both sides of lung were fixed in 4% formaldehyde before processing and staining 
with H&E. Each slide was evaluated by two independent investigators in a blinded 
manner. To generate the lung injury score,
 
a total of 300 alveoli were counted on each 
slide at x400 magnification. Within each field, points were assigned according to 
predetermined
 
criteria. All of the points for each category were
 
added and weighted 
according to their relative importance. The
 
injury score was calculated according to 
the following formula:
 
injury score = [(alveolar hemorrhage points/no. of fields) +
 
2 x 
(alveolar infiltrate points/no. of fields) + 3 x (fibrin points/no. of fields) + (alveolar 
septal congestion/no. of fields)]/total
 
number of alveoli counted.
  
 
As expected all three IRF-4 genotypes mice infected with the PR8 InfAV has 
higher lung histopathology scores compared to the control groups. Surprisingly, male 
and female IRF-4 +/- mice had slightly higher lung histopathology scores than the rest 
of the infected groups. Differences in sex was also found to not contribute nor 
exacerbate the histopathology scores as the scores remained statistically highly 
significant between IRF-4 +/+ and IRF-4 +/- (p = 0.01); IRF-4 -/- and IRF-4 +/- (p < 









Figures 3.15 (A) & (B). Lung histopathology scores of IRF-4 mice infected intra-
tracheally with 500pfu PR8 H1N1 InfAV. To generate scores, a total of 100 alveoli 
were counted on each slide at x400 magnification. Within each field, points were 
assigned according to a set of predetermined criteria.  As expected all groups of mice 
infected with the lethal dose of PR8 virus had worse scores compared to the control 
groups. (A) Lung histopathology scores of IRF-4 infected mice, segregated by sex. 
While the male and female IRF-4 +/- mice had slightly higher histopathology scores, 
these were not statistically significant when compared to the rest of the infected 
groups. (B) Lung histopathology scores of all IRF-4 infected mice. Combining the 
data of both sexes, scores were statistically highly significant between IRF-4 +/+ and 
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IRF-4 +/- (p = 0.01); IRF-4 -/- and IRF-4 +/- (p < 0.05); but not significant between 
IRF-4 +/+ and IRF-4 -/- (p > 0.5).  
 
Lung histopathology data exhibits the average from 2 rounds of investigation.  
‘n’ represents total number of individual mice lung sections scored.  










Figure 3.16. H&E stained lung section of IRF-4 +/+ female mouse (Animal 
Number #EP2; Uninfected [PBS] control group), culled on Day 14 post-infection 
at +1% of original body weight displaying mild septal congestion (A) and mild 
alveolar hemorrhage (B).  
Scores: [Alveolar septa = 1] + [Alveolar hemorrhage = 1]. Total lung 




Figure 3.17. H&E stained lung section of IRF-4 +/- female mouse (Animal 
Number #EP54; Uninfected [PBS] control group), culled on Day 14 post-infection 
at +5.8% of original body weight displaying mild septal congestion (A), mild 
alveolar hemorrhage(B) and moderate inflammatory cellular infiltrate (C).  
Scores: [Alveolar septa = 1] + [Alveolar hemorrhage = 1] + [Cellular infiltrates 









Figure 3.18. H&E stained lung section of IRF-4 +/- female mouse (Animal 
Number #EP67; Infected [500pfu PR8 H1N1 InfAV] group), culled on Day 8 
post-infection at -25.7% of original body weight displaying moderate septal 
congestion, mild alveolar hemorrhage, fibrin exudates and moderate inflammatory 
cellular infiltrate.  
Scores: [Alveolar septa = 2] + [Alveolar hemorrhage = 1] + [Intra-alveolar fibrin 





Figure 3.19. H&E stained lung section of IRF-4 +/- male mouse (Animal Number 
#EP59; Infected [500pfu PR8 H1N1 InfAV] group), culled on Day 9 post-
infection at -26% of original body weight displaying marked septal congestion, 
moderate alveolar hemorrhage and moderate fibrin exudates and marked 
inflammatory cellular infiltrate.  
Scores: [Alveolar septa = 3] + [Alveolar hemorrhage = 3] + [Intra-alveolar fibrin 





Figure 3.20. H&E stained lung section of IRF-4 +/- male mouse (Animal Number 
#EP83; Infected [500pfu PR8 H1N1 InfAV] group), discovered dead on Day 8 
post-infection at -27.2% of original body weight displaying marked septal 
congestion, moderate alveolar hemorrhage, moderate fibrin exudates and 
moderate inflammatory cellular infiltrate.  
Scores: [Alveolar septa = 3] + [Alveolar hemorrhage=2] + [Intra-alveolar fibrin 





Figure 3.21. H&E stained lung section of IRF-4 -/- female mouse (Animal 
Number #EP99; Infected [500pfu PR8 H1N1 InfAV] group), culled on Day 9 
post-infection at -28.7% of original body weight displaying marked septal 
congestion, mild alveolar hemorrhage, marked fibrin exudates and marked 
inflammatory cellular infiltrate.  
Scores: [Alveolar septa = 3] + [Alveolar hemorrhage=1] + [Intra-alveolar fibrin 




3.5.4. Terminal Lung viral load determined by plaque assay and qRT-PCR 
From the infected mice data, it was observed that IRF-4 -/- mice were able to 
survive slightly longer than its IRF-4 +/+ and IRF-4 -/- counterparts. Terminal lung 
viral titres were determined in IRF-4 mice infected intra-tracheally with 500pfu PR8 
H1N1 InfAV. Mice were culled once its bodyweight reached 25-30% of the initial 
weight or after Days 14 Post-Infection. A third of each side of lungs were processed 
in unison to produce a homogenate solution and used in a MDCK-plaque assay to 
quantify the viral titres of the lung homogenate. Analyzed separately, the lung 
homogenates of male and female IRF-4 -/- mice showed higher viral titres compared 
to IRF-4 +/+ and IRF-4 -/-. Male IRF-4 -/- lung samples had approximately three and 
7 times the viral load as compared to IRF-4 +/+ and IRF-4 +/- lung samples, 
respectively. Lung samples of female IRF-4 -/- had approximately 3 times more virus 
compared to both IRF-4 +/+ and IRF-4 +/- (Fig. 3.22 (A)).  
With the differences in sex omitted, the statistical analysis showed that lung 
viral titres for IRF-4 -/- remained higher compared to IRF-4 +/+ and -/-. Lungs of 
infected IRF-4 -/- mice had a significantly higher viral titres compared to those of 
IRF-4 +/+ [p < 0.001 (+/+ vs -/-)] and IRF-4 +/- [p < 0.001 (+/- vs -/-)]. mRNA 
expression of NS1 (Non-Structural 1 Protein) of  PR8 in lungs of infected IRF-4 mice 
was also performed to provide cross-referencing, as determined by qRT-PCR. 
Amount of NS1 were highly significant more in lungs of infected IRF-4 (p < 0.001) 
mice compared to those of IRF-4 +/+ and +/- (Fig. 3.22(B)). 
The expression of NS1 protein in lung homogenate samples collected during 
the terminal phase of the infection, at Day 7-11 Post Infection, was also examined by 
qRT-PCR. There was an extremely significant increase in NS1 expression in IRF-4 -/- 
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(fold change 1325840.9) compared to those in the IRF-4 +/+ (fold change 65040.7) 






















Figures 3.22 (A) (B) (C). Terminal lung viral titres of IRF-4 mice infected intra-
tracheally with 500pfu PR8 H1N1 InfAV (at Days 14 Post-Infection or upon weight 
loss reaching 25-30% of the initial weight of the mouse). Quantitation of titres from 
plaque assay was based on the number of plaques formed indicating the ability of 
virus to infect MDCK cells. Lungs were harvested by three cross sections of roughly 
equal sizes of both sides of lungs and snapped frozen in liquid nitrogen until 
processed. Upon thawing, a pair of lung slice was homogenized in 0.5ml sterile ice-
cold 1xPBS.    Lung homogenate was obtained from the supernatant after a brief 
centrifugation and viral titres determined by performing plaque assay. Lung 





, before an hour infection to previously-overnight-seeded-confluent 
MDCK cells in 24-well plates. After the infection medium containing the virus was 
aspirated, cells were overlayed with Avicel and incubated at 35°C for three days, after 
which plaques were visualized by fixing cells with formaldehyde and staining with 
Crystal Violet. (A) Mice lungs viral titres (Days 7-9 Post-Infection), sex-segregated. 
Lung viral titres for both sexes of IRF-4 -/- were higher compared to IRF-4 +/+ and -
/-. (B) Mice lungs viral titres (Days 7-9 Post-Infection). Lungs of infected IRF-4 -/- 
mice had a highly significant higher viral titres compared to those of IRF-4 +/+ [p < 
0.001 (+/+ vs -/-)] and IRF-4 +/- [p < 0.001 (+/- vs -/-)]. Viral titres between IRF-4 
+/+ and IRF-4 were not significant [p > 0.05 (+/+ vs +/-)]. (C) Viral titres of NS1 PR8 
in lungs of infected IRF-4 mice, as determined by qRT-PCR. Amount of NS1 were 
highly significant more in lungs of infected IRF-4 (p < 0.001) mice compared to those 
of IRF-4 +/+ and +/-. 
 
Virus titres for each group represent the mean values calculated from mice lung 
performed over two rounds. 
‘n’ represents total number of individual mice lung sections scored.  








3.5.5. Neutralization Assay 
 
A total of 10 Control PBS-mock infected and 20 Test PR8-infected mice were 
used per genotype strain (+/+, +/- and -/-) and sex. Control mice were given 50ul PBS 
intra-tracheally while anesthetized, whereas 500pfu of PR8 H1N1 InfAV (ATCC) 
were used to infect test mice intra-tracheally. Mice were monitored daily for weight 
changes and culled once weight loss was approximately 30% of original weight (Days 
9-11 post-infection). Mice found dead were excluded from the study. Cardiac 
puncture was performed on live mice and sera were processed by centrifugation at 





dilution of original concentration.1 x 10
-3
 TCID50 of PR8 H1N1 Influenza A Virus 
was then added to the sera and incubated at 35°C for 2 hrs after which 50ul was added 
to a fresh 96-well plate of MDCK cells previously grown overnight to achieve 
confluence. The plate was then incubated at 35°C for 3 days after which cytopathic 
effect (CPE) was scored. Wells having an absence of CPE, thereby a neutralizing 
effect by the antibodies was noted. Control mice of both sexes, of all three genotypes 
did not mount any detectable antibody response. Male and female mice of +/+ and +/- 
genotypes mounted an equal antibody response whereas -/- mice had no antibody 




























Figures 3.23 (A), (B) and (C). 72-hours virus neutralization assay from sera collected 
from mice (Control PBS-mock infected mice and Test Influenza A/Puerto 
Rico/8/1934 (PR8) H1N1 virus infected mice [Days 9-11 post-infection]). Control 
mice were given 50ul PBS intratracheally while anesthetized, whereas 500pfu of PR8 
were used to infect test mice intratracheally. Mice were monitored daily for weight 
changes and culled once weight loss was approximately 30% of original weight. Mice 
found dead were excluded from the study. Wells having an absence of cytopathic 
effect, indicated complete neutralization by sera. (A) Neutralization assay of sex-
segregated IRF-4 mice sera against PR8. Control mice of both sexes, of all three 
genotypes did not mount any antibody response. IRF-4 male and female mice of +/+ 
and +/- genotypes mounted an equal antibody response whereas -/- mice had no 
antibody response in both sexes. (B) Neutralization assay of all IRF-4 mice sera 
against PR8. IRF-4 -/- sera failed to mount any detectable neutralization response 
against PR8. This is statistically highly significant reduction in neutralization 
response when compared to responses in IRF-4 +/+ and IRF-4 +/- (P < 0.001). (C) 
PR8-infected-IRF-4 mice sera dilution at virus neutralization. Sera dilution < 8 
signified no detectable virus neutralization. All IRF-4 -/- mice sera investigated (n=20 
uninfected control and n=38 infected) did not neutralize the PR8 H1N1 in the 
neutralization assay.  
 
Neutralization assay for each group represent the mean values calculated from mice 
lung performed over two rounds. 
‘n’ represents total number of individual mice sera investigated for neutralization 
assay.  
One way ANOVA was performed to determine statistical significance (p < 0.05). 
Uninf: 50ul PBS-mock infected (n=5 mice/investigation round);   








3.5.6. Lung homogenate cytokine level analysis 
Harvested lungs were homogenized to determined cytokine levels. A total of 7 
to 8 lungs samples per infected test and mock-infected control in each genotype group 
were picked randomly, processed individually and cytokine analysis performed using 
the Bio-Rad BioPlex system on a 23-Plex panel.  
The 23-Plex panel of cytokines can be divided into its characteristic groups 
based on the investigated cytokines, namely, the proinflammatory and T subsets 
cytokines, as well as chemokines. Data of cytokines / chemokines deemed having a 
significant difference upon statistical analysis are presented here. Data is also 
presented as a fold change of the infected test over the mock-infected control samples. 
The absolute amounts are also presented here as reference. 
In the panel of proinflammatory cytokines, it was discovered that IL-1α, IL-1β, 
IL-6, GM-CSF and TNF-α had significant differences in cytokines levels when 
compared between IRF-4 +/+ and -/-. In IL-1α levels, there was a fold change of 1.4 
in the +/+ samples (Test +/+: 37.9pg/ml; Control +/+: 26.9pg/ml) and 1.5 fold change 
in the -/- samples (Test -/- 48.9pg/ml; Control -/- 32.0pg/ml). Surprisingly, the 
expression of IL-1α in +/- samples was, however, had a reduction fold change of -1.9 
(Test +/- 23.3pg/ml; Control +/- 44.7). There was no significant difference between 
the +/+ and -/-. In IL-1β levels, a fold change of 22.9 was observed in +/+ samples 
(Test 15,843.4pg/ml; Control 693pg/ml). There was a significant reduction in the fold 
change of +/- samples, at a fold change of 7.8 (Test 954.0pg/ml; Control 122pg/ml). A 
further reduction in fold change was observed in -/- samples, at a fold change of 6.4 
(Test 304.0pg/ml; Control 47.8pg/ml). A similar trend was observed in fold change 
for IL-6 expression levels. Samples of +/+ genotype had a fold change of 286.3 (Test 
206.1pg/ml; Control 0.7pg/ml), followed by 76.7 in +/- (Test 118.2pg/ml; Control 
 156 
 
1.5pg/ml) and 57.2 in -/- (Test 118.2pg/ml; Control 2.1pg/ml). There was an opposite 
trend observed in GM-CSF and TNF-α. In GM-CSF, +/+ samples had a fold change 
of 2.8 (Test 131.9pg/ml; Control 47.8pg/ml). Almost at similar levels were +/- at fold 
change of 2.2 (Test 85.5pg/ml; Control 38.7pg/ml). However there was a highly 
significant increase in fold change of 7.2 in -/- samples (Test 158.4pg/ml; Control 
22.1pg/ml). TNF-α had similar levels for +/+ (Fold change 2.4; Test 48.3pg/ml; 
Control 20.2pg/ml) and +/- (Fold change 2.6; Test 48.7pg/ml; Control 19.1pg/ml), but 
a significant increase at fold change of 7.7 in -/- samples (Test 121.2pg/ml; Control 
15.7pg/ml). A closely related cytokine to have proinflammatory characteristics, IL3, 
had a similar upward fold change trend from +/+ (Fold change 4.4; Test 2.8pg/ml; 
Control 0.7pg/ml), +/- (Fold change 5.4; Test 2.5pg/ml; Control 0.5pg/ml) to -/- 
samples (Fold change 10.6; Test 3.6pg/ml; Control 0.3pg/ml). The presence of the 
IRF-4 gene in +/+ samples, heterozygousity in +/- samples, or total absence in -/- 
samples appeared to cause a random non-standard trend in the increase or decrease of 
fold change in proinflammatory cytokine levels.  
Th1 cytokines of IL-2 and IFN-γ had a downward fold change trend in 
samples of as the presence of IRF-4 diminishes in +/+, +/- and -/- samples. In IL-2, 
+/+ samples had a fold change of 2.2 (Test 2.9pg/ml; Control 1.3pg/ml), whereas it 
was found that in +/- samples, a suppression of IL-2 levels occurred, with a reduction 
fold change of -1.3 (Test 1.4pg/ml; Control 1.9pg/ml) due to the InfAV infection. 
Surprisingly, no IL-2 could be detectable in -/- samples in both the Mock-Infected 
Control as well as the Infected Test group. It appears there was a total suppression of 
IL-2 protein level in IRF-4 -/- mice. Another Th1 cytokine investigated in this panel 
was IFN-γ. It appeared to follow the IL-2 trend, where in the progressive absence of 
IRF-4 in the mouse model, the expression fold change of IFN- γ caused by the PR8 
 157 
 
H1N1 InfAV infection decreased as well. Samples of +/+ had a fold change of 45.1 
(Test 256.1pg/ml; Control 5.7pg/ml) and followed by +/-, with a fold change of 19.6 
(Test 125.0pg/ml; Control 6.4pg/ml). There was a significant lower fold change in -/- 
samples (Fold change 7.7; Test 41.2pg/ml; Control 5.3pg/ml).  
 Infection with the PR8 H1N1 InfAV caused Th2 and Th17 cytokines of IL-4, 
IL-10 and IL-17 to respond significantly with an upward fold change trend in samples 
from IRF-4 +/+ to -/-. IL-4 in +/+ had a fold change of 1.9 (Test 6.8pg/ml; Control 
3.5pg/ml). Samples of +/- had similar levels of fold change, at 1.7 (Test 5.3pg/ml; 
Control 3.1pg/ml). However, there was a significant increase in -/- samples, with fold 
change of 9.4 (Test 6.9pg/ml; Control 0.7pg/ml). Similarly in IL-10 levels, samples 
from +/+ group had a fold change of 4.9 (Test 396.2pg/ml; Control 81.3pg/ml), 
following an upward trend in +/- samples, with a fold change of 6.7 (Test 397.7pg/ml; 
Control 59.5pg/ml) and in -/- sample, with a fold change of 14.4 (Test 118.6pg/ml; 
Control 8.2pg/ml). IL-17 secreted by Th17 cells appeared to have an increase in fold 
change in the absence of IRF-4, as displayed in the -/- sample. In +/+ and +/- samples, 
however, there was a slight suppression in IL-17 expression caused by the InfAV 
infection. The suppression in fold change were found to be -1.3 and -1.4, respectively 
(+/+; Test 4.8pg/ml; Control 6.2pg/ml) (+/-; Test 4.3pg/ml; Control 6.0pg/ml). 
However in the absence of IRF-4 gene, the InfAV infection caused a fold change of 
1.5 in -/- samples (Test 10.5pg/ml; Control 6.8pg/ml). From the data, it appeared that 
IRF-4 functions to suppress IL-17 expression during the InfAV infection. However in 
the absence of IRF-4, an infection would trigger an increase in IL-17.  
In essence in the traditional classification of Th1 and Th2 cytokines 
investigated, it appears that Th1 cytokines had a lower fold change in -/- samples. The 
IRF-4 gene appears to cause a suppression of IL-2 and IFN-γ. In Th2 cytokines, it 
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appears that there was an augmentation of the fold change in an infection model 
caused by the absence of the IRF-4 gene.    
For chemokines investigated by this panel, CXCL1 had a downward trend in -
/- samples whereas the opposite trend was observed in CCL3 and CCL5. In +/+ 
samples, CXCL1 (KC) had a fold change of 13.7 (Test 1017.3pg/ml, Ctrl 74.4pg/ml). 
A stepwise drop in fold change was observed in +/- samples, with a fold change of 8.6 
(Test 367.9pg/ml; Ctrl 42.7pg/ml). Compared to +/+ samples, a significant drop in 
fold change was also observed in -/- samples, with only a fold change of 3.3 (Test 
222.9pg/ml; Ctrl 68.1pg/ml). The absence of the IRF-4 gene appeared to have an 
effect on CCL3 (MIP-1α) during InfAv infection. In +/+ samples, a fold change of 2.0 
was observed (Test 1004.6pg/ml; Ctrl 500.4pg/ml). However in +/- and -/- samples, a 
single or double knock out of the IRF-4 gene caused a significant increase in fold 
change of CCL3 during the infection with fold changes at 10.4 and 9.6, respectively 
[(+/-: Test 3698.6pg/ml; Ctrl 355.8pg/ml) and (-/-: Test 1290.4pg/ml; Ctrl 
135.1pg/ml)]. CCL5 (RANTES) was affected positively in term of the fold change by 
the graduated absence of the IRF-4 gene. In +/+ samples, a fold change of 2.8 was 
observed (Test 2853.7pg/ml; Ctrl 1014.0pg/ml). However, a significant increase was 
seen in +/- and -/-, with fold changes of 4.9 and 5.6, respectively [(+/-: Test 
6622.4pg/ml; Ctrl 1359.3pg/ml) and (-/-: Test 3395.3pg/ml; Ctrl 709.8pg/ml)].  
CCL4 (MIP-1β) had a general increase in fold change in all three genotypes as 
a result of the InfAV infection. (+/+: fold change 4.1; Test 482.6pg/ml; Ctrl 
116.7pg/ml) (+/-: fold change 8.1; Test 633.5; Ctrl 78.1pg/ml) (-/-: fold change 5.1; 
Test 328.2pg/ml; 64.8pg/ml). However, the graduated absence of the IRF-4 gene 
appeared to make no significant difference to the fold changes. 
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Surprisingly, the cytokines responsible for airway inflammation IL-9 and IL-
13 appeared to be not affected by the graduated absence of the IRF-4 at the terminal 
phase of the InfAV infection. [IL9: (+/+: fold change 1.5; Test 33721.6pg/ml; Ctrl 
22185.0pg/ml) (+/-: fold change -1.5; Test 4047.9pg/ml; Ctrl) (-/-: fold change -1.1; 
Test 184.2pg/ml; Ctrl 206.0pg/ml)] [IL-13: (+/+: fold change 1.0; Test 9805.4pg/ml; 
Ctrl 9461.2pg/ml) (+/-: fold change -1.3; Test 1460.4pg/ml; Ctrl 1961.8pg/ml) (-/-: 
fold change 1.5; Test 92.4pg/ml; Ctrl 60.9pg/ml)]. 
Other cytokines examined found to be not affected by the graded absence of 
IRF-4 during the terminal phase of InfAV infection included IL-5 and G-CSF.  [IL-5: 
(+/+: fold change 15.1; Test 70.0pg/ml; Ctrl 4.6pg/ml) (-/-: fold change 21.0; Test 
73.5pg/ml; Ctrl 3.5pg/ml)] [G-CSF: (+/+: fold change 101.2; Test 1334.1pg/ml; Ctrl 
13.2pg/ml) (+/-: fold change 81.7; Test 903.3pg/ml; Ctrl 11.1pg/ml) (-/-: fold change 






























































Figures 3.24 (A), (B), (C), (D), (E), (F) (G) and (H). Cytokine expression in lung 
homogenates of IRF-4 mice infected with 500 PFU of PR8 H1N1 InfAV, (harvested 
at Days 14 Post-Infection or upon weight loss reaching 25-30% of the initial weight of 
the mouse), as determined by Bio-Plex PRO
TM
 Cytokine Assay. (A), (B) and (C) Fold 
change in Lung homogenate pro-inflammatory cytokine (IL-1α, Il-1β, GM-CSF, 
TNF-α, IL-6 and IL-3) expression of IRF-4 mice infected with PR8 H1N1 InfAV. (D) 
and (E) Fold change in Lung homogenate Th1, Th2 and Th17-related cytokine (IL-2, 
IL-4, IL-10, IL-12p70, IL-17 and IFN-γ) expression of IRF-4 mice infected with PR8 
H1N1 InfAV.  (F) Fold change of IL-3 in IRF-4 mice lung homogenate. (G) Fold 
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Change in Lung homogenate chemokine (CXCL1, CCL3, CCL4 and CCL5) 
expression of IRF-4 mice infected with PR8 H1N1 InfAV.  
 
Data expressed as Average Fold Change (conducted over 2 investigation rounds), 
derived from the ratio of absolute amounts of cytokine in PR8-infected Test IRF-4 
mice (n=20/experimental round) over Control PBS-mock infected IRF-4 mice 
(n=10/experimental round) of same genotype. Mice found dead were excluded from 
study. One way ANOVA was performed to determine statistical significance (p < 
0.05). 
 
3.5.7. Quantitative Real-Time PCR to detect for gene expression 
 Levels of expressed genes at the mRNA level will change under a variety of 
conditions such as those investigated in this project such as the presence of an 
infectious agent. The analysis of gene expression requires a sensitive, precise and 
reproducible measurement of specific mRNA sequences. Gene expression data can 
then be evaluated from real-time quantitative PCR by amplifying cDNA synthesized 
from mRNA. In order to quantify gene expression, real-time RT-PCR was used. The 
quantitative endpoint for RT-PCR is the threshold cycle (CT), where this can be 
defined as the PCR cycle at which the fluorescent signal of the reporter dye crosses an 
arbitrarily placed threshold. The comparative CT method (2
-ΔΔC
T method) used here 
makes the assumption that the PCR has perfect efficiency and the PCR of the target 
gene is similar to the internal control gene (Livak and Schmittgen 2001, Schmittgen 
and Livak 2008). Advantage of this method includes the ease of use and the ability to 
present data as ‘fold change’ in expression.  
In order to attempt to decipher the relationship of the IRF-4 gene to the innate 
and adaptive immune responses involved in influenza viral infections, the mRNA 
expression of particularly important genes linked to such responses were investigated. 
Additionally, the relationship of the IRF-4 gene to other family members of the 
transcription factor of IRFs was looked at. Genes of interest included IRF-1, -3, -4, -5, 
-7, -8, IFN-α, -β, -γ, , MyD88 and NFKB2.  
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Mice infected intra-tracheally with 500pfu PR8 H1N1 InfAV were culled 
when the weight loss achieved 25-30% of its original body weight, approximately 
Days 7-11 Post Infection, whereas PBS-mock-infected control mice were culled at 
Days 14 Post Infection. Lungs were harvested and RNA extraction was performed 
before reverse-transcription reactions were done to synthesize cDNA.  
In innate immunity, the gene expression of Type I Interferons (IFN-α and IFN-
β) were found to have a non-significant general reduction in fold change [(IFN-α; +/+ 
fold change -3.6; +/- fold change -1.5; -/- fold change -6.1) (IFN-β; +/+ fold change -
14.9; +/- fold change -8.4; -/- fold change 32.6)]. Expression of MyD88 were found to 
have undergone significant reduction in fold change in the IRF-4 -/- sample (fold 
change -2.9) when compared to the upregulated IRF-4 +/+ (fold change 2.3) and IRF-
4 +/- (fold change 1.6) samples.  
As for adaptive immunity, expression of NFKβ also showed a similar 
significant trend where there was a upregulation in the IRF-4 +/+ samples (fold 
change 1.4) but a reduction in fold change in the IRF-4 +/- (fold change -1.3) and 
IRF-4 -/- (fold change -3.8) samples. This trend was also common in the Type II 
Interferon (IFN-γ). The IFN-γ gene expression was affected with the graded absence 
of the IRF-4 gene during the terminal phase of the InfAV infection, where a lower 
upregulation of IFN- γ was observed in IRF-4 +/- (fold change 4.3) and IRF-4 -/- (fold 
change). 
Gene expression of IRF-4 during InfAV infection was also examined. In IRF-
4 +/+ there was a fold change of 1.1. However, a significant reduction in fold change 
existed in IRF-4 -/- (fold change -4.4). As IRF-8 interacted closely with IRF-4, gene 
expression of IRF-8 was also examined. Fold change followed the trend as well. In 
IRF-4 +/+, expression of IRF-8 was increased 2.2 times, followed by 1.3 times in 
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IRF-4 +/-. However, there was suppression in IRF-8 gene expression in IRF-4 -/- 
(fold change -3.3). In fact, gene expression of IRF-1 also followed the same trend 
where there was a significant suppression in IRF-1 gene expression in IRF-4 -/- (fold 
change -1.4) as compared to IRF-4 +/+ (fold change 4.1) and IRF-4 +/- (fold change 
2.0).  
Being direct transducers of virus-mediated signaling, the gene expression of 
IRF-3, -5 and -7 were examined. It appeared that the total absence of IRF-4 
significantly affected the gene expression of all three transcription factors. The graded 
absence of IRF-4 gene caused a significant reduction in IRF-3. In IRF-4 -/- a 
reduction in fold change -7.6 was observed compared to the fold changes of IRF-4 
+/+ (fold change -1.9) and IRF-4 +/- (fold change -1.8). A similar suppression in gene 
expression of IRF-5 was also observed in IRF-4 -/- (fold change -2.5). This, compared 
to the significant increase in IRF-5 gene expression in IRF-4 +/+ (fold change 3.0) 
and IRF-4 +/- (fold change 2.1). The InfAV infection caused an upregulation of IRF-7 
in IRF-4 +/+ (fold change 1.4). However there was a significant suppression in IRF-7 

































Figures 3.25 (A), (B) and (C). Cytokine expression in lung homogenates of IRF-4 
mice infected with 500pfu PR8 H1N1 InfAV, (harvested at Days 14 Post-Infection or 
upon weight loss reaching 25-30% of the initial weight of the mouse), by quantitative 
real-time polymerase chain reaction (qRT-PCR) analysis. (A) and (B) Expression of 
Interferon Type I and II and important key genes involve in innate and adaptive 
immune responses in lung homogenates of PR8 H1N1 InfAV-infected IRF-4 mice. (C) 
Expression of other members of IRF family in lung homogenates of PR8 H1N1 
InfAV-infected IRF-4 mice. 
 
Data expressed as ‘the expression of the gene of interest relative to the internal control 
in InfAV infected-samples compared with the Control mock-infected control’ - 
Comparative Mean Expression levels [2
-∆∆C
P], derived from the following steps: (i) 
average Cp (threshold cycle) calculated for both the gene of interest (GOI) and the 
housekeeping gene (Beta Actin), (ii) the mean of difference between Cp of GOI and 
normalizer (housekeeping) gene is determined (∆Cp), (iii) ∆∆Cp is determined from 
the difference between the Infected and Uninfected samples and (iv) Comparative 
Mean Expression levels (2
-∆∆C
P) is then obtained. 
 
Number of mice used: PR8-infected Test IRF-4 mice (n=20/genotype/experimental 
round) and Control PBS-mock infected IRF-4 mice (n=10/genotype/experimental 
round), conducted over 2 investigation rounds. Mice found dead from InfAv infection 
were excluded from study. One way ANOVA was performed to determine statistical 
significance (p < 0.05). 
 
 
3.5.8. Microarray analysis 
 
The experimental design initially consisted of three variables. They are the 
IRF-4 mice genotype (+/+, +/- and -/-), sex and infection status.  
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Normalized data was first plotted on a Box Whisker plot where percentile shift and 
quantile analysis revealed the similarities of the IRF-4 -/- Mock-Infected Control and 
Infected groups (Figs. 3.25 (A) and (B)).  The box-whisker plot shows the median in 
the middle of the box, the 25th quartile and the 75th quartile. Entities with intensity 
values beyond 1.5 times the inter-quartile range are shown in red. 
The normalised intensity data range of Female IRF-4 -/- PBS-Mock-Infected 
(bordered by black box) were of similar values to that of Female IRF-4 -/- PR8-
infected (bordered by grey box). This similarities was most noticeable in the box 
whisker plot of the percentile shifted (Fig. 3.25 (A)).  
Principal component analysis (PCA) was performed to check data quality. The PCA 
plot allows visualization of separation between groups of replicates. PCA plot shows 
one point per array and is colored by genotype and shaped by infection. Ideally, 
replicates within a group should cluster together and separately from arrays in other 
groups. Additionally, the Partek PCA plot also showed the irregularness of the IRF-4 
-/- Mock-Infected Control group compared to other non-infected groups (Fig. 3.26 
(C)).  
By this it was concluded that the data in either groups may be of poor quality. 
In order to salvage this, some of the planned investigated variables for the microarray 
analysis were removed. Therefore it was decided that a One-Way ANOVA be 
completed between the PR8-infected data set of the three genotypes (IFR-4 +/+ , +/- 



































Partek PCA plot 
 
Figures 3.26 (A) and (B). Analysis of data on Genespring GX displayed as Box 
whisker plot of normalized data of percentile shift and quantile. Box-whisker plot 
showing the distribution of normalized intensity values of each sample. A box-
whisker plot shows the samples on the X-axis and the log normalized expression 
values on the Y axis. Data of Female IRF-4 -/- PBS-Mock-Infected (bordered by 
black box) showed extreme similarity to the data of Female IRF-4 -/- PR8-infected 
(bordered by grey box). The Partek Principal Component Analysis (PCA) was 
performed to check data quality (C). The PCA plot allows visualization between 
groups of replicates. Ideally, replicates within a group should cluster together and 
separately from arrays in other groups. The same conclusion can be drawn where the 
proximity of the Female IRF-4 -/- of Control and Infected groups (red small sphere 
and big sphere, respectively) is much greater when compared to the rest of the paired 
variables investigated. With this evidence, a three-way ANOVA of sex, genotype and 
infection status was unable to be performed. Therefore, the variables of sex and 
infection status were removed from further analysis, allowing only data analysis on 
the PR8-infected group of the three genotypes to be done.  
 
 A Flag system used in Genespring GX was used to categorize the quality 
control system from the respective platform. These flags functioned as categorical 
indicator from the scanner and indicated which probes were suspected to be erroneous. 
Probes flagged as “Not Detected” or “Compromised” were typically detected to be 
non-uniform outlier features or not positive / significant. Therefore from an initial 
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target of 25,697 features present for the PR8 H1N1 InfAV-infected data set a total of 





Figure 3.27. Heatmap of PR8 H1N1 InfAV-infected of IRF-4 +/+, +/- and -/- dataset. 
Comparison of sex variability was not performed. By this, biological replicates were 




ProbeID Symbol Definition p 
FC ([+/- Test] vs [+/+ 
Test])
FC ([-/- Test] vs [+/+ 
Test])
FC ([-/- Test] vs [+/- 
Test])
6940184 Ccl4 0.03325 -1.4 -2.0 -1.4
3610082 Cxcl1
Mus musculus chemokine (C-X-C motif) ligand 
1 (Cxcl1), mRNA.
0.0145 -1.5 1.8 2.6
4780072 Ifna1
Mus musculus interferon alpha 1 (Ifna1), 
mRNA.
0.02945 1.1 -1.4 -1.5
6280592 Ifnb1
Mus musculus interferon beta 1, fibroblast 
(Ifnb1), mRNA.
0.00609 -1.2 2.1 2.5
6280477 Ifng
Mus musculus interferon gamma (Ifng), 
mRNA.
0.03848 -1.2 -1.8 -1.5
3420139 Il1 0.00759 1.0 1.4 1.4
1260632 Il10 Mus musculus interleukin 10 (Il10), mRNA. 0.00769 -1.1 -2.2 -2.0
3420754 Il1b 0.00457 -1.3 3.3 4.3
3400288 Irf1
Mus musculus interferon regulatory factor 1 
(Irf1), mRNA.
0.02809 -1.5 -1.2 1.2
 
Table 3.8. Fold Change of significant differentially expressed genes between PR8 
H1N1 InfAV-infected IRF-4 +/+ vs IRF-4 +/- vs IRF-4 -/-, concurrently investigated 
for Cytokine Analysis by BioPlex and mRNA expression by qRT-PCR. Significance 
analysis was performed with 1-way ANOVA with fold change analysis and genelist is 


























Table 3.9. Genesrping generated Gene Ontology and cross-referenced to 
WikiPathway for IRF-4 gene, arranged in ascending order of p-value. 
 
 
Besides IRF-4’s involvement in innate and adaptive immune pathways, such 
as Cytokines and Inflammatory Response, T cell receptor signaling pathway, IL-2 
Signaling pathway, Type II IFN signaling and Inflammatory response pathway, the 
transcription factor is also involve in other unknown pathways. This includes 












3.5.9. IRF-4 mice infection with mouse-adapted Influenza A/Aichi/2/1968 H3N2 
 
To investigate whether the strain specificity of the influenza A virus 
contributes to any difference to the infection of the IRF-4 mice, a pilot study was 
performed where a mouse adapted Influenza A/Aichi/2/1968 H3N2 strain was used 
for infection. The mouse adapted virus was previously described (Narasaraju, Sim et 
al. 2009).  
Firstly, IRF-4 +/+ C57BL/6 mice were infected intra-nasally with the human 
infectious/non-mouse adapted H3N2 virus as well as the 10
th
 lung passage mouse-
adapted H3N2 virus at low (1 x 10
4
) and high (1 x 10
5
) TCID50 concentrations (Fig. 
3.28). It was found that none of the mice were infected by this virus whether the non-
mouse adapted or the mouse-adapted virus was used. Mice were found to gain weight 
over the observation period after the infection.  
 However when IRF-4 +/- and -/- mice were infected with high (1 x 10
5
) 
TCID50, both genotypes immediately succumb to the infection (Fig. 3.29). Mice of 
IRF-4 +/- genotype were able to recover as can be observed from the weight loss but 
the IRF-4 -/- mice loss a higher amount of weight with the male IRF-4 -/- 









Figure 3.28. Weight loss of IRF-4 +/+ C57BL/6 mice infected with P0 and P10 at low 
and high TCID50 of Influenza A/Aichi/2/68 H3N2. Five C57BL/6 mice each of either 
sex were intra-nasally infected with either human-infectious non-mouse-adapted (PO) 
or 10
th
 serial-passage-mouse-adapted (P10) Aichi H3N2 InfAV at 1 x 10
4
 (low) or 1 x 
10
5
 (high) TCID50. All mice were discovered to have a positive weight change and 
survived the Aic68 infection. There was no significant difference between the mice 
sexes, viral passage virulence (P0 and P10) as well as the viral load (TCID50 low and 




Figure 3.29. Weight loss of IRF-4 +/- and -/- mice infected with P10 at high TCID50 
of Influenza A/Aichi/2/68 H3N2. Five C57BL/6 mice each of either sex were intra-
nasally infected with the 10
th





TCID50. All mice were discovered to be affected by the infection with a negative 
weight change over the initial phase of the infection, with the exception of Male IRF-
4 -/- group where weight change continued to plummet to an average of 35% of 
original body weight until the monitoring ended on Day 15 Post Infection. The mean 
of Female mice of IRF-4 +/- and -/- genotypes showed a positive change in body 
weight after Days 11 Post Infection. However, each group suffered some mortality as 
well. Male +/- group were also affected by the infection but maintained a fairly 
constant weight loss and majority survived the infection till the monitoring ended on 
Day 15 Post Infection.  There was also no significant difference between the mice sex 
and genotype (IRF-4 +/- and -/-) at a higher virulent viral passage (P10) and high viral 




Mice were then culled at a specified timepoints and lungs were harvested and 
its histopathology in terms of from the influenza virus infection determined, as 
mentioned earlier. Figures 3.30 to 3.43 represent the sample of the H&E-stained lungs 
sections observed. As mentioned earlier, scores for lung histopathology were obtained 
blindly and tabulated in Table 3.10, where the scores for individual mice are 
presented. Clearly, in each group there can be observed a few mice having worse off 
lung histopathology scores. IRF-4 +/+ mice clearly do not show any susceptibility to 
the virus infection whether used at a low or high concentration (Figs. 3.44 to 3.47).  
However in IRF-4 +/- and -/- mice, the results became more obvious where 
IRF-4 -/- mice of both sexes and female IRF-4 +/- mice fared worse than the controls, 
in this case the IRF-4 +/+ infected mice, which did not show much lung damage. 
When the sex of infected mice were omitted from analysis, it was clear that lung 
histopathology scores were indeed influenced by genotype of the mice where IRF-4 





Figure 3.30. Lung section, H&E stained, of male IRF-4 +/+ mouse (EP1) infected 
with low dose (1 x 10
4
 TCID50) of mice-adapted H3N2 (P10), exhibiting minimal 
septal congestion (A). No inflammatory cellular infiltrates present. Total lung 





Figure 3.31. Lung section, H&E stained, of male IRF-4 +/+ mouse (EP1) infected 
with low dose (1 x 10
4
 TCID50) of mice-adapted H3N2 (P10), exhibiting minimal 
septal congestion (A). No inflammatory cellular infiltrates present. Total lung 






Figure 3.32. Lung section, H&E stained, of female IRF-4 +/+ mouse (EP5) infected 
with low dose (1 x 10
4
 TCID50) of mice-adapted H3N2 (P10), exhibiting mild septal 






Figure 3.33. Lung section, H&E stained, of male IRF-4 -/- mouse (EP11) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting alveolar 
hemorrhage (A) and inflammatory infiltrates of neutrophils within bronchioles (B). 









Figure 3.34. Lung section, H&E stained, of male IRF-4 -/- mouse (EP11) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), displaying 
inflammatory infiltrates of neutrophils within bronchioles (A). Total lung 





Figure 3.35. Lung section, H&E stained, of female IRF-4 +/- mouse (EP21) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting alveolar 









Figure 3.36. Lung section, H&E stained, of female IRF-4 +/- mouse (EP21) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting alveolar 
hemorrhage (A) and inflammatory infiltrates made up of a mixture of lymphocytes 





Figure 3.37. Lung section, H&E stained, of female IRF-4 +/- mouse (EP21) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting 
inflammatory infiltrates made up of a mixture of lymphocytes and neutrophils (A). 








Figure 3.38. Lung section, H&E stained, of male IRF-4 -/- mouse (EP38) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting alveolar 
hemorrhage (A) and inflammatory infiltrates (B). Total lung histopathology score 17. 





Figure 3.39. Lung section, H&E stained, of male IRF-4 -/- mouse (EP38) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting fibrin 
deposits (A) and inflammatory infiltrates made up of a mixture of lymphocytes and 








Figure 3.40. Lung section, H&E stained, of male IRF-4 -/- mouse (EP38) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting fibrin 





Figure 3.41. Lung section, H&E stained, of male IRF-4 -/- mouse (EP38) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting fibrin 
exudate (A) and inflammatory infiltrates mainly of neutrophils and some lymphocytes 







Figure 3.42. Lung section, H&E stained, of female IRF-4 +/- mouse (EP21) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting septal 
congestion and mild alveolar hemorrhage (A). Total lung histopathology score 19. 





Figure 3.43. Lung section, H&E stained, of female IRF-4 +/- mouse (EP21) infected 
with high dose (1 x 10
5
 TCID50) of mice-adapted H3N2 (P10), exhibiting fibrin 
exudate (A), alveolar congestion (B)  and cellular infiltrates of neutrophils and 










Table 3.10. Lung histopathology scores of individual mice infected intra-nasally with 
either human-infectious non-mouse-adapted (P0) or 10
th
 serial-passage-mouse-
adapted (P10) Aichi H3N2 InfAV at 1 x 10
4
 (low) or 1 x 10
5
 (high) TCID50. Upon 
infection, mice were weighed daily until weight loss was 20% of its original body 
weight. Mice were culled by CO2 asphyxiation and lungs harvested before samples 
were fixed in formalin. Histology slides of lung sections were processed and stained 
with Hematoxylin and eosin before scoring was performed in a double-blinded 
manner, following the scoring procedure described in the Materials and Methods 
section. As observed from the lung histopathology scores of individual mice, the 
intra-nasal route infection caused a higher variability in lung histopathology. 
Mice Sex IRF4 Virus TCID50 Alveolar Alveolar Intraaveolar Cellular Total 
EP No.   Genotype Passage Dose septa (x1) haemorrhage (x2) Fibrin (x3) Infiltrates (x2) score 
1 ♀ +/+ P0 1 x 104 2 1 0 0 3 
2 ♀ +/+ P0 1 x 104 2 1 0 0 3 
3 ♀ +/+ P0 1 x 105 2 1 0 1 3 
4 ♀ +/+ P0 1 x 105 2 1 0 0 3 
1 ♂ +/+ P10 1 x 104 1 0 0 1 3 
2 ♂ +/+ P10 1 x 104 1 1 0 1 4 
3 ♂ +/+ P10 1 x 105 1 1 0 0 2 
4 ♂ +/+ P10 1 x 105 1 2 0 0 3 
5 ♀ +/+ P10 1 x 104 2 2 0 0 4 
6 ♀ +/+ P10 1 x 104 2 1 0 2 7 
7 ♀ +/+ P10 1 x 105 2 1 0 0 3 
8 ♀ +/+ P10 1 x 105 2 1 0 1 5 
71 ♀ +/+ P10 1 x 105 2 1 0 0 3 
1 ♂ +/- P10 1 x 105 2 2 0 0 4 
15 ♂ +/- P10 1 x 105 2 1 0 1 5 
17 ♀ +/- P10 1 x 105 1 1 3 3 17 
19 ♀ +/- P10 1 x 105 2 1 0 1 5 
21 ♀ +/- P10 1 x 105 2 2 3 3 19 
11 ♂ -/- P10 1 x 105 2 2 1 1 9 
38 ♂ -/- P10 1 x 105 1 1 3 3 17 
46 ♂ -/- P10 1 x 105 2 1 0 0 3 
48 ♂ -/- P10 1 x 105 2 1 3 3 18 
49 ♂ -/- P10 1 x 105 2 2 1 2 11 
26 ♀ -/- P10 1 x 105 3 2 2 2 15 
28 ♀ -/- P10 1 x 105 2 1 0 0 3 
44 ♀ -/- P10 1 x 105 1 1 3 3 17 
50 ♀ -/- P10 1 x 105 2 2 1 3 13 




Figure 3.44. Mean lung histopathology scores of IRF-4 +/+ C57BL/6 mice infected 
either with human-infectious non-mouse-adapted (P0) or 10
th
 serial-passage-mouse-
adapted (P10) Aichi H3N2 InfAV at 1 x 10
4
 (low) or 1 x 10
5
 (high) TCID50. There 
was significant difference between 1 x 10
4
 (low) or 1 x 10
5
 (high) TCID50 
concentration for mice infected with the 10
th
 serial-passage-mouse-adapted (P10) 
Aichi H3N2 InfAV, but none between the human-infectious non-mouse-adapted (P0). 
There was also significant difference between mice infected with the 10
th
 serial-
passage-mouse-adapted (P10) Aichi H3N2 InfAV and human-infectious non-mouse-
adapted (P0) at 1 x 10
4
 (low) TCID50. However, no significant difference was 
observed for mice infected with 1 x 10
5
 (high) TCID50. 
 
 
Figure 3.45. Mean lung histopathology scores of IRF-4 +/+ C57BL/6 mice of both 
sexes, infected with 10
th
 serial-passage-mouse-adapted (P10) Aichi H3N2 InfAV at 1 
x 10
4
 (low) or 1 x 10
5
 (high) TCID50. There was significant difference between mice 
of both sexes infected with 1 x 10
4
 (low) and 1 x 10
5
 (high) TCID50. Futhermore, a 
significant difference was also observed where female mice fared worse than male 
mice in those infected with 1 x 10
4
 (low) and 1 x 10
5





Figure 3.46. Mean lung histopathology scores of IRF-4 +/+, +/- and -/- mice infected 
with 10
th
 serial-passage-mouse-adapted (P10) Aichi H3N2 InfAV at 1 x 10
5
 (high) 
TCID50.  Infected female +/- fared worse than its infected male counterpart as well as 
infected female +/+. No difference was observed between mice sexes of IRF-4 -/-. In 
male mice, there was a significant difference between the three genotypes. 
Histopathology scores were higher in infected IRF-4 +/- and -/- mice, when compared 




Figure 3.47. Mean lung histopathology scores of total IRF-4 +/+, +/- and -/- mice 
infected with 10
th
 serial-passage-mouse-adapted (P10) Aichi H3N2 InfAV at 1 x 10
5
 
(high) TCID50. There was a significant difference between IRF-4 +/+ with, IRF-4 +/- 





3.6. DISCUSSION  
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The respiratory tract mucosa represents the infection site for InfV as well as the 
site of defense against virus infection. The innate immune mechanisms exist to 
initially detect and non-specifically destroy viruses, but should these viruses escape 
the early defense mechanisms, the adaptive immune mechanisms would detect these 
viruses are detected and eliminated in a more specific manner.  
IRF-4 is a lymphoid- and myeloid-restricted transcription factor (Gauzzi, 
Purificato et al. 2005). Its expression is a key regulator of several steps in lymphoid, 
myeloid and dendritic cell differentiation (Shaffer, Emre et al. 2009). In B and T cells, 
IRF-4 is primarily regulated by pathways known to drive lymphocyte activation 
(Mittrucker, Matsuyama et al. 1997). There exist, no evidence to date that IRF-4 is 
regulated by the Type I or Type II IFNs (Gupta, Jiang et al. 1999). 
Physical signs such as lethargy, ruffled fur and weight loss can be used as 
measureable outcomes and markers for influenza virus virulence in the mouse animal 
model (Belser, Szretter et al. 2009). Reduction in animal body weight during an 
infection may indicate that they are ill and as a result in the decreased in appetite and 
feeding. The mock-infected control and PR8- as well as Aic68-infected mice were 
characteristically found to lose body weight of approximately 5% during the first 2 
days post-infection due to the effects of anaesthesia. From Day 2 Post-infection there 
appeared to have diverging body weight loss between the mock-infected control and 
the InfV-infected mice. Where the body weight of the mock-infected control mice 
were maintained or even increased over the course of monitoring, the infected mice 
lost weight at a steady rate achieving a body weight reduction of 25-30% in the range 
of Days 7-11 Post Infection, in the PR8-infected mice and Days 11-14 Post Infection 
in the Aic68-infected mice. However, as weight loss is a crude measure of virulence, 
no significant difference was observed between the virus strains used, sex of mice and 
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IRF-4 genotype of the infected mice. When the body weight loss of 25-30% was used 
as a surrogate to mortality, there was significant difference in the PR8-infected IRF-4 
-/- mice and PR8-infected IRF-4 +/+ and +/- mice. Surprisingly, the IRF-4 -/- mice 
were able to survive longer as compared to the rest of the genotypes. As weight loss is 
a crude qualitative measurement, it needs to be corroborated with other meaningful 
measurement such as lung viral titres.  
The acute phase response to differing lethality of PR8 InfV intra-nasal 
inoculation in mice was investigated (Conn, Mcclellan et al. 1995). Inoculation leads 
to a dose-dependent increase in clinical symptoms as well as mortality. When given a 
sub-lethal dose, food and water intake in mice decreased gradually to nearly zero over 
6 days, after which intakes were found to slowly increase. It was found that the 
declines were parallel to decreases in body temperature and general locomotor 
activity. At lethal doses, food and water intake fell drastically to near zero within two 
days, as with the significant decrease in temperature and locomotor activity.  
Lung histopathology was assessed in a double-blinded manner by the qualitative 
observation of H&E-stained lung sections and from there, a quantitative score was 
generated based on a pre-determined set of criteria (Matute-Bello, Winn et al. 2001).  
Histopathology scores among infected mice from different IRF-4 genotypes revealed 
that there was no significant difference between the IRF-4 +/+ and IRF-4 -/- infected 
the lethal dose PR8 H1N1 InfV at the terminal phase of the infection at Days 7-11 
Post Infection. However, in the preliminary study of mouse-adapted Aic68 H3N2 
InfV infection, there was significance between the infected groups of IRF-4 +/+ and 
IRF-4 -/- mice. This may indicate that there appeared to be antigenic differences 
between the PR8 H1N1 and the mouse-adapted Aic68 H3N2. This mirrors the same 
observation seen in another related study involving the exact same two viruses used, 
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where both strains behaved differently (Li, Lim et al. 2010). Other studies have 
observed similar patterns (Garigliany, Habyarimana et al. 2010).  
Also of interest, the lungs of mice infected with the PR8 H1N1 were harvested 
between Days 7-11 Post Infection when its weight lost was above 25%. The mouse-
adapted Aic68 H3N2 infected mice were harvested between Days 11-15 Post-
Infection. Histopathological changes in adult mice can be somewhat different from 
those of young mice. In a study examining pathological changes in lung tissues of 
young (2-4 month old) and aged (25-27 month old) mice intra-nasally infected with 
25μl of the PR8 virus in each nostril, infected young mice showed body weight loss at 
Days 4 Post Infection (while body weight decrease only started Days 9 Post Infection 
in aged mice) (Muto, Sunden et al. 2012). More importantly when lungs were 
examined histopathologically, it was discovered that viral antigen-positive 
bronchiolar and alveolar epithelial cells number at Days 3 Post Infection were 
significantly higher in young mice than in aged ones. These viral antigen-positive 
cells were cleared by Day 9 Post Infection in young mice but were still present in the 
aged group. Diffuse and severe bronchointerstitial pneumonia identified by 
polymorphonuclear leukocytes accumulations was seen at Day 6 Post Infection in 
young mice.  
In our study with IRF-4 mice, while all efforts to use mice of approximately 3-5 
months old were put in place, it was difficult to standardized experimental mice age 
within a mouse colony. This article provided some detailed insights into the age-
specific course of infection in young and aged mice with associated differences in 




Aerosol exposure of mice to a sublethal dose of PR8 InfV produced IFNs, 
measurable in tracheobrochial washings on Days 1-8 Post Infection, which peaked on 
Day 5 and disappeared thereafter (Iwasaki and Nozima 1977). 
In the three main compartment of the lung, there exist: (i) airway cells in the 
bronchial and bronchiolar epithelium and bronchial glands (made up of basal, 
secretory, ciliated, Clara and neuroendocrine cells); (2) alveolar unit cells (Type I and 
2 cells, fibroblast in the interstitium) and (3) pulmonary vascular cells (endothelial 
cells) (Franks, Colby et al. 2008). The kinetics of airway epithelial remodeling and 
inflammation in the airways of C57BL/6 mice infected with 50pfu PR8 intranasally 
were examined at different timepoints (Buchweitz, Harkema et al. 2007). Neutrophils 
peaks at 3 and 7 days post infection (dpi), whereas monocytes, lymphocytes and 
eosinophils peaked at 10dpi. Pulmonary histopathology of mice sacrificed at 7-10dpi 
demonstarted a marked bronchiolitis and alveolitis restricted to the hilar region of the 
lung lobe. Associated inflammatory cell infiltrate in and around the bronchiolar walls, 
adjacent blood vessel and alveolar septa was observed in mice sacrificed at 7-10dpi. It 
was also found that inflammatory cells started to enter airways following a classic 
pattern of inflammation, whereby an early proinflammatory response, represented by 
neutrophilic influx followed by monocytes and macrophages was observed early at 3 
dpi and 7dpi, respectively. An influx of lymphocytes and eosinophils appeared to 
peak at 10dpi. 
The cellular immune responses of mice to InfV infections has been studied 
(Reiss and Schulman 1980). Peak virus titers were within 2-3dpi and decreased 
rapidly. Gross pulmonary lesions appeared on fourth day and reached maximum 
between seventh and ninth, before declining in severity. B lymphocytes appeared only 
after 7 dpi. Cytotoxic activity in lungs observed to peaked at 7dpi.  
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It is of interest to note then that the viral load titers determined showed an 
extremely significant increase in viral load titers in the infected-IRF-4 -/- lungs, as 
compared to the other groups. In human volunteers, virus is usually detected in nasal 
secretions within one day after inoculation, but is no longer detectable after 5-7 days 
of shedding (Van Reeth 2000). The detectable presence of virus in the IRF-4 -/- 
cohort demonstrates some interesting observation. The knockout genotype of the IRF-
4 gene had caused a failure to clear virus in terms of the innate as well as the adaptive 
response. As observed in male and female lung homogenate samples, viral loads on 
Days 7 to 9 post-infection, were higher in those from IRF-4 -/- than IRF-4 +/- and +/+. 
IRF-4 is known to interact with MyD88 to act as a negative regulator of TLR 
signaling (Negishi, Ohba et al. 2005). In InfV infected patients, TLR responses were 
found to be significantly lower (Heltzer, Coffin et al. 2009). As such the ability to 
produce TNF-α and IFN-α was affected. One would expect that lung viral titres to be 
low as seen in the IRF-4 +/+ or IRF-4 +/-, as harvesting was performed on 7-11dpi, 
sufficient time for the innate and adaptive immune mechanism to clear the virus.  
In B-cell lineage, IRF-4 is known to be critical for plasma cell differentiation 
and isotype switching (Klein, Casola et al. 2006, Sciammas, Shaffer et al. 2006). 
Besides crucial for the differentiation of Th2, Th9 and Th17 cells, IRF-4 has also been 
shown to be important for the development and differentiation of follicular T-helper 
(TFH) cells (Bollig, Brustle et al. 2012). This subset of T-cells cooperates with 
germinal center (GC) B cells to induce antibody maturation. Using a Leishmania 
major infection mouse model where strong B- and T-cell interactions as well as 
lymph nodes hyperplasia were generated, the formation of GCs, differentiation of GC 
B cells and survival of LN cells during an immune response were seen, all of which 
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demonstrated the importance of IRF4 in the center of antibody production toward T-
cell-dependent antigens.   
 In this study, we are the first to demonstrate the knockout genotype of the 
IRF-4 gene failed to raise a neutralization antibody response against the PR8 H1N1 
InfAV. The failure to raise a sufficient and functional humoral immune response 
stems from the effect of IRF-4 on B-cell development (Mittrucker, Matsuyama et al. 
1997, Lu, Medina et al. 2003, Nishiya, Yamamoto et al. 2004, Ma, Turetsky et al. 
2006, Lu 2008). 
 In the cytokine analysis of lung homogenate obtained 7-11dpi, various 
cytokines were looked at: proinflammatory, Th1, Th2 and chemokines. There 
appeared to be no defined trend in the fold changes between the three genotypes of 
IRF-4 +/+, +/- and -/-. There was significant increase in fold change of 
proinflammatory cytokines GM-CSF, TNF-α and IL-3 whereas a decrease in fold 
change, occurred for IL-1β and IL-6, in the IRF-4 -/- compared to other groups. In 
patients infected with severe InfV, plasma levels of TNF-α, MIP-1α, IL-1β, IL-18 and 
IFN-α did not increase (Heltzer, Coffin et al. 2009). However an elevation of plasma 
levels of IL-6 and IL-10 was observed.  
Monocytes and macrophages are the major source of these proinflammatory 
cytokines (Thacker 2006). It appeared that the proinflammatory cytokines do not peak 
at concurrent times but rather spaced out (Hayden, Fritz et al. 1998). IL-6 and IFN-
alpha levels in nasal lavage fluids peaked at day 2 and correlated directly with viral 
titers, temperature, mucus production, and symptom scores. IL-6 elevations were also 
found in the circulation at this time point. In contrast, TNF-alpha responses peaked at 
day 4 in nasal fluids, when viral shedding and symptoms were subsiding. Similarly, 
IL-8 peaked late in the illness course (days 4-6) and correlated only with lower 
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respiratory symptoms, which also occurred late. None of IL-1beta, IL-2, or TGF-beta 
levels increased significantly. Therefore with harvesting done only at 7-11dpi, the 
upward trend or peak of these cytokines could have been missed. What is certain is 
that IRF-4 is a negative regulator to the production of proinflammatory cytokines 
(Honma, Udono et al. 2005), where in response to LPS stimulation which triggers the 
TLR pathway, IRF-4 -/- macrophages were observed to secrete an increase amount of 
proinflammatory cytokines (TNF-α and IL-6). Also observed was the activation of 
NF-κ B and the Jnk signaling pathway.  
 There was also a general increase in fold change for Th2 cytokines in the IRF-
4 -/- lung homogenates. This is contrary to what is known where there exist a 
development of Th1 immune responses with a suppression of Th2 responses in the 
absence of IRF-4 (Tominaga, Ohkusu-Tsukada et al. 2003). It is also of interest that 
IRF-4 activates IL-2 and IL-4 promoters in cooperation with the NF-κB family 
member, c-Rel (Shindo, Yasui et al. 2011). Strangely enough, as seen in the extremely 
significant increase in fold change of IL-4 in IRF-4 -/- lung homogenate, IL-4 could 
be the cause of the delayed virus clearance.  
 IL-4 can function to inhibit antiviral immunity (Moran, Isobe et al. 1996). The 
clearance of PR8 from the lungs of infected BALB/c mice was significantly delayed 
after the transfer of virus-specific T cells secondarily stimulated in the presence of IL-
4 in comparison to virus clearance in recipients of cells stimulated in the absence of 
IL-4. In contrast to the adoptive transfer results, the treatment of PR8 virus-infected 
mice with IL-4 during primary infection greatly suppressed the generation of 
cytotoxic T-cell precursors, as assessed by secondary stimulation in vitro. More 
importantly, the treatment of mice with IL-4 resulted in an extremely significant delay 
in virus clearance.  
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 The fold change of IFN-γ in IRF-4 -/- lung homogenate was found to be 
significantly reduced as compared to other genotypes. There exist no evidence to 
support the direct involvement of IRF-4 to the function and secretion of Type II IFN. 
IFN-γ is detected during the acute stages of illness in the upper respiratory tract 
secretions of InfAV-infected individuals (Uetani, Hiroi et al. 2008). It appears that 
InfAV subverts antiviral host defense mediated by IFN-γ through effects on the 
intracellular signaling pathways. IFN-γ is not required for recovery from primary 
infection with influenza virus (Nguyen, van Ginkel et al. 2000). IFN-γ is not 
necessary for the development of an effective humoral or cellular immune response to 
challenge with InfAV (Graham, Dalton et al. 1993). However, the involvement of 
IFN-γ in mechanisms that regulate increased leucocyte traffic in the inflamed lung 
parenchyma has been shown (Baumgarth and Kelso 1996). It demonstrates that IFN-γ 
affects the local cellular response in the respiratory tract as well as the systemic 
humoral response to influenza virus infection. 
The IL-8-like chemokine CXCL1 was found to have a significant less increase 
in fold change in the IRF-4 -/-. CXCL1 is expressed by macrophages, neutrophils and 
epithelial cells (Moser, Clark-Lewis et al. 1990, Becker, Quay et al. 1994) and has 
neutrophil chemoattractant activity. It is involved in the processes of angiogenesis, 
inflammation, wound healing and tumorigenesis. This would indicate that in IRF-4 -/- 
mice, there appeared to be a dysfunction in neutrophil chemoattractant to the lung 
injury site. While neutrophils play an important role in the InfV pathophysiology by 
causing the narrowing of terminal bronchi and bronchioli (Van Reeth 2000), this 
dysfunction seen in the IRF-4 -/- cohort demonstrates a similar and not worse, lung 
pathology than the IRF-4 +/+ and +/- cohort.  
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 There was a significant increase in inflammatory IL-17 in terms of a 1.5 times 
fold change in the infected IRF-4 -/- as compared to the other PR8-infected groups, 
where there was a suppression in IL-17 levels due to the infection. IRF-4 -/- Th cells 
are known to not able to differentiate into Th17 cells as IRF-4 is a crucial regulator of 
Th17 differentiation (Brustle, Heink et al. 2007). Therefore, strangely, the data 
suggest that another source of IL-17 probably exist. As it is known Th17 cells are the 
only secretors of IL-17 (Korn, Bettelli et al. 2009). The data does not agree with the 
known literature as in the presence of IRF-4 gene, there is suppression on the IL-17 
cytokine levels as seen in the IRF-4 +/+ and +/- groups. However in its absence, there 
is no regulation of IL-17, hence an increase in levels. 
 The mRNA expression of other IRF family members by qRT-PCR yielded 
some interesting data. It appeared that the mRNA expression of other IRF family 
members (IRF-1, IRF-3, IRF5, IRF-7 and IRF-8) was directly proportional to the 
graded absence of the IRF-4 gene during the PR8 infection. Currently three members 
of the IRF family, IRF-3, IRF-5 and IRF-7 have been identified as acting as direct 
transducers of virus-mediated signaling (Barnes, Lubyova et al. 2002). As 
demonstrated from the viral plaque assay and NS1 qRT-PCR, there appeared an 
extermely high level of titres in the IRF-4 -/- lung homogenate. One would then 
expect that these infected cells would have sufficient levels of IRF-3 and IRF-7 to 
play its role in the inducible expression of Type I IFN genes. IRF-5 itself would be 
activated as its activation is virus specific. However as the lung homogenate was 
harvest at Days 7-11 Post Infection, one would definitely expect that levels of the 
Type I IFNs be low as these IFNs are responsible in innate immunity. In terms of host 
defense, IRF-1 stimulates the expression of IFN responsive gene and proinflammatory 
cytokines as well as promotes the Th1 responses (Honda, Takaoka et al. 2006, Honda, 
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Takaoka et al. 2006). Interestingly, in IRF-4 -/- mice, Th1 immune responses are also 
favoured over Th2 immune response (Tominaga, Ohkusu-Tsukada et al. 2003). This 
gives evidence that IRF-1 and IRF-4 seems to work in cooperation in skewing of the 
immune response towards a Th1 response. However this may be in contrast to other 
reports (Yoshida, Yamamoto et al. 2005). 
IRF-8 is constitutive in B cells, macrophage, CD8α+ dendritic cells (DC) and 
plasmacytoid DCs. A defect in IRF-4 causes a deficiency in mature T and B cells (Lu, 
Medina et al. 2003) as well as CD4
+
 DCs. B cells are not able to form germinal 
centers in spleen and lymph nodes (Mittrucker, Matsuyama et al. 1997) and prevents 
the differentiation of B lymphocytes into plasma cells. This culminates in the 
disability to secrete antibodies. IRF-8 also stimulates IFN-γ and other PAMP-
inducible genes. As there is cooperative regulation of B cell differentiation by IRF-4 
and IRF-8, the knock –out phenotype in the IRF-4 -/- mice would also affect IRF-8 
levels. As also shown in IFN-γ level in the lung homogenate when measured by 
BioPlex and its mRNA expression by qRT-PCR, it is not surprising that IFN-γ is also 
affected.  
 Chen et al (2008) examined the molecular profile of T-helper genes involved 
during dengue virus infection of human monocytes, lymphocytes and hepatocytes. 
Genes found to be strongly-upregulated contributed to the immunopathogenecity of 
the viral infection by regulating inflammation, thrombocytopenia and vascular 
permeability. These included chemokine receptor CC-CKR-3 / CD193, chemokine 
ligand RANTES, early activation marker CD69, IL-6, TLR6 and IRF-4. 
 Finally, in an infection model of Nippostrongyrus brasiliensis, it was found 
that naïve IRF-4 -/- CD4
+ 
T cells produced Th2 cytokines (including IL-4, IL-5 and 
IL-10) (Honma, Kimura et al. 2008). IL-2 and IFN-γ were not detectable. However, 
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on the other hand, effector memory IRF-4 -/- CD4
+ 
T cells did not exhibit any 
increase in these Th2 cytokines. It appears that IRF-4 play a differential roles in the 
regulation of Th2 cytokines production in native CD4
+
 T cells and effector/memory 
CD4
+
 T cells. While it inhibits Th2 cytokine production in naïve CD4
+ 
T cells, it 
promotes the same cytokine production in effector/memory CD4
+
 T cells. A similar 
study showed that IRF-4 promotes the development of Th2 immune responses 
(Tominaga, Ohkusu-Tsukada et al. 2003).  The development of CD4
+
 T cell subsets 
differentially depends on IRF-4; induction of Th1 response does not depend on IRF-4, 
while Th2 response depends entirely on IRF-4. In the context of InfAV infection, Th1 
cells are cytolytic and protective against lethal challenge whereas Th2 cells are 
noncytolytic and not protective (Graham, Braciale et al. 1994). Therefore virus-
specific CD4+ T cells of the Th2 subset may not play a primary role in virus clearance 
and recovery and may lead to immune mediated potentiation of injury. 
 The intra-tracheal instillation of the PR8 virus and intra-nasal instillation of 
the Aic68 virus appeared to be similar in its delivery. A study comparing the 
pharmacokinetics of intranasal and intratracheal instillation of drugs in rabbits 
appeared to have similar profiles (Adcock, Kyle et al. 2007). The instillation of the 
PR8 at an intratracheal site administers the virus directly to the lower respiratory tract, 
and therefore avoids deposition in the nasal passages, as done in the intra-nasal 
method. However, the difference lies in the InfAV strains used: the PR8 strain, a non-
mice adapted InfAV H1N1, whereas the Aic68 H3N2 was adapted to the mouse 
animal model (Narasaraju, Sim et al. 2009). Serially-adapted to mice over 12 passages, 
the Aic68 H3N2 virus was more lethal to mice on a one-to-one pfu viral load scale as 
mutations were naturally introduced over the course of the adaptation. Studies have 
looked at distinct strains of InfAV with respect to its pathology and kinetics of the 
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infection. The avian H5N1 and H1N1 1918 pandemic influenza viruses are of 
different strains but behave somewhat similarly as both viruses exhibit early and 
sustained replication in murine lung tissue following intranasal infection (Perrone, 
Plowden et al. 2008). Both strains are also both to elicit significantly high levels of 
pro-inflammatory cytokines in lungs. While some aspects are shared among the 
different InfV strains, others differ somewhat. A comparison of  the pathology of the 
H1N1, H5N1, and H3N2 InfAV was made in human cases and animal models 
(Guarner and Falcon-Escobedo 2009). The 1918 H1N1, the novel 2009 H1N1 
pandemic virus, and H5N1 showed inflammation, congestion, and epithelial necrosis 
of the larger airways (trachea, bronchi and bronchioles). Highly virulence viruses 
such as the 1918 H1N1, H5N1, and 2009 H1N1, also tend to infect pneumocytes and 
intraalveolar macrophages. However low-virulence viruses such as the seasonal H3N2 




In the study of the involvement of IRF-4 in InfAV infection, we found that 
pro-inflammatory cytokines were dysregulated in the absence of IRF-4. There was 
suppression in IL-1β and IL-6 levels and an augmentation of GM-CSF and TNF-α. 
Th-1 cytokines of IL-2 and IFN-γ showed a marked reduction whereas Th2 cytokines 
of IL-4 and IL-10 showed an increase. Chemokine CXCL1 indicated a dysfunctional 
level of neutrophil attractant. IFN-α and IFN-β mRNA levels were not affected by the 
IRF-4 gene knockout despite the influenza virus infection. However, IFN-γ mRNA 
was non-existent possibly due to dysfunctional T lymphocytes which are responsible 
for IFN-γ secretion, chiefly CD4+ T helper and CD8+ T lymphocytes.  
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The absence of IRF-4 which has critical function in the development of 
lymphoid and myeloid cells appears to be detrimental to InfV-infected mice, resulting 
in the failure to arm the mice with the necessary protective immunity to mount an 
efficient adaptive immune response.  
 
CHAPTER 4 
Serendipitous observations and preliminary data on spontaneous tumour 




 The IRF-4 gene is a critical factor for the regulation of B-cell proliferation and 
differentiation. It has been suggested that the deregulated expression may contribute 
to B-cell malignancies. IRF-4 up-regulation seems to induce lymphoma or multiple 
myeloma growth (Iida, Rao et al. 1997, Tsuboi, Iida et al. 2000). However, IRF-4 
overexpression alone may not be sufficient for leukemogenesis of transgenic mice 
with an IRF-4 overexpression in lymphocytes (Saito, Yamagata et al. 1999). 
Additional unknown factors may be required for the oncogenic activity of IRF-4 in 
vivo.  
 Mutations of the IRF-4 gene has been implicated in Multiple Myeloma (MM), 
B-cell chronic lymphocytic leukemia (B-CLL), Adult T-cell leukemia/lymphoma 
(ATLL) and Primary effusion lymphoma (Tsuboi, Iida et al. 2000, Rasi and Gaidano 
2009). Tsuboi, Iida et al. (2000) analyzed the expression of IRF-4 in reactive 
lymphoid and lymphoma tissues using immunohistochemistry. They detected the IRF-





were found to be mostly plasma cells. In B cell NHL, IRF-4 expression was found in 
diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma and small 
lymphocytic lymphoma but were absent in mantle cell lymphoma and follicle center 
lymphoma. A high level of IRF-4 expression was detected in various T cell 
lymphoma including ATLL and anaplastic large cell lymphoma (ALCL) and in 
majority of Hodgkin’s diseases. It was found that a major proportion of lymphomas 
comprise either physiologically or aberrantly activated neoplastic lymphocytes 
expressing IRF-4 protein. 
  MM is characterized by a complex molecular aetiology of malignant 
monoclonal plasma cell proliferation defined by gene expression profiling and 
recurrent chromosomal translocation. The chromosomal translocation causes 
transcriptional activation of IRF-4 and as a result of the overexpression, contribute to 
tumourigenesis IRF-4 inhibition is disastrous to myeloma cell lines.  The IRF-4 gene 
targets Myc (myelocytomatosis viral oncogene homolog) in activated B-cells and in 
MM. An autoregulatory circuit exist in myeloma cells where IRF-4 is itself a target 
for Myc transactivation.  
 Schmidt, Hochhaus et al. (2000) investigated the involvement of IRF-4 in 
human leukemogenesis by studying the expression of IRF-4 in various hematologic 
disorders (chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic 
myelomonocytic leukemia (CMMol), acute lymphoblastic leukemia, chronic 
lymphoid leukemia) and its effects to IFN-α treatment, through the use of qRT-PCR 
to analyze susceptible human cell lines and primary human leukemias. Additionally, 
the effects of IFN-α therapy on IRF-4 expression in CML samples were looked at. 
IRF-4 expression was down-regulated in CML, AML and CMMol samples. The 
impaired IRF-4 levels in CML samples were found in T cells. IFN-α therapy in CML 
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patients resulted in the up-regulation of IRF-4 levels. However, IRF-4 expression 
levels were not changed after in vitro IFN-γ or IFN-α incubations. It is thought that 
the IRF-4 promoter lacks an IFN-γ activated site and an IFN-stimulated response 
element needed for a direct response to IFN-γ and IFN-α, respectively (Schmidt, 
Hochhaus et al. 2000). 
 The usage of IRF-4 expression as a prognostic marker in B-CLL is 
inconclusive. Chang, Lorek et al. (2002) evaluated the prognostic significance of IRF-
4 expression in B-CLL and concluded that the absence of IRF-4 expression showed 
the highest relative risk among factors analysed by them in determining the death 
probability in B-CLL patients. Patients without IRF-4 expression generally fared 
worse in survivability. However this was contradicted by Ito, Iida et al. (2002) where 
B-CLL/ small lymphocytic lymphoma (SLL) patients who were IRF-4 positive 
showed shorter overall survival times than those who were IRF-4 negative.  
 In Adult T-cell leukemia/lymphoma (ATLL), the T-cell lymphoid neoplasia is 
caused by HTLV1 (human T-cell leukemia/lymphotropic virus-1) infection (Cuneo 
and Castoldi 2005) (Imaizumi, Kohno et al. 2001). ATLL is characterized by an 
aggressive CD4
+
 T lymphoma and is associated with peripheral blood and bone 
marrow involvement, diffuse adenopathies, hepatomegaly, bone lesions and 
hypercalcemia. In ATLL patients and HTLV-1 infected cell lines, IRF-4 has been 
shown to be upregulated. The expression increases during ATLL progression with 
level reaching the maximum during the late phase. HTLV-1 is potentially oncogenic 
caused by the viral transactivator Tax protein that disrupts cell cycle regulation (Jin, 
Spencer et al. 1998), gene transcription and signal transduction (Neuveut and Jeang 
2002). IRF-4 may represent an endogenous transcriptional repressor of DNA repair 
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mechanisms where repression increases the risk of mutations (Imaizumi, Kohno et al. 
2001). 
 
 B-cell NHL include a number of clinicopathologic subsets of lymphoid 
neoplasms having heterogeneous features (Cuneo 2000). Burkitt’s lymphoma consists 
of a monomorphic infiltrate of the lymph node by medium-sized cells showing round 
nuclei with several nucleoli and basophilic cytoplasm (Cuneo and Castoldi 2001). 
Teng, Takahashi et al. (2007) established germinal center B cell-derived Burkitt’s 
lymphoma cell likes that exogenously expressed IRF-4 in order to investigate the 
probable role of IRF-4 in B-cell development. They suggested that IRF-4 inhibits cell 
cycle progression of these lymphoma cells and induced terminal differentiation of 
mature B cells to plasma cells using mechanisms which are BCL6 independent.  
 
4.2. MATERIALS AND METHODS 
4.2.1. CD3 and CD20 immunohistochemistry 
Target Retrieval Solution (TRS) pH9 (Dako, Denmark) was prepared by 
heating in a microwave to near boiling temparature. 4 µm-lymph node sections 
mounted on glass slides were deparaffinized and rehydrated and washed in water. 
Sections were then immersed in Coplin Jars filled with pre-heated TRS for 20 min 
before washing in water, blocking with 3% H2O2 and washed again. Primary 
antibodies (CD3 Rabbit polyclonal, ab5690, Abcam, UK and CD20 Rabbit 
monoclonal, ab78237, Abcam, UK) were then diluted to 100 to 1000 times, 
respectively, in room temperature TRS and stained for 1hr at room temperature with 
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gently rocking. Peroxidase labeled polymer was then applied and incubated for 30 
min, followed by washing. DAB + Chromogen solution was applied for 6 min, 
followed by washing. Sections were counterstained with Mayer’s Hematoxylin before 
washing with water and in ammonia water and finally mounting.  
 
4.3. RESULTS 
4.3.1. Tumourigenesis model in recovered IRF-4 +/- infected with P12 mouse-
adapted Influenza A/Aichi/2/68 H3N2 
Maintained in a SPF-free colony, five 6- to 9-months old IRF-4 +/- mice were 




-serially passaged BALB/C mouse adapted-
A/Aichi/2/1968 H3N2. Two of the five mice died within days of the infection as 
described in the previous chapter, whereas three mice (Animal Identification Number 
EP-16, -20 and -44) recovered fully after the characteristic weight loss of no more 
than 20% of original body weight. Approximately four months post-infection, growth 
was observed within the neck region and mice were culled as specified by IACUC 
protocols. Growth and organs were harvested as fixed with 4% formaldehyde before 
processing and staining with H&E. 
 Upon dissection, a massive growth within the neck region was evident in two 
of the mice (EP-16 and -20), inclusive of lymphadenopathy of the inguinal and 
axiliary lymph nodes. The mediastinal lymph nodes of EP-44 was found to have a 
reactive proliferation but not as lymphomatous, as with the inguinal lymph nodes.  





Figure 4.1: Gross anatomy of EP16 and EP20 IRF-4 +/- mice displaying axillary, 
brachial and inguinal lymphadenopathy. Mice, aged 6- to 9- months old, were 
infected with the mouse-adapted Aichi H3N2 InfAV but recovered from the infection. 
Four months post-infection, growth located within the neck region was observed and 
mice were culled as specified by IACUC protocols. The age of mice during culling 








Hematoxylin & Eosin (H&E) staining of various sections of organs and 
growth revealed that there was atypical lymphocytic proliferation in the auxiliary, 
inguinal, abdomen, chest and neck lymph nodes. This is consistent with large cell 
lymphoma. Lungs were found to have undergone perivascular and peribronchiolar 
proliferation accompanied with congestion and hemorrhage. There were portal / 
periportal lymphoid proliferation in the liver. The spleen was observed to have white 
pulp expansion similar to lymphoid proliferation. The kidney was observed to have 
patchy cortex and medulla lymphoid proliferation.  
 
 
Figure 4.3. Lung histological section, H&E stained, of female IRF-4 +/- mouse (EP16) 
infected with of mice-adapted H3N2 (P10), exhibiting abnormal lymphoid infiltrates 







Figure 4.4. Liver histological section, H&E stained, of female IRF-4 +/- mouse (EP16) 
infected with of mice-adapted H3N2 (P10), exhibiting abnormal lymphoid infiltrates 





Figure 4.5. Kidney histological section, H&E stained, of female IRF-4 +/- mouse 
(EP16) infected with of mice-adapted H3N2 (P10), exhibiting abnormal lymphoid 









4.3.2. Spontaneous tumourigenesis IRF-4 -/- mice  
 
 Throughout the course of breeding and maintenance of the SPF-free IRF-4 
mice for the earlier experimental work, there have been occasions where growth was 
observed in non-infected IRF-4 -/- mice. These were observed in mice above the age 
of 6 months old. The frequency of encountering such mice is about three to five mice 
for every 300 mice bred and maintained.  
We describe here, the common histological observations of the growth in these 
non-infected tumour-affected IRF-4 -/- mice housed and maintained in SPF conditions.  
 The neck and lymph nodes were found to have atypical lymphocytic 
proliferation, consistent with lymphoblastic / Burkitt-like lymphoma. This was 
accompanied by tingible body of macrophages as well as necrosis. Lungs were 
evident for focal lymphocytic proliferation, hemorrhage and congestion. The 
sinusoids of the liver and focal pericentral vein had lymphoid cell infiltrates. The 
spleen exhibited a typical lymphocytic proliferation and underwent white pulp 







Figure 4.6. Case 2 IRF-4 -/- Spontaneous Liver exhibiting abnormal lymphoid 




Figure 4.7. Case 2 IRF-4 -/- Spontaneous Liver. Exhibiting abnormal lymphoid 
infiltrates (A). Liver parenchymal tissue with abnormal aggregates of atypical 











Figure 4.8. Case 2 IRF-4 -/- Spontaneous Lung. Abnormal lymphoid infiltrates (A) 
Lung parenchymal tissue with focal involvement by a diffuse sheet-like infiltrate of 




Figure 4.9. Case 2 IRF-4 -/- Spontaneous Lung. Abnormal lymphoid infiltrates 
characterized by monotonous lymnphoid cells with enlarged hyperchromatic nucleus 
(A). Atypical hematolymphoid cells have rather uniform/monomorphic appearance 
and are most likely of lymphoid lineage based on cellular morphology.  
The presence of tangible body macrophages impart a starry sky appearance. 






4.3.3. CD3 and CD20 staining 
Proliferation of mixed small and large lymphocytes were found in lymph 
nodes of recovered IRF-4 +/- H3N2 influenza virus infected mice. In tumour-
spontaneous IRF-4 mice, a more monotonous blastic lymphoid proliferation with 





























Figure 4.10. CD3 Ab staining IRF-4 +/- Flu infected recovered. Positive for CD3 









Figure 4.12. CD20 Ab staining IRF-4 +/- Flu Infected recovered. Positive for CD20 







Figure 4.13. CD20 Ab staining IRF-4 -/- Spontaneous Negative for CD20 reaction. 
Magnification 400x 
 
4.4. DISCUSSION  
  There appeared a difference in histopathology findings of tumors discovered 
between influenza recovered IRF-4 +/- mice from non-infected spontaneous IRF-4 -/- 
mice. There is the possibility that influenza primed immune cells migrating to lymph 
nodes in influenza recovered IRF-4 +/- mice. With a described defect in apoptosis in 
IRF-4 -/- mice, this may result in the accumulation of cells in lymph nodes. As this is 
a preliminary observation, more work must be done in this area. 
The role of IRF-4 in T cell-specific gene regulation was examined using a 
Jurkat cell line transfected with IRF-4 (Mamane, Grandvaux et al. 2002, Mamane, 
Sharma et al. 2002). cDNA array analysis revealed that IRF-4 primarily functions as a 
repressor in T cells.  Genes involves in regulatory functions were found to be 
decreased in this IRF-4-expressing Jurkat cell line. They suggested an important role 
in IRF-4 in the repression of multiple genes involved in mitotic checkpoint, actin 
cytoskeletal rearrangement, DNA repair, apoptosis, metastasis and immune 
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recognition (Mamane, Grandvaux et al. 2002). Dysregulation of these genes by IRF-4 
could lead to an increase in cellular proliferation and activation, a decrease in 
apoptosis and DNA repair. These are notably observed in HTLV-1-induced T cell 
leukemogenesis (Mamane, Sharma et al. 2000, Mariner, Mamane et al. 2002, Sharma, 
Grandvaux et al. 2002, Ramos, Ruiz et al. 2007, Shindo, Yasui et al. 2011). 
 Dendritic cells (DCs) reside in all peripheral organs and lymphoid tissues 
(Banchereau, Briere et al. 2000). Respiratory DCs are essential for the sampling and 
presentation of residual viral antigens (Kim, Hufford et al. 2010). These cells capture 
residual viral antigen from the infection site and transport these to the draining lymph 
nodes, where the antigens are presented to memory T cells. IRF-1, -4 and -8 have 
been identified to be important in DC development (Gabriele, Fragale et al. 2006). 
IRF-4 and -8 are differentially expressed in distinct DC subsets (Tailor, Tamura et al. 
2006) where they control the generation of diverse DC subsets by impacting on their 
developmental pathways. IRF-4 is known to be essential for the development of CD4
+
 
CD8α- myeloid DCs (Tamura, Tailor et al. 2005).  
 IRF-4 is a critical component of the activation program of mature T cells. In 
addition to mature T cell function defect, IRF-4 -/- mice has lymphoproliferative 
disorder with a progressive accumulation of T and B cells in the spleen and lymph 
nodes upon aging (Mittrucker, Matsuyama et al. 1997). This would suggest that IRF-4 
is critical in the regulation of T cell activation, and control of apoptosis in 
lymphocytes.  The transfection of IRF-4 construct into Jurkat T cells, which lacks its 
own endogenous IRF-4 enhanced the cells sensitivity to Fas-mediated apoptosis 
(Fanzo, Hu et al. 2003). However, in conflict with the earlier report, an IRF-4 -/- 
mouse infection model of the protozoan parasite Leishmania major, showed that 
CD4
+
 Th cells lacking IRF-4 gene were highly sensitive to apoptosis (Lohoff, 
 213 
 
Mittrucker et al. 2004). Lesion-draining lymph nodes of these IRF-4 -/- mice infected 
with L. major developed the prototypic lymphadenopathy after 4 weeks, but 










Conclusion / Epilogue 
 As to be forewarned is to be forearmed, a greater preparation and 
understanding is needed for the next pandemic of respiratory viral pathogens. The 
recent 2003 SARS and 2009 H1N1 Influenza virus pandemic had all the potential to 
cause mortality at a global scale similar to those of the 1918 Spanish Flu pandemic 
where approximately 500 million people or 27% of the global population were 
infected and between 50 to 130 million people perished, or 3% of the global 
population (Taubenberger and Morens 2006).  
 Studies of immunology to viruses necessarily require an understanding of the 
virus infectious agent, the human host and the pathology induced, as well as the 
ability to manipulate the virus, antigen and host is crucial to gain the upperhand in 
managing pandemics caused by infectious agents. The immune system has evolved to 
counteract assault on the body by non-self entities that may compromise an 
individual’s health. Just as viruses mutate to produce variation which enable them to 
have cross-species specificity, the immune system in humans have evolve as well. 
The innate and adaptive portions of the immune system work together and not in spite 
of each other. The adaptive arm, composing the B and T cells, would be unable to 
function without the input of the innate system. T cells are useless without antigen-
presenting cells to activate them and B cells are crippled without T cell help. However, 
on the other hand, the innate immune response would likely be overrun with 






1. Using in silico methods and confirmed with in vitro assay, we have identified 
numerous immunodominant epitope present within the SARS coronavirus 
spike domain. While some has been discovered by other earlier, some are 
novel.  
 
2. We characterized the adaptive cell-mediated immune responses in C57BL/6 
mice immunized with the RGD integrin binding site fused-DNA vaccine 
encoding for the extracellular SARS coronavirus spike domain and found that 
it performed equally well compared to other DNA vaccine constructed by us.  
 
3. We have established an Influenza A/Puerto Rico/8/1934 H1N1 virus infection 
model in IRF-4 +/- and IRF-4 -/- C57BL/6 background mice by using the 
intratracheal infection route method. 
 
4. We were elucidated the role of IRF-4 for the Humoral Immune responses 
against the Influenza A/Puerto Rice/8/1934 H1N1 virus infection in IRF-4 +/+ 
wildtype mice versus IRF-4 -/- mice. 
 
5. We determined that the innate immunity arm in IRF-4 -/- function somewhat 
normally in response to the dose at which the influenza virus infection was 
carried out.  
 
6. We have determined that there is a difference in the lung pathology of mice 
infected with the Influenza A/Puerto Rico/8/1934 H1N1 virus and mouse-
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adapted Influenza A/Aichi/2/1968 H3N2 virus. We are in the process of 
confirming our results. 
 
 
7. We have determined that the oncogenic profile of recovered influenza-virus 
infected animal were different from those IRF-4 -/- animal which 







 Adoptive transfer of T-cells permits the delivery of T-cell immunity with 
defined specificities. Adoptive transfer of virus-specific T-cells has been used 
successfully to prevent and treat severe virus infections in stem cell transplant 
recipients (Rooney 2012). In transgenic mouse models of spontaneous tumourigenesis 
involving oncoprotein expression, the adoptive transfer of T-cells specific for 
oncoprotein-derived epitope, derived from non-transgenic mice containing T-cells 
resulted in anti-tumour activity (Romieu, Baratin et al. 1998, Granziero, Krajewski et 
al. 1999). The use of adoptive transfer of defined T-cell populations for the treatment 
of cytomegalovirus and Epstein-Barr virus infection has been investigated (Rooney, 
Smith et al. 1995, Walter, Greenberg et al. 1995).  
 In the mouse model of Leishmania major infection to study the development 
of follicular T-helper cells in vivo where IRF-4 -/- mice were used (Watanabe, Takagi 
et al. 2008), adoptive transfer of normal CD4
+
 cells rescued both LN cell survival and 
normalized the appearance of germinal centers (GC) and GC B cells markers. 
  IRF-4 -/- mice were incapable of mounting a CD8
+
 T cell response 
(Mittrucker, Matsuyama et al. 1997). However, it is known that this transcription 
factor plays a differential role in the regulation of Th2 cytokine production in naive 
CD
+
 T cells and effector/memory CD4
+
 T cells (Honma, Kimura et al. 2008). IRF-4 
inhibits Th2 cytokine production in naive CD4
+
 T cells, whereas it promotes Th2 
cytokine production in effector/memory CD4
+
 T cells.  
Mice infected either intravenously or intranasally with live influenza virus 
results in the recruitment of CD8
+
 T cells being present in the lungs and 
bronchoalveolar washings (Yap and Ada 1977, Braciale and Yap 1978).  
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 Adoptive transfer of lymphocytes in influenza studies have been 
commonplace (Yap and Ada 1978, Yap and Ada 1978, Volgarev, Maiorova et al. 
1987, Graham, Braciale et al. 1994, Stevenson, Hawke et al. 1997, Lawrence and 
Braciale 2004). The transfer of primary and secondary influenza-infected splenocytes 
to mice infected intra-nasally have resulted in significant clearance of virus from 
lungs and its protection of recipients from death (Yap and Ada 1978, Yap, Ada et al. 
1978).  
 Therefore, it is of interest to examine if an adoptive transfer of CD8
+
 cytotoxic 
T cells from C57BL6 or similar mice infected with Influenza A/Puerto Rico/8/1934 
H1N1 virus would result in the rescue of PR8 H1N1-infected IRF-4 -/- mice in its 





 T cells have both been shown to contribute to immunity to 
influenza A infection. The role of CD4
+ 
T cells in influenza virus immunity has been 
elucidated from studies in CD8
+
 T cell deficient mice. IRF-4 have a pivotal role in the 
development of immune cells such as dendritic cells, myeloid, NK, B and T cells.  
 As IRF-4 is a single knockout in this study that we studied, an improvement 
would be to titrate the viral dose down even further. While the original idea was to 
use a lethal dose to simulate a viral strain similar to one which causes pandemic scale 
of InfAV, in knockout studies, a lethal dose may pose a great load on the mouse 
model that effectively blankets changes between the wildtype and knockout genotype. 
This was seen clearly in the infected animal weight loss studies as well as lung 
histopathology scoring. In fact in a pandemic scale infection simulation involving 
mouse model, a strain of high virulence and as well as high viral titer loads would not 
work well in any study involving knockouts. It is a known fact that the direct 
involvement of IRF-4 in the immune clearance and relationship to other transcription 
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factor is not fully known. Therefore a semi lethal dose would be more suitable in this 
case. A dose in which the weight lost and the time taken to recover fully to its original 
body weight would be very useful. Instead of death, different genotypes would have 
different rates of body weights recovery.  
 The monitoring of body weights in this original plan was put in place till the 
terminal stage of the InfAV infection. This effectively was Day 7-11 Post Infection, 
corresponding to a weight loss of 25-30%. This allowed us to study the adaptive 
response but not the innate response as this would be considered too late a stage for 
the innate immunity to still be in place. Therefore, instead of Day 7 and onwards, an 
earlier timepoint would be desirable, especially to study the innate immune response 
that IRF-4 may have an impact on. Days 2-5 would be an excellent timepoint as 
innate immune cells start to make an appearance in the infection site.  
 Finally as IRF-4 is present only in immune cells of myeloid and lymphoid 
lineage, it would be desirable to study this transcription factor’s involvement in an 
infection such as InfAV in vitro. Animal model studies are often complex. The 
immune system of higher complex organisms usually has redundancy put in place to 
prevent catastrophic failure of its immune system. Therefore, there may be 
redundancy in which multiple pathways exist to complement IRF-4’s function. It 
would also be a study of greater detail as only a certain cell population is examined 










Achdout, H., T. I. Arnon, G. Markel, T. Gonen-Gross, G. Katz, N. Lieberman, R. 
Gazit, A. Joseph, E. Kedar and O. Mandelboim (2003). "Enhanced recognition of 
human NK receptors after influenza virus infection." J Immunol 171(2): 915-923. 
Adachi, M., S. Matsukura, H. Tokunaga and F. Kokubu (1997). "Expression of 
cytokines on human bronchial epithelial cells induced by influenza virus A." Int Arch 
Allergy Immunol 113(1-3): 307-311. 
Adcock, K. G., P. B. Kyle, J. S. Deaton, J. H. Olivier and S. M. Hogan (2007). 
"Pharmacokinetics of intranasal and intratracheal pentoxifylline in rabbits." 
Pharmacotherapy 27(2): 200-206. 
Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller and D. J. 
Lipman (1997). "Gapped BLAST and PSI-BLAST: a new generation of protein 
database search programs." Nucleic Acids Res 25(17): 3389-3402. 
Aosai, F., C. Ohlen, H. G. Ljunggren, P. Hoglund, L. Franksson, H. Ploegh, A. 
Townsend, K. Karre and H. J. Stauss (1991). "Different types of allospecific CTL 
clones identified by their ability to recognize peptide loading-defective target cells." 
Eur J Immunol 21(11): 2767-2774. 
 221 
 
Arnon, R. (2011). Overview of Vaccine Strategies. Vaccine Design: Innovative 
Approaches and Novel Strategies. R. Rappuoli and F. Bagnoli. Norfolk, Caister 
Academic Press: 1-19. 
Au, W. C., P. A. Moore, W. Lowther, Y. T. Juang and P. M. Pitha (1995). 
"Identification of a member of the interferon regulatory factor family that binds to the 
interferon-stimulated response element and activates expression of interferon-induced 
genes." Proc Natl Acad Sci U S A 92(25): 11657-11661. 
Babcock, G. J., D. J. Esshaki, W. D. Thomas, Jr. and D. M. Ambrosino (2004). 
"Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike 
protein are required for interaction with receptor." J Virol 78(9): 4552-4560. 
Babiuk, S., M. E. Baca-Estrada, M. Foldvari, M. Storms, D. Rabussay, G. Widera and 
L. A. Babiuk (2002). "Electroporation improves the efficacy of DNA vaccines in 
large animals." Vaccine 20(27-28): 3399-3408. 
Baeuerle, P. A. and T. Henkel (1994). "Function and activation of NF-kappa B in the 
immune system." Annu Rev Immunol 12: 141-179. 
Baldwin, A. S., Jr. (1996). "The NF-kappa B and I kappa B proteins: new discoveries 
and insights." Annu Rev Immunol 14: 649-683. 
Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. T. Liu, B. Pulendran 
and K. Palucka (2000). "Immunobiology of dendritic cells." Annual Review of 
Immunology 18: 767-+. 
 222 
 
Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, 
A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog 
and Y. S. Babu (2001). "Comparison of the anti-influenza virus activity of RWJ-
270201 with those of oseltamivir and zanamivir." Antimicrob Agents Chemother 
45(4): 1162-1167. 
Barchet, W., A. Krug, M. Cella, C. Newby, J. A. Fischer, A. Dzionek, A. Pekosz and 
M. Colonna (2005). "Dendritic cells respond to influenza virus through TLR7- and 
PKR-independent pathways." Eur J Immunol 35(1): 236-242. 
Barnes, B., B. Lubyova and P. M. Pitha (2002). "On the role of IRF in host defense." 
Journal of Interferon and Cytokine Research 22(1): 59-71. 
Baumgarth, N. and A. Kelso (1996). "In vivo blockade of gamma interferon affects 
the influenza virus-induced humoral and the local cellular immune response in lung 
tissue." J Virol 70(7): 4411-4418. 
Becker, S., J. Quay, H. S. Koren and J. S. Haskill (1994). "Constitutive and stimulated 
MCP-1, GRO alpha, beta, and gamma expression in human airway epithelium and 
bronchoalveolar macrophages." Am J Physiol 266(3 Pt 1): L278-286. 
Behrens, G. and M. Stoll (2006). Pathogenesis and Immunology. Influenza Report 
2006. B. S. Kamps, C. Hoffman and W. Preiser. Paris, Flying Publisher: 92-109. 
Bellone, M., G. Iezzi, A. A. Manfredi, M. P. Protti, P. Dellabona, G. Casorati and C. 
Rugarli (1994). "In vitro priming of cytotoxic T lymphocytes against poorly 
 223 
 
immunogenic epitopes by engineered antigen-presenting cells." Eur J Immunol 24(11): 
2691-2698. 
Bellone, M., G. Iezzi, A. Martin-Fontecha, L. Rivolta, A. A. Manfredi, M. P. Protti, 
M. Freschi, P. Dellabona, G. Casorati and C. Rugarli (1997). "Rejection of a 
nonimmunogenic melanoma by vaccination with natural melanoma peptides on 
engineered antigen-presenting cells." J Immunol 158(2): 783-789. 
Belser, J. A., K. J. Szretter, J. M. Katz and T. M. Tumpey (2009). "Use of animal 
models to understand the pandemic potential of highly pathogenic avian influenza 
viruses." Adv Virus Res 73: 55-97. 
Bender, B. S., T. Croghan, L. Zhang and P. A. Small, Jr. (1992). "Transgenic mice 
lacking class I major histocompatibility complex-restricted T cells have delayed viral 
clearance and increased mortality after influenza virus challenge." J Exp Med 175(4): 
1143-1145. 
Bender, B. S. and P. A. Small, Jr. (1992). "Influenza: pathogenesis and host defense." 
Semin Respir Infect 7(1): 38-45. 
Bergmann, C. C., Q. Yao, M. Lin and S. A. Stohlman (1996). "The JHM strain of 
mouse hepatitis virus induces a spike protein-specific Db-restricted cytotoxic T cell 
response." J Gen Virol 77 ( Pt 2 ): 315-325. 
Blachere, N. E., R. B. Darnell and M. L. Albert (2005). "Apoptotic cells deliver 
processed antigen to dendritic cells for cross-presentation." PLoS Biol 3(6): e185. 
 224 
 
Bockamp, E., M. Maringer, C. Spangenberg, S. Fees, S. Fraser, L. Eshkind, F. Oesch 
and B. Zabel (2002). "Of mice and models: improved animal models for biomedical 
research." Physiol Genomics 11(3): 115-132. 
Boehm, M. and E. G. Nabel (2002). "Angiotensin-converting enzyme 2--a new 
cardiac regulator." N Engl J Med 347(22): 1795-1797. 
Bollig, N., A. Brustle, K. Kellner, W. Ackermann, E. Abass, H. Raifer, B. Camara, C. 
Brendel, G. Giel, E. Bothur, M. Huber, C. Paul, A. Elli, R. A. Kroczek, R. Nurieva, C. 
Dong, R. Jacob, T. W. Mak and M. Lohoff (2012). "Transcription factor IRF4 
determines germinal center formation through follicular T-helper cell differentiation." 
Proceedings of the National Academy of Sciences of the United States of America 
109(22): 8664-8669. 
Braciale, T. J. and K. L. Yap (1978). "Role of viral infectivity in the induction of 
influenza virus-specific cytotoxic T cells." J Exp Med 147(4): 1236-1252. 
Brass, A. L., E. Kehrli, C. F. Eisenbeis, U. Storb and H. Singh (1996). "Pip, a 
lymphoid-restricted IRF, contains a regulatory domain that is important for 
autoinhibition and ternary complex formation with the Ets factor PU.1." Genes Dev 
10(18): 2335-2347. 
Brett, I. C. and B. E. Johansson (2009). Mouse Models of Influenza 
Handbook on Immunosenescence. T. Fulop, Springer. 
 225 
 
Brustle, A., S. Heink, M. Huber, C. Rosenplanter, C. Stadelmann, P. Yu, E. Arpaia, T. 
W. Mak, T. Kamradt and M. Lohoff (2007). "The development of inflammatory 
T(H)-17 cells requires interferon-regulatory factor 4." Nat Immunol 8(9): 958-966. 
Büchen-Osmond, C., Ed. (2006). Influenza A virus. ICTVdB - The Universal Virus 
Database. New York, Columbia University. 
Büchen-Osmond, C., Ed. (2006). Influenza B virus. ICTVdB - The Universal Virus 
Database. New York, Columbia University. 
Büchen-Osmond, C., Ed. (2006). Influenza C virus. ICTVdB - The Universal Virus 
Database. New York, Columbia University. 
Buchholz, U. J., A. Bukreyev, L. Yang, E. W. Lamirande, B. R. Murphy, K. Subbarao 
and P. L. Collins (2004). "Contributions of the structural proteins of severe acute 
respiratory syndrome coronavirus to protective immunity." Proc Natl Acad Sci U S A 
101(26): 9804-9809. 
Buchweitz, J. P., J. R. Harkema and N. E. Kaminski (2007). "Time-dependent airway 
epithelial and inflammatory cell responses induced by influenza virus A/PR/8/34 in 
C57BL/6 mice." Toxicol Pathol 35(3): 424-435. 
Burgess-Brown, N. A., S. Sharma, F. Sobott, C. Loenarz, U. Oppermann and O. 
Gileadi (2008). "Codon optimization can improve expression of human genes in 
Escherichia coli: A multi-gene study." Protein Expr Purif 59(1): 94-102. 
 226 
 
Bussfeld, D., A. Kaufmann, R. G. Meyer, D. Gemsa and H. Sprenger (1998). 
"Differential mononuclear leukocyte attracting chemokine production after 
stimulation with active and inactivated influenza A virus." Cell Immunol 186(1): 1-7. 
Callendret, B., V. Lorin, P. Charneau, P. Marianneau, H. Contamin, J. M. Betton, S. 
van der Werf and N. Escriou (2007). "Heterologous viral RNA export elements 
improve expression of severe acute respiratory syndrome (SARS) coronavirus spike 
protein and protective efficacy of DNA vaccines against SARS." Virology 363(2): 
288-302. 
Castro, R. F. and S. Perlman (1995). "CD8+ T-cell epitopes within the surface 
glycoprotein of a neurotropic coronavirus and correlation with pathogenicity." J Virol 
69(12): 8127-8131. 
Chan, J. F., K. S. Li, K. K. To, V. C. Cheng, H. Chen and K. Y. Yuen (2012). "Is the 
discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the 
beginning of another SARS-like pandemic?" J Infect 65(6): 477-489. 
Chen, H., J. Hou, X. Jiang, S. Ma, M. Meng, B. Wang, M. Zhang, M. Zhang, X. Tang, 
F. Zhang, T. Wan, N. Li, Y. Yu, H. Hu, R. Yang, W. He, X. Wang and X. Cao (2005). 
"Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) 
coronavirus in recovered SARS patients and healthy individuals." Journal of 
Immunology 175(1): 591-598. 
Chen, J. and K. Subbarao (2007). "The Immunobiology of SARS*." Annu Rev 
Immunol 25: 443-472. 
 227 
 
Chen, Z., L. Zhang, C. Qin, L. Ba, C. E. Yi, F. Zhang, Q. Wei, T. He, W. Yu, J. Yu, H. 
Gao, X. Tu, A. Gettie, M. Farzan, K. Y. Yuen and D. D. Ho (2005). "Recombinant 
modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute 
respiratory syndrome coronavirus induces protective neutralizing antibodies primarily 
targeting the receptor binding region." J Virol 79(5): 2678-2688. 
Cheung, C. Y., L. L. Poon, I. H. Ng, W. Luk, S. F. Sia, M. H. Wu, K. H. Chan, K. Y. 
Yuen, S. Gordon, Y. Guan and J. S. Peiris (2005). "Cytokine responses in severe 
acute respiratory syndrome coronavirus-infected macrophages in vitro: possible 
relevance to pathogenesis." J Virol 79(12): 7819-7826. 
Chow, Y. H., W. L. Huang, W. K. Chi, Y. D. Chu and M. H. Tao (1997). 
"Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis 
B surface antigen and interleukin-2." J Virol 71(1): 169-178. 
Cinatl, J., Jr., M. Michaelis and H. W. Doerr (2007). "The threat of avian influenza A 
(H5N1). Part IV: Development of vaccines." Med Microbiol Immunol 196(4): 213-
225. 
Colamonici, O. R., P. Domanski, J. J. Krolewski, X. Y. Fu, N. C. Reich, L. M. Pfeffer, 
M. E. Sweet and L. C. Platanias (1994). "Interferon alpha (IFN alpha) signaling in 
cells expressing the variant form of the type I IFN receptor." J Biol Chem 269(8): 
5660-5665. 
Comeron, J. M. and M. Aguade (1998). "An evaluation of measures of synonymous 
codon usage bias." J Mol Evol 47(3): 268-274. 
 228 
 
Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson and L. D. Falo, Jr. (1996). 
"DNA-based immunization by in vivo transfection of dendritic cells." Nature 
Medicine 2(10): 1122-1128. 
Conn, C. A., J. L. Mcclellan, H. F. Maassab, C. W. Smitka, J. A. Majde and M. J. 
Kluger (1995). "Cytokines and the Acute-Phase Response to Influenza-Virus in 
Mice." American Journal of Physiology-Regulatory Integrative and Comparative 
Physiology 268(1): R78-R84. 
Connor, R. J., Y. Kawaoka, R. G. Webster and J. C. Paulson (1994). "Receptor 
specificity in human, avian, and equine H2 and H3 influenza virus isolates." Virology 
205(1): 17-23. 
Corman, V. M., I. Eckerle, T. Bleicker, A. Zaki, O. Landt, M. Eschbach-Bludau, S. 
van Boheemen, R. Gopal, M. Ballhause, T. M. Bestebroer, D. Muth, M. A. Muller, J. 
F. Drexler, M. Zambon, A. D. Osterhaus, R. M. Fouchier and C. Drosten (2012). 
"Detection of a novel human coronavirus by real-time reverse-transcription 
polymerase chain reaction." Euro Surveill 17(39). 
Cottey, R., C. A. Rowe and B. S. Bender (2001). Influenza Virus. Current Protocols 
in Immunology. R. Coico, John Wiley & Sons: 19.11.11-19.11.32. 
Couceiro, J. N., J. C. Paulson and L. G. Baum (1993). "Influenza virus strains 
selectively recognize sialyloligosaccharides on human respiratory epithelium; the role 




Cox, G. J., T. J. Zamb and L. A. Babiuk (1993). "Bovine herpesvirus 1: immune 
responses in mice and cattle injected with plasmid DNA." J Virol 67(9): 5664-5667. 
Cuneo, A. (2000) "Classification of B-cell non-Hodgkin lymphomas (NHL) 
Atlas of Genetics and Cytogenetics in Oncology and Haematology." 
Cuneo, A. and G. Castoldi (2001) "Burkitt's lymphoma (BL).  
Atlas of Genetics and Cytogenetics in Oncology and Haematology." 
Cuneo, A. and G. Castoldi (2005) "Adult T-cell leukemia/lymphoma (ATLL) 
Atlas of Genetics and Cytogenetics in Oncology and Haematology." 
Darnell, J. E., Jr., I. M. Kerr and G. R. Stark (1994). "Jak-STAT pathways and 
transcriptional activation in response to IFNs and other extracellular signaling 
proteins." Science 264(5164): 1415-1421. 
Davis, H. L., M. L. Michel and R. G. Whalen (1993). "DNA-based immunization 
induces continuous secretion of hepatitis B surface antigen and high levels of 
circulating antibody." Hum Mol Genet 2(11): 1847-1851. 
Day, P. M., F. Esquivel, J. Lukszo, J. R. Bennink and J. W. Yewdell (1995). "Effect 
of TAP on the generation and intracellular trafficking of peptide-receptive major 
histocompatibility complex class I molecules." Immunity 2(2): 137-147. 
De Bruijn, M. L., T. N. Schumacher, J. D. Nieland, H. L. Ploegh, W. M. Kast and C. J. 
Melief (1991). "Peptide loading of empty major histocompatibility complex 
 230 
 
molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte 
responses." Eur J Immunol 21(12): 2963-2970. 
Deliyannis, G., J. S. Boyle, J. L. Brady, L. E. Brown and A. M. Lew (2000). "A 
fusion DNA vaccine that targets antigen-presenting cells increases protection from 
viral challenge." Proc Natl Acad Sci U S A 97(12): 6676-6680. 
Demirci, F. Y., S. Manzi, R. Ramsey-Goldman, R. L. Minster, M. Kenney, P. S. Shaw, 
C. M. Dunlop-Thomas, A. H. Kao, E. Rhew, F. Bontempo, C. Kammerer and M. I. 
Kamboh (2007). "Association of a common interferon regulatory factor 5 (IRF5) 
variant with increased risk of systemic lupus erythematosus (SLE)." Ann Hum Genet 
71(Pt 3): 308-311. 
Dimitrov, D. S. (2003). "The secret life of ACE2 as a receptor for the SARS virus." 
Cell 115(6): 652-653. 
Ding, Y., L. He, Q. Zhang, Z. Huang, X. Che, J. Hou, H. Wang, H. Shen, L. Qiu, Z. 
Li, J. Geng, J. Cai, H. Han, X. Li, W. Kang, D. Weng, P. Liang and S. Jiang (2004). 
"Organ distribution of severe acute respiratory syndrome (SARS) associated 
coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus 
transmission pathways." J Pathol 203(2): 622-630. 
Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch and P. C. Doherty (1991). 
"Clearance of influenza virus respiratory infection in mice lacking class I major 
histocompatibility complex-restricted CD8+ T cells." J Exp Med 174(4): 875-880. 
 231 
 
Eisenbeis, C. F., H. Singh and U. Storb (1995). "Pip, a novel IRF family member, is a 
lymphoid-specific, PU.1-dependent transcriptional activator." Genes Dev 9(11): 
1377-1387. 
Engvall, E. and U. M. Wewer (1996). "Domains of laminin." J Cell Biochem 61(4): 
493-501. 
Epstein, S. L., W. P. Kong, J. A. Misplon, C. Y. Lo, T. M. Tumpey, L. Xu and G. J. 
Nabel (2005). "Protection against multiple influenza A subtypes by vaccination with 
highly conserved nucleoprotein." Vaccine 23(46-47): 5404-5410. 
Escalante, C. R., A. L. Brass, J. M. Pongubala, E. Shatova, L. Shen, H. Singh and A. 
K. Aggarwal (2002). "Crystal structure of PU.1/IRF-4/DNA ternary complex." Mol 
Cell 10(5): 1097-1105. 
Esquivel, F., J. Yewdell and J. Bennink (1992). "RMA/S cells present endogenously 
synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes." J Exp 
Med 175(1): 163-168. 
Fanzo, J. C., C. M. Hu, S. Y. Jang and A. B. Pernis (2003). "Regulation of 
lymphocyte apoptosis by interferon regulatory factor 4 (IRF-4)." Journal of 
Experimental Medicine 197(3): 303-314. 
Fleischer, B., H. Becht and R. Rott (1985). "Recognition of viral antigens by human 
influenza A virus-specific T lymphocyte clones." J Immunol 135(4): 2800-2804. 
 232 
 
Fox, J. M. and I. Erill (2010). "Relative codon adaptation: a generic codon bias index 
for prediction of gene expression." DNA Res 17(3): 185-196. 
Franks, T. J., T. V. Colby, W. D. Travis, R. M. Tuder, H. Y. Reynolds, A. R. Brody, 
W. V. Cardoso, R. G. Crystal, C. J. Drake, J. Engelhardt, M. Frid, E. Herzog, R. 
Mason, S. H. Phan, S. H. Randell, M. C. Rose, T. Stevens, J. Serge, M. E. Sunday, J. 
A. Voynow, B. M. Weinstein, J. Whitsett and M. C. Williams (2008). "Resident 
cellular components of the human lung: current knowledge and goals for research on 
cell phenotyping and function." Proc Am Thorac Soc 5(7): 763-766. 
Fynan, E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro and H. L. 
Robinson (1993). "DNA vaccines: protective immunizations by parenteral, mucosal, 
and gene-gun inoculations." Proc Natl Acad Sci U S A 90(24): 11478-11482. 
Gabriele, L., A. Fragale, P. Borghi, P. Sestili, E. Stellacci, M. Venditti, G. Schiavoni, 
M. Sanchez, F. Belardelli and A. Battistini (2006). "IRF-1 deficiency skews the 
differentiation of dendritic cells toward plasmacytoid and tolerogenic features." 
Journal of Leukocyte Biology 80(6): 1500-1511. 
Gallagher, T. M. and M. J. Buchmeier (2001). "Coronavirus spike proteins in viral 
entry and pathogenesis." Virology 279(2): 371-374. 
Garg, S., A. E. Oran, H. Hon and J. Jacob (2004). "The hybrid cytomegalovirus 
enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus 
posttranscriptional regulatory element enhances the protective efficacy of DNA 
vaccines." J Immunol 173(1): 550-558. 
 233 
 
Garigliany, M. M., A. Habyarimana, B. Lambrecht, E. Van de Paar, A. Cornet, T. van 
den Berg and D. Desmecht (2010). "Influenza A strain-dependent pathogenesis in 
fatal H1N1 and H5N1 subtype infections of mice." Emerg Infect Dis 16(4): 595-603. 
Gauzzi, M. C., C. Purificato, L. Conti, L. Adorini, F. Belardelli and S. Gessani (2005). 
"IRF-4 expression in the human myeloid lineage: up-regulation during dendritic cell 
differentiation and inhibition by 1alpha,25-dihydroxyvitamin D3." J Leukoc Biol 
77(6): 944-947. 
Gentile, D., W. Doyle, T. Whiteside, P. Fireman, F. G. Hayden and D. Skoner (1998). 
"Increased interleukin-6 levels in nasal lavage samples following experimental 
influenza A virus infection." Clin Diagn Lab Immunol 5(5): 604-608. 
Gerondakis, S., R. Grumont, I. Rourke and M. Grossmann (1998). "The regulation 
and roles of Rel/NF-kappa B transcription factors during lymphocyte activation." Curr 
Opin Immunol 10(3): 353-359. 
Gillim-Ross, L. and K. Subbarao (2006). "Emerging respiratory viruses: challenges 
and vaccine strategies." Clin Microbiol Rev 19(4): 614-636. 
Glass, W. G., K. Subbarao, B. Murphy and P. M. Murphy (2004). "Mechanisms of 
host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) 
pulmonary infection of mice." J Immunol 173(6): 4030-4039. 
 234 
 
Glass, W. G., K. Subbarao, B. Murphy and P. M. Murphy (2004). "Mechanisms of 
host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) 
pulmonary infection of mice." Journal of Immunology 173(6): 4030-4039. 
Godet, M., J. Grosclaude, B. Delmas and H. Laude (1994). "Major receptor-binding 
and neutralization determinants are located within the same domain of the 
transmissible gastroenteritis virus (coronavirus) spike protein." J Virol 68(12): 8008-
8016. 
Goodbourn, S., L. Didcock and R. E. Randall (2000). "Interferons: cell signalling, 
immune modulation, antiviral response and virus countermeasures." J Gen Virol 81(Pt 
10): 2341-2364. 
Gordon, J. W., G. A. Scangos, D. J. Plotkin, J. A. Barbosa and F. H. Ruddle (1980). 
"Genetic transformation of mouse embryos by microinjection of purified DNA." Proc 
Natl Acad Sci U S A 77(12): 7380-7384. 
Graham, M. B., V. L. Braciale and T. J. Braciale (1994). "Influenza Virus-Specific 
Cd4+ T-Helper Type-2 T-Lymphocytes Do Not Promote Recovery from 
Experimental Virus-Infection." Journal of Experimental Medicine 180(4): 1273-1282. 
Graham, M. B., V. L. Braciale and T. J. Braciale (1994). "Influenza virus-specific 
CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental 
virus infection." J Exp Med 180(4): 1273-1282. 
 235 
 
Graham, M. B., D. K. Dalton, D. Giltinan, V. L. Braciale, T. A. Stewart and T. J. 
Braciale (1993). "Response to influenza infection in mice with a targeted disruption in 
the interferon gamma gene." J Exp Med 178(5): 1725-1732. 
Graham, R. R., S. V. Kozyrev, E. C. Baechler, M. V. Reddy, R. M. Plenge, J. W. 
Bauer, W. A. Ortmann, T. Koeuth, M. F. Gonzalez Escribano, Argentine, G. Spanish 
Collaborative, B. Pons-Estel, M. Petri, M. Daly, P. K. Gregersen, J. Martin, D. 
Altshuler, T. W. Behrens and M. E. Alarcon-Riquelme (2006). "A common haplotype 
of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is 
associated with increased risk of systemic lupus erythematosus." Nat Genet 38(5): 
550-555. 
Granziero, L., S. Krajewski, P. Farness, L. Yuan, M. K. Courtney, M. R. Jackson, P. 
A. Peterson and A. Vitiello (1999). "Adoptive immunotherapy prevents prostate 
cancer in a transgenic animal model." Eur J Immunol 29(4): 1127-1138. 
Griffiths, G. and P. Rottier (1992). "Cell biology of viruses that assemble along the 
biosynthetic pathway." Semin Cell Biol 3(5): 367-381. 
Grossman, A., H. W. Mittrucker, J. Nicholl, A. Suzuki, S. Chung, L. Antonio, S. 
Suggs, G. R. Sutherland, D. P. Siderovski and T. W. Mak (1996). "Cloning of human 
lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the 
gene to 6p23-p25." Genomics 37(2): 229-233. 
Guarner, J. and R. Falcon-Escobedo (2009). "Comparison of the pathology caused by 
H1N1, H5N1, and H3N2 influenza viruses." Arch Med Res 40(8): 655-661. 
 236 
 
Guarner, J., W. J. Shieh, J. Dawson, K. Subbarao, M. Shaw, T. Ferebee, T. Morken, K. 
B. Nolte, A. Freifeld, N. Cox and S. R. Zaki (2000). "Immunohistochemical and in 
situ hybridization studies of influenza A virus infection in human lungs." Am J Clin 
Pathol 114(2): 227-233. 
Guillot, L., R. Le Goffic, S. Bloch, N. Escriou, S. Akira, M. Chignard and M. Si-
Tahar (2005). "Involvement of toll-like receptor 3 in the immune response of lung 
epithelial cells to double-stranded RNA and influenza A virus." J Biol Chem 280(7): 
5571-5580. 
Guo, Y., S. Sun, K. Wang, S. Zhang, W. Zhu and Z. Chen (2005). "Elicitation of 
immunity in mice after immunization with the S2 subunit of the severe acute 
respiratory syndrome coronavirus." DNA Cell Biol 24(8): 510-515. 
Gupta, S., M. Jiang, A. Anthony and A. B. Pernis (1999). "Lineage-specific 
modulation of interleukin 4 signaling by interferon regulatory factor 4." J Exp Med 
190(12): 1837-1848. 
Gurtler, L. (2006). Virology of Human Influenza. Influenza Report 2006. B. S. 
Kamps, C. Hoffman and W. Preiser. Paris, Flying Publisher: 87-91. 
Haagmans, B. L. (2011). Vaccines against newly emerging viral diseases: the 
example of SARS. Vaccine design: innovative approaches and novel strategies. R. 
Rappuoli and F. Bagnoli. Norfolk, UK, Caister Academic Press: 353-372. 
 237 
 
Haagmans, B. L. and A. D. Osterhaus (2006). "Nonhuman primate models for 
SARS." PLoS Med 3(5): e194. 
Haas, J., E. C. Park and B. Seed (1996). "Codon usage limitation in the expression of 
HIV-1 envelope glycoprotein." Current Biology 6(3): 315-324. 
Hamming, I., W. Timens, M. L. Bulthuis, A. T. Lely, G. J. Navis and H. van Goor 
(2004). "Tissue distribution of ACE2 protein, the functional receptor for SARS 
coronavirus. A first step in understanding SARS pathogenesis." J Pathol 203(2): 631-
637. 
Harbottle, R. P., R. G. Cooper, S. L. Hart, A. Ladhoff, T. McKay, A. M. Knight, E. 
Wagner, A. D. Miller and C. Coutelle (1998). "An RGD-oligolysine peptide: a 
prototype construct for integrin-mediated gene delivery." Hum Gene Ther 9(7): 1037-
1047. 
Harms, J. S. and G. A. Splitter (1995). "Interferon-gamma inhibits transgene 
expression driven by SV40 or CMV promoters but augments expression driven by the 
mammalian MHC I promoter." Hum Gene Ther 6(10): 1291-1297. 
Hayden, F. G., R. Fritz, M. C. Lobo, W. Alvord, W. Strober and S. E. Straus (1998). 
"Local and systemic cytokine responses during experimental human influenza A virus 




He, H., Y. Tang, X. Qin, W. Xu, Y. Wang, X. Liu, X. Liu, S. Xiong, J. Li, M. Zhang 
and M. Duan (2005). "Construction of a eukaryotic expression plasmid encoding 
partial S gene fragments of the SARS-CoV and its potential utility as a DNA 
vaccine." DNA Cell Biol 24(8): 516-520. 
He, Y., H. Lu, P. Siddiqui, Y. Zhou and S. Jiang (2005). "Receptor-binding domain of 
severe acute respiratory syndrome coronavirus spike protein contains multiple 
conformation-dependent epitopes that induce highly potent neutralizing antibodies." J 
Immunol 174(8): 4908-4915. 
He, Y., H. Lu, P. Siddiqui, Y. Zhou and S. Jiang (2005). "Receptor-binding domain of 
severe acute respiratory syndrome coronavirus spike protein contains multiple 
conformation-dependent epitopes that induce highly potent neutralizing antibodies." 
Journal of Immunology 174(8): 4908-4915. 
He, Z., C. Zhao, Q. Dong, H. Zhuang, S. Song, G. Peng and D. E. Dwyer (2005). 
"Effects of severe acute respiratory syndrome (SARS) coronavirus infection on 
peripheral blood lymphocytes and their subsets." Int J Infect Dis 9(6): 323-330. 
Heltzer, M. L., S. E. Coffin, K. Maurer, A. Bagashev, Z. Zhang, J. S. Orange and K. E. 
Sullivan (2009). "Immune dysregulation in severe influenza." J Leukoc Biol 85(6): 
1036-1043. 
Hemmi, H., T. Kaisho, K. Takeda and S. Akira (2003). "The roles of Toll-like 
receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects 
of two distinct CpG DNAs on dendritic cell subsets." J Immunol 170(6): 3059-3064. 
 239 
 
Hennet, T., H. J. Ziltener, K. Frei and E. Peterhans (1992). "A kinetic study of 
immune mediators in the lungs of mice infected with influenza A virus." J Immunol 
149(3): 932-939. 
Hida, S., K. Ogasawara, K. Sato, M. Abe, H. Takayanagi, T. Yokochi, T. Sato, S. 
Hirose, T. Shirai, S. Taki and T. Taniguchi (2000). "CD8(+) T cell-mediated skin 
disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta 
signaling." Immunity 13(5): 643-655. 
Hinshaw, V. S., C. W. Olsen, N. Dybdahl-Sissoko and D. Evans (1994). "Apoptosis: a 
mechanism of cell killing by influenza A and B viruses." J Virol 68(6): 3667-3673. 
Ho, T. Y., S. L. Wu, S. E. Cheng, Y. C. Wei, S. P. Huang and C. Y. Hsiang (2004). 
"Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike 
protein." Biochem Biophys Res Commun 313(4): 938-947. 
Hogan, R. J., G. Gao, T. Rowe, P. Bell, D. Flieder, J. Paragas, G. P. Kobinger, N. A. 
Wivel, R. G. Crystal, J. Boyer, H. Feldmann, T. G. Voss and J. M. Wilson (2004). 
"Resolution of primary severe acute respiratory syndrome-associated coronavirus 
infection requires Stat1." J Virol 78(20): 11416-11421. 
Holmes, K. V. (2001). Coronaviruses. Fields Virology. D. M. Knipe and P. M. 
Howley. Philadephia, Lippincott-Raven. 4th: 1187-1203. 
 240 
 
Holmes, K. V. and M. M. C. Lai (1996). Coronaviridae: The viruses and Their 
Replication. Fundamental Virology. B. N. Fields, D. M. Knipe and P. M. Howley. 
Philadelphia, Lippincott - Raven: 541-559. 
Honda, K., A. Takaoka and T. Taniguchi (2006). "Type I inteferon gene induction by 
the interferon regulatory factor family of transcription factors." Immunity 25(3): 349-
360. 
Honda, K., A. Takaoka and T. Taniguchi (2006). "Type I interferon gene induction by 
the interferon regulatory factor family of transcription factors (vol 25, pg 349, 2006)." 
Immunity 25(5): 849-849. 
Honda, K. and T. Taniguchi (2006). "IRFs: master regulators of signalling by Toll-
like receptors and cytosolic pattern-recognition receptors." Nat Rev Immunol 6(9): 
644-658. 
Honma, K., D. Kimura, N. Tominaga, M. Miyakoda, T. Matsuyama and K. Yui 
(2008). "Interferon regulatory factor 4 differentially regulates the production of Th2 
cytokines in naive vs. effector/memory CD4+ T cells." Proc Natl Acad Sci U S A 
105(41): 15890-15895. 
Honma, K., H. Udono, T. Kohno, K. Yamamoto, A. Ogawa, T. Takemori, A. 
Kumatori, S. Suzuki, T. Matsuyama and K. Yui (2005). "Interferon regulatory factor 
4 negatively regulates the production of proinflammatory cytokines by macrophages 
in response to LPS." Proc Natl Acad Sci U S A 102(44): 16001-16006. 
 241 
 
Hopp, T. P. and K. R. Woods (1981). "Prediction of protein antigenic determinants 
from amino acid sequences." Proc Natl Acad Sci U S A 78(6): 3824-3828. 
Hosken, N. A. and M. J. Bevan (1992). "An endogenous antigenic peptide bypasses 
the class I antigen presentation defect in RMA-S." J Exp Med 175(3): 719-729. 
Hsueh, P. R., L. M. Huang, P. J. Chen, C. L. Kao and P. C. Yang (2004). 
"Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after 
infection with SARS-associated coronavirus." Clin Microbiol Infect 10(12): 1062-
1066. 
Hu, H., X. Y. Lu, L. Tao, B. K. Bai, Z. F. Zhang, Y. Chen, F. L. Zheng, J. J. Chen, Z. 
Chen and H. Z. Wang (2007). "Induction of specific immune responses by severe 
acute respiratory syndrome coronavirus spike DNA vaccine with or without 
interleukin-2 immunization using different vaccination routes in mice." Clinical and 
Vaccine Immunology 14(7): 894-901. 
Huang, J., R. Ma and C. Y. Wu (2006). "Immunization with SARS-CoV S DNA 
vaccine generates memory CD4+ and CD8+ T cell immune responses." Vaccine 
24(23): 4905-4913. 
Hung, C. F., W. F. Cheng, C. Y. Chai, K. F. Hsu, L. He, M. Ling and T. C. Wu (2001). 
"Improving vaccine potency through intercellular spreading and enhanced MHC class 
I presentation of antigen." J Immunol 166(9): 5733-5740. 
 242 
 
Hynes, R. O. (1992). "Integrins: versatility, modulation, and signaling in cell 
adhesion." Cell 69(1): 11-25. 
Iida, S., P. H. Rao, M. Butler, P. Corradini, M. Boccadoro, B. Klein, R. S. Chaganti 
and R. Dalla-Favera (1997). "Deregulation of MUM1/IRF4 by chromosomal 
translocation in multiple myeloma." Nat Genet 17(2): 226-230. 
Imaizumi, Y., T. Kohno, Y. Yamada, S. Ikeda, Y. Tanaka, M. Tomonaga and T. 
Matsuyama (2001). "Possible involvement of interferon regulatory factor 4 (IRF4) in 
a clinical subtype of adult T-cell leukemia." Jpn J Cancer Res 92(12): 1284-1292. 
Ingraham, C. R., A. Kinoshita, S. Kondo, B. L. Yang, S. Sajan, K. J. Trout, M. I. 
Malik, M. Dunnwald, S. L. Goudy, M. Lovett, J. C. Murray and B. C. Schutte (2006). 
"Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon 
regulatory factor 6 (Irf6)." Nat Genet 38(11): 1335-1340. 
Ito, T., J. N. Couceiro, S. Kelm, L. G. Baum, S. Krauss, M. R. Castrucci, I. Donatelli, 
H. Kida, J. C. Paulson, R. G. Webster and Y. Kawaoka (1998). "Molecular basis for 
the generation in pigs of influenza A viruses with pandemic potential." J Virol 72(9): 
7367-7373. 
Iwasaki, T. and T. Nozima (1977). "Defense-Mechanisms against Primary Influenza-
Virus Infection in Mice .1. Roles of Interferon and Neutralizing Antibodies and 




Janeway, C. A., Jr. and R. Medzhitov (2002). "Innate immune recognition." Annu 
Rev Immunol 20: 197-216. 
Jiang, Y., J. Xu, C. Zhou, Z. Wu, S. Zhong, J. Liu, W. Luo, T. Chen, Q. Qin and P. 
Deng (2005). "Characterization of cytokine/chemokine profiles of severe acute 
respiratory syndrome." Am J Respir Crit Care Med 171(8): 850-857. 
Jin, D. Y., F. Spencer and K. T. Jeang (1998). "Human T cell leukemia virus type 1 
oncoprotein Tax targets the human mitotic checkpoint protein MAD1." Cell 93(1): 
81-91. 
Kaiser, J. (2006). "A one-size-fits-all flu vaccine?" Science 312(5772): 380-382. 
Kang, Y., A. Chen, B. Wang and G. Zheng (2009). "Protein transfer enhances cellular 
immune responses to DNA vaccination against SARS-CoV." Viral Immunology 22(6): 
417-422. 
Kawaoka, Y., N. J. Cox, O. Haller, S. Hongo, N. Kaverin, H.-D. Klenk, R. A. Lamb, J. 
McCauley, P. Palese, R. E. and R. G. Webster (2006). Index of Viruses - 
Orthomyxoviridae C. Büchen-Osmond. New York, Columbia University. 
Keng, C. T., A. Zhang, S. Shen, K. M. Lip, B. C. Fielding, T. H. Tan, C. F. Chou, C. 
B. Loh, S. Wang, J. Fu, X. Yang, S. G. Lim, W. Hong and Y. J. Tan (2005). "Amino 
acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus 
S protein induce neutralizing antibodies: implications for the development of vaccines 
and antiviral agents." J Virol 79(6): 3289-3296. 
 244 
 
Kim, J. H. and J. Jacob (2009). "DNA vaccines against influenza viruses." Curr Top 
Microbiol Immunol 333: 197-210. 
Kim, T. S., M. M. Hufford, J. Sun, Y. X. Fu and T. J. Braciale (2010). "Antigen 
persistence and the control of local T cell memory by migrant respiratory dendritic 
cells after acute virus infection." Journal of Experimental Medicine 207(6): 1161-
1172. 
Kim, T. W., J. H. Lee, C. F. Hung, S. Peng, R. Roden, M. C. Wang, R. Viscidi, Y. C. 
Tsai, L. He, P. J. Chen, D. A. Boyd and T. C. Wu (2004). "Generation and 
characterization of DNA vaccines targeting the nucleocapsid protein of severe acute 
respiratory syndrome coronavirus." J Virol 78(9): 4638-4645. 
Kimura, T., Y. Kadokawa, H. Harada, M. Matsumoto, M. Sato, Y. Kashiwazaki, M. 
Tarutani, R. S. Tan, T. Takasugi, T. Matsuyama, T. W. Mak, S. Noguchi and T. 
Taniguchi (1996). "Essential and non-redundant roles of p48 (ISGF3 gamma) and 
IRF-1 in both type I and type II interferon responses, as revealed by gene targeting 
studies." Genes Cells 1(1): 115-124. 
Klein, U., S. Casola, G. Cattoretti, Q. Shen, M. Lia, T. Mo, T. Ludwig, K. Rajewsky 
and R. Dalla-Favera (2006). "Transcription factor IRF4 controls plasma cell 
differentiation and class-switch recombination." Nat Immunol 7(7): 773-782. 
Klein, U., S. Casola, G. Cattoretti, Q. Shen, M. Lia, T. W. Mo, T. Ludwig, K. 
Rajewsky and R. Dalla-Favera (2006). "Transcription factor IRF4 controls plasma 
 245 
 
cell differentiation and class-switch recombination." Nature Immunology 7(7): 773-
782. 
Kong, W. P., L. Xu, K. Stadler, J. B. Ulmer, S. Abrignani, R. Rappuoli and G. J. 
Nabel (2005). "Modulation of the immune response to the severe acute respiratory 
syndrome spike glycoprotein by gene-based and inactivated virus immunization." J 
Virol 79(22): 13915-13923. 
Korn, T., E. Bettelli, M. Oukka and V. K. Kuchroo (2009). "IL-17 and Th17 Cells." 
Annu Rev Immunol 27: 485-517. 
Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. 
A. Koretzky and D. M. Klinman (1995). "CpG motifs in bacterial DNA trigger direct 
B-cell activation." Nature 374(6522): 546-549. 
Kuiken, T., R. A. Fouchier, M. Schutten, G. F. Rimmelzwaan, G. van Amerongen, D. 
van Riel, J. D. Laman, T. de Jong, G. van Doornum, W. Lim, A. E. Ling, P. K. Chan, 
J. S. Tam, M. C. Zambon, R. Gopal, C. Drosten, S. van der Werf, N. Escriou, J. C. 
Manuguerra, K. Stohr, J. S. Peiris and A. D. Osterhaus (2003). "Newly discovered 
coronavirus as the primary cause of severe acute respiratory syndrome." Lancet 
362(9380): 263-270. 
Kurokawa, M., M. Imakita, C. A. Kumeda and K. Shiraki (1996). "Cascade of fever 
production in mice infected with influenza virus." J Med Virol 50(2): 152-158. 
 246 
 
Kyte, J. and R. F. Doolittle (1982). "A simple method for displaying the hydropathic 
character of a protein." J Mol Biol 157(1): 105-132. 
Lagging, L. M., K. Meyer, D. Hoft, M. Houghton, R. B. Belshe and R. Ray (1995). 
"Immune responses to plasmid DNA encoding the hepatitis C virus core protein." J 
Virol 69(9): 5859-5863. 
Lamb, J. R., J. N. Woody, R. J. Hartzman and D. D. Eckels (1982). "In vitro influenza 
virus-specific antibody production in man: antigen-specific and HLA-restricted 
induction of helper activity mediated by cloned human T lymphocytes." J Immunol 
129(4): 1465-1470. 
Lamb, R. A. (1989). Genes and Proteins of the Influenza Viruses. The Influenza 
Viruses. R. M. Krug. New York, Plenum Press: 1 - 87. 
Lamb, R. A. and P. W. Choppin (1983). "The gene structure and replication of 
influenza virus." Annu Rev Biochem 52: 467-506. 
Law, H. K., C. Y. Cheung, H. Y. Ng, S. F. Sia, Y. O. Chan, W. Luk, J. M. Nicholls, J. 
S. Peiris and Y. L. Lau (2005). "Chemokine up-regulation in SARS-coronavirus-
infected, monocyte-derived human dendritic cells." Blood 106(7): 2366-2374. 
Lawrence, C. W. and T. J. Braciale (2004). "Activation, differentiation, and migration 
of naive virus-specific CD8(+) T cells during pulmonary influenza virus infection." 
Journal of Immunology 173(2): 1209-1218. 
 247 
 
Leth-Larsen, R., F. Zhong, V. T. Chow, U. Holmskov and J. Lu (2007). "The SARS 
coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D 
and activates macrophages." Immunobiology 212(3): 201-211. 
Lew, A. M., B. J. Brady and B. J. Boyle (2000). "Site-directed immune responses in 
DNA vaccines encoding ligand-antigen fusions." Vaccine 18(16): 1681-1685. 
Li, J., H. Rao, D. Burkin, S. J. Kaufman and C. Wu (2003). "The muscle integrin 
binding protein (MIBP) interacts with alpha7beta1 integrin and regulates cell 
adhesion and laminin matrix deposition." Dev Biol 261(1): 209-219. 
Li, J., J. Tzu, Y. Chen, Y. P. Zhang, N. T. Nguyen, J. Gao, M. Bradley, D. R. Keene, 
A. E. Oro, J. H. Miner and M. P. Marinkovich (2003). "Laminin-10 is crucial for hair 
morphogenesis." EMBO J 22(10): 2400-2410. 
Li, R., A. Lim, M. C. Phoon, T. Narasaraju, J. K. Ng, W. P. Poh, M. K. Sim, V. T. 
Chow, C. Locht and S. Alonso (2010). "Attenuated Bordetella pertussis protects 
against highly pathogenic influenza A viruses by dampening the cytokine storm." J 
Virol 84(14): 7105-7113. 
Li, W., M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. 
Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, H. Choe and M. Farzan 
(2003). "Angiotensin-converting enzyme 2 is a functional receptor for the SARS 
coronavirus." Nature 426(6965): 450-454. 
 248 
 
Liu, M. A., B. Wahren and G. B. Karlsson Hedestam (2006). "DNA vaccines: recent 
developments and future possibilities." Hum Gene Ther 17(11): 1051-1061. 
Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method." Methods 
25(4): 402-408. 
Ljunggren, H. G., C. Ohlen, P. Hoglund, L. Franksson and K. Karre (1991). "The 
RMA-S lymphoma mutant; consequences of a peptide loading defect on 
immunological recognition and graft rejection." Int J Cancer Suppl 6: 38-44. 
Ljunggren, H. G., N. J. Stam, C. Ohlen, J. J. Neefjes, P. Hoglund, M. T. Heemels, J. 
Bastin, T. N. Schumacher, A. Townsend, K. Karre and et al. (1990). "Empty MHC 
class I molecules come out in the cold." Nature 346(6283): 476-480. 
Lohoff, M., H. W. Mittrucker, A. Brustle, F. Sommer, B. Casper, M. Huber, D. A. 
Ferrick, G. S. Duncan and T. W. Mak (2004). "Enhanced TCR-induced apoptosis in 
interferon regulatory factor 4-deficient CD4(+) Th cells." J Exp Med 200(2): 247-253. 
Lu, L., I. Manopo, B. P. Leung, H. H. Chng, A. E. Ling, L. L. Chee, E. E. Ooi, S. W. 
Chan and J. Kwang (2004). "Immunological characterization of the spike protein of 
the severe acute respiratory syndrome coronavirus." J Clin Microbiol 42(4): 1570-
1576. 
Lu, R. (2008). "Interferon regulatory factor 4 and 8 in B-cell development." Trends 
Immunol 29(10): 487-492. 
 249 
 
Lu, R., K. L. Medina, D. W. Lancki and H. Singh (2003). "IRF-4,8 orchestrate the 
pre-B-to-B transition in lymphocyte development." Genes Dev 17(14): 1703-1708. 
Lu, R. Q., K. L. Medina, D. W. Lancki and H. Singh (2003). "IRF-4,8 orchestrate the 
pre-B-to-B transition in lymphocyte development." Genes & Development 17(14): 
1703-1708. 
Lukacher, A. E., V. L. Braciale and T. J. Braciale (1984). "In vivo effector function of 
influenza virus-specific cytotoxic T lymphocyte clones is highly specific." J Exp Med 
160(3): 814-826. 
Lund, J. M., L. Alexopoulou, A. Sato, M. Karow, N. C. Adams, N. W. Gale, A. 
Iwasaki and R. A. Flavell (2004). "Recognition of single-stranded RNA viruses by 
Toll-like receptor 7." Proc Natl Acad Sci U S A 101(15): 5598-5603. 
Ma, S., A. Turetsky, L. Trinh and R. Lu (2006). "IFN regulatory factor 4 and 8 
promote Ig light chain kappa locus activation in pre-B cell development." J Immunol 
177(11): 7898-7904. 
Mackie, P. L. (2003). "The classification of viruses infecting the respiratory tract." 
Paediatr Respir Rev 4(2): 84-90. 
Mamane, Y., N. Grandvaux, E. Hernandez, S. Sharma, S. A. Innocente, J. M. Lee, N. 
Azimi, R. Lin and J. Hiscott (2002). "Repression of IRF-4 target genes in human T 
cell leukemia virus-1 infection." Oncogene 21(44): 6751-6765. 
 250 
 
Mamane, Y., C. Heylbroeck, P. Genin, M. Algarte, M. J. Servant, C. LePage, C. 
DeLuca, H. Kwon, R. Lin and J. Hiscott (1999). "Interferon regulatory factors: the 
next generation." Gene 237(1): 1-14. 
Mamane, Y., S. Sharma, N. Grandvaux, E. Hernandez and J. Hiscott (2002). "IRF-4 
activities in HTLV-I-induced T cell leukemogenesis." J Interferon Cytokine Res 22(1): 
135-143. 
Mamane, Y., S. Sharma, R. T. Lin and J. Hiscott (2000). "Activation and regulation of 
the IRF-4 transcription factor in human T cell leukemia virus (HTLV-1) infected 
cells." Leukemia 14(3): 536-536. 
Mancl, M. E., G. Hu, N. Sangster-Guity, S. L. Olshalsky, K. Hoops, P. Fitzgerald-
Bocarsly, P. M. Pitha, K. Pinder and B. J. Barnes (2005). "Two discrete promoters 
regulate the alternatively spliced human interferon regulatory factor-5 isoforms. 
Multiple isoforms with distinct cell type-specific expression, localization, regulation, 
and function." J Biol Chem 280(22): 21078-21090. 
Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T. I. Arnon, Y. Bushkin, D. M. 
Davis, J. L. Strominger, J. W. Yewdell and A. Porgador (2001). "Recognition of 
haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK 
cells." Nature 409(6823): 1055-1060. 
Marecki, S., C. J. Riendeau, M. D. Liang and M. J. Fenton (2001). "PU.1 and multiple 
IFN regulatory factor proteins synergize to mediate transcriptional activation of the 
human IL-1 beta gene." J Immunol 166(11): 6829-6838. 
 251 
 
Mariner, J. M., Y. Mamane, J. Hiscott, T. A. Waldmann and N. Azimi (2002). "IFN 
regulatory factor 4 participates in the human T cell lymphotropic virus type I-
mediated activation of the IL-15 receptor alpha promoter." Journal of Immunology 
168(11): 5667-5674. 
Marra, M. A., S. J. M. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S. N. 
Butterfield, J. Khattra, J. K. Asano, S. A. Barber, S. Y. Chan, A. Cloutier, S. M. 
Coughlin, D. Freeman, N. Girn, O. L. Griffith, S. R. Leach, M. Mayo, H. McDonald, 
S. B. Montgomery, P. K. Pandoh, A. S. Petrescu, A. G. Robertson, J. E. Schein, A. 
Siddiqui, D. E. Smailus, J. E. Stott, G. S. Yang, F. Plummer, A. Andonov, H. Artsob, 
N. Bastien, K. Bernard, T. F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, 
R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. 
Kabani, Y. Li, S. Normand, U. Stroher, G. A. Tipples, S. Tyler, R. Vogrig, D. Ward, 
B. Watson, R. C. Brunham, M. Krajden, M. Petric, D. M. Skowronski, C. Upton and 
R. L. Roper (2003). "The genome sequence of the SARS-associated coronavirus." 
Science 300(5624): 1399-1404. 
Martin, J. E., M. K. Louder, L. A. Holman, I. J. Gordon, M. E. Enama, B. D. Larkin, 
C. A. Andrews, L. Vogel, R. A. Koup, M. Roederer, R. T. Bailer, P. L. Gomez, M. 
Nason, J. R. Mascola, G. J. Nabel, B. S. Graham and V. R. C. S. Team (2008). "A 
SARS DNA vaccine induces neutralizing antibody and cellular immune responses in 
healthy adults in a Phase I clinical trial." Vaccine 26(50): 6338-6343. 
Martina, B. E., B. L. Haagmans, T. Kuiken, R. A. Fouchier, G. F. Rimmelzwaan, G. 
Van Amerongen, J. S. Peiris, W. Lim and A. D. Osterhaus (2003). "Virology: SARS 
virus infection of cats and ferrets." Nature 425(6961): 915. 
 252 
 
Matsuyama, T., A. Grossman, H. W. Mittrucker, D. P. Siderovski, F. Kiefer, T. 
Kawakami, C. D. Richardson, T. Taniguchi, S. K. Yoshinaga and T. W. Mak (1995). 
"Molecular cloning of LSIRF, a lymphoid-specific member of the interferon 
regulatory factor family that binds the interferon-stimulated response element 
(ISRE)." Nucleic Acids Res 23(12): 2127-2136. 
Matute-Bello, G., R. K. Winn, M. Jonas, E. Y. Chi, T. R. Martin and W. C. Liles 
(2001). "Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications 
for acute pulmonary inflammation." Am J Pathol 158(1): 153-161. 
McAuliffe, J., L. Vogel, A. Roberts, G. Fahle, S. Fischer, W. J. Shieh, E. Butler, S. 
Zaki, M. St Claire, B. Murphy and K. Subbarao (2004). "Replication of SARS 
coronavirus administered into the respiratory tract of African Green, rhesus and 
cynomolgus monkeys." Virology 330(1): 8-15. 
McGowan, K. A. and M. P. Marinkovich (2000). "Laminins and human disease." 
Microsc Res Tech 51(3): 262-279. 
McKercher, S. R., B. E. Torbett, K. L. Anderson, G. W. Henkel, D. J. Vestal, H. 
Baribault, M. Klemsz, A. J. Feeney, G. E. Wu, C. J. Paige and R. A. Maki (1996). 
"Targeted disruption of the PU.1 gene results in multiple hematopoietic 
abnormalities." EMBO J 15(20): 5647-5658. 
Meager, T. (1998). Cytokines and Pathology. The Molecular Biology of Cytokines. K. 
James and A. Morris. England, John Wiley & Sons: 215-236. 
 253 
 
Mittrucker, H. W., T. Matsuyama, A. Grossman, T. M. Kundig, J. Potter, A. 
Shahinian, A. Wakeham, B. Patterson, P. S. Ohashi and T. W. Mak (1997). 
"Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte 
function." Science 275(5299): 540-543. 
Moore, M. J., T. Dorfman, W. H. Li, S. K. Wong, Y. H. Li, J. H. Kuhn, J. Coderre, N. 
Vasilieva, Z. C. Han, T. C. Greenough, M. Farzan and H. Choe (2004). "Retroviruses 
pseudotyped with the severe acute respiratory syndrome coronavirus spike protein 
efficiently infect cells expressing angiotensin-converting enzyme 2." J Virol 78(19): 
10628-10635. 
Moran, T. M., H. Isobe, A. Fernandez-Sesma and J. L. Schulman (1996). 
"Interleukin-4 causes delayed virus clearance in influenza virus-infected mice." J 
Virol 70(8): 5230-5235. 
Moser, B., I. Clark-Lewis, R. Zwahlen and M. Baggiolini (1990). "Neutrophil-
activating properties of the melanoma growth-stimulatory activity." J Exp Med 171(5): 
1797-1802. 
Mosmann, T. R. and R. L. Coffman (1989). "TH1 and TH2 cells: different patterns of 
lymphokine secretion lead to different functional properties." Annu Rev Immunol 7: 
145-173. 
Mount, A. M. and G. T. Belz (2010). Mouse models of viral infection: influenza 
infection in the lung. Methods Mol Biol. B. K. Na. 595: 299-318. 
 254 
 
Muto, N. A., Y. Sunden, T. Hattori, D. Fujikura, Y. Nakayama, T. Miyazaki, M. 
Maruyama, T. Kimura and H. Sawa (2012). "Pathological examination of lung tissues 
in influenza a virus-infected mice." Jpn J Infect Dis 65(5): 383-391. 
Nagaraju, K. (2001). "Immunological capabilities of skeletal muscle cells." Acta 
Physiologica Scandinavica 171(3): 215-223. 
Nakamura, Y., T. Gojobori and T. Ikemura (2000). "Codon usage tabulated from 
international DNA sequence databases: status for the year 2000." Nucleic Acids Res 
28(1): 292. 
Narasaraju, T., M. K. Sim, H. H. Ng, M. C. Phoon, N. Shanker, S. K. Lal and V. T. 
Chow (2009). "Adaptation of human influenza H3N2 virus in a mouse pneumonitis 
model: insights into viral virulence, tissue tropism and host pathogenesis." Microbes 
Infect 11(1): 2-11. 
Negishi, H., Y. Ohba, H. Yanai, A. Takaoka, K. Honma, K. Yui, T. Matsuyama, T. 
Taniguchi and K. Honda (2005). "Negative regulation of Toll-like-receptor signaling 
by IRF-4." Proc Natl Acad Sci U S A 102(44): 15989-15994. 
Neuveut, C. and K. T. Jeang (2002). "Cell cycle dysregulation by HTLV-I: role of the 
tax oncoprotein." Front Biosci 7: d157-163. 
Nguyen, H., J. Hiscott and P. M. Pitha (1997). "The growing family of interferon 
regulatory factors." Cytokine Growth Factor Rev 8(4): 293-312. 
 255 
 
Nguyen, H. H., F. W. van Ginkel, H. L. Vu, M. J. Novak, J. R. McGhee and J. 
Mestecky (2000). "Gamma interferon is not required for mucosal cytotoxic T-
lymphocyte responses or heterosubtypic immunity to influenza A virus infection in 
mice." J Virol 74(12): 5495-5501. 
Nishiya, N., K. Yamamoto, Y. Imaizumi, T. Kohno and T. Matsuyama (2004). 
"Identification of a novel GC-rich binding protein that binds to an indispensable 
element for constitutive IRF-4 promoter activity in B cells." Mol Immunol 41(9): 855-
861. 
Novick, D., B. Cohen and M. Rubinstein (1994). "The human interferon alpha/beta 
receptor: characterization and molecular cloning." Cell 77(3): 391-400. 
O'Donnell, R., R. C. Tasker and M. F. Roe (2003). "SARS: understanding the 
coronavirus: apoptosis may explain lymphopenia of SARS." BMJ 327(7415): 620. 
Ogasawara, K., S. Hida, Y. Weng, A. Saiura, K. Sato, H. Takayanagi, S. Sakaguchi, T. 
Yokochi, T. Kodama, M. Naitoh, J. A. De Martino and T. Taniguchi (2002). 
"Requirement of the IFN-alpha/beta-induced CXCR3 chemokine signalling for CD8+ 
T cell activation." Genes Cells 7(3): 309-320. 
Ortiz-Navarrete, V. and G. J. Hammerling (1991). "Surface appearance and instability 
of empty H-2 class I molecules under physiological conditions." Proc Natl Acad Sci 
U S A 88(9): 3594-3597. 
 256 
 
Osterlund, P. I., T. E. Pietila, V. Veckman, S. V. Kotenko and I. Julkunen (2007). 
"IFN regulatory factor family members differentially regulate the expression of type 
III IFN (IFN-lambda) genes." J Immunol 179(6): 3434-3442. 
Overbergh, L., A. Giulietti, D. Valckx, R. Decallonne, R. Bouillon and C. Mathieu 
(2003). "The use of real-time reverse transcriptase PCR for the quantification of 
cytokine gene expression." J Biomol Tech 14(1): 33-43. 
Ozaki, T., M. Yauchi, K. Q. Xin, F. Hirahara and K. Okuda (2005). "Cross-reactive 
protection against influenza A virus by a topically applied DNA vaccine encoding M 
gene with adjuvant." Viral Immunol 18(2): 373-380. 
Palese, P. and M. L. Shaw (2006). Orthomyxoviridae: The Viruses and Their 
Replication Fields Virology. D. M. Knipe and P. M. Howley. Philadelphia, Lippencott 
Williams and Wilkins: 1647 - 1689. 
Palladino, G., K. Mozdzanowska, G. Washko and W. Gerhard (1995). "Virus-
neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes 
can cure influenza virus pneumonia in SCID mice." J Virol 69(4): 2075-2081. 
Panesar, N. S. (2003). "Lymphopenia in SARS." Lancet 361(9373): 1985. 
Parker, S. E., T. M. Gallagher and M. J. Buchmeier (1989). "Sequence analysis 
reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein 
gene of several strains of murine hepatitis virus." Virology 173(2): 664-673. 
 257 
 
Pattyn, F., F. Speleman, A. De Paepe and J. Vandesompele (2003). "RTPrimerDB: 
the real-time PCR primer and probe database." Nucleic Acids Res 31(1): 122-123. 
Peper, R. L. and H. Van Campen (1995). "Tumor necrosis factor as a mediator of 
inflammation in influenza A viral pneumonia." Microb Pathog 19(3): 175-183. 
Perrone, L. A., J. K. Plowden, A. Garcia-Sastre, J. M. Katz and T. M. Tumpey (2008). 
"H5N1 and 1918 pandemic influenza virus infection results in early and excessive 
infiltration of macrophages and neutrophils in the lungs of mice." PLoS Pathog 4(8): 
e1000115. 
Pestka, S., J. A. Langer, K. C. Zoon and C. E. Samuel (1987). "Interferons and their 
actions." Annu Rev Biochem 56: 727-777. 
Pfeffer, L. M., C. A. Dinarello, R. B. Herberman, B. R. Williams, E. C. Borden, R. 
Bordens, M. R. Walter, T. L. Nagabhushan, P. P. Trotta and S. Pestka (1998). 
"Biological properties of recombinant alpha-interferons: 40th anniversary of the 
discovery of interferons." Cancer Res 58(12): 2489-2499. 
Platanias, L. C. (1995). "Interferons: laboratory to clinic investigations." Curr Opin 
Oncol 7(6): 560-565. 
Platanias, L. C. and E. N. Fish (1999). "Signaling pathways activated by interferons." 
Exp Hematol 27(11): 1583-1592. 
 258 
 
Poh, W. P., T. Narasaraju, N. A. Pereira, F. Zhong, M. C. Phoon, P. A. Macary, S. H. 
Wong, J. Lu, D. R. Koh and V. T. Chow (2009). "Characterization of cytotoxic T-
lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine 
expressing the RGD-integrin-binding motif." J Med Virol 81(7): 1131-1139. 
Pongubala, J. M., S. Nagulapalli, M. J. Klemsz, S. R. McKercher, R. A. Maki and M. 
L. Atchison (1992). "PU.1 recruits a second nuclear factor to a site important for 
immunoglobulin kappa 3' enhancer activity." Mol Cell Biol 12(1): 368-378. 
Pongubala, J. M., C. Van Beveren, S. Nagulapalli, M. J. Klemsz, S. R. McKercher, R. 
A. Maki and M. L. Atchison (1993). "Effect of PU.1 phosphorylation on interaction 
with NF-EM5 and transcriptional activation." Science 259(5101): 1622-1625. 
Prabakaran, P., X. Xiao and D. S. Dimitrov (2004). "A model of the ACE2 structure 
and function as a SARS-CoV receptor." Biochem Biophys Res Commun 314(1): 235-
241. 
Pribila, J. T., A. C. Quale, K. L. Mueller and Y. Shimizu (2004). "Integrins and T 
cell-mediated immunity." Annu Rev Immunol 22: 157-180. 
Qin, C., J. Wang, Q. Wei, M. She, W. A. Marasco, H. Jiang, X. Tu, H. Zhu, L. Ren, H. 
Gao, L. Guo, L. Huang, R. Yang, Z. Cong, Y. Wang, Y. Liu, Y. Sun, S. Duan, J. Qu, 
L. Chen, W. Tong, L. Ruan, P. Liu, H. Zhang, J. Zhang, D. Liu, Q. Liu, T. Hong and 
W. He (2005). "An animal model of SARS produced by infection of Macaca mulatta 
with SARS coronavirus." J Pathol 206(3): 251-259. 
 259 
 
Ramos, J. C., P. Ruiz, L. Ratner, I. M. Reis, C. Brites, C. Pedroso, G. E. Byrne, N. L. 
Toomey, V. Andela, E. W. Harhaj, I. S. Lossos and W. J. Harrington (2007). "IRF-4 
and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma." Blood 
109(7): 3060-3068. 
Rasi, S. and G. Gaidano (2009) "IRF4 (interferon regulatory factor 4).  
Atlas of Genetics and Cytogenetics in Oncology and Haematology." 
Reiss, C. S. and J. L. Schulman (1980). "Cellular immune responses of mice to 
influenza virus infection." Cell Immunol 56(2): 502-509. 
Renegar, K. B., P. A. Small, Jr., L. G. Boykins and P. F. Wright (2004). "Role of IgA 
versus IgG in the control of influenza viral infection in the murine respiratory tract." J 
Immunol 173(3): 1978-1986. 
Richmond, J. F., S. Lu, J. C. Santoro, J. Weng, S. L. Hu, D. C. Montefiori and H. L. 
Robinson (1998). "Studies of the neutralizing activity and avidity of anti-human 
immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein 
boosting." J Virol 72(11): 9092-9100. 
Roberts, A., E. W. Lamirande, L. Vogel, J. P. Jackson, C. D. Paddock, J. Guarner, S. 
R. Zaki, T. Sheahan, R. Baric and K. Subbarao (2008). "Animal models and vaccines 
for SARS-CoV infection." Virus Res 133(1): 20-32. 
 260 
 
Roberts, A., C. Paddock, L. Vogel, E. Butler, S. Zaki and K. Subbarao (2005). "Aged 
BALB/c mice as a model for increased severity of severe acute respiratory syndrome 
in elderly humans." J Virol 79(9): 5833-5838. 
Roberts, A., L. Vogel, J. Guarner, N. Hayes, B. Murphy, S. Zaki and K. Subbarao 
(2005). "Severe acute respiratory syndrome coronavirus infection of golden Syrian 
hamsters." J Virol 79(1): 503-511. 
Robinson, H. L. and C. A. Torres (1997). "DNA vaccines." Seminars in immunology 
9(5): 271-283. 
Rock, K. L., C. Gramm and B. Benacerraf (1991). "Low temperature and peptides 
favor the formation of class I heterodimers on RMA-S cells at the cell surface." Proc 
Natl Acad Sci U S A 88(10): 4200-4204. 
Romieu, R., M. Baratin, M. Kayibanda, V. Lacabanne, M. Ziol, J. G. Guillet and M. 
Viguier (1998). "Passive but not active CD8+ T cell-based immunotherapy interferes 
with liver tumor progression in a transgenic mouse model." J Immunol 161(10): 5133-
5137. 
Ronni, T., T. Sareneva, J. Pirhonen and I. Julkunen (1995). "Activation of IFN-alpha, 
IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected 
human peripheral blood mononuclear cells." J Immunol 154(6): 2764-2774. 
Rooney, C. M. (2012). "Adoptive transfer of virus-directed T cells: will this fly for 
flu?" Cytotherapy 14(2): 133-134. 
 261 
 
Rooney, C. M., C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner 
and H. E. Heslop (1995). "Use of gene-modified virus-specific T lymphocytes to 
control Epstein-Barr-virus-related lymphoproliferation." Lancet 345(8941): 9-13. 
Ross, T. M., Y. Xu, R. A. Bright and H. L. Robinson (2000). "C3d enhancement of 
antibodies to hemagglutinin accelerates protection against influenza virus challenge." 
Nat Immunol 1(2): 127-131. 
Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P. Icenogle, S. 
Penaranda, B. Bankamp, K. Maher, M. H. Chen, S. X. Tong, A. Tamin, L. Lowe, M. 
Frace, J. L. DeRisi, Q. Chen, D. Wang, D. D. Erdman, T. C. T. Peret, C. Burns, T. G. 
Ksiazek, P. E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, 
M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A. D. M. E. Osterhaus, C. Drosten, M. 
A. Pallansch, L. J. Anderson and W. J. Bellini (2003). "Characterization of a novel 
coronavirus associated with severe acute respiratory syndrome." Science 300(5624): 
1394-1399. 
Rowe, T., G. Gao, R. J. Hogan, R. G. Crystal, T. G. Voss, R. L. Grant, P. Bell, G. P. 
Kobinger, N. A. Wivel and J. M. Wilson (2004). "Macaque model for severe acute 
respiratory syndrome." J Virol 78(20): 11401-11404. 
Ruoslahti, E. (1996). "RGD and other recognition sequences for integrins." Annu Rev 
Cell Dev Biol 12: 697-715. 
 262 
 
Sailaja, G., S. Husain, B. P. Nayak and A. M. Jabbar (2003). "Long-term maintenance 
of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope 
genes linked to the gene encoding Flt-3 ligand." J Immunol 170(5): 2496-2507. 
Saito, T., T. Yamagata, T. Takahashi, H. Honda and H. Hirai (1999). "ICSAT 
overexpression is not sufficient to cause adult T-cell leukemia or multiple myeloma." 
Biochem Biophys Res Commun 260(2): 329-331. 
Sareneva, T., S. Matikainen, M. Kurimoto and I. Julkunen (1998). "Influenza A virus-
induced IFN-alpha/beta and IL-18 synergistically enhance IFN-gamma gene 
expression in human T cells." J Immunol 160(12): 6032-6038. 
SARS, N. R. P. f. (2004). "The involvement of natural killer cells in the pathogenesis 
of severe acute respiratory syndrome." Am J Clin Pathol 121(4): 507-511. 
Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, M. 
Katsuki, S. Noguchi, N. Tanaka and T. Taniguchi (2000). "Distinct and essential roles 
of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta 
gene induction." Immunity 13(4): 539-548. 
Savitsky, D., T. Tamura, H. Yanai and T. Taniguchi (2010). "Regulation of immunity 
and oncogenesis by the IRF transcription factor family." Cancer Immunol 
Immunother 59(4): 489-510. 
Schmidt, M., A. Hochhaus, S. A. Konig-Merediz, C. Brendel, J. Proba, G. J. Hoppe, 
B. Wittig, G. Ehninger, R. Hehlmann and A. Neubauer (2000). "Expression of 
 263 
 
interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response 
to interferon alfa therapy." J Clin Oncol 18(19): 3331-3338. 
Schmittgen, T. D. and K. J. Livak (2008). "Analyzing real-time PCR data by the 
comparative C(T) method." Nat Protoc 3(6): 1101-1108. 
Schumacher, T. N., M. T. Heemels, J. J. Neefjes, W. M. Kast, C. J. Melief and H. L. 
Ploegh (1990). "Direct binding of peptide to empty MHC class I molecules on intact 
cells and in vitro." Cell 62(3): 563-567. 
Sciammas, R., A. L. Shaffer, J. H. Schatz, H. Zhao, L. M. Staudt and H. Singh (2006). 
"Graded expression of interferon regulatory factor-4 coordinates isotype switching 
with plasma cell differentiation." Immunity 25(2): 225-236. 
Scott, E. W., M. C. Simon, J. Anastasi and H. Singh (1994). "Requirement of 
transcription factor PU.1 in the development of multiple hematopoietic lineages." 
Science 265(5178): 1573-1577. 
Shaffer, A. L., N. C. Emre, P. B. Romesser and L. M. Staudt (2009). "IRF4: Immunity. 
Malignancy! Therapy?" Clin Cancer Res 15(9): 2954-2961. 
Sharma, S., N. Grandvaux, Y. Mamane, P. Genin, N. Azimi, T. Waldmann and J. 
Hiscott (2002). "Regulation of IFN regulatory factor 4 expression in human T cell 
leukemia virus-I-transformed T cells." Journal of Immunology 169(6): 3120-3130. 
 264 
 
Sharpe, M., D. Lynch, S. Topham, D. Major, J. Wood and P. Loudon (2007). 
"Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination 
using particle mediated epidermal delivery." Vaccine 25(34): 6392-6398. 
Sheahan, T., T. E. Morrison, W. Funkhouser, S. Uematsu, S. Akira, R. S. Baric and M. 
T. Heise (2008). "MyD88 is required for protection from lethal infection with a 
mouse-adapted SARS-CoV." PLoS Pathog 4(12): e1000240. 
Shindo, H., K. Yasui, K. Yamamoto, K. Honma, K. Yui, T. Kohno, Y. Ma, K. J. Chua, 
Y. Kubo, H. Aihara, T. Ito, T. Nagayasu, T. Matsuyama and H. Hayashi (2011). 
"Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with 
c-Rel." Cytokine 56(3): 564-572. 
Shindo, H., K. Yasui, K. Yamamoto, K. Honma, K. Yui, T. Kohno, Y. H. Ma, K. J. 
Chua, Y. Kubo, H. Aihara, T. Ito, T. Nagayasu, T. Matsuyama and H. Hayashi (2011). 
"Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with 
c-Rel." Cytokine 56(3): 564-572. 
Sijts, A. J., M. L. De Bruijn, J. D. Nieland, W. M. Kast and C. J. Melief (1992). 
"Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor 
cell line." Eur J Immunol 22(6): 1639-1642. 
Small, P. A., Jr. (1990). "Influenza: pathogenesis and host defense." Hosp Pract (Off 
Ed) 25(11): 51-54, 57-62. 
 265 
 
Smith, H. and C. Sweet (1988). "Lessons for human influenza from pathogenicity 
studies with ferrets." Rev Infect Dis 10(1): 56-75. 
Spandidos, A., X. Wang, H. Wang, S. Dragnev, T. Thurber and B. Seed (2008). "A 
comprehensive collection of experimentally validated primers for Polymerase Chain 
Reaction quantitation of murine transcript abundance." BMC Genomics 9: 633. 
Spandidos, A., X. Wang, H. Wang and B. Seed (2010). "PrimerBank: a resource of 
human and mouse PCR primer pairs for gene expression detection and 
quantification." Nucleic Acids Res 38(Database issue): D792-799. 
Spiegel, M., A. Pichlmair, L. Martinez-Sobrido, J. Cros, A. Garcia-Sastre, O. Haller 
and F. Weber (2005). "Inhibition of Beta interferon induction by severe acute 
respiratory syndrome coronavirus suggests a two-step model for activation of 
interferon regulatory factor 3." J Virol 79(4): 2079-2086. 
Sprenger, H., R. G. Meyer, A. Kaufmann, D. Bussfeld, E. Rischkowsky and D. 
Gemsa (1996). "Selective induction of monocyte and not neutrophil-attracting 
chemokines after influenza A virus infection." J Exp Med 184(3): 1191-1196. 
Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman and R. D. Schreiber (1998). 
"How cells respond to interferons." Annu Rev Biochem 67: 227-264. 
Staudt, L. M. and M. J. Lenardo (1991). "Immunoglobulin gene transcription." Annu 
Rev Immunol 9: 373-398. 
 266 
 
Stegmann, T. (2000). "Membrane fusion mechanisms: the influenza hemagglutinin 
paradigm and its implications for intracellular fusion." Traffic 1(8): 598-604. 
Stevenson, P. G., S. Hawke and C. R. M. Bangham (1997). "Protection against 
influenza virus encephalitis by adoptive lymphocyte transfer." Virology 232(1): 158-
166. 
Subbarao, K., J. McAuliffe, L. Vogel, G. Fahle, S. Fischer, K. Tatti, M. Packard, W. J. 
Shieh, S. Zaki and B. Murphy (2004). "Prior infection and passive transfer of 
neutralizing antibody prevent replication of severe acute respiratory syndrome 
coronavirus in the respiratory tract of mice." J Virol 78(7): 3572-3577. 
Suzuki, S., K. Honma, T. Matsuyama, K. Suzuki, K. Toriyama, I. Akitoyo, K. 
Yamamoto, T. Suematsu, M. Nakamura, K. Yui and A. Kumatori (2004). "Critical 
roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell 
development." Proc Natl Acad Sci U S A 101(24): 8981-8986. 
Sweet, C., K. J. Jakeman, D. I. Rushton and H. Smith (1988). "Role of upper 
respiratory tract infection in the deaths occurring in neonatal ferrets infected with 
influenza virus." Microb Pathog 5(2): 121-125. 
Sweet, C., J. C. Macartney, R. A. Bird, D. Cavanagh, M. H. Collie, R. H. Husseini 
and H. Smith (1981). "Differential distribution of virus and histological damage in the 
lower respiratory tract of ferrets infected with influenza viruses of differing 
virulence." J Gen Virol 54(Pt 1): 103-114. 
 267 
 
Tailor, P., T. Tamura and K. Ozato (2006). "IRF family proteins and type I interferon 
induction in dendritic cells." Cell Research 16(2): 134-140. 
Takaoka, A., T. Tamura and T. Taniguchi (2008). "Interferon regulatory factor family 
of transcription factors and regulation of oncogenesis." Cancer Sci 99(3): 467-478. 
Takaoka, A. and H. Yanai (2006). "Interferon signalling network in innate defence." 
Cell Microbiol 8(6): 907-922. 
Takaoka, A., H. Yanai, S. Kondo, G. Duncan, H. Negishi, T. Mizutani, S. Kano, K. 
Honda, Y. Ohba, T. W. Mak and T. Taniguchi (2005). "Integral role of IRF-5 in the 
gene induction programme activated by Toll-like receptors." Nature 434(7030): 243-
249. 
Tamura, T., P. Tailor, K. Yamaoka, H. J. Kong, H. Tsujimura, J. J. O'Shea, H. Singh 
and K. Ozato (2005). "IFN regulatory factor-4 and-8 govern dendritic cell subset 
development and their functional diversity." Journal of Immunology 174(5): 2573-
2581. 
Tamura, T., H. Yanai, D. Savitsky and T. Taniguchi (2008). "The IRF family 
transcription factors in immunity and oncogenesis." Annu Rev Immunol 26: 535-584. 
Tan, Y. J., S. G. Lim and W. Hong (2005). "Characterization of viral proteins 
encoded by the SARS-coronavirus genome." Antiviral Res 65(2): 69-78. 
 268 
 
Taniguchi, T., K. Ogasawara, A. Takaoka and N. Tanaka (2001). "IRF family of 
transcription factors as regulators of host defense." Annu Rev Immunol 19: 623-655. 
Taubenberger, J. K. and D. M. Morens (2006). "1918 Influenza: the mother of all 
pandemics." Emerg Infect Dis 12(1): 15-22. 
Thacker, E. L. (2006). "Lung inflammatory responses." Vet Res 37(3): 469-486. 
Tominaga, N., K. Ohkusu-Tsukada, H. Udono, R. Abe, T. Matsuyama and K. Yui 
(2003). "Development of T(h)1 and not T(h)2 immune responses in mice lacking IFN-
regulatory factor-4." International Immunology 15(1): 1-10. 
Tominaga, N., K. Ohkusu-Tsukada, H. Udono, R. Abe, T. Matsuyama and K. Yui 
(2003). "Development of Th1 and not Th2 immune responses in mice lacking IFN-
regulatory factor-4." Int Immunol 15(1): 1-10. 
Treanor, J. J. (2004). Influenza virus. Mandel, Douglas, and Bennett's Principles and 
Practice of Infectious Diseases. G. L. Mandell, J. E. Bennett and R. Dolin, Churchill 
Livingstone: 2060-2085. 
Tsao, Y. P., J. Y. Lin, J. T. Jan, C. H. Leng, C. C. Chu, Y. C. Yang and S. L. Chen 
(2006). "HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) 




Tsuboi, K., S. Iida, H. Inagaki, M. Kato, Y. Hayami, I. Hanamura, K. Miura, S. 
Harada, M. Kikuchi, H. Komatsu, S. Banno, A. Wakita, S. Nakamura, T. Eimoto and 
R. Ueda (2000). "MUM1/IRF4 expression as a frequent event in mature lymphoid 
malignancies." Leukemia 14(3): 449-456. 
Tuting, T., J. Austyn, W. J. Storkus and L. D. Falo, Jr. (2000). "The immunology of 
DNA vaccines." Methods Mol Med 29: 37-64. 
Uddin, S., A. Chamdin and L. C. Platanias (1995). "Interaction of the transcriptional 
activator Stat-2 with the type I interferon receptor." J Biol Chem 270(42): 24627-
24630. 
Uetani, K., M. Hiroi, T. Meguro, H. Ogawa, T. Kamisako, Y. Ohmori and S. C. 
Erzurum (2008). "Influenza A virus abrogates IFN-gamma response in respiratory 
epithelial cells by disruption of the Jak/Stat pathway." Eur J Immunol 38(6): 1559-
1573. 
Ulmer, J. B., B. Wahren and M. A. Liu (2006). "DNA vaccines: recent technological 
and clinical advances." Discov Med 6(33): 109-112. 
Uze, G., G. Lutfalla and K. E. Mogensen (1995). "Alpha and beta interferons and 
their receptor and their friends and relations." J Interferon Cytokine Res 15(1): 3-26. 
Vacheron, F., A. Rudent, S. Perin, C. Labarre, A. M. Quero and M. Guenounou 
(1990). "Production of interleukin 1 and tumour necrosis factor activities in 
 270 
 
bronchoalveolar washings following infection of mice by influenza virus." J Gen 
Virol 71 ( Pt 2): 477-479. 
van Boheemen, S., M. de Graaf, C. Lauber, T. M. Bestebroer, V. S. Raj, A. M. Zaki, 
A. D. Osterhaus, B. L. Haagmans, A. E. Gorbalenya, E. J. Snijder and R. A. Fouchier 
(2012). "Genomic characterization of a newly discovered coronavirus associated with 
acute respiratory distress syndrome in humans." MBio 3(6). 
van Drunen Littel-van den Hurk, S., V. Gerdts, B. I. Loehr, R. Pontarollo, R. Rankin, 
R. Uwiera and L. A. Babiuk (2000). "Recent advances in the use of DNA vaccines for 
the treatment of diseases of farmed animals." Adv Drug Deliv Rev 43(1): 13-28. 
Van Reeth, K. (2000). "Cytokines in the pathogenesis of influenza." Vet Microbiol 
74(1-2): 109-116. 
Veals, S. A., C. Schindler, D. Leonard, X. Y. Fu, R. Aebersold, J. E. Darnell, Jr. and 
D. E. Levy (1992). "Subunit of an alpha-interferon-responsive transcription factor is 
related to interferon regulatory factor and Myb families of DNA-binding proteins." 
Mol Cell Biol 12(8): 3315-3324. 
Vilcek, J. and G. Sen (1996). Interferons and other cytokines. Fields Virology. B. N. 
Fields, D. M. Knipe and P. M. Howley. Philadelphia, Lippincott-Raven: 375-399. 
Volgarev, A. P., L. P. Maiorova and A. A. Smorodintsev (1987). "Effect of 
Regulatory Cells Induced by Influenza-Virus during Adoptive Transfer." Bulletin of 
Experimental Biology and Medicine 103(1): 97-100. 
 271 
 
Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. 
Thomas and S. R. Riddell (1995). "Reconstitution of cellular immunity against 
cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones 
from the donor." N Engl J Med 333(16): 1038-1044. 
Wang, B., H. Chen, X. Jiang, M. Zhang, T. Wan, N. Li, X. Zhou, Y. Wu, F. Yang, Y. 
Yu, X. Wang, R. Yang and X. Cao (2004). "Identification of an HLA-A*0201-
restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein." Blood 104(1): 
200-206. 
Wang, B., K. E. Ugen, V. Srikantan, M. G. Agadjanyan, K. Dang, Y. Refaeli, A. I. 
Sato, J. Boyer, W. V. Williams and D. B. Weiner (1993). "Gene inoculation generates 
immune responses against human immunodeficiency virus type 1." Proc Natl Acad 
Sci U S A 90(9): 4156-4160. 
Wang, P., J. Chen, A. Zheng, Y. Nie, X. Shi, W. Wang, G. Wang, M. Luo, H. Liu, L. 
Tan, X. Song, Z. Wang, X. Yin, X. Qu, X. Wang, T. Qing, M. Ding and H. Deng 
(2004). "Expression cloning of functional receptor used by SARS coronavirus." 
Biochem Biophys Res Commun 315(2): 439-444. 
Wang, S., T. H. Chou, P. V. Sakhatskyy, S. Huang, J. M. Lawrence, H. Cao, X. 
Huang and S. Lu (2005). "Identification of two neutralizing regions on the severe 
acute respiratory syndrome coronavirus spike glycoprotein produced from the 
mammalian expression system." J Virol 79(3): 1906-1910. 
 272 
 
Wang, X. and B. Seed (2003). "A PCR primer bank for quantitative gene expression 
analysis." Nucleic Acids Res 31(24): e154. 
Wang, X., W. Xu, D. Tong, J. Ni, H. Gao, Y. Wang, Y. Chu, P. Li, X. Yang and S. 
Xiong (2008). "A chimeric multi-epitope DNA vaccine elicited specific antibody 
response against severe acute respiratory syndrome-associated coronavirus which 
attenuated the virulence of SARS-CoV in vitro." Immunology Letters 119(1-2): 71-77. 
Wang, Y. D., W. Y. Sin, G. B. Xu, H. H. Yang, T. Y. Wong, X. W. Pang, X. Y. He, H. 
G. Zhang, J. N. Ng, C. S. Cheng, J. Yu, L. Meng, R. F. Yang, S. T. Lai, Z. H. Guo, Y. 
Xie and W. F. Chen (2004). "T-cell epitopes in severe acute respiratory syndrome 
(SARS) coronavirus spike protein elicit a specific T-cell immune response in patients 
who recover from SARS." J Virol 78(11): 5612-5618. 
Wang, Z., Z. Yuan, M. Matsumoto, U. R. Hengge and Y. F. Chang (2005). "Immune 
responses with DNA vaccines encoded different gene fragments of severe acute 
respiratory syndrome coronavirus in BALB/c mice." Biochem Biophys Res Commun 
327(1): 130-135. 
Watanabe, M., Y. Takagi, M. Kotani, Y. Hara, A. Inamine, K. Hayashi, S. Ogawa, K. 
Takeda, K. Tanabe and R. Abe (2008). "Down-regulation of ICOS ligand by 
interaction with ICOS functions as a regulatory mechanism for immune responses." 
Journal of Immunology 180(8): 5222-5234. 
 273 
 
Webster, R. G., W. J. Bean, O. T. Gorman, T. M. Chambers and Y. Kawaoka (1992). 
"Evolution and Ecology of Influenza A Viruses." Microbiological Reviews 56(1): 
152-179. 
Welliver, R. C. and P. L. Ogra (1988). "Immunology of respiratory viral infections." 
Annu Rev Med 39: 147-162. 
Wells, M. A., F. A. Ennis and P. Albrecht (1981). "Recovery from a viral respiratory 
infection. II. Passive transfer of immune spleen cells to mice with influenza 
pneumonia." J Immunol 126(3): 1042-1046. 
Wentworth, D. E., L. Gillim-Ross, N. Espina and K. A. Bernard (2004). "Mice 
susceptible to SARS coronavirus." Emerg Infect Dis 10(7): 1293-1296. 
Willerford, D. M., J. Chen, J. A. Ferry, L. Davidson, A. Ma and F. W. Alt (1995). 
"Interleukin-2 receptor alpha chain regulates the size and content of the peripheral 
lymphoid compartment." Immunity 3(4): 521-530. 
Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani and P. L. 
Felgner (1990). "Direct gene transfer into mouse muscle in vivo." Science 247(4949 
Pt 1): 1465-1468. 
Wong, C. K., C. W. Lam, A. K. Wu, W. K. Ip, N. L. Lee, I. H. Chan, L. C. Lit, D. S. 
Hui, M. H. Chan, S. S. Chung and J. J. Sung (2004). "Plasma inflammatory cytokines 




Wong, K. F., T. S. To and J. K. Chan (2003). "Severe acute respiratory syndrome 
(SARS)." Br J Haematol 122(2): 171. 
Wong, S. K., W. Li, M. J. Moore, H. Choe and M. Farzan (2004). "A 193-amino acid 
fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting 
enzyme 2." J Biol Chem 279(5): 3197-3201. 
Woodland, D. L. (2003). "Cell-mediated immunity to respiratory virus infections." 
Curr Opin Immunol 15(4): 430-435. 
Woodland, D. L. and T. D. Randall (2004). "Anatomical features of anti-viral 
immunity in the respiratory tract." Semin Immunol 16(3): 163-170. 
Wright, P. F., G. Neumann and Y. Kawaoka (2006). Orthomyxoviruses. Fields 
Virology. D. M. Knipe and P. M. Howley. Philadelphia, Lippencott Williams and 
Wilkins: 1691-1740. 
Xiang, Z. Q., S. Spitalnik, M. Tran, W. H. Wunner, J. Cheng and H. C. Ertl (1994). 
"Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene 
induces protective immunity against rabies virus." Virology 199(1): 132-140. 
Xiao, X., S. Chakraborti, A. S. Dimitrov, K. Gramatikoff and D. S. Dimitrov (2003). 
"The SARS-CoV S glycoprotein: expression and functional characterization." 
Biochem Biophys Res Commun 312(4): 1159-1164. 
 275 
 
Yamagata, T., J. Nishida, S. Tanaka, R. Sakai, K. Mitani, M. Yoshida, T. Taniguchi, 
Y. Yazaki and H. Hirai (1996). "A novel interferon regulatory factor family 
transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of 
interferon-regulated genes." Mol Cell Biol 16(4): 1283-1294. 
Yanai, H., H. M. Chen, T. Inuzuka, S. Kondo, T. W. Mak, A. Takaoka, K. Honda and 
T. Taniguchi (2007). "Role of IFN regulatory factor 5 transcription factor in antiviral 
immunity and tumor suppression." Proc Natl Acad Sci U S A 104(9): 3402-3407. 
Yang, Z. Y., Y. Huang, L. Ganesh, K. Leung, W. P. Kong, O. Schwartz, K. Subbarao 
and G. J. Nabel (2004). "pH-dependent entry of severe acute respiratory syndrome 
coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell 
transfer through DC-SIGN." J Virol 78(11): 5642-5650. 
Yang, Z. Y., W. P. Kong, Y. Huang, A. Roberts, B. R. Murphy, K. Subbarao and G. J. 
Nabel (2004). "A DNA vaccine induces SARS coronavirus neutralization and 
protective immunity in mice." Nature 428(6982): 561-564. 
Yano, A., A. Onozuka, Y. Asahi-Ozaki, S. Imai, N. Hanada, Y. Miwa and T. 
Nisizawa (2005). "An ingenious design for peptide vaccines." Vaccine 23(17-18): 
2322-2326. 
Yano, A., A. Onozuka, K. Matin, S. Imai, N. Hanada and T. Nisizawa (2003). "RGD 
motif enhances immunogenicity and adjuvanicity of peptide antigens following 
intranasal immunization." Vaccine 22(2): 237-243. 
 276 
 
Yap, K. L. and G. L. Ada (1977). "Cytotoxic T cells specific for influenza virus-
infected target cells." Immunology 32(2): 151-159. 
Yap, K. L. and G. L. Ada (1978). "Recovery of Mice from Influenza-Virus Infection - 
Adoptive Transfer of Immunity with Immune T-Lymphocytes." Scandinavian Journal 
of Immunology 7(5): 389-397. 
Yap, K. L. and G. L. Ada (1978). "Recovery of Mice from Influenza a Virus-Infection 
- Adoptive Transfer of Immunity with Influenza Virus-Specific Cytotoxic T-
Lymphocytes Recognizing a Common Virion Antigen." Scandinavian Journal of 
Immunology 8(5): 413-420. 
Yap, K. L. and G. L. Ada (1978). "The recovery of mice from influenza A virus 
infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T 
lymphocytes recognizing a common virion antigen." Scandinavian Journal of 
Immunology 8(5): 413-420. 
Yap, K. L., G. L. Ada and I. F. McKenzie (1978). "Transfer of specific cytotoxic T 
lymphocytes protects mice inoculated with influenza virus." Nature 273(5659): 238-
239. 
Yewdell, J. W. and C. J. Hackett (1989). Specificity and Function of T Lymphocytes 
Induced by Influenza A Viruses. The Influenza Viruses. R. M. Krug. New York and 
London, Plenum Press: 361-429. 
 277 
 
Yilla, M., B. H. Harcourt, C. J. Hickman, M. McGrew, A. Tamin, C. S. Goldsmith, W. 
J. Bellini and L. J. Anderson (2005). "SARS-coronavirus replication in human 
peripheral monocytes/macrophages." Virus Res 107(1): 93-101. 
Yoshida, K., K. Yamamoto, T. Kohno, N. Hironaka, K. Yasui, C. Kojima, H. Mukae, 
J. Kadota, S. Suzuki, K. Honma, S. Kohno and T. Matsuyama (2005). "Active 
repression of IFN regulatory factor-1-mediated transactivation by IFN regulatory 
factor-4." Int Immunol 17(11): 1463-1471. 
Zakhartchouk, A. N., S. Viswanathan, J. B. Mahony, J. Gauldie and L. A. Babiuk 
(2005). "Severe acute respiratory syndrome coronavirus nucleocapsid protein 
expressed by an adenovirus vector is phosphorylated and immunogenic in mice." J 
Gen Virol 86(Pt 1): 211-215. 
Zakhartchouk, A. N., S. Viswanathan, I. Moshynskyy, M. Petric and L. A. Babiuk 
(2007). "Optimization of a DNA vaccine against SARS." DNA Cell Biol 26(10): 721-
726. 
Zaki, A. M., S. van Boheemen, T. M. Bestebroer, A. D. Osterhaus and R. A. Fouchier 
(2012). "Isolation of a novel coronavirus from a man with pneumonia in Saudi 
Arabia." N Engl J Med 367(19): 1814-1820. 
Zeng, F., K. Y. Chow, C. C. Hon, K. M. Law, C. W. Yip, K. H. Chan, J. S. Peiris and 
F. C. Leung (2004). "Characterization of humoral responses in mice immunized with 
plasmid DNAs encoding SARS-CoV spike gene fragments." Biochem Biophys Res 
Commun 315(4): 1134-1139. 
 278 
 
Zeng, F., C. C. Hon, C. W. Yip, K. M. Law, Y. S. Yeung, K. H. Chan, J. S. Malik 
Peiris and F. C. Leung (2006). "Quantitative comparison of the efficiency of 
antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus 
neutralization and blocking of receptor binding: implications for the functional roles 
of S2 subunit." Febs Letters 580(24): 5612-5620. 
Zhang, H., G. Wang, J. Li, Y. Nie, X. Shi, G. Lian, W. Wang, X. Yin, Y. Zhao, X. Qu, 
M. Ding and H. Deng (2004). "Identification of an antigenic determinant on the S2 
domain of the severe acute respiratory syndrome coronavirus spike glycoprotein 
capable of inducing neutralizing antibodies." J Virol 78(13): 6938-6945. 
Zhang, Z., S. Schwartz, L. Wagner and W. Miller (2000). "A greedy algorithm for 
aligning DNA sequences." J Comput Biol 7(1-2): 203-214. 
Zhao, K., B. Yang, Y. Xu and C. Wu (2010). "CD8+ T cell response in HLA-A*0201 
transgenic mice is elicited by epitopes from SARS-CoV S protein." Vaccine 28(41): 
6666-6674. 
Zhao, P., J. S. Ke, Z. L. Qin, H. Ren, L. J. Zhao, J. G. Yu, J. Gao, S. Y. Zhu and Z. T. 
Qi (2004). "DNA vaccine of SARS-Cov S gene induces antibody response in mice." 
Acta Biochim Biophys Sin (Shanghai) 36(1): 37-41. 
Zhi, Y., G. P. Kobinger, H. Jordan, K. Suchma, S. R. Weiss, H. Shen, G. Schumer, G. 
Gao, J. L. Boyer, R. G. Crystal and J. M. Wilson (2005). "Identification of murine 
CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein." 
Virology 335(1): 34-45. 
 279 
 
Zhong, F., Z. Y. Zhong, S. Liang and X. J. Li (2006). "High expression level of 
soluble SARS spike protein mediated by adenovirus in HEK293 cells." World J 
Gastroenterol 12(9): 1452-1457. 
Zhou, T., H. Wang, D. Luo, T. Rowe, Z. Wang, R. J. Hogan, S. Qiu, R. J. Bunzel, G. 
Huang, V. Mishra, T. G. Voss, R. Kimberly and M. Luo (2004). "An exposed domain 
in the severe acute respiratory syndrome coronavirus spike protein induces 
neutralizing antibodies." J Virol 78(13): 7217-7226. 
Zhou, X., R. Glas, F. Momburg, G. J. Hammerling, M. Jondal and H. G. Ljunggren 
(1993). "TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T 
lymphocytes." Eur J Immunol 23(8): 1796-1801. 











8.1 Nucleotide and amino acid sequence of extracellular domain of codon-
optimized SARS-CoV spike glycoprotein (derived from Tor2 SARS-CoV strain) 
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8.2 Nucleotide and amino acid sequence of Spike glycoprotein of SARS-
CoV Tor2 (GenBank: AY274119.3) 
 































































































8.3 Nucleotide and amino acid sequence comparison of codon-optimized 
SARS-CoV Spike glycoprotein (Farzan) versus original SARS-CoV TOR2 strain 
 
Query: Nucleotide / Amino acid sequence of codon-optimized Spike glycoprotein 
(Farzan) 
Subject: Nucleotide / Amino Acid spike glycoprotein TOR2 SARS-CoV  
 
 
Score Expect Identities Gaps Strand 
 
1595 bits(1768)    0.0    2481/3544(70%)    4/3544(0%)   Plus/Plus 
 
 
Query  73    AGCGGCAGCGACCTGGACCGCTGCACCACGTTCGATGACGTGCAGGCGCCCAACTACACC  132 
             || || || ||||| ||||| |||||||| || ||||| || || || || || |||||  
Sbjct  34    AGTGGTAGTGACCTTGACCGGTGCACCACTTTTGATGATGTTCAAGCTCCTAATTACACT  93 
 
Query  133   CAGCACACCTCCAGCATGCGCGGCGTGTACTATCCCGACGAGATCTTCCGCAGCGACACC  192 
             || || || ||    ||| | || || |||||||| || || || ||  |    |||||  
Sbjct  94    CAACATACTTCATCTATGAGGGGGGTTTACTATCCTGATGAAATTTTTAGATCAGACACT  153 
 
Query  193   CTGTACCTCACCCAGGACCTGTTCCTGCCCTTCTACTCCAACGTGACCGGCTTCCACACC  252 
             || ||  | || |||||  | || || || || || || || || || || || || ||  
Sbjct  154   CTTTATTTAACTCAGGATTTATTTCTTCCATTTTATTCTAATGTTACAGGGTTTCATACT  213 
 
Query  253   ATCAACCACACCTTCGGCAACCCCGTGATCCCGTTCAAGGACGGCATCTACTTCGCCGCG  312 
             || || || || || |||||||| || || || || ||||| || || || || || ||  
Sbjct  214   ATTAATCATACGTTTGGCAACCCTGTCATACCTTTTAAGGATGGTATTTATTTTGCTGCC  273 
 
Query  313   ACCGAGAAGAGCAACGTGGTCCGCGGCTGGGTGTTCGGGAGCACCATGAATAACAAGTCC  372 
             || |||||    || || ||||| || ||||| || ||    |||||||| ||||||||  
Sbjct  274   ACAGAGAAATCAAATGTTGTCCGTGGTTGGGTTTTTGGTTCTACCATGAACAACAAGTCA  333 
 
Query  373   CAGAGCGTGATCATTATCAATAACTCCACCAACGTCGTGATCCGCGCCTGCAACTTCGAG  432 
             |||   ||||| ||||| || || || || || || || || || || || ||||| ||  
Sbjct  334   CAGTCGGTGATTATTATTAACAATTCTACTAATGTTGTTATACGAGCATGTAACTTTGAA  393 
 
Query  433   CTGTGTGACAACCCGTTCTTTGCCGTGAGCAAGCCCATGGGCACCCAGACGCACACCATG  492 
              ||||||||||||| |||||||| ||    || |||||||| || ||||| || || ||| 
Sbjct  394   TTGTGTGACAACCCTTTCTTTGCTGTTTCTAAACCCATGGGTACACAGACACATACTATG  453 
 
Query  493   ATCTTCGACAACGCCTTCAACTGCACCTTCGAGTACATCAGCGACGCCTTCTCCCTGGAC  552 
             || ||||| || || || || ||||| |||||||||||    || ||||| || || ||  
Sbjct  454   ATATTCGATAATGCATTTAATTGCACTTTCGAGTACATATCTGATGCCTTTTCGCTTGAT  513 
 
Query  553   GTGAGCGAGAAGTCCGGAAACTTCAAGCACCTGCGCGAGTTCGTGTTCAAGAACAAAGAC  612 
             ||    || ||||| || || || || ||| | || ||||| ||||| || || |||||  
Sbjct  514   GTTTCAGAAAAGTCAGGTAATTTTAAACACTTACGAGAGTTTGTGTTTAAAAATAAAGAT  573 
 
Query  613   GGCTTCCTGTACGTGTACAAGGGCTACCAGCCCATCGACGTCGTGCGCGACCTGCCCAGC  672 
             || || || || || || |||||||| || || || || || || || || || ||     
Sbjct  574   GGGTTTCTCTATGTTTATAAGGGCTATCAACCTATAGATGTAGTTCGTGATCTACCTTCT  633 
 
Query  673   GGCTTCAACACCCTGAAGCCCATCTTCAAGCTGCCCCTCGGCATTAACATCACCAACTTC  732 
             || || |||||  |||| || || || ||| |||| || || |||||||| || || ||  
Sbjct  634   GGTTTTAACACTTTGAAACCTATTTTTAAGTTGCCTCTTGGTATTAACATTACAAATTTT  693 
 
Query  733   CGCGCCATCCTGACCGCCTTCAGCCCTGCCCAGGACATCTGGGGCACCAGCGCCGCGGCC  792 
              | ||||| || || |||||    ||||| || ||||| ||||||||    || || ||| 
Sbjct  694   AGAGCCATTCTTACAGCCTTTTCACCTGCTCAAGACATTTGGGGCACGTCAGCTGCAGCC  753 
 
Query  793   TACTTCGTCGGCTACCTGAAGCCCACGACCTTCATGCTGAAGTACGACGAGAACGGCACG  852 
             || || || |||||  | ||||| || || || ||||| ||||| || || || || ||  





Query  853   ATCACCGATGCCGTGGACTGCAGCCAGAACCCGCTCGCCGAGCTGAAGTGCAGCGTGAAG  912 
             ||||| ||||| || || ||    || || || || || || || || |||   || ||| 
Sbjct  814   ATCACAGATGCTGTTGATTGTTCTCAAAATCCACTTGCTGAACTCAAATGCTCTGTTAAG  873 
 
Query  913   TCCTTCGAGATCGACAAGGGCATCTACCAGACCAGCAACTTCCGCGTGGTACCCAGCGGC  972 
               ||| ||||| ||||| || || |||||||||   || ||| | || || |||   ||  
Sbjct  874   AGCTTTGAGATTGACAAAGGAATTTACCAGACCTCTAATTTCAGGGTTGTTCCCTCAGGA  933 
 
Query  973   GACGTGGTCCGCTTCCCGAACATCACCAACCTGTGTCCCTTCGGCGAGGTGTTCAACGCC  1032 
             || || ||  | ||||| || || || ||| ||||||| || || ||||| || || ||  
Sbjct  934   GATGTTGTGAGATTCCCTAATATTACAAACTTGTGTCCTTTTGGAGAGGTTTTTAATGCT  993 
 
Query  1033  ACCAAGTTCCCGAGCGTGTACGCCTGGGAGCGCAAGAAGATCAGCAACTGCGNGGCCGAC  1092 
             || || |||||    || || || |||||| | || || ||    || || |  || ||  
Sbjct  994   ACTAAATTCCCTTCTGTCTATGCATGGGAGAGAAAAAAAATTTCTAATTGTGTTGCTGAT  1053 
 
Query  1093  TACAGCGTGCTGTACAACTCCACCTTCTTTAGCACCTTCAAGTGCTACGGCGTGAGCGCC  1152 
             |||   ||||| |||||||| || || |||   ||||| |||||||| |||||    ||| 
Sbjct  1054  TACTCTGTGCTCTACAACTCAACATTTTTTTCAACCTTTAAGTGCTATGGCGTTTCTGCC  1113 
 
Query  1153  ACCAAGCTCAACGACCTGTGCTTCAGCAACGTGTACGCCGACAGCTTCGTGGTCAAGGGC  1212 
             || ||| | || || || ||||||  ||| || || || ||    || || ||||||||  
Sbjct  1114  ACTAAGTTGAATGATCTTTGCTTCTCCAATGTCTATGCAGATTCTTTTGTAGTCAAGGGA  1173 
 
Query  1213  GACGATGTGCGCCAGATCGCGCCCGGCCAGACCGGCGTGATCGCCGACTACAACTACAAG  1272 
             || |||||  | || || ||||| || || || || || || || || || || || ||  
Sbjct  1174  GATGATGTAAGACAAATAGCGCCAGGACAAACTGGTGTTATTGCTGATTATAATTATAAA  1233 
 
Query  1273  CTGCCCGATGACTTCATGGGCTGCGTGCTGGCCTGGAACACCCGCAACATCGACGCCACG  1332 
              |||| ||||| |||||||| || || || || ||||| ||  | ||||| || || ||  
Sbjct  1234  TTGCCAGATGATTTCATGGGTTGTGTCCTTGCTTGGAATACTAGGAACATTGATGCTACT  1293 
 
Query  1333  AGCACCGGCAACTACAACTACAAGTATCGCTACCTGCGCCACGGCAAGCTGCGGCCCTTC  1392 
                || || || || || || || ||| | || ||  | || ||||||||  |||||||  
Sbjct  1294  TCAACTGGTAATTATAATTATAAATATAGGTATCTTAGACATGGCAAGCTTAGGCCCTTT  1353 
 
Query  1393  GAGCGCGACATCTCCAACGTGCCCTTCAGCCCGGACGGCAAGCCCTGCACGCCGCCCGCC  1452 
             ||| | ||||| || || ||||| |||  ||| || ||||| || ||||| || || ||  
Sbjct  1354  GAGAGAGACATATCTAATGTGCCTTTCTCCCCTGATGGCAAACCTTGCACCCCACCTGCT  1413 
 
Query  1453  CTGAACTGCTACTGGCCGCTGAACGACTATGGCTTCTACACTACGACCGGTATCGGCTAC  1512 
             || || || || |||||  | || || ||||| || ||||| || || || || |||||| 
Sbjct  1414  CTTAATTGTTATTGGCCATTAAATGATTATGGTTTTTACACCACTACTGGCATTGGCTAC  1473 
 
Query  1513  CAGCCCTACCGCGTGGTCGTGCTGAGCTTCGAGCTCCTGAACGCGCCCGCCACCGTGTGC  1572 
             || || ||| | || || || ||    || || ||  | || || || ||||| || ||  
Sbjct  1474  CAACCTTACAGAGTTGTAGTACTTTCTTTTGAACTTTTAAATGCACCGGCCACGGTTTGT  1533 
 
Query  1573  GGCCCGAAGCTGAGCACCGACCTGATCAAGAACCAGTGCGTGAACTTCAATTTCAACGGC  1632 
             || || ||  |   ||| ||||| || ||||||||||| || || || ||||| || ||  
Sbjct  1534  GGACCAAAATTATCCACTGACCTTATTAAGAACCAGTGTGTCAATTTTAATTTTAATGGA  1593 
 
Query  1633  CTGACCGGCACCGGCGTGCTGACGCCCAGCTCCAAGCGCTTCCAGCCCTTCCAGCAGTTC  1692 
             || || || || || ||| | || ||    || ||| | || || || || || || ||  
Sbjct  1594  CTCACTGGTACTGGTGTGTTAACTCCTTCTTCAAAGAGATTTCAACCATTTCAACAATTT  1653 
 
Query  1693  GGCCGCGACGTCAGCGACTTCACCGACAGCGTGCGCGACCCGAAGACCAGCGAGATCCTG  1752 
             ||||| || ||    || ||||| ||   ||| || || || || ||    || ||  |  
Sbjct  1654  GGCCGTGATGTTTCTGATTTCACTGATTCCGTTCGAGATCCTAAAACATCTGAAATATTA  1713 
 
Query  1753  GACATCTCTCCCTGCTCCTTCGGCGGTGTCAGCGTGATCACGCCCGGCACCAACGCCAGC  1812 
             ||||| || || ||| | || || ||||| || || || || || || || || ||     
Sbjct  1714  GACATTTCACCTTGCGCTTTTGGGGGTGTAAGTGTAATTACACCTGGAACAAATGCTTCA  1773 
 
Query  1813  TCCGAGGTGGCCGTCCTGTACCAGGACGTGAACTGCACCGACGTCAGCACCGCCATCCAC  1872 
             || || || || || || || || || || |||||||| || ||    || || || ||  
Sbjct  1774  TCTGAAGTTGCTGTTCTATATCAAGATGTTAACTGCACTGATGTTTCTACAGCAATTCAT  1833 
 
Query  1873  GCGGACCAGCTGACGCCCGCCTGGCGCATCTACAGCACCGGCAACAACGTGTTCCAGACC  1932 
             || || || || || || || |||||||| ||    || || ||||| || ||||||||  
Sbjct  1834  GCAGATCAACTCACACCAGCTTGGCGCATATATTCTACTGGAAACAATGTATTCCAGACT  1893 
 
Query  1933  CAGGCCGGCTGCCTGATCGGCGCCGAGCACGTCGACACCAGCTACGAGTGCGACATCCCG  1992 
             || || ||||| || || || || ||||| ||||||||    || ||||||||||| ||  
Sbjct  1894  CAAGCAGGCTGTCTTATAGGAGCTGAGCATGTCGACACTTCTTATGAGTGCGACATTCCT  1953 
 




             ||||| || || || || || || ||||| || ||     |  | ||    || |||||  
Sbjct  1954  ATTGGAGCTGGCATTTGTGCTAGTTACCATACAGTTTCTTTATTACGTAGTACTAGCCAA  2013 
 
Query  2053  AAGTCCATCGTGGCCTACACCATGAGCCTGGGCGCCGACAGCAGCATCGCCTACAGCAAC  2112 
             || || || ||||| || || |||    | || || || ||    || || |||   ||  
Sbjct  2014  AAATCTATTGTGGCTTATACTATGTCTTTAGGTGCTGATAGTTCAATTGCTTACTCTAAT  2073 
 
Query  2113  AACACCATCGCCATCCCGACCAACTTCTCCATCAGCATCACGACCGAGGTGATGCCCGTG  2172 
             |||||||| || || || || ||||| || || ||||| || || || || ||||| ||  
Sbjct  2074  AACACCATTGCTATACCTACTAACTTTTCAATTAGCATTACTACAGAAGTAATGCCTGTT  2133 
 
Query  2173  AGCATGGCCAAGACCAGCGTGGACTGCAACATGTACATCTGCGGCGACAGCACCGAGTGC  2232 
                ||||| || |||  ||| || || || |||||||||||||| ||    || || ||  
Sbjct  2134  TCTATGGCTAAAACCTCCGTAGATTGTAATATGTACATCTGCGGAGATTCTACTGAATGT  2193 
 
Query  2233  GCCAACCTGCTCCTGCAGTACGGCTCCTTCTGCACCCAGCTGAACCGCGCCCTGAGCGGC  2292 
             || ||  |||| || || || ||   ||| ||||| || || || || || ||    ||  
Sbjct  2194  GCTAATTTGCTTCTCCAATATGGTAGCTTTTGCACACAACTAAATCGTGCACTCTCAGGT  2253 
 
Query  2293  ATCGCCGCCGAGCAGGACCGCAACACCCGCGAGGTGTTCGCCCAGGTGAAGCAGATGTAC  2352 
             || || || || ||||| |||||||| || || |||||||| || || || || |||||| 
Sbjct  2254  ATTGCTGCTGAACAGGATCGCAACACACGTGAAGTGTTCGCTCAAGTCAAACAAATGTAC  2313 
 
Query  2353  AAGACGCCCACCCTGAAGTACTTCGGCGGCTTCAACTTCAGCCAGATCCTGCCCGACCCG  2412 
             || || || ||  |||| || || || || || || ||    || ||  | || |||||  
Sbjct  2314  AAAACCCCAACTTTGAAATATTTTGGTGGTTTTAATTTTTCACAAATATTACCTGACCCT  2373 
 
Query  2413  CTGAAGCCCACCAAGCGCAGCTTCATCGAGGACCTGCTCTTCAACAAGGTGACGCTGGCC  2472 
             || ||||| || ||| |    || || |||||| ||||||| || |||||||| || ||  
Sbjct  2374  CTAAAGCCAACTAAGAGGTCTTTTATTGAGGACTTGCTCTTTAATAAGGTGACACTCGCT  2433 
 
Query  2473  GACGCCGGCTTCATGAAGCAGTACGGCGAGTGCCTGGGCGACATCAACGCCCGCGACCTG  2532 
             || || |||||||||||||| || ||||| ||||| || || || || ||  | || ||  
Sbjct  2434  GATGCTGGCTTCATGAAGCAATATGGCGAATGCCTAGGTGATATTAATGCTAGAGATCTC  2493 
 
Query  2533  ATCTGCGCCCAGAAGTTCAACGGCCTGACCGTGCTCCCGCCGCTGCTGACCGACGACATG  2592 
             || || || ||||||||||| || || || ||| | || || ||||| || || || ||| 
Sbjct  2494  ATTTGTGCGCAGAAGTTCAATGGACTTACAGTGTTGCCACCTCTGCTCACTGATGATATG  2553 
 
Query  2593  ATCGCCGCGTACACCGCCGCGCTGGTGAGCGGCACCGCCACGGCCGGCTGGACCTTCGGC  2652 
             || || || ||||| || || || || || || || ||||| || || ||||| || ||  
Sbjct  2554  ATTGCTGCCTACACTGCTGCTCTAGTTAGTGGTACTGCCACTGCTGGATGGACATTTGGT  2613 
 
Query  2653  GCCGGCGCGGCCCTGCAGATCCCGTTCGCCATGCAGATGGCCTACCGCTTCAACGGCATC  2712 
             || ||||| || || || || || || || ||||| ||||| ||  | ||||| |||||  
Sbjct  2614  GCTGGCGCTGCTCTTCAAATACCTTTTGCTATGCAAATGGCATATAGGTTCAATGGCATT  2673 
 
Query  2713  GGCGTGACCCAGAACGTGCTGTACGAGAACCAGAAGCAGATCGCCAACCAGTTCAACAAG  2772 
             || || ||||| || || || || |||||||| || || ||||||||||| || |||||| 
Sbjct  2674  GGAGTTACCCAAAATGTTCTCTATGAGAACCAAAAACAAATCGCCAACCAATTTAACAAG  2733 
 
Query  2773  GCCATCAGCCAGATCCAGGAGAGCCTGACCACGACCAGCACGGCCCTGGGCAAGCTGCAG  2832 
             || || || || || || ||    || || || ||    || ||  |||||||||||||  
Sbjct  2734  GCGATTAGTCAAATTCAAGAATCACTTACAACAACATCAACTGCATTGGGCAAGCTGCAA  2793 
 
Query  2833  GACGTGGTCAACCAGAACGCCCAGGCCCTGAACACCCTGGTGAAGCAGCTGTCCAGCAAC  2892 
             ||||| || |||||||| || || ||  | ||||| || || || || ||   |   ||  
Sbjct  2794  GACGTTGTTAACCAGAATGCTCAAGCATTAAACACACTTGTTAAACAACTTAGCTCTAAT  2853 
 
Query  2893  TTCGGCGCCAT--CAGCTCCGTGCTGAACGATATCCTGAGCCGCCTGGACAAGGTGGAGG  2950 
             || || || ||  ||  |  ||||| || ||||||||    || || || || || |||| 
Sbjct  2854  TTTGGTGCAATTTCAAGT--GTGCTAAATGATATCCTTTCGCGACTTGATAAAGTCGAGG  2911 
 
Query  2951  CCGAGGTGCAGATCGATCGCCTGATCACCGGCCGCCTGCAGAGCCTGCAGACCTACGTGA  3010 
             | ||||| || || ||  |  | || || ||| | || || ||||| || ||||| || | 
Sbjct  2912  CGGAGGTACAAATTGACAGGTTAATTACAGGCAGACTTCAAAGCCTTCAAACCTATGTAA  2971 
 
Query  3011  CCCAGCAGCTGATCCGCGCCGCGGAGATCCGCGCCAGCGCGAACCTGGCCGCCACCAAGA  3070 
             | || || || ||| | || || || ||| | ||    || || || || || || || | 
Sbjct  2972  CACAACAACTAATCAGGGCTGCTGAAATCAGGGCTTCTGCTAATCTTGCTGCTACTAAAA  3031 
 
Query  3071  TGTCCGAGTGCGTGCTGGGCCAGAGCAAGCGCGTGGACTTCTGCGGCAAGGGCTACCACC  3130 
             |||| ||||| || || || ||    ||  | || ||||| || || ||||||||||||| 
Sbjct  3032  TGTCTGAGTGTGTTCTTGGACAATCAAAAAGAGTTGACTTTTGTGGAAAGGGCTACCACC  3091 
 
Query  3131  TGATGAGCTTCCCGCAGGCCGCGCCGCACGGCGTGGTCTTCCTGCACGTGACCTACGTGC  3190 




Sbjct  3092  TTATGTCCTTCCCACAAGCAGCCCCGCATGGTGTTGTCTTCCTACATGTCACGTATGTGC  3151 
 
Query  3191  CCAGCCAGGAGCGCAACTTCACCACGGCGCCCGCCATCTGCCACGAGGGCAAGGCCTACT  3250 
             |   ||||||| | ||||||||||| ||||| || || || || || ||||| || |||| 
Sbjct  3152  CATCCCAGGAGAGGAACTTCACCACAGCGCCAGCAATTTGTCATGAAGGCAAAGCATACT  3211 
 
Query  3251  TCCCGCGCGAGGGCGTGTTCGTGTTCAACGGCACCAGCTGGTTCATCACCCAGCGCAACT  3310 
             |||| || || || || || ||||| || |||||    ||||| || || ||| | |||| 
Sbjct  3212  TCCCTCGTGAAGGTGTTTTTGTGTTTAATGGCACTTCTTGGTTTATTACACAGAGGAACT  3271 
 
Query  3311  TCTTCAGCCCGCAAATCATCACCACGGACAACACCTTCGTGAGCGGCAACTGCGACGTCG  3370 
             ||||    || ||||| || || || ||||| || || ||    || || || || |||| 
Sbjct  3272  TCTTTTCTCCACAAATAATTACTACAGACAATACATTTGTCTCAGGAAATTGTGATGTCG  3331 
 
Query  3371  TGATCGGCATCATCAACAACACCGTGTACGACCCGCTGCAGCCCGAGCTGGACTCCTTCA  3430 
             | || |||||||| |||||||| || || || || ||||| || ||||| ||||| |||| 
Sbjct  3332  TTATTGGCATCATTAACAACACAGTTTATGATCCTCTGCAACCTGAGCTTGACTCATTCA  3391 
 
Query  3431  AGGAGGAGCTGGACAAGTACTTCAAGAACCACACCAGCCCGGACGTGGACCTGGGCGACA  3490 
             | || |||||||||||||||||||| || || ||    || || || || || ||||||| 
Sbjct  3392  AAGAAGAGCTGGACAAGTACTTCAAAAATCATACATCACCAGATGTTGATCTTGGCGACA  3451 
 
Query  3491  TCAGCGGCATCAACGCCAGCGTCGTGAACATCCAGAAGGAGATCGACCGCCTGAACGAGG  3550 
             |    ||||| |||||    ||||| ||||| || || || || |||||||| || |||| 
Sbjct  3452  TTTCAGGCATTAACGCTTCTGTCGTCAACATTCAAAAAGAAATTGACCGCCTCAATGAGG  3511 
 
Query  3551  TGGCCAAGAACCTGAACGAGAGCCTGATCGACCTCCAGGAGCTGGGCAAGTACGAGCAGT  3610 
             | || || ||  | || ||    || || ||||| || ||  |||| || || ||||| | 
Sbjct  3512  TCGCTAAAAATTTAAATGAATCACTCATTGACCTTCAAGAATTGGGAAAATATGAGCAAT  3571 
 
Query  3611  ACAT  3614 
             | || 
Sbjct  3572  ATAT  3575 
 
 
Score Expect Method Identities Positives Gaps  
2443 bits(6331)    0.0 Compositional matrix adjust.  1181/1189(99%)  1183/1189(99%)   0/1189(0%) 
 
 
Query  17    MLVASVLASGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFY  76 
              L+   L SGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFY 
Sbjct  4     FLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFY  63 
 
Query  77    SNVTGFHTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNV  136 
             SNVTGFHTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNV 
Sbjct  64    SNVTGFHTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNV  123 
 
Query  137   VIRACNFELCDNPFFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLR  196 
             VIRACNFELCDNPFFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLR 
Sbjct  124   VIRACNFELCDNPFFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLR  183 
 
Query  197   EFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQD  256 
             EFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQD 
Sbjct  184   EFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQD  243 
 
Query  257   IWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTS  316 
             IWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTS 
Sbjct  244   IWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTS  303 
 
Query  317   NFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCXADYSVLYNSTFFST  376 
             NFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNC ADYSVLYNSTFFST 
Sbjct  304   NFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFST  363 
 
Query  377   FKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAW  436 
             FKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAW 
Sbjct  364   FKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAW  423 
 
Query  437   NTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGF  496 
             NTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGF 
Sbjct  424   NTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGF  483 
 
Query  497   YTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSK  556 
             YTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSK 
Sbjct  484   YTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSK  543 
 




             RFQPFQQFGRDVSDFTDSVRDPKTSEILDISPC+FGGVSVITPGTNASSEVAVLYQDVNC 
Sbjct  544   RFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCAFGGVSVITPGTNASSEVAVLYQDVNC  603 
 
Query  617   TDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTV  676 
             TDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTV 
Sbjct  604   TDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTV  663 
 
Query  677   SLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMY  736 
             SLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMY 
Sbjct  664   SLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMY  723 
 
Query  737   ICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFN  796 
             ICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFN 
Sbjct  724   ICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFN  783 
 
Query  797   FSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVL  856 
             FSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVL 
Sbjct  784   FSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVL  843 
 
Query  857   PPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQK  916 
             PPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQK 
Sbjct  844   PPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQK  903 
 
Query  917   QIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL  976 
             QIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL 
Sbjct  904   QIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL  963 
 
Query  977   SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVD  1036 
             SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVD 
Sbjct  964   SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVD  1023 
 
Query  1037  FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTS  1096 
             FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTS 
Sbjct  1024  FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTS  1083 
 
Query  1097  WFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTS  1156 
             WFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTS 
Sbjct  1084  WFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTS  1143 
 
Query  1157  PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI  1205 
             PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI 




8.4 Amino Acid sequence comparison of codon-optimized SARS-CoV spike 
glycoprotein (Farzan) versus Beijing302 SARS-CoV spike protein used in ELISA  



















Query: Amino acid sequence of codon-optimized Spike glycoprotein (Farzan) 
Subject: Amino Acid spike glycoprotein Beijing302 SARS-CoV  
Score Expect Method Identities Positives Gaps 
 
2426 bits(6287) 0.0 Compositional matrix adjust. 1176/1189(99%) 1178/1189(99%) 0/1189(0%) 
 
 
Query  17    MLVASVLASGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFY  76 
              L+   L SGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFY 
Sbjct  4     FLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFY  63 
 
Query  77    SNVTGFHTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNV  136 
             SNVTGFHTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNV 
Sbjct  64    SNVTGFHTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNV  123 
 
Query  137   VIRACNFELCDNPFFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLR  196 
             VIRAC FELCDNPFFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLR 
Sbjct  124   VIRACIFELCDNPFFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLR  183 
 
Query  197   EFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQD  256 
             EFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQD 
Sbjct  184   EFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQD  243 
 
Query  257   IWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTS  316 
              WGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTS 
Sbjct  244   TWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTS  303 
 
Query  317   NFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCXADYSVLYNSTFFST  376 
             NFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNC ADYSVLYNSTFFST 
Sbjct  304   NFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFST  363 
 




             FKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAW 
Sbjct  364   FKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAW  423 
 
Query  437   NTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGF  496 
             NTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPL+DYGF 
Sbjct  424   NTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYWPLSDYGF  483 
 
Query  497   YTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSK  556 
             YTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSK 
Sbjct  484   YTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSK  543 
 
Query  557   RFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNC  616 
             RFQPFQQFGRDVSDFTDSVRDPKTSEILDISP SFGGVSVITPGTNASSEVAVLYQDVNC 
Sbjct  544   RFQPFQQFGRDVSDFTDSVRDPKTSEILDISPRSFGGVSVITPGTNASSEVAVLYQDVNC  603 
 
Query  617   TDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTV  676 
             TDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTV 
Sbjct  604   TDVSTAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTV  663 
 
Query  677   SLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMY  736 
             SLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMY 
Sbjct  664   SLLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMY  723 
 
Query  737   ICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFN  796 
             ICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFN 
Sbjct  724   ICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFAQVKQMYKTPTLKYFGGFN  783 
 
Query  797   FSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVL  856 
             FSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVL 
Sbjct  784   FSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVL  843 
 
Query  857   PPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQK  916 
             PPLLT DMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQK 
Sbjct  844   PPLLTVDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQK  903 
 
Query  917   QIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL  976 
             QIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL 
Sbjct  904   QIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDIL  963 
 
Query  977   SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVD  1036 
             SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRV  
Sbjct  964   SRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVG  1023 
 
Query  1037  FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTS  1096 
             FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTS 
Sbjct  1024  FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTS  1083 
 
Query  1097  WFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTS  1156 
             WFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTS 
Sbjct  1084  WFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTS  1143 
 
Query  1157  PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI  1205 
             PDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI 






8.5 Reagents for genotyping PCR 
 
1.5% Agarose Gel 
 
 
Disperse 1.5 g of agarose powder in 100 ml 1x Tris-Acetate buffer. Microwave to 
melt agarose. Cool molten agarose to about 50°C and add 0.5 μg of ethidium 
bromide (10 mg/ml stock) per millitre of gel. Pour gel onto casting tray and 
leave, for about 15 minutes, to set at room temperature.  
 
 
Tail lysis buffer For 100 ml 
100 mM Tris-hydrochloride (Tris-HCl)  10 ml 1 M Tris-HCl (pH 8.5) 
(pH 8.5) 4 ml 5 M NaCl 
200 mM sodium chloride (NaCl) 1 ml 0.5 M EDTA (pH 8.0) 
5 mM EDTA (pH 8.0) 2 ml 10% (v/v) SDS 
 




8.6 Reagents for plaque assay 
 
Avicel® suspension For 250 ml of 2.4% Avicel® suspension 
Avicel® Microcrystalline Cellulose & 
carboxylmethylcellulose sodium (RC-591) 




Disperse the 6 g of powder in 250 ml filtered sterilized water. Mix on a shaker for 
1 h. Sterilize Avicel® stock by autoclaving. 
 
The overlay medium was prepared by mixing 250 ml 2.4% Avicel® suspension 
with 250 ml of double-strength Minimum Essential Medium. 
 
 
20% Formalin fixative For 500 ml 
37% Formaldehyde solution 100 ml 
 
Make up to 500 ml with 1x phosphate buffered saline (PBS) 
 
 
1% Crystal violet solution For 500 ml 
Crystal violet 5 g 
37% Formaldehyde solution 100 ml 
 
Make up to 500 ml with 1x PBS. Filter to remove particles. 
10-1 10-2 10-3 10-4 10-5 10-6 
 
  
A respresentative image of plaque assay of influenza A/PR/8/34 (H1N1) on 
MDCK cells and stained with cystal violet. A ten-fold serial dilution was 
performed and the dilution indicated at the top of each well. An inoculum of 100 
μl from each diluent was added to each well in duplicate. This example shows 
a virus titre of 8.5 x 105 PFU/100μl which equates to 8.5 x 106 PFU/ml. 
 
 
2x Minimum Essential Medium 
 
For 500 ml ( Store at 4°C) 





1 M HEPES (PAA Laboratories GmbH, Austria) 10 ml 




8.7 Microarray procedure and data analysis 
 
Illumina® TotalPrep™ RNA Amplification 
 
 
Adapted from Manual 4397949 Revision B 
Illumina® TotalPrep™-96 RNA Amplification Kit 
Revision Date: May 4, 2011 
Figure 8.1. Illumina® TotalPrep™-96 RNA Amplification procedure overview. 
 
 
Illumina® TotalPrep RNA Amplification kit (Ambion® Inc., Texas, USA) 
was used to prepare RNA samples for microarray analysis. The procedure is 




single array was prepared by pooling equal amounts of total RNA from 3 mice for 
each group, namely, +/+ Mock-infected, -/- Mock-infected, +/+ Infected, -/- Infected. 
Arrays were performed in triplicates for each group with each array representing a 
biological replicate. 
 
Reverse transcription (RT) was performed to synthesize first-strand cDNA by adding 
9μl of the RT Master Mix to each total RNA sample (500ng in 11μl) and incubating 
for 2hrs at 42°C. 
 
The components of the Reverse Transcription Master Mix were prepared as 
follows. 
For a 20μl reaction:- 
T7 Oligo(dT) primer  1μl 
10X first strand buffer 2μl 
dNTP mix   4μl 
RNase inhibitor  1μl 
ArrayScript enzyme  1μl 
 
Next, second strand cDNA synthesis converted the single strand cDNA into a 
dsDNA template for transcription. For a 100μl reaction, 80μl of the Second Strand 
Master Mix was added to each sample, on ice. Second strand cDNA synthesis 
reactions were incubated for 2hrs at 16°C. 
 
The components of the Second Strand Master Mix were prepared as follows. 




Nuclease-free water  63μl 
10X second strand buffer 10μl 
dNTP mix   4μl 
DNA Polymerase  2μl 
RNase H   1μl 
 
Purification of cDNA was performed using a cDNA filter cartridge system which 
included a cDNA binding step, a wash step and a final elution of cDNA with 19μl of 
55°C nuclease-free water. For the synthesis of cRNA, a 25μl IVT reaction was 
prepared for each sample by adding of 7.5μl of IVT Master Mix to the sample and 
incubating for 14 hours at 37°C. 
 
The components of the In Vitro Transcription Master Mix were prepared as follows. 
For a 25μl reaction:- 
Biotin-NTP Mix  2.5μl 
T7 10X Reaction Buffer 2.5μl 
T7 Enzyme Mix  2.5μl 
 
The reaction was stopped by adding 75μl of nuclease-free water. The cRNA 
generated was purified in cRNA filter cartridges using a cRNA binding buffer, wash 






Whole-genome gene expression direct hybridization assay 
Single-channel SENTRIX® BeadChip Array MouseRef-8 v2.0 Microarray 
for Gene Expression (Illumina®, Inc., California, USA) targets approximately 19,100 
unique genes. About 25,600 70-mer oligonucleotide probe sequences, representative 
of individual genes, of the mouse genome were represented on each array. 10μl of 
hybridization buffer GEX-HYB was added to 750ng of cRNA in 5μl of nuclease-free 
water for each sample. The cRNA samples were then pre-heated to 65°C for 5 min, 
cooled to room temperature. Then, 15μl of each sample was loaded onto an array. 
The microarray slide was positioned in a hybridization chamber loaded with 200μl of 
humidifying buffer GEX-HCB. The microarray slides were incubated for 18 hours in 
a rocker at 58°C to allow for hybridization. 
After hybridization, the microarray slides were submerged in 250ml of wash 
buffer E1BC solution, then transferred to a high temperature wash buffer and 
incubated static for 10min at 55°C. The microarray slides were then washed in the 
following sequence: 250ml of E1BC solution for 5min, 25 ml of 100% ethanol for 
10min, and 250ml of E1BC solution for 2min. The slides were incubated on a rocker 
with 4ml of blocking buffer E1 for 10min. To allow the binding of Cy3 fluorescent 
dye to the array, 2 μl of 1 mg/ml Cy3 coupled-streptavidin in 2ml of E1 was then 
incubated with each microarray slide for 10min with rocking. Washing was carried 
out  after  Cy3-binding  with  E1BC  solution  to remove unbound dye and the slides 
were centrifuged for 4min at 275 xg (rcf) to dry the slides. 
The direct hybridization gene expression arrays were scanned using the 
BeadArray Reader (Illumina®, Inc., California, USA). All slides were scanned with 






Microarray DNA analysis 
Fluorescence emission by Cy3 was quantitatively detected using the 
GenomeStudio software (Illumina®, Inc., California, USA) and converted into a 
format compatible with GeneSpring GX12.1 (Agilent Technologies, California, 
USA), an advanced microarray analysis software. The probability of seeing a certain 
signal value without probe-specific target hybridization is termed the detection p-
value.   Detection   p-values   were   computed   in   GenomeStudio (Illumina®, Inc., 
California, USA) prior exporting to Genespring GX 12.1 using the Wilcoxon Signed 
Ranked Test. 
GeneSpring GX 12.1 
 The probe ID, average signal value and detection p-values obtained from 
GenomeStudio as the sample probe profile and were imported into GeneSpring GX 
12.1’s ‘Illumina Single Color Guided Workflow to find differentially expressed 
genes’ for the normalisation of raw data. The guided workflow does a thresholding 
of the signal values to 5. It then normalizes the data to 75th percentile and performs 
baseline transformation to median of all samples. 
GeneSpring Fold Change Analysis 
Fold change analysis is used to identify genes with expression ratios or 
differences between a treatment and a control that are beyond a threshold. Fold 
change is the ratio between Condition 1 and Condition 2. It is calculated as Fold 
change = Condition 1 / Condition 2. Fold change gives the absolute ratio of 
normalized intensities (no log scale) between the average intensities of the samples 
grouped. A fold-change cut-off of 1.5 was used in the analysis 1-way ANOVA 





8.8 Statistical Analysis of fold changes in lung homogenate cytokine 





13 113.51701 211.621876 58.693348 -14.36481 241.39883 17.161 809.238
13 81.73654 68.809139 19.084222 40.15559 123.31749 25.857 290.382
13 101.19786 69.655883 19.319066 59.10524 143.29049 26.193 198.324





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = G-CSFa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
31.780474 52.803680 1.000 -100.81170 164.37265
12.319150 52.803680 1.000 -120.27302 144.91132
-31.780474 52.803680 1.000 -164.37265 100.81170
-19.461324 52.803680 1.000 -152.05350 113.13085
-12.319150 52.803680 1.000 -144.91132 120.27302














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval












14 7.17439 2.858574 .763986 5.52390 8.82488 2.775 12.553
13 2.20824 .863141 .239392 1.68665 2.72983 1.242 4.343
14 2.75709 1.507686 .402946 1.88657 3.62760 .842 6.189





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = GM-CSFa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent Variable: Fold Change
Bonf erroni
4.966154* .751654 .000 3.08355 6.84876
4.417305* .737603 .000 2.56989 6.26472
-4.966154* .751654 .000 -6.84876 -3.08355
-.548849 .751654 1.000 -2.43145 1.33375
-4.417305* .737603 .000 -6.26472 -2.56989














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














13 7.71162 8.108790 2.248974 2.81153 12.61171 2.126 32.475
12 19.58692 21.959014 6.339021 5.63483 33.53902 5.040 85.125
12 45.08713 35.704951 10.307132 22.40129 67.77298 15.071 134.594





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IFN-gammaa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
-11.875307 9.737430 .693 -36.39668 12.64607
-37.375515* 9.737430 .002 -61.89689 -12.85414
11.875307 9.737430 .693 -12.64607 36.39668
-25.500208* 9.930269 .044 -50.50720 -.49322
37.375515* 9.737430 .002 12.85414 61.89689














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














14 14.38794 12.356027 3.302287 7.25378 21.52210 1.386 46.980
14 6.67941 2.496145 .667123 5.23818 8.12064 1.246 11.702
8 5.07771 1.528971 .540573 3.79946 6.35596 2.827 6.976





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-10a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
7.708530* 3.002230 .045 .13627 15.28079
9.310232* 3.520427 .037 .43097 18.18950
-7.708530* 3.002230 .045 -15.28079 -.13627
1.601702 3.520427 1.000 -7.27756 10.48097
-9.310232* 3.520427 .037 -18.18950 -.43097














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














1 .11241 . . . . .112 .112
3 1.23077 .477843 .275883 .04374 2.41780 .690 1.597
2 1.29589 .046330 .032761 .87963 1.71215 1.263 1.329





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.










10 2.38134 2.066481 .653479 .90307 3.85962 .061 5.653
7 .95809 .174903 .066107 .79633 1.11985 .604 1.105
11 1.09752 .078951 .023805 1.04449 1.15056 .941 1.190





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-12 p70a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
1.423255 .612975 .086 -.14963 2.99614
1.283819 .543477 .079 -.11073 2.67837
-1.423255 .612975 .086 -2.99614 .14963
-.139436 .601393 1.000 -1.68260 1.40373
-1.283819 .543477 .079 -2.67837 .11073














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval















12 1.51823 .553184 .159690 1.16676 1.86971 .888 2.665
12 .74440 1.310256 .378238 -.08810 1.57689 .011 3.654
12 1.03639 1.237607 .357266 .25005 1.82272 .005 3.807





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-13a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
.773835 .444376 .273 -.34697 1.89465
.481847 .444376 .858 -.63896 1.60266
-.773835 .444376 .273 -1.89465 .34697
-.291989 .444376 1.000 -1.41280 .82882
-.481847 .444376 .858 -1.60266 .63896














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval















14 1.54399 .609871 .162995 1.19186 1.89612 .734 2.863
12 .70847 .254971 .073604 .54647 .87047 .252 1.118
14 .77036 .397830 .106325 .54066 1.00006 .087 1.334





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-17a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent Variable: Fold Change
Bonf erroni
.835521* .178387 .000 .38817 1.28287
.773629* .171388 .000 .34383 1.20343
-.835521* .178387 .000 -1.28287 -.38817
-.061893 .178387 1.000 -.50924 .38545
-.773629* .171388 .000 -1.20343 -.34383














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














10 1.52710 1.014902 .320940 .80109 2.25312 .591 3.379
10 .52118 .604917 .191292 .08844 .95391 .006 1.858
12 1.40974 .904029 .260971 .83535 1.98413 .269 2.832





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-1aa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
1.005928* .385545 .043 .02629 1.98556
.117364 .369131 1.000 -.82056 1.05529
-1.005928* .385545 .043 -1.98556 -.02629
-.888563 .369131 .068 -1.82649 .04937
-.117364 .369131 1.000 -1.05529 .82056














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














13 6.35674 2.738818 .759611 4.70169 8.01179 3.553 13.618
11 7.81745 9.538129 2.875854 1.40965 14.22525 1.076 24.596
13 22.85307 22.311067 6.187977 9.37063 36.33551 1.514 69.067





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-1ba. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
-1.460713 5.866965 1.000 -16.23525 13.31383
-16.496331* 5.617191 .018 -30.64187 -2.35079
1.460713 5.866965 1.000 -13.31383 16.23525
-15.035618* 5.866965 .045 -29.81016 -.26108
16.496331* 5.617191 .018 2.35079 30.64187














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














7 .75092 .508825 .192318 .28033 1.22150 .037 1.688
14 2.22455 1.769980 .473047 1.20260 3.24651 .342 5.943




N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.









14 10.64912 5.131322 1.371403 7.68638 13.61186 3.285 19.499
13 5.44930 3.019112 .837351 3.62487 7.27373 .454 12.729
14 4.36573 1.789872 .478363 3.33229 5.39917 1.749 7.995





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-3a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
5.199822* 1.387779 .002 1.72397 8.67567
6.283390* 1.361837 .000 2.87251 9.69427
-5.199822* 1.387779 .002 -8.67567 -1.72397
1.083568 1.387779 1.000 -2.39228 4.55942
-6.283390* 1.361837 .000 -9.69427 -2.87251














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














14 9.44814 3.612702 .965535 7.36223 11.53405 2.918 16.260
14 1.69335 1.009233 .269729 1.11064 2.27606 .176 3.506
14 1.92515 .922024 .246421 1.39279 2.45751 .302 3.338





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-4a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
7.754791* .842906 .000 5.64613 9.86345
7.522988* .842906 .000 5.41433 9.63165
-7.754791* .842906 .000 -9.86345 -5.64613
-.231803 .842906 1.000 -2.34046 1.87686
-7.522988* .842906 .000 -9.63165 -5.41433














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














13 21.01575 25.340013 7.028055 5.70294 36.32857 2.876 77.769
14 3.30235 3.295517 .880764 1.39958 5.20513 .029 12.297
14 15.09350 23.718675 6.339083 1.39875 28.78826 .983 89.508





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-5a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
17.713400 7.693162 .081 -1.55500 36.98180
5.922250 7.693162 1.000 -13.34615 25.19065
-17.713400 7.693162 .081 -36.98180 1.55500
-11.791150 7.549352 .380 -30.69936 7.11706
-5.922250 7.693162 1.000 -25.19065 13.34615














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval















14 57.21429 69.640141 18.612111 17.00527 97.42331 1.335 274.873
13 76.65380 72.963893 20.236543 32.56217 120.74544 7.576 228.752
14 286.29464 280.120515 74.865357 124.55787 448.03141 33.792 1020.611





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-6a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent Variable: Fold Change
Bonf erroni
-19.439519 66.917207 1.000 -187.04128 148.16224
-229.08036* 65.666308 .004 -393.54910 -64.61162
19.439519 66.917207 1.000 -148.16224 187.04128
-209.64084* 66.917207 .010 -377.24260 -42.03908
229.080357* 65.666308 .004 64.61162 393.54910














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














14 .89428 .251000 .067083 .74935 1.03920 .498 1.422
10 .65733 1.337433 .422933 -.29942 1.61407 .021 3.477
9 1.52002 2.162622 .720874 -.14232 3.18235 .006 5.716





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = IL-9a. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
.236950 .557202 1.000 -1.17597 1.64987
-.625740 .574976 .855 -2.08373 .83225
-.236950 .557202 1.000 -1.64987 1.17597
-.862690 .618339 .520 -2.43064 .70526
.625740 .574976 .855 -.83225 2.08373














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval















13 3.27493 1.754237 .486538 2.21485 4.33500 .404 6.500
13 8.60980 7.557836 2.096167 4.04264 13.17695 1.750 23.431
14 13.67384 10.474268 2.799366 7.62618 19.72151 2.075 33.904





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = KCa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent Variable: Fold Change
Bonf erroni
-5.334874 2.988970 .247 -12.83042 2.16067
-10.398919* 2.935110 .003 -17.75940 -3.03844
5.334874 2.988970 .247 -2.16067 12.83042
-5.064045 2.935110 .278 -12.42453 2.29644
10.398919* 2.935110 .003 3.03844 17.75940














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














13 9.55345 7.945246 2.203615 4.75218 14.35471 2.920 33.690
7 10.39606 2.060396 .778756 8.49051 12.30161 7.434 12.847
2 2.00744 .754429 .533462 -4.77084 8.78572 1.474 2.541





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = MIP-1aa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
-.842611 3.010611 1.000 -8.74578 7.06056
7.546006 4.877748 .415 -5.25860 20.35061
.842611 3.010611 1.000 -7.06056 8.74578
8.388617 5.148938 .359 -5.12789 21.90512
-7.546006 4.877748 .415 -20.35061 5.25860














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval















13 5.06358 1.008175 .279617 4.45434 5.67281 3.090 6.971
8 8.11074 3.004582 1.062280 5.59885 10.62264 2.295 12.221
2 4.13192 .945869 .668830 -4.36638 12.63021 3.463 4.801





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = MIP-1ba. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent Variable: Fold Change
Bonf erroni
-3.047164* .877598 .007 -5.33996 -.75436
.931662 1.483411 1.000 -2.94388 4.80720
3.047164* .877598 .007 .75436 5.33996
3.978826 1.543983 .054 -.05496 8.01261
-.931662 1.483411 1.000 -4.80720 2.94388














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 














10 5.62859 4.129808 1.305960 2.67430 8.58287 1.157 12.083
13 4.87179 5.206986 1.444158 1.72524 8.01834 .161 18.690
13 2.81443 1.440841 .399617 1.94374 3.68512 .959 5.408





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = RANTESa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: Fold Change
Bonf erroni
.756797 1.643419 1.000 -3.38825 4.90185
2.814158 1.643419 .289 -1.33089 6.95921
-.756797 1.643419 1.000 -4.90185 3.38825
2.057361 1.532496 .566 -1.80792 5.92264
-2.814158 1.643419 .289 -6.95921 1.33089














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval















13 7.70673 8.939466 2.479362 2.30467 13.10880 1.830 34.314
13 2.55600 2.233045 .619335 1.20658 3.90541 .517 8.590
13 2.39292 1.435040 .398008 1.52573 3.26010 .540 4.975





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
group = TNF-Aa. 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent Variable: Fold Change
Bonf erroni
5.150736 2.111748 .059 -.15195 10.45342
5.313815* 2.111748 .049 .01113 10.61650
-5.150736 2.111748 .059 -10.45342 .15195
.163079 2.111748 1.000 -5.13961 5.46576
-5.313815* 2.111748 .049 -10.61650 -.01113














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 






8.9 Absolute cytokine concentrations and fold changes in lung homogenates 
 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.10 Sample for processing raw data, calculation of mean comparative 
expression levels and statistical analysis 
A B C D E F G H I J K
ΔCp (Target - 
Normaliser)








Samples Mean Cp Cp ACTB ΔCp / ACTB / ACTB / ACTB / ACTB / ACTB / ACTB
-ve Ctrl A13, A14, A15 0
++ Ctrl M 1 EP75 I1, I2, I3 31.9 27.8 4.1
EP76 B1, B2, B3 36.3 29.1 7.3
EP77 C1, C2, C3 35.3 28.7 6.6
EP88 D1, D2, D3 35.3 28.6 6.6
EP91 E1, E2, E3 37.4 29.3 8.2
++ Ctrl M 2 EP18 A7, A8, A9 35.0 29.4 5.6
EP20 B7, B8, B9 35.2 30.1 5.1
EP24 C7, C8, C9 36.4 29.4 6.9
EP25 D7, D8, D9 35.3 30.4 4.9
EP55 E7, E8, E9 36.8 29.3 7.5
++ Ctrl F 1 EP1 A4, A5, A6 32.4 28.7 3.7
EP2 B4, B5, B6 32.4 28.9 3.5
EP3 C4, C5, C6 35.8 29.6 6.2
2 EP1 D4, D5, D6 34.9 29.1 5.8
2 EP2 E4, E5, E6 34.0 29.0 5.1
++ Ctrl F 2 EP26 A10, A11, A12 38.7 30.6 8.1
EP52 B10, B11, B12 35.7 31.3 4.4
EP53 C10, C11, C12 35.5 30.4 5.1
EP80 D10, D11, D12 35.5 31.1 4.4
EP81 E10, E11, E12 35.9 30.4 5.6 5.7
++ Test M 1 EP57 G1, G2, G3 26.5 19.4 7.1 1.4 0.4
EP76 H1, H2, H3 35.6 29.8 5.8 0.1 0.9
EP78 I1, I2, I3 34.7 30.4 4.3 -1.4 2.7
EP79 J1, J2, J3 28.3 23.5 4.8 -0.9 1.9
EP80 K1, K2, K3 34.9 30.3 4.7 -1.1 2.1
EP82 L1, L2, L3 28.1 20.1 8.0 2.3 0.2
EP7 M1, M2, M3 25.6 19.7 5.9 0.1 0.9
EP8 N1, N2, N3 26.3 18.4 7.8 2.1 0.2
++ Test M 2 EP48 G7, G8, G9 37.9 30.2 7.8 2.0 0.2
EP49 H7, H8, H9 23.7 18.7 5.0 -0.7 1.6
EP50 I7, I8, I9 33.1 27.2 6.0 0.2 0.8
EP51 J7, J8, J9 31.7 26.3 5.4 -0.3 1.3
EP56 K7, K8, K9 25.9 19.2 6.7 1.0 0.5
EP66 L7, L8, L9 35.6 28.6 7.0 1.3 0.4
EP67 M7, M8, M9 33.4 27.4 6.1 0.3 0.8
EP71 N7, N8, N9 35.6 28.9 6.7 1.0 0.5
EP73 O7, O8, O9 33.9 29.1 4.8 -1.0 2.0
++ Test F 1 EP4 G4, G5, G6 24.5 18.6 6.0 0.2 0.8
EP73 H4, H5, H6 33.4 26.9 6.4 0.7 0.6
EP85 I4, I5, I6 32.9 26.1 6.8 1.1 0.5
EP86 J4, J5, J6 30.0 22.7 7.3 1.5 0.3
EP88 K4, K5, K6 28.5 20.2 8.3 2.6 0.2
EP7 L4, L5, L6 33.5 27.3 6.2 0.5 0.7
EP12 M4, M5, M6 31.1 24.5 6.6 0.8 0.6
EP13 N4, N5, N6 31.9 24.9 7.0 1.2 0.4
++ Test F 2 EP82 G10, G11, G12 27.5 20.5 7.0 1.3 0.4
EP84 H10, H11, H12 33.7 28.0 5.6 -0.1 1.1
EP87 I10, I11, I12 29.4 23.1 6.2 0.5 0.7
EP93 J10, J11, J12 34.5 29.1 5.3 -0.4 1.3
EP96 K10, K11, K12 33.7 29.7 4.0 -1.7 3.3
EP97 L10, L11, L12 25.9 17.6 8.2 2.5 0.2
EP2 M10, M11, M12 28.6 21.5 7.1 1.3 0.4
EP3 N10, N11, N12 27.6 24.6 3.0 -2.8 6.7 1.1 1.3
+- Ctrl M 1 EP70 A13, A14, A15 35.8 30.3 5.5
EP72 B13, B14, B15 35.3 29.9 5.4
EP89 C13, C14, C15 34.0 29.7 4.3
EP90 D13, D14, D15 34.9 29.8 5.2
EP92 E13, E14, E15 35.5 30.0 5.5
+- Ctrl M 2 EP17 A19, A20, A21 31.9 28.4 3.4
EP19 B19, B20, B21 30.6 25.7 5.0
EP21 C19, C20, C21 35.2 30.3 4.9
EP22 D19, D20, D21 35.0 30.5 4.5
EP23 E19, E20, E21 32.1 26.6 5.5
+- Ctrl F 1 EP54 A16, A17, A18 34.2 31.4 2.9
EP55 B16, B17, B18 34.4 31.5 2.9
EP60 C16, C17, C18 36.7 31.6 5.1
EP61 D16, D17, D18 36.9 31.7 5.2
EP63 E16, E17, E18 36.3 31.7 4.5
+- Ctrl F 2 EP94 A22, A23, A24 34.7 30.3 4.4
EP95 B22, B23, B24 35.2 31.5 3.7
EP16 C22, C23, C24 36.6 31.9 4.7
EP98 D22, D23, D24 34.6 30.4 4.2
EP5 E22, E23, E24 36.4 31.9 4.5 4.6
+- Test M 1 EP52 G13, G14, G15 24.8 20.7 4.1 -0.5 1.4
EP53 H13, H14, H15 25.2 18.8 6.4 1.9 0.3
EP56 I13, I14, I15 28.5 19.6 9.0 4.4 0.0
EP77 J13, J14, J15 34.1 28.1 5.9 1.4 0.4
EP84 K13, K14, K15 33.1 26.6 6.6 2.0 0.3
+- Test M 2 EP28 G19, G20, G21 34.4 29.7 4.6 0.1 1.0
EP29 H19, H20, H21 31.5 29.2 2.3 -2.3 4.8
EP33 I19, I20, I21 34.7 27.9 6.8 2.3 0.2
EP42 J19, J20, J21 33.3 27.0 6.2 1.6 0.3
EP43 K19, K20, K21 34.3 29.0 5.3 0.7 0.6
EP65 L19, L20, L21 35.7 29.0 6.7 2.1 0.2
+- Test F 1 EP64 G16, G17, G18 37.3 29.2 8.1 3.5 0.1
EP66 H16, H17, H18 30.3 23.4 6.9 2.3 0.2
EP67 I16, I17, I18 35.9 30.1 5.8 1.2 0.4
EP68 J16, J17, J18 28.3 19.5 8.9 4.3 0.1
EP70 K16, K17, K18 30.4 25.0 5.4 0.9 0.6
EP74 L16, L17, L18 30.0 22.0 8.1 3.5 0.1
EP89 M16, M17, M18 29.7 21.6 8.1 3.5 0.1
EP90 N16, N17, N18 31.5 24.4 7.1 2.5 0.2
EP91 O16, O17, O18 35.8 29.9 5.9 1.3 0.4
+- Test F 2 EP6 G22, G23, G24 28.1 20.0 8.1 3.5 0.1
EP8 H22, H23, H24 26.5 17.5 9.0 4.5 0.0
EP9 I22, I23, I24 25.8 17.3 8.6 4.0 0.1
EP34 J22, J23, J24 28.6 24.2 4.4 -0.1 1.1
EP35 K22, K23, K24 31.5 24.8 6.7 2.1 0.2
EP36 L22, L23, L24 34.5 27.4 7.1 2.5 0.2
EP37 M22, M23, M24 31.0 23.2 7.8 3.2 0.1
EP38 N22, N23, N24 35.5 28.2 7.2 2.7 0.2
EP39 O22, O23, O24 31.7 27.5 4.2 -0.4 1.3
EP40 P22, P23, P24 32.0 26.7 5.4 0.8 0.6 0.5 0.9
-- Ctrl M 1 EP17 A1, A2, A3 38.6 29.5 9.2
EP76 B1, B2, B3 55.0 30.0 25.0
EP77 C1, C2, C3 37.3 23.0 14.3
EP78 D1, D2, D3 55.0 29.7 25.3
EP79 E1, E2, E3 12.8 28.2 -15.4
-- Ctrl M 2 EP69 A7, A8, A9 55.0 30.6 24.4
EP47 B7, B8, B9 24.3 28.0 -3.7
EP13 C7, C8, C9 36.6 26.3 10.3
EP14 D7, D8, D9 36.8 27.0 9.8
EP16 E7, E8, E9 55.0 32.4 22.6
-- Ctrl F 1 EP5 A4, A5, A6 37.0 31.9 5.0
EP6 B4, B5, B6 41.0 30.5 10.6
EP8 C4, C5, C6 45.0 30.4 14.6
EP9 D4, D5, D6 38.0 22.7 15.3
EP10 E4, E5, E6 15.0 24.0 -9.0
-- Ctrl F 2 EP62 A10, A11, A12 44.0 18.7 25.3
EP18 B10, B11, B12 38.2 30.4 7.8
EP3 C10, C11, C12 36.3 30.8 5.5
EP4 D10, D11, D12 55.0 18.0 37.0
EP38 E10, E11, E12 45.0 20.2 24.8 12.9
-- Test M 1 EP45 G1, G2, G3 55.0 27.9 27.1 14.2 0.0
EP56 K1, K2, K3 30.5 16.8 13.7 0.8 0.6
EP65 M1, M2, M3 55.0 21.3 33.7 20.8 0.0
EP66 N1, N2, N3 37.0 24.1 12.8 -0.1 1.1
EP68 O1, O2, O3 55.0 24.2 30.8 17.8 0.0
EP81 P1, P2, P3 55.0 25.8 29.2 16.2 0.0
-- Test M 2 EP15 G7, G8, G9 35.8 17.8 17.9 5.0 0.0
EP54 H7, H8, H9 55.0 22.7 32.3 19.3 0.0
EP10 I7, I8, I9 37.2 22.6 14.7 1.7 0.3
EP11 J7, J8, J9 55.0 17.4 37.6 24.7 0.0
-- Test F 1 EP11 G4, G5, G6 37.5 18.5 19.0 6.0 0.0
EP14 H4, H5, H6 55.0 27.3 27.7 14.8 0.0
EP15 I4, I5, I6 55.0 26.7 28.3 15.3 0.0
EP16 J4, J5, J6 55.0 22.0 33.0 20.1 0.0
EP71 K4, K5, K6 39.3 20.8 18.5 5.6 0.0
EP72 L4, L5, L6 55.0 24.0 31.0 18.0 0.0
EP97 N4, N5, N6 38.2 27.3 10.9 -2.0 4.1
EP99 O4, O5, O6 55.0 26.3 28.7 15.8 0.0
-- Test F 2 EP1 G10, G11, G12 55.0 16.8 38.2 25.3 0.0
EP2 H10, H11, H12 45.0 16.7 28.3 15.3 0.0
EP3 I10, I11, I12 42.0 16.4 25.6 12.7 0.0
EP4 J10, J11, J12 40.4 16.2 24.2 11.3 0.0
EP5 K10, K11, K12 43.6 17.3 26.4 13.4 0.0
EP42 L10, L11, L12 45.0 17.6 27.4 14.5 0.0
EP53 M10, M11, M12 45.0 16.6 28.4 15.5 0.0
EP61 N10, N11, N12 41.8 16.2 25.6 12.6 0.0






8.11 Statistical analysis of gene expression in lung homogenate measured by 






28 .164 .4336 .0819 -.004 .332 .0 2.3
28 .652 1.5312 .2894 .058 1.245 .0 6.9
32 .277 .8184 .1447 -.018 .572 .0 4.4





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IFN Alphaa. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.4877 .2737 .235 -1.156 .181
-.1135 .2650 1.000 -.761 .534
.4877 .2737 .235 -.181 1.156
.3742 .2650 .485 -.273 1.021
.1135 .2650 1.000 -.534 .761














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval


















35 .031 .1803 .0305 -.031 .093 .0 1.1
30 .119 .1969 .0359 .045 .192 .0 .9
33 .067 .1112 .0194 .028 .107 .0 .4





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IFN Betaa. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.0881 .0414 .107 -.189 .013
-.0366 .0403 1.000 -.135 .062
.0881 .0414 .107 -.013 .189
.0515 .0419 .668 -.051 .154
.0366 .0403 1.000 -.062 .135














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
























36 2.428 2.6749 .4458 1.523 3.333 .0 9.7
29 4.302 3.7426 .6950 2.878 5.725 .8 20.4
31 89.850 44.0350 7.9089 73.698 106.002 32.2 192.8





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IFN Gammaa. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-1.8739 6.2749 1.000 -17.173 13.425
-87.4222* 6.1618 .000 -102.445 -72.399
1.8739 6.2749 1.000 -13.425 17.173
-85.5483* 6.4968 .000 -101.388 -69.709
87.4222* 6.1618 .000 72.399 102.445














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 .709 .9479 .1580 .388 1.030 .0 4.2
30 2.003 2.0195 .3687 1.249 2.757 .1 9.1
33 4.087 3.9681 .6908 2.680 5.494 .4 17.7





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IRF1a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-1.2936 .6450 .143 -2.865 .278
-3.3777* .6288 .000 -4.910 -1.845
1.2936 .6450 .143 -.278 2.865
-2.0841* .6582 .006 -3.688 -.480
3.3777* .6288 .000 1.845 4.910














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 .132 .1162 .0194 .092 .171 .0 .6
30 .549 .4264 .0778 .390 .708 .1 1.6
33 .518 .4392 .0764 .363 .674 .1 2.3





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IRF3a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.4173* .0871 .000 -.630 -.205
-.3866* .0849 .000 -.594 -.180
.4173* .0871 .000 .205 .630
.0307 .0889 1.000 -.186 .247
.3866* .0849 .000 .180 .594














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























27 .228 .8153 .1569 -.095 .551 .0 4.1
30 .515 .8988 .1641 .179 .850 .0 4.8
33 1.085 1.2656 .2203 .636 1.534 .2 6.7





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IRF4a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.2868 .2727 .888 -.953 .379
-.8568* .2668 .006 -1.508 -.205
.2868 .2727 .888 -.379 .953
-.5700 .2594 .092 -1.203 .063
.8568* .2668 .006 .205 1.508














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 .402 .4024 .0671 .265 .538 .0 2.0
27 2.129 1.3021 .2506 1.614 2.644 .4 6.2
32 3.023 1.2832 .2268 2.561 3.486 1.6 6.3





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IRF5a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-1.7271* .2665 .000 -2.377 -1.077
-2.6216* .2543 .000 -3.242 -2.001
1.7271* .2665 .000 1.077 2.377
-.8945* .2735 .005 -1.562 -.228
2.6216* .2543 .000 2.001 3.242














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 1.718 2.1121 .3520 1.004 2.433 .0 10.2
30 8.563 7.4828 1.3662 5.768 11.357 .8 24.2
33 18.420 14.6363 2.5478 13.230 23.610 2.1 59.4





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IRF7a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-6.8442* 2.3445 .013 -12.557 -1.131
-16.7014* 2.2857 .000 -22.271 -11.132
6.8442* 2.3445 .013 1.131 12.557
-9.8571* 2.3925 .000 -15.687 -4.027
16.7014* 2.2857 .000 11.132 22.271














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 .321 .2287 .0381 .244 .399 .0 1.0
29 1.311 .9142 .1698 .963 1.658 .4 3.6
33 2.020 1.2841 .2235 1.565 2.476 .6 4.6





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = IRF8a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.9892* .2261 .000 -1.540 -.438
-1.6990* .2184 .000 -2.231 -1.167
.9892* .2261 .000 .438 1.540
-.7098* .2306 .008 -1.272 -.148
1.6990* .2184 .000 1.167 2.231














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 .344 .3173 .0529 .237 .452 .1 1.7
29 1.619 1.3673 .2539 1.099 2.139 .3 5.8
33 2.348 1.7750 .3090 1.719 2.978 .5 8.4





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = MyD88a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-1.2744* .3205 .000 -2.055 -.493
-2.0042* .3095 .000 -2.758 -1.250
1.2744* .3205 .000 .493 2.055
-.7298 .3269 .084 -1.526 .067
2.0042* .3095 .000 1.250 2.758














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 .262 .2973 .0495 .162 .363 .0 1.6
29 .763 .4849 .0900 .578 .947 .1 2.0
33 1.410 1.5461 .2691 .862 1.958 .0 8.1





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = NFKBa. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.5004 .2376 .114 -1.080 .079
-1.1477* .2295 .000 -1.707 -.588
.5004 .2376 .114 -.079 1.080
-.6474* .2424 .027 -1.238 -.057
1.1477* .2295 .000 .588 1.707














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























33 1325841 1838114.4622 319974.7 674073.865 1977607.961 2720.6 7893452.3
22 3959.682 3978.7929 848.2815 2195.584 5723.780 146.1 13111.6
29 65040.694 100212.6060 18609.01 26921.857 103159.531 700.1 447502.8





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = NS1a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
1321881.2* 318407.1 .000 543466.836 2100295.626
1260800.2* 294448.7 .000 540957.361 1980643.077
-1321881.2* 318407.1 .000 -2100295.626 -543466.836
-61081.012 327072.8 1.000 -860680.621 738518.596
-1260800.2* 294448.7 .000 -1980643.077 -540957.361














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 .280 .2791 .0465 .185 .374 .0 1.6
29 .558 .3325 .0618 .432 .685 .2 1.7
33 1.008 .8310 .1447 .713 1.303 .0 4.6





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = TLR4a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.2787 .1353 .126 -.608 .051
-.7284* .1307 .000 -1.047 -.410
.2787 .1353 .126 -.051 .608
-.4497* .1380 .005 -.786 -.113
.7284* .1307 .000 .410 1.047














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























35 .541 .5834 .0986 .340 .741 .0 2.8
27 1.508 1.0388 .1999 1.097 1.919 .2 3.9
33 1.181 .8060 .1403 .896 1.467 .1 3.2





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = TLR9a. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-.9672* .2076 .000 -1.473 -.461
-.6409* .1966 .005 -1.120 -.161
.9672* .2076 .000 .461 1.473
.3263 .2103 .372 -.186 .839
.6409* .1966 .005 .161 1.120














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 























36 1.409 1.8447 .3075 .784 2.033 .0 8.6
30 3.584 3.5722 .6522 2.250 4.918 .3 15.0
32 21.467 17.1666 3.0347 15.278 27.656 3.4 68.1





N Mean Std.  Dev iat ion Std.  Error Lower Bound Upper Bound
95% Conf idence Interval f or
Mean
Minimum Maximum











Squares df Mean Square F Sig.
gene = TNF Alphaa. 
 
 
Post Hoc Tests 
Multiple Comparisonsa
Dependent  Variable: ACTB
Bonf erroni
-2.1757 2.4882 1.000 -8.240 3.888
-20.0585* 2.4455 .000 -26.018 -14.099
2.1757 2.4882 1.000 -3.888 8.240
-17.8828* 2.5579 .000 -24.117 -11.649
20.0585* 2.4455 .000 14.099 26.018














(I-J) Std.  Error Sig. Lower Bound Upper Bound
95% Conf idence Interval
The mean dif f erence is signif icant at the .05 lev el.*. 







8.12 Graphical data of invidual gene expression analysis in  lung homogenate 
  









Corrected Mean Comparative 
Expression Level, If MCE < 1, 
Reduction Fold Change (-
1/MCE)
SD
/ ACTB / ACTB / ACTB
NS1 PR8 H1N1 WT +/+ 65040.7 65040.7 100212.6
HZ +/- 3959.7 3959.7 3978.8
KO -/- 1325840.9 1325840.9 1838114.5
IRF-4 WT +/+ 1.1 1.1 1.3
HZ +/- 0.5 -1.9 -0.9
KO -/- 0.2 -4.4 -0.8
IFN-Alpha WT +/+ 0.3 -3.6 -0.82
HZ +/- 0.7 -1.5 -1.53
KO -/- 0.2 -6.1 -0.43
IFN-Beta WT +/+ 0.1 -14.9 -0.1
HZ +/- 0.1 -8.4 -0.2






































Terminal (Days 7-11 Post Infection) Mean Comparative 












































Terminal (Days 7-11 Post Infection) IRF-4 Fold Change in 







































Terminal (Days 7-11 Post Infection) IFN-Alpha Fold Change 






































Terminal (Days 7-11 Post-Infection) IFN-Beta Fold Change 
in IRF-4 mice lung homogenate
 












Corrected Mean Comparative 
Expression Level, If MCE < 1, 
Reduction Fold Change (-
1/MCE)
SD
/ ACTB / ACTB / ACTB
IFN-Gamma WT +/+ 89.9 89.9 44.0
HZ +/- 4.3 4.3 3.7
KO -/- 2.4 2.4 2.7
IRF-1 WT +/+ 4.1 4.1 4.0
HZ +/- 2.0 2.0 2.0
KO -/- 0.7 -1.4 -0.9
IRF-3 WT +/+ 0.5 -1.9 -0.4
HZ +/- 0.5 -1.8 -0.4
KO -/- 0.1 -7.6 -0.1
IRF-5  WT +/+ 3.0 3.0 1.3
HZ +/- 2.1 2.1 1.3








































Terminal (Days 7-11 Post-Infection) IFN-Gamma Fold 









































Terminal (Days 7-11 Post Infection) IRF-1 Fold Change in 













































Terminal (Days 7-11 Post-Infection) IRF-3 Fold Change in 













































Terminal (Days 7-11 Post Infection) IRF-5 Fold Change in 
















Corrected Mean Comparative 
Expression Level, If MCE < 1, 
Reduction Fold Change (-
1/MCE)
SD
/ ACTB / ACTB / ACTB
IRF-7 WT +/+ 18.4 18.4 14.6
HZ +/- 8.6 8.6 7.5
KO -/- 1.7 1.7 2.1
IRF-8 WT +/+ 2.0 2.0 1.3
HZ +/- 1.3 1.3 0.9
KO -/- 0.3 -3.1 -0.2
MyD88 WT +/+ 2.3 2.3 1.8
HZ +/- 1.6 1.6 1.4
KO -/- 0.3 -2.9 -0.3
NFKb WT +/+ 1.4 1.4 1.5
HZ +/- 0.8 -1.3 -0.5




































Terminal (Days 7-11 Post-Infection) IRF-7 Fold Change in 









































Terminal (Days 7-11 Post Infection) IRF-8 Fold Change in 









































Terminal (Days 7-11 Post Infection) MyD88 Fold Change in 









































Terminal (Days 7-11 Post Infection) NFKb Fold Change in 











Table 8.1. Top 30 differentially expressed genes between IRF-4 +/+ WT vs +/- HZ vs 
-/- KO. Comparison was made between the PR8 H1N1 InfAV-infected mice of three 
IRF-4 genotypes (IRF4 +/+ WT, IRF-4 +/- HZ and IRF-4 -/- KO). Significance 
analysis was performed with 1-way ANOVA with fold change analysis and the 
genelist is arranged by the p-value.  
ProbeID Symbol Definition p 
FC ([+/- Test] vs 
[+/+ Test])
FC ([-/- Test] vs 
[+/+ Test])








Mus musculus microtubule-associated protein 1 
B (Mtap1b), mRNA. 4.17E-05
-1.1 -1.4 -1.3
1580519









Mus musculus solute carrier family 7 (cationic 


















Mus musculus RIKEN cDNA 2410042D21 














Mus musculus RIKEN cDNA 1500012F01 









Mus musculus splicing factor, arginine/serine-









Mus musculus RIKEN cDNA 1700007G11 




Mus musculus A kinase (PRKA) anchor 




Mus musculus C-type lectin domain family 3, 












Mus musculus selectin, platelet (p-selectin) 












Mus musculus mitogen activated protein kinase 

































Mus musculus formin binding protein 1 (Fnbp1), 
transcript variant 1, mRNA. 3.05E-04












Table 8.2. Fold Change of significant and non-signifcant differentially expressed 
genes between IRF-4 +/+ WT vs IRF-4 +/- HZ vs IRF-4 -/- KO, concurrently 
investigated for Cytokine Analysis by BioPlex and mRNA expression by qRT-PCR, 
arranged alphabetically by gene name. 
ProbeID Symbol Definition p 
FC ([+/- Test] vs [+/+ 
Test])
FC ([-/- Test] vs [+/+ 
Test])
FC ([-/- Test] vs [+/- 
Test])
1190241 Ccl1
Mus musculus chemokine (C-C motif) ligand 1 (Ccl1), 
mRNA. 0.04464356 -1.1 -1.3 -1.2
110112 Ccl2 0.3512405 -1.3 1.5 1.9
2760047 Ccl3 0.9349415 1.0 1.2 1.1
6940184 Ccl4 0.03324678 -1.4 -2.0 -1.4
7150500 Ccl4 0.6306312 -1.3 -1.5 -1.1
1690768 Ccl5
Mus musculus chemokine (C-C motif) ligand 5 (Ccl5), 
mRNA. 0.5489506 -1.1 1.0 1.2
2480296 Ccl8
Mus musculus chemokine (C-C motif) ligand 8 (Ccl8), 
mRNA. 0.61776745 1.2 -1.0 -1.2
3610082 Cxcl1
Mus musculus chemokine (C-X-C motif) ligand 1 (Cxcl1), 
mRNA. 0.01450484 -1.5 1.8 2.6
3140209 Cxcl10
Mus musculus chemokine (C-X-C motif) ligand 10 (Cxcl10), 
mRNA. 0.17187747 -1.2 2.8 3.3
7550112 Cxcl12 0.00694924 -1.2 1.6 1.9
1030025 Cxcl12 0.009921 1.0 1.7 1.7
20088 Cxcl12
Mus musculus chemokine (C-X-C motif) ligand 12 (Cxcl12), 
transcript variant 3, mRNA. 0.11567923 -1.4 -1.3 1.1
7550112 Cxcl12 0.00694924 -1.2 1.6 1.9
3060040 Cxcl13 0.00224982 -1.2 3.6 4.3
3060040 Cxcl13 0.00224982 -1.2 3.6 4.3
150746 Cxcl14 0.7883063 -1.0 -1.1 -1.0
3520349 Cxcl14 0.8685516 1.1 1.0 -1.1
520403 Cxcl15 0.13632338 1.3 3.6 2.8
630274 Cxcl16 0.0301476 -1.2 -1.3 -1.0
5390639 Cxcl2
Mus musculus chemokine (C-X-C motif) ligand 2 (Cxcl2), 
mRNA. 0.02922661 1.7 1.9 1.2
4040524 Cxcl4
Mus musculus chemokine (C-X-C motif) ligand 4 (Cxcl4), 
mRNA. 0.1228403 1.0 1.4 1.4
10598 Cxcl9 0.3372854 -1.5 -1.1 1.4
4780072 Ifna1 Mus musculus interferon alpha 1 (Ifna1), mRNA. 0.02945433 1.1 -1.4 -1.5
6280592 Ifnb1 Mus musculus interferon beta 1, fibroblast (Ifnb1), mRNA. 0.00609144 -1.2 2.1 2.5
6280477 Ifng Mus musculus interferon gamma (Ifng), mRNA. 0.03848248 -1.2 -1.8 -1.5
2850092 Ifng Mus musculus interferon gamma (Ifng), mRNA. 0.22179013 -1.0 -1.7 -1.6
3420139 Il1 0.00759154 1.0 1.4 1.4
1260632 Il10 Mus musculus interleukin 10 (Il10), mRNA. 0.00768979 -1.1 -2.2 -2.0
2070468 Il12a 0.14338186 1.2 -1.1 -1.3
5270719 Il13 Mus musculus interleukin 13 (Il13), mRNA. 0.2135997 -1.0 -1.3 -1.3
3420754 Il1b 0.00457027 -1.3 3.3 4.3
6020224 Il4i1 Mus musculus interleukin 4 induced 1 (Il4i1), mRNA. 0.36216855 1.2 1.3 1.2
3400288 Irf1 Mus musculus interferon regulatory factor 1 (Irf1), mRNA. 0.02809242 -1.5 -1.2 1.2
6660634 Irf1 Mus musculus interferon regulatory factor 1 (Irf1), mRNA. 0.14142697 -1.3 -1.4 -1.1
3360138 Irf1 Mus musculus interferon regulatory factor 1 (Irf1), mRNA. 0.3168505 -1.3 -1.1 1.2
1190088 Irf1 Mus musculus interferon regulatory factor 1 (Irf1), mRNA. 0.35852087 -1.1 1.0 1.1
4250291 Irf3 0.13625193 1.1 1.2 1.2
4280193 Irf3 0.14759001 1.0 1.1 1.1
1010397 Irf4 Mus musculus interferon regulatory factor 4 (Irf4), mRNA. 0.08393885 1.6 1.1 -1.5
3140646 Irf5 Mus musculus interferon regulatory factor 5 (Irf5), mRNA. 0.0900343 -1.2 -1.1 1.1
6590653 Irf7 0.05245507 -1.4 1.2 1.7
4810286 Myd88
Mus musculus myeloid differentiation primary response 
gene 88 (Myd88), mRNA. 0.21271646 -1.3 -1.0 1.2
2070014 Nfkb2 0.9164811 1.0 1.1 1.0









Figure 8.10. This pathway is initiated by IFNG binding to its receptor and a 
subsequent phosphorylation cascade involving a number of the JAK and STAT family 
of proteins. Several transcriptionally active complexes are formed (STAT1 
homodimer, ISGF3 complex, STAT1:STAT1:IRF9 complex) and the pathway 
culminates with the transcriptional activation of target genes. 
 
 
 
 
 
 
